@article{abreu2020,
  title = {Preexisting Subtype Immunodominance Shapes Memory {{B}} Cell Recall Response to Influenza Vaccination},
  author = {Abreu, Rodrigo B. and Kirchenbaum, Greg A. and Clutter, Emily F. and Sautto, Giuseppe A. and Ross, Ted M.},
  year = {2020},
  journal = {JCI Insight},
  volume = {5},
  number = {1},
  pages = {e132155},
  issn = {2379-3708},
  doi = {10.1172/jci.insight.132155},
  urldate = {2023-03-22},
  abstract = {Influenza is a highly contagious viral pathogen with more than 200,000 cases reported in the United States during the 2017\textendash 2018 season. Annual vaccination is recommended by the World Health Organization, with the goal to reduce influenza severity and transmission. Currently available vaccines are about 60\% effective, and vaccine effectiveness varies from season to season, as well as between different influenza subtypes within a single season. Immunological imprinting from early-life influenza infection can prominently shape the immune response to subsequent infections. Here, the impact of preexisting B cell memory in the response to quadrivalent influenza vaccine was assessed using blood samples collected from healthy subjects (18\textendash 85 years old) prior to and 21\textendash 28 days following influenza vaccination. Influenza vaccination increased both HA-specific antibodies and memory B cell frequency. Despite no apparent differences in antigenicity between vaccine components, most individuals were biased toward one of the vaccine strains. Specifically, responses to H3N2 were reduced in magnitude relative to the other vaccine components. Overall, this study unveils a potentially new mechanism underlying differential vaccine effectiveness against distinct influenza subtypes.,  , People are imprinted with a bias to one of the four seasonal influenza subtypes that persists following seasonal influenza vaccination.},
  pmcid = {PMC7030826},
  pmid = {31794433},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\5YNACZCU\\Abreu et al. - Preexisting subtype immunodominance shapes memory .pdf}
}

@article{adabor2018,
  title = {Bayesian Inference of Antigenic and Non-Antigenic Variables from Haemagglutination Inhibition Assays for Influenza Surveillance},
  author = {Adabor, Emmanuel S. and Ndifon, Wilfred},
  year = {2018},
  month = jul,
  journal = {Royal Society Open Science},
  volume = {5},
  number = {7},
  pages = {180113},
  doi = {10.1098/rsos.180113},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\56NLSDZM\\Adabor and Ndifon - 2018 - Bayesian inference of antigenic and non-antigenic .pdf}
}

@article{allen2021,
  title = {Evaluation of {{Next-Generation H3 Influenza Vaccines}} in {{Ferrets Pre-Immune}} to {{Historical H3N2 Viruses}}},
  author = {Allen, James D. and Ross, Ted M.},
  year = {2021},
  journal = {Front Immunol},
  volume = {12},
  pages = {707339},
  issn = {1664-3224},
  doi = {10.3389/fimmu.2021.707339},
  abstract = {Each person has a unique immune history to past influenza virus infections. Exposure to influenza viruses early in life establishes memory B cell populations that influence future immune responses to influenza vaccination. Current influenza vaccines elicit antibodies that are typically strain specific and do not offer broad protection against antigenically drifted influenza strains in all age groups of people. This is particularly true for vaccine antigens of the A(H3N2) influenza virus subtype, where continual antigenic drift necessitates frequent vaccine reformulation. Broadly-reactive influenza virus vaccine antigens offer a solution to combat antigenic drift, but they also need to be equally effective in all populations, regardless of prior influenza virus exposure history. This study examined the role that pre-existing immunity plays on influenza virus vaccination. Ferrets were infected with historical A(H3N2) influenza viruses isolated from either the 1970's, 1980's, or 1990's and then vaccinated with computationally optimized broadly reactive antigens (COBRA) or wild-type (WT) influenza virus like particles (VLPs) expressing hemagglutinin (HA) vaccine antigens to examine the expansion of immune breadth. Vaccines with the H3 COBRA HA antigens had more cross-reactive antibodies following a single vaccination in all three pre-immune regimens than vaccines with WT H3 HA antigens against historical, contemporary, and future drifted A(H3N2) influenza viruses. The H3 COBRA HA vaccines also induced antibodies capable of neutralizing live virus infections against modern drifted A(H3N2) strains at higher titers than the WT H3 HA vaccine comparators.},
  langid = {english},
  pmcid = {PMC8406686},
  pmid = {34475872},
  keywords = {Animals,Antibodies; Viral,Antigenic Drift and Shift,Antigens; Viral,Broadly Neutralizing Antibodies,broadly reactive antibody,COBRA,Cross Reactions,Female,Ferrets,H3N2,Hemagglutinin Glycoproteins; Influenza Virus,hemagglutinin vaccine,imprinting,influenza,Influenza A Virus; H3N2 Subtype,Influenza Vaccines,Orthomyxoviridae Infections,pre-immunity}
}

@article{altman2019,
  title = {Human {{Influenza A Virus Hemagglutinin Glycan Evolution Follows}} a {{Temporal Pattern}} to a {{Glycan Limit}}},
  author = {Altman, Meghan O. and Angel, Matthew and Ko{\v s}{\'i}k, Ivan and Trov{\~a}o, N{\'i}dia S. and Zost, Seth J. and Gibbs, James S. and Casalino, Lorenzo and Amaro, Rommie E. and Hensley, Scott E. and Nelson, Martha I. and Yewdell, Jonathan W.},
  year = {2019},
  month = apr,
  journal = {mBio},
  volume = {10},
  number = {2},
  pages = {e00204-19},
  issn = {2150-7511},
  doi = {10.1128/mBio.00204-19},
  abstract = {Human antibody-based immunity to influenza A virus is limited by antigenic drift resulting from amino acid substitutions in the hemagglutinin (HA) head domain. Glycan addition can cause large antigenic changes but is limited by fitness costs to viral replication. Here, we report that glycans are added to H1 and H3 HAs at discrete 5-to-7-year intervals, until they reach a functional glycan limit, after which glycans are swapped at approximately 2-fold-longer intervals. Consistent with this pattern, 2009 pandemic H1N1 added a glycan at residue N162 over the 2015-2016 season, an addition that required two epistatic HA head mutations for complete glycosylation. These strains rapidly replaced H1N1 strains globally, by 2017 dominating H3N2 and influenza B virus strains for the season. The pattern of glycan modulation that we outline should aid efforts for tracing the epidemic potential of evolving human IAV strains.IMPORTANCE Frequent mutation of its major antibody target, the glycoprotein hemagglutinin, ensures that the influenza virus is perennially both a rapidly emerging virus and a major threat to public health. One type of mutation escapes immunity by adding a glycan onto an area of hemagglutinin that many antibodies recognize. This study revealed that these glycan changes follow a simple temporal pattern. Every 5 to 7 years, hemagglutinin adds a new glycan, up to a limit. After this limit is reached, no net additions of glycans occur. Instead, glycans are swapped or lost at longer intervals. Eventually, a pandemic replaces the terminally glycosylated hemagglutinin with a minimally glycosylated one from the animal reservoir, restarting the cycle. This pattern suggests the following: (i) some hemagglutinins are evolved for this decades-long process, which is both defined by and limited by successive glycan addition; and (ii) hemagglutinin's antibody dominance and its capacity for mutations are highly adapted features that allow influenza to outpace our antibody-based immunity.},
  langid = {english},
  pmcid = {PMC6445938},
  pmid = {30940704},
  keywords = {Evolution; Molecular,glycosylation,Glycosylation,hemagglutinin,Hemagglutinin Glycoproteins; Influenza Virus,Humans,immune evasion,influenza,Influenza A virus,Mutation,Polysaccharides,Protein Processing; Post-Translational,viral evolution},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\9PZ8RY4M\\Altman et al. - 2019 - Human Influenza A Virus Hemagglutinin Glycan Evolu.pdf}
}

@article{amitai2020,
  title = {Defining and {{Manipulating B Cell Immunodominance Hierarchies}} to {{Elicit Broadly Neutralizing Antibody Responses}} against {{Influenza Virus}}},
  author = {Amitai, Assaf and Sangesland, Maya and Barnes, Ralston M. and Rohrer, Daniel and Lonberg, Nils and Lingwood, Daniel and Chakraborty, Arup K.},
  year = {2020},
  month = dec,
  journal = {Cell Syst},
  volume = {11},
  number = {6},
  pages = {573-588.e9},
  issn = {2405-4720},
  doi = {10.1016/j.cels.2020.09.005},
  abstract = {The antibody repertoire possesses near-limitless diversity, enabling the adaptive immune system to accommodate essentially any antigen. However, this diversity explores the antigenic space unequally, allowing some pathogens like influenza virus to impose complex immunodominance hierarchies that distract antibody responses away from key sites of virus vulnerability. We developed a computational model of affinity maturation to map the patterns of immunodominance that evolve upon immunization with natural and engineered displays of hemagglutinin (HA), the influenza vaccine antigen. Based on this knowledge, we designed immunization protocols that subvert immune distraction and focus serum antibody responses upon a functionally conserved, but immunologically recessive, target of human broadly neutralizing antibodies. We tested in silico predictions by vaccinating transgenic mice in which antibody diversity was humanized to mirror clinically relevant humoral output. Collectively, our results demonstrate that complex patterns in antibody immunogenicity can be rationally defined and then manipulated to elicit engineered immunity.},
  langid = {english},
  pmcid = {PMC7746579},
  pmid = {33031741},
  keywords = {affinity maturation,Animals,antibody targeting,B cell,B-Lymphocytes,Broadly Neutralizing Antibodies,Disease Models; Animal,germinal center,Humans,immunodominance,in silico,inÂ vivo,Influenza A Virus; H1N1 Subtype,influenza virus,Mice,universal,vaccine},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\6RF2YV9S\\Amitai et al. - 2020 - Defining and Manipulating B Cell Immunodominance H.pdf}
}

@article{anderson2018,
  title = {Antigenic Cartography of {{H1N1}} Influenza Viruses Using Sequence-Based Antigenic Distance Calculation},
  author = {Anderson, Christopher S. and McCall, Patrick R. and Stern, Harry A. and Yang, Hongmei and Topham, David J.},
  year = {2018},
  month = feb,
  journal = {BMC Bioinformatics},
  volume = {19},
  number = {1},
  pages = {51},
  issn = {1471-2105},
  doi = {10.1186/s12859-018-2042-4},
  abstract = {BACKGROUND: The ease at which influenza virus sequence data can be used to estimate antigenic relationships between strains and the existence of databases containing sequence data for hundreds of thousands influenza strains make sequence-based antigenic distance estimates an attractive approach to researchers. Antigenic mismatch between circulating strains and vaccine strains results in significantly decreased vaccine effectiveness. Furthermore, antigenic relatedness between the vaccine strain and the strains an individual was originally primed with can affect the cross-reactivity of the antibody response. Thus, understanding the antigenic relationships between influenza viruses that have circulated is important to both vaccinologists and immunologists. RESULTS: Here we develop a method of mapping antigenic relationships between influenza virus stains using a sequence-based antigenic distance approach (SBM). We used a modified version of the p-all-epitope sequence-based antigenic distance calculation, which determines the antigenic relatedness between strains using influenza hemagglutinin (HA) genetic coding sequence data and provide experimental validation of the p-all-epitope calculation. We calculated the antigenic distance between 4838 H1N1 viruses isolated from infected humans between 1918 and 2016. We demonstrate, for the first time, that sequence-based antigenic distances of H1N1 Influenza viruses can be accurately represented in 2-dimenstional antigenic cartography using classic multidimensional scaling. Additionally, the model correctly predicted decreases in cross-reactive antibody levels with 87\% accuracy and was highly reproducible with even when small numbers of sequences were used. CONCLUSION: This work provides a highly accurate and precise bioinformatics tool that can be used to assess immune risk as well as design optimized vaccination strategies. SBM accurately estimated the antigenic relationship between strains using HA sequence data. Antigenic maps of H1N1 virus strains reveal that strains cluster antigenically similar to what has been reported for H3N2 viruses. Furthermore, we demonstrated that genetic variation differs across antigenic sites and discuss the implications.},
  langid = {english},
  pmcid = {PMC5809904},
  pmid = {29433425},
  keywords = {Algorithms,Amino Acid Sequence,Antigenic cartography,Antigenic distance,Antigens; Viral,Epitope Mapping,Epitopes,H1N1,Hamming distance,Hemagglutinin,Hemagglutinin Glycoproteins; Influenza Virus,Humans,Influenza,Influenza A Virus; H1N1 Subtype,Reproducibility of Results}
}

@article{anderson2020,
  title = {Implementing Sequence-Based Antigenic Distance Calculation into Immunological Shape Space Model},
  author = {Anderson, Christopher S. and Sangster, Mark Y. and Yang, Hongmei and Mariani, Thomas J. and Chaudhury, Sidhartha and Topham, David J.},
  year = {2020-06-19, 2020-06},
  journal = {BMC Bioinformatics},
  volume = {21},
  number = {1},
  doi = {10.1186/s12859-020-03594-3},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\FH8ISSBV\\Anderson et al. - 2020 - Implementing sequence-based antigenic distance cal.pdf}
}

@article{andrews2015,
  title = {Immune History Profoundly Affects Broadly Protective {{B}} Cell Responses to Influenza},
  author = {Andrews, Sarah F. and Huang, Yunping and Kaur, Kaval and Popova, Lyubov I. and Ho, Irvin Y. and Pauli, Noel T. and Dunand, Carole J. Henry and Taylor, William M and Lim, Samuel and Huang, Min and Qu, Xinyan and Lee, Jane-Hwei and {Salgado-Ferrer}, Marlene and Krammer, Florian and Palese, Peter and Wrammert, Jens and Ahmed, Rafi and Wilson, Patrick C.},
  year = {2015},
  month = dec,
  journal = {Sci Transl Med},
  volume = {7},
  number = {316},
  pages = {316ra192},
  issn = {1946-6234},
  doi = {10.1126/scitranslmed.aad0522},
  urldate = {2021-06-30},
  abstract = {Generating a broadly protective influenza vaccine is critical to global health. Understanding how immune memory influences influenza immunity is central to this goal. We undertook an in-depth study of the B cell response to the pandemic 2009 H1N1 vaccine over consecutive years. Analysis of monoclonal Abs generated from vaccine-induced plasmablasts demonstrated that individuals with low preexisting serological titers to the vaccinating strain generated a broadly reactive, HA stalk-biased, response. Higher preexisting serum antibody levels correlated with a strain-specific HA head-dominated response. We demonstrate that this HA head immunodominance encompasses poor accessibility of the HA stalk epitopes. Further, we show polyreactivity of HA stalk-reactive antibodies that could cause counterselection of these cells. Thus, preexisting memory against HA head epitopes predominate, inhibiting a broadly protective response against the HA stalk upon revaccination with similar strains. Consideration of influenza exposure history is critical for new vaccine strategies designed to elicit broadly neutralizing antibodies.},
  pmcid = {PMC4770855},
  pmid = {26631631},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\CFHKNABM\\Andrews et al. - 2015 - Immune history profoundly affects broadly protecti.pdf}
}

@article{andrews2022,
  title = {A Single Residue in Influenza Virus {{H2}} Hemagglutinin Enhances the Breadth of the {{B}} Cell Response Elicited by {{H2}} Vaccination},
  author = {Andrews, Sarah F. and Raab, Julie E. and Gorman, Jason and Gillespie, Rebecca A. and Cheung, Crystal S. F. and Rawi, Reda and Cominsky, Lauren Y. and Boyington, Jeffrey C. and Creanga, Adrian and Shen, Chen-Hsiang and Harris, Darcy R. and Olia, Adam S. and Nazzari, Alexandra F. and Zhou, Tongqing and Houser, Katherine V. and Chen, Grace L. and Mascola, John R. and Graham, Barney S. and Kanekiyo, Masaru and Ledgerwood, Julie E. and Kwong, Peter D. and McDermott, Adrian B.},
  year = {2022},
  month = feb,
  journal = {Nat Med},
  volume = {28},
  number = {2},
  pages = {373--382},
  issn = {1078-8956, 1546-170X},
  doi = {10.1038/s41591-021-01636-8},
  urldate = {2023-03-21},
  langid = {english}
}

@article{archetti1950,
  title = {{{PERSISTENT ANTIGENIC VARIATION OF INFLUENZA A VIRUSES AFTER INCOMPLETE NEUTRALIZATION IN OVO WITH HETEROLOGOUS IMMUNE SERUM}}},
  author = {Archetti, Italo and Horsfall, Frank L.},
  year = {1950-11-01, 1950-11},
  journal = {Journal of Experimental Medicine},
  volume = {92},
  number = {5},
  pages = {441--462},
  doi = {10.1084/jem.92.5.441},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\I3LFVLKE\\Archetti and Horsfall - 1950 - PERSISTENT ANTIGENIC VARIATION OF INFLUENZA A VIRU.pdf}
}

@article{arevalo2020,
  title = {Earliest Infections Predict the Age Distribution of Seasonal Influenza {{A}} Cases},
  author = {Arevalo, Philip and McLean, Huong Q and Belongia, Edward A and Cobey, Sarah},
  editor = {Cooper, Ben S and Ferguson, Neil M and Cooper, Ben S and Baguelin, Marc},
  year = {2020},
  month = jul,
  journal = {eLife},
  volume = {9},
  pages = {e50060},
  publisher = {{eLife Sciences Publications, Ltd}},
  issn = {2050-084X},
  doi = {10.7554/eLife.50060},
  urldate = {2021-06-09},
  abstract = {Seasonal variation in the age distribution of influenza A cases suggests that factors other than age shape susceptibility to medically attended infection. We ask whether these differences can be partly explained by protection conferred by childhood influenza infection, which has lasting impacts on immune responses to influenza and protection against new influenza A subtypes (phenomena known as original antigenic sin and immune imprinting). Fitting a statistical model to data from studies of influenza vaccine effectiveness (VE), we find that primary infection appears to reduce the risk of medically attended infection with that subtype throughout life. This effect is stronger for H1N1 compared to H3N2. Additionally, we find evidence that VE varies with both age and birth year, suggesting that VE is sensitive to early exposures. Our findings may improve estimates of age-specific risk and VE in similarly vaccinated populations and thus improve forecasting and vaccination strategies to combat seasonal influenza.},
  keywords = {imprinting,influenza,original antigenic sin,vaccine effectiveness}
}

@misc{arevalo2020a,
  title = {Earliest Infections Predict the Age Distribution of Seasonal Influenza {{A}} Cases},
  author = {Arevalo, Philip and McLean, Huong Q. and Belongia, Edward A. and Cobey, Sarah},
  year = {2020},
  month = mar,
  pages = {19001875},
  publisher = {{medRxiv}},
  doi = {10.1101/19001875},
  urldate = {2023-03-02},
  abstract = {Seasonal variation in the age distribution of influenza A cases suggests that factors other than age shape susceptibility to medically attended infection. We ask whether these differences can be partly explained by protection conferred by childhood influenza infection, which has lasting impacts on immune responses to influenza and protection against new influenza A subtypes (phenomena known as original antigenic sin and immune imprinting). Fitting a statistical model to data from studies of influenza vaccine effectiveness (VE), we find that primary infection appears to reduce the risk of medically attended infection with that subtype throughout life. This effect is stronger for H1N1 compared to H3N2. Additionally, we find evidence that VE varies with both age and birth year, suggesting that VE is sensitive to early exposures. Our findings may improve estimates of age-specific risk and VE in similarly vaccinated populations and thus improve forecasting and vaccination strategies to combat seasonal influenza.},
  archiveprefix = {medRxiv},
  copyright = {\textcopyright{} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\D4RITBU2\\Arevalo et al. - 2020 - Earliest infections predict the age distribution o.pdf}
}

@article{arevalo2020b,
  title = {Original Antigenic Sin Priming of Influenza Virus Hemagglutinin Stalk Antibodies},
  author = {Arevalo, Claudia P. and Le Sage, Valerie and Bolton, Marcus J. and Eilola, Theresa and Jones, Jennifer E. and Kormuth, Karen A. and Nturibi, Eric and Balmaseda, Angel and Gordon, Aubree and Lakdawala, Seema S. and Hensley, Scott E.},
  year = {2020},
  journal = {Proc Natl Acad Sci U S A},
  volume = {117},
  number = {29},
  pages = {17221--17227},
  issn = {1091-6490},
  doi = {10.1073/pnas.1920321117},
  abstract = {Immunity to influenza viruses can be long-lived, but reinfections with antigenically distinct viral strains and subtypes are common. Reinfections can boost antibody responses against viral strains first encountered in childhood through a process termed "original antigenic sin." It is unknown how initial childhood exposures affect the induction of antibodies against the hemagglutinin (HA) stalk domain of influenza viruses. This is an important consideration since broadly reactive HA stalk antibodies can protect against infection, and universal vaccine platforms are being developed to induce these antibodies. Here we show that experimentally infected ferrets and naturally infected humans establish strong "immunological imprints" against HA stalk antigens first encountered during primary influenza virus infections. We found that HA stalk antibodies are surprisingly boosted upon subsequent infections with antigenically distinct influenza A virus subtypes. Paradoxically, these heterosubtypic-boosted HA stalk antibodies do not bind efficiently to the boosting influenza virus strain. Our results demonstrate that an individual's HA stalk antibody response is dependent on the specific subtype of influenza virus that they first encounter early in life. We propose that humans are susceptible to heterosubtypic influenza virus infections later in life since these viruses boost HA stalk antibodies that do not bind efficiently to the boosting antigen.},
  langid = {english},
  pmcid = {PMC7382271},
  pmid = {32631992},
  keywords = {Animals,Antibodies; Viral,Antigens; Viral,Ferrets,hemagglutinin,Hemagglutinin Glycoproteins; Influenza Virus,Hemagglutinins,Humans,Immunization; Secondary,Immunoglobulin G,influenza virus,original antigenic sin,Orthomyxoviridae Infections,Recombinant Proteins},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\XGUTHTLQ\\Arevalo et al. - 2020 - Original antigenic sin priming of influenza virus .pdf}
}

@article{attias2021,
  title = {Antibody Response to the {{BNT162b2}} Vaccine in Maintenance Hemodialysis Patients},
  author = {Attias, Philippe and Sakhi, Hamza and Rieu, Philippe and Soorkia, Arvish and Assayag, David and Bouhroum, Sabrina and Nizard, Patrice and El Karoui, Khalil},
  year = {2021},
  month = jun,
  journal = {Kidney Int},
  volume = {99},
  number = {6},
  pages = {1490--1492},
  issn = {1523-1755},
  doi = {10.1016/j.kint.2021.04.009},
  langid = {english},
  pmcid = {PMC8055946},
  pmid = {33887317},
  keywords = {Antibody Formation,BNT162 Vaccine,COVID-19,COVID-19 Vaccines,Humans,Renal Dialysis,Vaccines}
}

@article{auladell2022,
  title = {Influenza Virus Infection History Shapes Antibody Responses to Influenza Vaccination},
  author = {Auladell, Maria and Phuong, Hoang Vu Mai and Mai, Le Thi Quynh and Tseng, Yeu-Yang and Carolan, Louise and Wilks, Sam and Thai, Pham Quang and Price, David and Duong, Nguyen Thanh and Hang, Nguyen Le Khang and Thanh, Le Thi and Thuong, Nguyen Thi Hong and Huong, Tran Thi Kieu and Diep, Nguyen Thi Ngoc and Bich, Vu Thi Ngoc and Khvorov, Arseniy and Hensen, Luca and Duong, Tran Nhu and Kedzierska, Katherine and Anh, Dang Duc and Wertheim, Heiman and Boyd, Scott D. and {Good-Jacobson}, Kim L. and Smith, Derek and Barr, Ian and Sullivan, Sheena and {van Doorn}, H. Rogier and Fox, Annette},
  year = {2022},
  month = feb,
  journal = {Nat Med},
  volume = {28},
  number = {2},
  pages = {363--372},
  issn = {1546-170X},
  doi = {10.1038/s41591-022-01690-w},
  abstract = {Studies of successive vaccination suggest that immunological memory against past influenza viruses may limit responses to vaccines containing current strains. The impact of memory induced by prior infection is rarely considered and is difficult to ascertain, because infections are often subclinical. This study investigated influenza vaccination among adults from the Ha Nam cohort (Vietnam), who were purposefully selected to include 72 with and 28 without documented influenza A(H3N2) infection during the preceding 9 years (Australian New Zealand Clinical Trials Registry 12621000110886). The primary outcome was the effect of prior influenza A(H3N2) infection on hemagglutinin-inhibiting antibody responses induced by a locally available influenza vaccine administered in November 2016. Baseline and postvaccination sera were titrated against 40 influenza A(H3N2) strains spanning 1968-2018. At each time point (baseline, day 14 and day 280), geometric mean antibody titers against 2008-2018 strains were higher among participants with recent infection (34 (29-40), 187 (154-227) and 86 (72-103)) than among participants without recent infection (19 (17-22), 91 (64-130) and 38 (30-49)). On days 14 and 280, mean titer rises against 2014-2018 strains were 6.1-fold (5.0- to 7.4-fold) and 2.6-fold (2.2- to 3.1-fold) for participants with recent infection versus 4.8-fold (3.5- to 6.7-fold) and 1.9-fold (1.5- to 2.3-fold) for those without. One of 72 vaccinees with recent infection versus 4 of 28 without developed symptomatic A(H3N2) infection in the season after vaccination (P\,=\,0.021). The range of A(H3N2) viruses recognized by vaccine-induced antibodies was associated with the prior infection strain. These results suggest that recall of immunological memory induced by prior infection enhances antibody responses to inactivated influenza vaccine and is important to attain protective antibody titers.},
  langid = {english},
  pmid = {35177857},
  keywords = {Adult,Antibodies; Viral,Antibody Formation,Australia,Hemagglutination Inhibition Tests,Humans,Influenza A Virus; H3N2 Subtype,Influenza Vaccines,Influenza; Human,Vaccination,Vaccines; Inactivated}
}

@article{bangaru2016,
  title = {Recognition of Influenza {{H3N2}} Variant Virus by Human Neutralizing Antibodies},
  author = {Bangaru, Sandhya and Nieusma, Travis and Kose, Nurgun and Thornburg, Natalie J. and Finn, Jessica A. and Kaplan, Bryan S. and King, Hannah G. and Singh, Vidisha and Lampley, Rebecca M. and Sapparapu, Gopal and Cisneros, Alberto and Edwards, Kathryn M. and Slaughter, James C. and Edupuganti, Srilatha and Lai, Lilin and Richt, Juergen A. and Webby, Richard J. and Ward, Andrew B. and Crowe, James E.},
  year = {2016},
  month = jul,
  journal = {JCI Insight},
  volume = {1},
  number = {10},
  pages = {e86673},
  issn = {2379-3708},
  doi = {10.1172/jci.insight.86673},
  abstract = {Since 2011, over 300 human cases of infection, especially in exposed children, with the influenza A H3N2 variant (H3N2v) virus that circulates in swine in the US have been reported. The structural and genetic basis for the lack of protection against H3N2v induced by vaccines containing seasonal H3N2 antigens is poorly understood. We isolated 17 human monoclonal antibodies (mAbs) that neutralized H3N2v virus from subjects experimentally immunized with an H3N2v candidate vaccine. Six mAbs exhibited very potent neutralizing activity (IC50 {$<$} 200 ng/ml) against the H3N2v virus but not against current human H3N2 circulating strains. Fine epitope mapping and structural characterization of antigen-antibody complexes revealed that H3N2v specificity was attributable to amino acid polymorphisms in the 150-loop and the 190-helix antigenic sites on the hemagglutinin protein. H3N2v-specific antibodies also neutralized human H3N2 influenza strains naturally circulating between 1995 and 2005. These results reveal a high level of antigenic relatedness between the swine H3N2v virus and previously circulating human strains, consistent with the fact that early human H3 seasonal strains entered the porcine population in the 1990s and reentered the human population, where they had not been circulating, as H3N2v about a decade later. The data also explain the increased susceptibility to H3N2v viruses in young children, who lack prior exposure to human seasonal strains from the 1990s.},
  langid = {english},
  pmcid = {PMC4962875},
  pmid = {27482543}
}

@article{bartoszko2021,
  title = {The Burden of Influenza in Older Adults: Meeting the Challenge},
  shorttitle = {The Burden of Influenza in Older Adults},
  author = {Bartoszko, Jessica and Loeb, Mark},
  year = {2021},
  month = mar,
  journal = {Aging Clin Exp Res},
  volume = {33},
  number = {3},
  pages = {711--717},
  issn = {1720-8319},
  doi = {10.1007/s40520-019-01279-3},
  urldate = {2023-03-17},
  langid = {english}
}

@article{bedford2015,
  title = {Global Circulation Patterns of Seasonal Influenza Viruses Vary with Antigenic Drift},
  author = {Bedford, Trevor and Riley, Steven and Barr, Ian G. and Broor, Shobha and Chadha, Mandeep and Cox, Nancy J. and Daniels, Rodney S. and Gunasekaran, C. Palani and Hurt, Aeron C. and Kelso, Anne and Klimov, Alexander and Lewis, Nicola S. and Li, Xiyan and McCauley, John W. and Odagiri, Takato and Potdar, Varsha and Rambaut, Andrew and Shu, Yuelong and Skepner, Eugene and Smith, Derek J. and Suchard, Marc A. and Tashiro, Masato and Wang, Dayan and Xu, Xiyan and Lemey, Philippe and Russell, Colin A.},
  year = {2015-06-08, 2015-06},
  journal = {Nature},
  volume = {523},
  number = {7559},
  pages = {217--220},
  doi = {10.1038/nature14460},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\UJN9KR46\\Bedford et al. - 2015 - Global circulation patterns of seasonal influenza .pdf}
}

@article{belongia2017,
  title = {Repeated Annual Influenza Vaccination and Vaccine Effectiveness: Review of Evidence},
  author = {Belongia, Edward A. and Skowronski, Danuta M. and McLean, Huong Q. and Chambers, Catharine and Sundaram, Maria E. and De Serres, Gaston},
  year = {2017-06-09, 2017-06},
  journal = {Expert Review of Vaccines},
  volume = {16},
  number = {7},
  pages = {723--736},
  doi = {10.1080/14760584.2017.1334554},
  langid = {english}
}

@article{bender2023,
  title = {Really Just a Little Prick? {{A}} Meta-Analysis on Adverse Events in Placebo Control Groups of Seasonal Influenza Vaccination {{RCTs}}},
  shorttitle = {Really Just a Little Prick?},
  author = {Bender, F. L. and Rief, W. and Wilhelm, M.},
  year = {2023},
  month = jan,
  journal = {Vaccine},
  volume = {41},
  number = {2},
  pages = {294--303},
  issn = {1873-2518},
  doi = {10.1016/j.vaccine.2022.11.033},
  abstract = {BACKGROUND: The Corona pandemic and ongoing mass vaccinations raise the question of the nocebo mechanisms involved. Since immunization is usually administered to healthy people as a preventive health measure, adverse events (AE) following immunization are less accepted and could contribute to vaccine hesitancy. Assuming that vaccinees experience nocebo responses, the aim of this meta-analysis was to investigate the effect sizes of solicited adverse events (or assumed reactogenicity) reported in placebo groups in RCTs on seasonal influenza vaccination. METHODS: Literature search via PubMed, Web of Science, and CENTRAL was conducted considering gray literature. Only RCTs with placebo groups using pharmacologically inert substances (like saline) were included. Quality was assessed using Cochrane Collaboration's Risk of Bias Tool. Effect sizes were estimated using a random mixed effects model based on k~=~31 studies covering 14,326 participants in placebo groups. RESULTS: Reported solicited AEs in placebo groups showed significant effect sizes of proportions (ESp). In k~=~13 analyzed placebo groups, 35~\% of the participants reported at least one solicited systemic AE (p~=~0.007). The most common particular solicited systemic AEs were headache (k~=~27; 17~\%; p~=~0.001), malaise (k~=~13; 12~\%; p~=~0.004), and hyperhidrosis (k~=~4; 12~\%; p~{$<~$}0.001) within one week after vaccination. CONCLUSION: The results show significant solicited AEs in placebo groups, indicating substantial nocebo responses after vaccination. Based on the fact that most vaccination programs include similar groups of healthy people, we expect that comparable nocebo effects occur during other campaigns. Health care professionals should be aware of the nocebo response and take action to prevent or decrease the burden of adverse events following immunization. Fear of side effects must be addressed early in order to diminish vaccine hesitancy. Prospero identifier: CRD42020156287, October 2019.},
  langid = {english},
  pmid = {36464541},
  keywords = {Control Groups,Drug-Related Side Effects and Adverse Reactions,Humans,Influenza,Influenza; Human,Nocebo,Randomized Controlled Trials as Topic,Reactogenicity,Seasons,Vaccination,Vaccine hesitancy},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\Q4F2YH7W\\Bender et al. - 2023 - Really just a little prick A meta-analysis on adv.pdf}
}

@article{benest2021,
  title = {Optimising {{Vaccine Dose}} in {{Inoculation}} against {{SARS-CoV-2}}, a {{Multi-Factor Optimisation Modelling Study}} to {{Maximise Vaccine Safety}} and {{Efficacy}}},
  author = {Benest, John and Rhodes, Sophie and Quaife, Matthew and Evans, Thomas G. and White, Richard G.},
  year = {2021},
  month = jan,
  journal = {Vaccines (Basel)},
  volume = {9},
  number = {2},
  pages = {78},
  issn = {2076-393X},
  doi = {10.3390/vaccines9020078},
  abstract = {Developing a vaccine against the global pandemic SARS-CoV-2 is a critical area of active research. Modelling can be used to identify optimal vaccine dosing; maximising vaccine efficacy and safety and minimising cost. We calibrated statistical models to published dose-dependent seroconversion and adverse event data of a recombinant adenovirus type-5 (Ad5) SARS-CoV-2 vaccine given at doses 5.0 \texttimes{} 1010, 1.0 \texttimes{} 1011 and 1.5 \texttimes{} 1011 viral particles. We estimated the optimal dose for three objectives, finding: (A) the minimum dose that may induce herd immunity, (B) the dose that maximises immunogenicity and safety and (C) the dose that maximises immunogenicity and safety whilst minimising cost. Results suggest optimal dose [95\% confidence interval] in viral particles per person was (A) 1.3 \texttimes{} 1011 [0.8-7.9 \texttimes{} 1011], (B) 1.5 \texttimes{} 1011 [0.3-5.0 \texttimes{} 1011] and (C) 1.1 \texttimes{} 1011 [0.2-1.5 \texttimes{} 1011]. Optimal dose exceeded 5.0 \texttimes{} 1010 viral particles only if the cost of delivery exceeded \textsterling 0.65 or cost per 1011 viral particles was less than \textsterling 6.23. Optimal dose may differ depending on the objectives of developers and policy-makers, but further research is required to improve the accuracy of optimal-dose estimates.},
  langid = {english},
  pmcid = {PMC7911627},
  pmid = {33499326},
  keywords = {adenovirus-vectored vaccines,COVID-19,dose dynamics,dose-response,dosing},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\MR5I6LFN\\Benest et al. - 2021 - Optimising Vaccine Dose in Inoculation against SAR.pdf}
}

@article{bernstein2019,
  title = {Immunogenicity of Chimeric Haemagglutinin-Based, Universal Influenza Virus Vaccine Candidates: Interim Results of a Randomised, Placebo-Controlled, Phase 1 Clinical Trial},
  shorttitle = {Immunogenicity of Chimeric Haemagglutinin-Based, Universal Influenza Virus Vaccine Candidates},
  author = {Bernstein, David I and Guptill, Jeffrey and Naficy, Abdollah and Nachbagauer, Raffael and {Berlanda-Scorza}, Francesco and Feser, Jodi and Wilson, Patrick C and Sol{\'o}rzano, Alicia and {Van der Wielen}, Marie and Walter, Emmanuel B and Albrecht, Randy A and Buschle, Kristen N and Chen, Yao-qing and Claeys, Carine and Dickey, Michelle and Dugan, Haley L and Ermler, Megan E and Freeman, Debra and Gao, Min and Gast, Christopher and Guthmiller, Jenna J and Hai, Rong and Henry, Carole and Lan, Linda Yu-Ling and McNeal, Monica and Palm, Anna-Karin E and Shaw, Dustin G and Stamper, Christopher T and Sun, Weina and Sutton, Victoria and Tepora, Micah E and Wahid, Rahnuma and Wenzel, Heather and Wohlbold, Teddy John and Innis, Bruce L and {Garc{\'i}a-Sastre}, Adolfo and Palese, Peter and Krammer, Florian},
  year = {2019},
  journal = {Lancet Infect Dis},
  volume = {20},
  number = {1},
  pages = {80--91},
  issn = {1473-3099},
  doi = {10.1016/S1473-3099(19)30393-7},
  urldate = {2021-06-17},
  abstract = {Background Influenza viruses cause substantial annual morbidity and mortality globally. Current vaccines protect against influenza only when well matched to the circulating strains. However, antigenic drift can cause considerable mismatches between vaccine and circulating strains, substantially reducing vaccine effectiveness. Moreover, current seasonal vaccines are ineffective against pandemic influenza, and production of a vaccine matched to a newly emerging virus strain takes months. Therefore, there is an unmet medical need for a broadly protective influenza virus vaccine. We aimed to test the ability of chimeric H1 haemagglutinin-based universal influenza virus vaccine candidates to induce broadly cross-reactive antibodies targeting the stalk domain of group 1 haemagglutinin-expressing influenza viruses. Methods We did a randomised, observer-blinded, phase 1 study in healthy adults in two centres in the USA. Participants were randomly assigned to one of three prime\textendash boost, chimeric haemagglutinin-based vaccine regimens or one of two placebo groups. The vaccine regimens included a chimeric H8/1, intranasal, live-attenuated vaccine on day 1 followed by a non-adjuvanted, chimeric H5/1, intramuscular, inactivated vaccine on day 85; the same regimen but with the inactivated vaccine being adjuvanted with AS03; and an AS03-adjuvanted, chimeric H8/1, intramuscular, inactivated vaccine followed by an AS03-adjuvanted, chimeric H5/1, intramuscular, inactivated vaccine. In this planned interim analysis, the primary endpoints of reactogenicity and safety were assessed by blinded study group. We also assessed anti-H1 haemagglutinin stalk, anti-H2, anti-H9, and anti-H18 IgG antibody titres and plasmablast and memory B-cell responses in peripheral blood. This trial is registered with ClinicalTrials.gov, number NCT03300050. Findings Between Oct 10, 2017, and Nov 27, 2017, 65 participants were enrolled and randomly assigned. The adjuvanted inactivated vaccine, but not the live-attenuated vaccine, induced a substantial serum IgG antibody response after the prime immunisation, with a seven times increase in anti-H1 stalk antibody titres on day 29. After boost immunisation, all vaccine regimens induced detectable anti-H1 stalk antibody (2{$\cdot$}2\textendash 5{$\cdot$}6 times induction over baseline), cross-reactive serum IgG antibody, and peripheral blood plasmablast responses. An unsolicited adverse event was reported for 29 (48\%) of 61 participants. Solicited local adverse events were reported in 12 (48\%) of 25 participants following prime vaccination with intramuscular study product or placebo, in 12 (33\%) of 36 after prime immunisation with intranasal study product or placebo, and in 18 (32\%) of 56 following booster doses of study product or placebo. Solicited systemic adverse events were reported in 14 (56\%) of 25 after prime immunisation with intramuscular study product or placebo, in 22 (61\%) of 36 after immunisation with intranasal study product or placebo, and in 21 (38\%) of 56 after booster doses of study product or placebo. Disaggregated safety data were not available at the time of this interim analysis. Interpretation The tested chimeric haemagglutinin-based, universal influenza virus vaccine regimens elicited cross-reactive serum IgG antibodies that targeted the conserved haemagglutinin stalk domain. This is the first proof-of-principle study to show that high anti-stalk titres can be induced by a rationally designed vaccine in humans and opens up avenues for further development of universal influenza virus vaccines. On the basis of the blinded study group, the vaccine regimens were tolerable and no safety concerns were observed. Funding Bill \& Melinda Gates Foundation.},
  pmcid = {PMC6928577},
  pmid = {31630990},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\KSHH97SH\\Bernstein et al. - 2019 - Immunogenicity of chimeric haemagglutinin-based, u.pdf}
}

@article{Biostrings,
  title = {Biostrings: {{Efficient}} Manipulation of Biological Strings},
  author = {Pag{\`e}s, H. and Aboyoun, P. and Gentleman, R. and DebRoy, S.},
  year = {2021}
}

@article{bodewes2011,
  title = {Prevalence of {{Antibodies}} against {{Seasonal Influenza A}} and {{B Viruses}} in {{Children}} in {{Netherlands}}},
  author = {Bodewes, R. and {de Mutsert}, G. and {van der Klis}, F. R. M. and Ventresca, M. and Wilks, S. and Smith, D. J. and Koopmans, M. and Fouchier, R. A. M and Osterhaus, A. D. M. E and Rimmelzwaan, G. F.},
  year = {2011},
  month = mar,
  journal = {Clinical and Vaccine Immunology},
  volume = {18},
  number = {3},
  doi = {10.1128/CVI.00396-10},
  urldate = {2021-06-24},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\I9IQNR35\\Prevalence of Antibodies against Seasonal Influenz.pdf;C\:\\Users\\Zane\\Zotero\\storage\\LPSWTM95\\CVI.html}
}

@article{bolek2023,
  title = {Clinical Outcomes and Economic Burden of Seasonal Influenza and Other Respiratory Virus Infections in Hospitalized Adults},
  author = {Bolek, Hatice and Ozisik, Lale and Caliskan, Zafer and Tanriover, Mine Durusu},
  year = {2023},
  month = jan,
  journal = {J Med Virol},
  volume = {95},
  number = {1},
  pages = {e28153},
  issn = {1096-9071},
  doi = {10.1002/jmv.28153},
  abstract = {The cost of influenza and other respiratory virus infections should be determined to analyze the real burden of these diseases. We aimed to investigate the clinical outcomes and cost of illness due to respiratory virus infections in hospitalized adult patients.~Hospitalized patients who had nasal swab sampling for a suspected viral infection between August 1, 2018 to March~31, 2019 were included. Outcome variables were oxygen requirement, mechanical ventilation need, intensive care unit admission, and cost.~At least one viral pathogen was detected in 125 (47.7\%) of 262 patients who were included in the study. Fifty-five (20.9\%) of the patients were infected with influenza. Influenza-positive patients had higher rates for respiratory support, intensive care unit admission, and mortality compared to all other patients. The average cost of hospitalization per person was 2879.76 USD in the influenza-negative group, while the same cost was 3274.03 USD in the influenza-positive group. Although all of the vaccinated influenza-positive patients needed oxygen support, neither of them required invasive mechanical ventilation or intensive care unit admission. The average hospitalization cost per person was 779.70 USD in the vaccinated group compared to 3762.01 USD in the unvaccinated group. Disease-related direct cost of influenza in the community was estimated as 22\,776\,075.61 USD in the 18-65 years of age group and 15\,756\,120.02 USD in the 65 years of age and over group per year.~Influenza, compared to other respiratory virus infections, can lead to untoward clinical outcomes and mortality as well as higher direct medical costs in adults.},
  langid = {english},
  pmid = {36110064},
  keywords = {Adult,Aged,Cost of Illness,Financial Stress,Hospitalization,hospitalization cost,Humans,influenza,Influenza; Human,Oxygen,respiratory virus infections,Seasons}
}

@article{bosaeed2018,
  title = {Seasonal Influenza Vaccine in Immunocompromised Persons},
  author = {Bosaeed, Mohammad and Kumar, Deepali},
  year = {2018},
  month = jun,
  journal = {Hum Vaccin Immunother},
  volume = {14},
  number = {6},
  pages = {1311--1322},
  issn = {2164-554X},
  doi = {10.1080/21645515.2018.1445446},
  abstract = {Immunocompromised persons are at high risk of complications from influenza infection. This population includes those with solid organ transplants, hematopoietic stem cell transplants, solid cancers and hematologic malignancy as well as those with autoimmune conditions receiving biologic therapies. In this review, we discuss the impact of influenza infection and evidence for vaccine effectiveness and immunogenicity. Overall, lower respiratory disease from influenza is common; however, vaccine immunogenicity is low. Despite this, in some populations, influenza vaccine has demonstrated effectiveness in reducing severe disease. Various strategies to improve influenza vaccine immunogenicity have been attempted including two vaccine doses in the same influenza season, intradermal, adjuvanted, and high-dose vaccines. The timing of influenza vaccine is also important to achieve optimal immunogenicity. Given the suboptimal immunogenicity, family members and healthcare professionals involved in the care of these populations should be vaccinated. Health care professional recommendation for vaccination is an important factor in vaccine coverage.},
  langid = {english},
  pmcid = {PMC6037456},
  pmid = {29485353},
  keywords = {Antineoplastic Agents,biologics,hematologic malignancy,Humans,Immune System Diseases,Immunization Schedule,Immunocompromised Host,Immunosuppressive Agents,Influenza Vaccines,Influenza; Human,Neoplasms,Organ transplant,stem cell transplant},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\3CBKMB9I\\Bosaeed and Kumar - 2018 - Seasonal influenza vaccine in immunocompromised pe.pdf}
}

@article{bouvier2008,
  title = {{{THE BIOLOGY OF INFLUENZA VIRUSES}}},
  author = {Bouvier, Nicole M. and Palese, Peter},
  year = {2008},
  month = sep,
  journal = {Vaccine},
  volume = {26},
  number = {Suppl 4},
  pages = {D49-D53},
  issn = {0264-410X},
  urldate = {2021-06-30},
  abstract = {The influenza viruses are characterized by segmented, negative-strand RNA genomes requiring an RNA-dependent RNA polymerase of viral origin for replication. The particular structure of the influenza virus genome and function of its viral proteins enable antigenic drift and antigenic shift. These processes result in viruses able to evade the long-term adaptive immune responses in many hosts.},
  pmcid = {PMC3074182},
  pmid = {19230160},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\CC656BNL\\Bouvier and Palese - 2008 - THE BIOLOGY OF INFLUENZA VIRUSES.pdf}
}

@article{boyoglu-barnum2021,
  title = {Quadrivalent Influenza Nanoparticle Vaccines Induce Broad Protection},
  author = {{Boyoglu-Barnum}, Seyhan and Ellis, Daniel and Gillespie, Rebecca A. and Hutchinson, Geoffrey B. and Park, Young-Jun and Moin, Syed M. and Acton, Oliver J. and Ravichandran, Rashmi and Murphy, Mike and Pettie, Deleah and Matheson, Nick and Carter, Lauren and Creanga, Adrian and Watson, Michael J. and Kephart, Sally and Ataca, Sila and Vaile, John R. and Ueda, George and Crank, Michelle C. and Stewart, Lance and Lee, Kelly K. and Guttman, Miklos and Baker, David and Mascola, John R. and Veesler, David and Graham, Barney S. and King, Neil P. and Kanekiyo, Masaru},
  year = {2021-03-24, 2021-03},
  journal = {Nature},
  volume = {592},
  number = {7855},
  pages = {623--628},
  doi = {10.1038/s41586-021-03365-x},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\YYJCWA9M\\Boyoglu-Barnum et al. - 2021 - Quadrivalent influenza nanoparticle vaccines induc.pdf}
}

@article{brodin2015,
  title = {Variation in the Human Immune System Is Largely Driven by Non-Heritable Influences},
  author = {Brodin, Petter and Jojic, Vladimir and Gao, Tianxiang and Bhattacharya, Sanchita and Angel, Cesar J. Lopez and Furman, David and {Shen-Orr}, Shai and Dekker, Cornelia L. and Swan, Gary E. and Butte, Atul J. and Maecker, Holden T. and Davis, Mark M.},
  year = {2015},
  month = jan,
  journal = {Cell},
  volume = {160},
  number = {1-2},
  pages = {37--47},
  issn = {1097-4172},
  doi = {10.1016/j.cell.2014.12.020},
  abstract = {There is considerable heterogeneity in immunological parameters between individuals, but its sources are largely unknown. To assess the relative contribution of heritable versus non-heritable factors, we have performed a systems-level analysis of 210 healthy twins between 8 and 82 years of age. We measured 204 different parameters, including cell population frequencies, cytokine responses, and serum proteins, and found that 77\% of these are dominated ({$>$}50\% of variance) and 58\% almost completely determined ({$>$}80\% of variance) by non-heritable influences. In addition, some of these parameters become more variable with age, suggesting the cumulative influence of environmental exposure. Similarly, the serological responses to seasonal influenza vaccination are also determined largely by non-heritable factors, likely due to repeated exposure to different strains. Lastly, in MZ twins discordant for cytomegalovirus infection, more than half of all parameters are affected. These results highlight the largely reactive and adaptive nature of the immune system in healthy individuals.},
  langid = {english},
  pmcid = {PMC4302727},
  pmid = {25594173},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Blood Proteins,Child,Cytokines,Cytomegalovirus Infections,Humans,Immunity,Influenza Vaccines,Middle Aged,Twins; Dizygotic,Twins; Monozygotic,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\PGVJGI7B\\Brodin et al. - 2015 - Variation in the human immune system is largely dr.pdf}
}

@article{brouwer2022,
  title = {Birth Cohort Relative to an Influenza {{A}} Virus's Antigenic Cluster Introduction Drives Patterns of Children's Antibody Titers},
  author = {Brouwer, Andrew F. and Balmaseda, Angel and Gresh, Lionel and Patel, Mayuri and Ojeda, Sergio and Schiller, Amy J. and Lopez, Roger and Webby, Richard J. and Nelson, Martha I. and Kuan, Guillermina and Gordon, Aubree},
  year = {2022},
  month = feb,
  journal = {PLOS Pathogens},
  volume = {18},
  number = {2},
  pages = {e1010317},
  publisher = {{Public Library of Science}},
  issn = {1553-7374},
  doi = {10.1371/journal.ppat.1010317},
  urldate = {2023-03-21},
  abstract = {An individual's antibody titers to influenza A strains are a result of the complicated interplay between infection history, cross-reactivity, immune waning, and other factors. It has been challenging to disentangle how population-level patterns of humoral immunity change as a function of age, calendar year, and birth cohort from cross-sectional data alone. We analyzed 1,589 longitudinal sera samples from 260 children across three studies in Nicaragua, 2006\textendash 16. Hemagglutination inhibition (HAI) titers were determined against four H3N2 strains, one H1N1 strain, and two H1N1pdm strains. We assessed temporal patterns of HAI titers using an age\textendash period\textendash cohort modeling framework. We found that titers against a given virus depended on calendar year of serum collection and birth cohort but not on age. Titer cohort patterns were better described by participants' ages relative to year of likely introduction of the virus's antigenic cluster than by age relative to year of strain introduction or by year of birth. These cohort effects may be driven by a decreasing likelihood of early-life infection after cluster introduction and by more broadly reactive antibodies at a young age. H3N2 and H1N1 viruses had qualitatively distinct cohort patterns, with cohort patterns of titers to specific H3N2 strains reaching their peak in children born 3 years prior to that virus's antigenic cluster introduction and with titers to H1N1 and H1N1pdm strains peaking for children born 1\textendash 2 years prior to cluster introduction but not being dramatically lower for older children. Ultimately, specific patterns of strain circulation and antigenic cluster introduction may drive population-level antibody titer patterns in children.},
  langid = {english},
  keywords = {Antibodies,Antibody response,Children,Cohort studies,H1N1,Influenza,Influenza A virus,Pandemics},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\RKEZCJ9Z\\Brouwer et al. - 2022 - Birth cohort relative to an influenza A virusâs an.pdf}
}

@article{burke2014,
  title = {A Recommended Numbering Scheme for Influenza {{A HA}} Subtypes},
  author = {Burke, David F. and Smith, Derek J.},
  year = {2014},
  journal = {PLoS One},
  volume = {9},
  number = {11},
  pages = {e112302},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0112302},
  abstract = {Comparisons of residues between sub-types of influenza virus is increasingly used to assess the zoonotic potential of a circulating strain and for comparative studies across subtypes. An analysis of N-terminal cleavage sites for thirteen subtypes of influenza A hemagglutinin (HA) sequences, has previously been described by Nobusawa and colleagues. We have expanded this analysis for the eighteen known subtypes of influenza. Due to differences in the length of HA, we have included strains from multiple clades of H1 and H5, as well as strains of H5 and H7 subtypes with both high and low pathogenicity. Analysis of known structures of influenza A HA enables us to define amino acids which are structurally and functionally equivalent across all HA subtypes using a numbering system based on the mature HA sequence. We provide a list of equivalences for amino acids which are known to affect the phenotype of the virus.},
  langid = {english},
  pmcid = {PMC4229193},
  pmid = {25391151},
  keywords = {Amino Acid Sequence,Hemagglutinins,Humans,Influenza A virus,Influenza; Human,Molecular Sequence Data,Phenotype,Sequence Alignment}
}

@article{cai2010,
  title = {A Computational Framework for Influenza Antigenic Cartography},
  author = {Cai, Zhipeng and Zhang, Tong and Wan, Xiu-Feng},
  editor = {Fraser, Christophe},
  year = {2010-10-07, 2010-10},
  journal = {PLoS Computational Biology},
  volume = {6},
  number = {10},
  pages = {e1000949},
  doi = {10.1371/journal.pcbi.1000949},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\CU7VS87J\\Cai et al. - 2010 - A computational framework for influenza antigenic .pdf}
}

@article{cai2012,
  title = {Antigenic Distance Measurements for Seasonal Influenza Vaccine Selection},
  author = {Cai, Zhipeng and Zhang, Tong and Wan, Xiu-Feng},
  year = {2012},
  month = jan,
  journal = {Vaccine},
  volume = {30},
  number = {2},
  pages = {448--453},
  doi = {10.1016/j.vaccine.2011.10.051},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\66AC2ELC\\Cai et al. - 2012 - Antigenic distance measurements for seasonal influ.pdf}
}

@article{carreno2020,
  title = {H1 {{Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity}} against {{H5N1 Challenge}} in the {{Mouse Model}}},
  author = {Carre{\~n}o, Juan Manuel and Strohmeier, Shirin and Kirkpatrick Roubidoux, Ericka and Hai, Rong and Palese, Peter and Krammer, Florian},
  year = {2020},
  month = dec,
  journal = {mBio},
  volume = {11},
  number = {6},
  pages = {e02090-20},
  publisher = {{American Society for Microbiology}},
  doi = {10.1128/mBio.02090-20},
  urldate = {2023-03-02},
  abstract = {Influenza virus infections leave a signature of immune memory that influences future responses to infections with antigenically related strains. It has been hypothesized that the first exposure in life to H1N1 influenza virus imprints the host immune system, potentially resulting in protection from severe infection with H5N1 later in life through hemagglutinin (HA) stalk-specific antibodies. To study the specific role of the HA on protection against infection without interference of cellular immunity or humoral antineuraminidase immunity, we primed mice with influenza B viruses that express an H1 HA (group 1; B-H1), H3 HA (group 2; B-H3), or wild-type influenza B virus and subsequently challenged them at different time points with an H5N1 virus. Weight loss and survival monitoring showed that the B-H1-primed mice exhibited better protection against H5N1 compared to the control mice. Analysis of H5-specific serum IgG, before and 21\,days after H5N1 challenge, evidenced the presence of anti-stalk H5 cross-reactive antibodies in the BH-1 group that were boosted by H5N1 infection. The increased immune responses and protection induced by priming with the B-H1 viruses lasted at least up to 1 year. Hence, a single HA priming based on natural infection induces long-lasting protective immunity against heterosubtypic strains from the same phylogenetic HA group in mice. This study gives mechanistic support to the earlier finding in humans that imprinting by H1 HA protects against H5N1 infections and that highly conserved regions on the HA, like the stalk, are involved in this phenomenon. IMPORTANCE Current studies point out that an HA-mediated immunological imprint is established early in life during the first exposure to influenza viruses, which critically shapes and biases future immune responses. However, studies in animal models are limited and the precise mechanisms of this phenomenon are under investigation. Studies that explore the effect of HA-specific immunity induced during natural infection on future exposures to heterosubtypic influenza strains are needed.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\QR5HR2AJ\\CarreÃ±o et al. - 2020 - H1 Hemagglutinin Priming Provides Long-Lasting Het.pdf}
}

@article{carter2019,
  title = {Safety and Immunogenicity of Investigational Seasonal Influenza Hemagglutinin {{DNA}} Vaccine Followed by Trivalent Inactivated Vaccine Administered Intradermally or Intramuscularly in Healthy Adults: {{An}} Open-Label Randomized Phase 1 Clinical Trial},
  shorttitle = {Safety and Immunogenicity of Investigational Seasonal Influenza Hemagglutinin {{DNA}} Vaccine Followed by Trivalent Inactivated Vaccine Administered Intradermally or Intramuscularly in Healthy Adults},
  author = {Carter, Cristina and Houser, Katherine V. and Yamshchikov, Galina V. and Bellamy, Abbie R. and May, Jeanine and Enama, Mary E. and Sarwar, Uzma and Larkin, Brenda and Bailer, Robert T. and Koup, Richard and Chen, Grace L. and Patel, Shital M. and Winokur, Patricia and Belshe, Robert and Dekker, Cornelia L. and Graham, Barney S. and Ledgerwood, Julie E. and {VRC 703 study team}},
  year = {2019},
  journal = {PLoS One},
  volume = {14},
  number = {9},
  pages = {e0222178},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0222178},
  abstract = {BACKGROUND: Seasonal influenza results in significant morbidity and mortality worldwide, but the currently licensed inactivated vaccines generally have low vaccine efficacies and could be improved. In this phase 1 clinical trial, we compared seasonal influenza vaccine regimens with different priming strategies, prime-boost intervals, and administration routes to determine the impact of these variables on the resulting antibody response. METHODS: Between August 17, 2012 and January 25, 2013, four sites enrolled healthy adults 18-70 years of age. Subjects were randomized to receive one of the following vaccination regimens: trivalent hemagglutinin (HA) DNA prime followed by trivalent inactivated influenza vaccine (IIV3) boost with a 3.5 month interval (DNA-IIV3), IIV3 prime followed by IIV3 boost with a 10 month interval (IIV3-IIV3), or concurrent DNA and IIV3 prime followed by IIV3 boost with a 10 month interval (DNA/IIV3-IIV3). Each regimen was additionally stratified by an IIV3 administration route of either intramuscular (IM) or intradermal (ID). DNA vaccines were administered by a needle-free jet injector (Biojector). Study objectives included evaluating the safety and tolerability of each regimen and measuring the antibody response by hemagglutination inhibition (HAI). RESULTS: Three hundred and sixteen subjects enrolled. Local reactogenicity was mild to moderate in severity, with higher frequencies recorded following DNA vaccine administered by Biojector compared to IIV3 by either route (p {$<$}0.02 for pain, swelling, and redness) and following IIV3 by ID route compared to IM route (p {$<$}0.001 for swelling and redness). Systemic reactogenicity was similar between regimens. Though no overall differences were observed between regimens, the highest titers post boost were observed in the DNA-IIV3 group by ID route and in the IIV3-IIV3 group by IM route. CONCLUSIONS: All vaccination regimens were found to be safe and tolerable. While there were no overall differences between regimens, the DNA-IIV3 group by ID route, and the IIV3-IIV3 group by IM route, showed higher responses compared to the other same-route regimens.},
  langid = {english},
  pmcid = {PMC6750650},
  pmid = {31532789},
  keywords = {Administration; Intranasal,Adult,Aged,Female,Healthy Volunteers,Hemagglutinins,Humans,Immunization; Secondary,Influenza Vaccines,Influenza; Human,Injections; Intradermal,Male,Middle Aged,Vaccines; DNA,Vaccines; Inactivated,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\A675TH2Y\\Carter et al. - 2019 - Safety and immunogenicity of investigational seaso.pdf}
}

@article{castro2020,
  title = {Early Prediction of Antigenic Transitions for Influenza {{A}}/{{H3N2}}},
  author = {Castro, Lauren A. and Bedford, Trevor and Ancel Meyers, Lauren},
  editor = {Kouyos, Roger Dimitri},
  year = {2020-02-18, 2020-02},
  journal = {PLOS Computational Biology},
  volume = {16},
  number = {2},
  pages = {e1007683},
  doi = {10.1371/journal.pcbi.1007683},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\JLI5UTTR\\Castro et al. - 2020 - Early prediction of antigenic transitions for infl.pdf}
}

@misc{cdc2021,
  title = {Estimated {{Flu-Related Illnesses}}, {{Medical}} Visits, {{Hospitalizations}}, and {{Deaths}} in the {{United States}} \textemdash{} 2018\textendash 2019 {{Flu Season}} | {{CDC}}},
  author = {{CDC}},
  year = {2021},
  month = oct,
  urldate = {2021-11-29},
  abstract = {CDC calculates estimates of disease burden in the United States using surveillance data and modeling to adjust for sources of under-detection. Burden estimates for the 2018-2019 season found here.},
  howpublished = {https://www.cdc.gov/flu/about/burden/2018-2019.html},
  langid = {american},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\YBHMIATU\\2018-2019.html}
}

@misc{cdc2023,
  title = {{{H5N1 Update}}: {{Two Human H5N1 Cases}} in {{Cambodia}}},
  shorttitle = {{{H5N1 Update}}},
  author = {CDC},
  year = {2023},
  month = feb,
  journal = {Centers for Disease Control and Prevention},
  urldate = {2023-03-21},
  abstract = {Learn about what CDC is doing and risk and prevention in the U.S.},
  howpublished = {https://www.cdc.gov/flu/avianflu/human-cases-cambodia.htm},
  langid = {american},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\N3IXN2E4\\human-cases-cambodia.html}
}

@article{chambers2018,
  title = {Should {{Sex Be Considered}} an {{Effect Modifier}} in the {{Evaluation}} of {{Influenza Vaccine Effectiveness}}?},
  author = {Chambers, Catharine and Skowronski, Danuta M and Rose, Caren and Serres, Gaston De and Winter, Anne-Luise and Dickinson, James A and Jassem, Agatha and Gubbay, Jonathan B and Fonseca, Kevin and Drews, Steven J and Charest, Hugues and Martineau, Christine and Petric, Martin and Krajden, Mel},
  year = {2018},
  month = sep,
  journal = {Open Forum Infect Dis},
  volume = {5},
  number = {9},
  issn = {2328-8957},
  doi = {10.1093/ofid/ofy211},
  urldate = {2021-04-14},
  abstract = {We investigated sex as a potential modifier of influenza vaccine effectiveness (VE) between 2010\textendash 2011 and 2016\textendash 2017 in Canada. Overall VE was 49\% (95\% confidence interval [CI], 43\% to 55\%) for females and 38\% (95\% CI, 28\% to 46\%) for males (absolute difference [AD], 11\%; P = .03). Sex differences were greatest for influenza A(H3N2) (AD, 17\%; P = .07) and B(Victoria) (AD, 20\%; P = .08) compared with A(H1N1)pdm09 (AD, 10\%; P = .19) or B(Yamagata) (AD, \textendash 3\%; P = .68). They were also more pronounced in older adults {$\geq$}50 years (AD, 19\%; P = .03) compared with those {$<$}20 years (AD, 4\%; P = .74) or 20\textendash 49 years (AD, \textendash 1\%; P = .90) but with variation by subtype/lineage. More definitive investigations of VE by sex and age are warranted to elucidate these potential interactions.},
  pmcid = {PMC6143149},
  pmid = {30263903},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\CKY4DQ5T\\Chambers et al. - 2018 - Should Sex Be Considered an Effect Modifier in the.pdf}
}

@article{chang2019,
  title = {Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Adults {$\geq$}65\,years of Age: {{A}} Phase 3 Randomized Clinical Trial},
  shorttitle = {Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Adults {$\geq$}65\,years of Age},
  author = {Chang, Lee-Jah and Meng, Ya and Janosczyk, Helene and Landolfi, Victoria and Talbot, H. Keipp and {QHD00013 Study Group}},
  year = {2019},
  month = sep,
  journal = {Vaccine},
  volume = {37},
  number = {39},
  pages = {5825--5834},
  issn = {1873-2518},
  doi = {10.1016/j.vaccine.2019.08.016},
  abstract = {BACKGROUND: A high-dose, split-virion inactivated trivalent influenza vaccine (IIV3-HD; Fluzone\textregistered{} High-Dose, Sanofi Pasteur) is available for adults {$\geq$}65\,years of age. This study examined the safety and immunogenicity of a quadrivalent high-dose split-virion inactivated influenza vaccine (IIV4-HD). METHODS: This was a randomized, modified double-blind, active-controlled, multi-center trial in healthy adults {$\geq$}65\,years of age. Subjects were randomized in a 4:1:1 ratio to receive a single intramuscular injection of IIV4-HD, the licensed IIV3-HD, or an IIV3-HD containing the alternate B-lineage strain. Hemagglutination inhibition (HAI), seroneutralisation, and anti-neuraminidase antibody titers were measured at baseline and day 28. Solicited reactions were collected for up to 7\,days, unsolicited adverse events up to 28\,days, and serious adverse events up to 180\,days. The primary immunogenicity objective was to demonstrate that IIV4-HD induces HAI geometric mean titers (GMTs) and seroconversion rates that are non-inferior to those induced by IIV3-HD. Secondary objectives were to describe the safety of IIV4-HD and IIV3-HD and to demonstrate that IIV4-HD induces HAI GMTs and seroconversion rates that are superior to those induced by IIV3-HD not containing the same B-lineage strain. RESULTS: The study included 2670 adults {$\geq$}65\,years of age. For all four strains, HAI GMTs and seroconversion rates induced by IIV4-HD were non-inferior to those induced by IIV3-HDs containing the same strains. For both B strains, HAI GMTs and seroconversion rates induced by IIV4-HD were superior to those induced by IIV3-HD not containing the same B-lineage strain. Seroneutralisation and anti-neuraminidase antibody responses, measured in a subset of subjects, were similar. No new safety concerns were identified, and the safety profiles of IIV4-HD and IIV3-HD were similar. CONCLUSIONS: Adding a second B strain in IIV4-HD resulted in improved immunogenicity against the added strain without compromising the immunogenicity of the other strains or the vaccine's tolerability. CLINICAL TRIAL REGISTRATION: NCT03282240.},
  langid = {english},
  pmid = {31431411},
  keywords = {Aged,Antibodies; Viral,Clinical trial,Double-Blind Method,Drug-Related Side Effects and Adverse Reactions,Elderly adults,Female,Hemagglutination Inhibition Tests,High-dose influenza vaccine,Humans,Immunogenicity,Immunogenicity; Vaccine,Influenza B virus,Influenza Vaccines,Influenza; Human,Injections; Intramuscular,Male,Neuraminidase,Quadrivalent influenza vaccine,Safety,Vaccines; Inactivated,Virion},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\HPZ8VGL7\\Chang et al. - 2019 - Safety and immunogenicity of high-dose quadrivalen.pdf}
}

@article{chen2018,
  title = {Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies},
  author = {Chen, Yao-Qing and Wohlbold, Teddy John and Zheng, Nai-Ying and Huang, Min and Huang, Yunping and Neu, Karlynn E. and Lee, Jiwon and Wan, Hongquan and Rojas, Karla Thatcher and Kirkpatrick, Ericka and Henry, Carole and Palm, Anna-Karin E. and Stamper, Christopher T. and Lan, Linda Yu-Ling and Topham, David J. and Treanor, John and Wrammert, Jens and Ahmed, Rafi and Eichelberger, Maryna C. and Georgiou, George and Krammer, Florian and Wilson, Patrick C.},
  year = {2018},
  month = apr,
  journal = {Cell},
  volume = {173},
  number = {2},
  pages = {417--429.e10},
  doi = {10.1016/j.cell.2018.03.030},
  langid = {english}
}

@article{cobey2017,
  title = {Immune History and Influenza Virus Susceptibility},
  author = {Cobey, Sarah and Hensley, Scott E.},
  year = {2017},
  month = feb,
  journal = {Curr Opin Virol},
  volume = {22},
  pages = {105--111},
  issn = {1879-6257},
  doi = {10.1016/j.coviro.2016.12.004},
  urldate = {2021-06-09},
  abstract = {Antibody responses to influenza viruses are critical for protection, but the ways in which repeated viral exposures shape antibody evolution and effectiveness over time remain controversial. Early observations demonstrated that the history of viral exposures has a profound effect on the specificity and magnitude of antibody responses to a new viral strain, a phenomenon called ``original antigenic sin.'' Although ``sin'' might suppress some aspects of the immune response, so far there is little indication that hosts with pre-existing immunity are more susceptible to viral infections compared to na\"ive hosts. However, the tendency of the immune response to focus on previously recognized conserved epitopes when encountering new viral strains can create an opportunity cost when mutations arise in these conserved epitopes. Hosts with different exposure histories may continue to experience distinct patterns of infection over time, which may influence influenza viruses' continued antigenic evolution. Understanding the dynamics of B cell competition that underlie the development of antibody responses might help explain the low effectiveness of current influenza vaccines and lead to better vaccination strategies.},
  pmcid = {PMC5467731},
  pmid = {28088686},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\EV6XV8NI\\Cobey and Hensley - 2017 - Immune history and influenza virus susceptibility.pdf}
}

@article{cobey2018,
  title = {Repeated {{Vaccination May Protect Children From Influenza Infection}}},
  author = {Cobey, Sarah},
  year = {2018},
  month = oct,
  journal = {JAMA Network Open},
  volume = {1},
  number = {6},
  pages = {e183730},
  issn = {2574-3805},
  doi = {10.1001/jamanetworkopen.2018.3730},
  urldate = {2023-03-21},
  abstract = {Influenza infections in children are problematic not only for the immediate symptoms they cause but also for their potentially large contribution to influenza infections in other age groups. Since 2008, the Advisory Committee on Immunization Practices has recommended that all children at least 6 months old be vaccinated annually against influenza. By historical standards, vaccination coverage in children in the United States is high, with nearly 60\% of children younger than age 18 years and 76\% of children aged 6 to 23 months receiving an influenza vaccine in the 2016-2017 season. Vaccination coverage in children has also expanded in the United Kingdom, where indirect benefits on other age groups have been observed.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\TQC76ARZ\\Cobey - 2018 - Repeated Vaccination May Protect Children From Inf.pdf;C\:\\Users\\Zane\\Zotero\\storage\\X4DC8M2D\\2709711.html}
}

@article{coleman2012,
  title = {Immunogenicity of a Half-Dose of Adjuvanted 2009 Pandemic {{H1N1}} Influenza Vaccine in Adults: A Prospective Cohort Study},
  shorttitle = {Immunogenicity of a Half-Dose of Adjuvanted 2009 Pandemic {{H1N1}} Influenza Vaccine in Adults},
  author = {Coleman, B. L. and Kuster, S. P. and Gubbay, J. and Scheifele, D. and Li, Y. and Low, D. and Crowcroft, N. and Mazzulli, T. and Shi, L. and Halperin, S. A. and Law, B. and McGeer, A. and {Working Adults Influenza Cohort Study Group}},
  year = {2012},
  month = apr,
  journal = {Eur J Clin Microbiol Infect Dis},
  volume = {31},
  number = {4},
  pages = {591--597},
  issn = {1435-4373},
  doi = {10.1007/s10096-011-1352-5},
  abstract = {We aimed to assess the immunogenicity of a single half-dose of AS03-adjuvanted monovalent 2009 pandemic H1N1 vaccine in healthy adults. Healthy subjects age 20-60~years were prospectively enrolled in a cohort receiving intramuscular administration of a single half-dose (1.875~{$\mu$}g of hemagglutinin [HA]) of adjuvanted 2009 pandemic H1N1 influenza vaccine. Data from participants enrolled in a concomitant study of immunogenicity following a full-dose (3.75~{$\mu$}g of HA) are presented concurrently. Sera for assessment of hemagglutination-inhibiting (HAI) antibody to the vaccine strain were obtained before and 14 or 21~days after vaccination. Ninety-seven participants received a half-dose and 50 received a full-dose of vaccine. In the half-dose cohort, Food and Drug Administration criteria for immunogenicity regarding seroprotection and seroconversion rates were met for subjects aged 20-45~years, but not for those aged 46-60~years. There was no statistically significant difference in the proportion of individuals achieving a post-vaccination HAI titre of {$\geq$}1:40, the geometric mean titres of post-vaccination antibody, or the proportion of individuals with a four-fold or greater increase in antibody levels between the two cohorts. Participants 46-60~years of age were significantly less likely to be seroprotected at day 21 than those 20-45~years old in both cohorts. Immunogenicity of a half dose of adjuvanted pH1N1 influenza vaccine was adequate in subjects aged 20-45~years. Dose reduction is a possible strategy for expanding the availability in the event of vaccine shortage in this age group.},
  langid = {english},
  pmid = {21796343},
  keywords = {Adjuvants; Immunologic,Adult,Age Factors,Antibodies; Viral,Cohort Studies,Female,Hemagglutination Inhibition Tests,Humans,Influenza A Virus; H1N1 Subtype,Influenza Vaccines,Influenza; Human,Injections; Intramuscular,Male,Middle Aged,Prospective Studies}
}

@article{coudeville2010,
  type = {Journal Article},
  title = {Relationship between Haemagglutination-Inhibiting Antibody Titres and Clinical Protection against Influenza: Development and Application of a Bayesian Random-Effects Model},
  author = {Coudeville, Laurent and Bailleux, Fabrice and Riche, Benjamin and Megas, Fran{\c c}oise and Andre, Philippe and Ecochard, Ren{\'e}},
  year = {2010},
  journal = {BMC Medical Research Methodology},
  volume = {10},
  number = {1},
  pages = {18},
  issn = {1471-2288},
  doi = {10.1186/1471-2288-10-18},
  abstract = {Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50\% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.}
}

@article{cowling2019,
  title = {Influenza {{Hemagglutination-inhibition Antibody Titer}} as a {{Mediator}} of {{Vaccine-induced Protection}} for {{Influenza B}}},
  author = {Cowling, Benjamin J and Lim, Wey Wen and Perera, Ranawaka A P M and Fang, Vicky J and Leung, Gabriel M and Peiris, J S Malik and Tchetgen Tchetgen, Eric J},
  year = {2019},
  month = may,
  journal = {Clin Infect Dis},
  volume = {68},
  number = {10},
  pages = {1713--1717},
  issn = {1058-4838},
  doi = {10.1093/cid/ciy759},
  urldate = {2021-06-24},
  abstract = {Influenza vaccination increases protection against influenza virus infection. In this study, we estimated that 57\% of the increase in protection can be attributed to the higher antibody titer after vaccination measured by the hemagglutination inhibition assay.},
  pmcid = {PMC6495017},
  pmid = {30202873},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\VST7N24P\\Cowling et al. - 2019 - Influenza Hemagglutination-inhibition Antibody Tit.pdf}
}

@article{cowling2020,
  title = {Comparative {{Immunogenicity}} of {{Several Enhanced Influenza Vaccine Options}} for {{Older Adults}}: {{A Randomized}}, {{Controlled Trial}}},
  shorttitle = {Comparative {{Immunogenicity}} of {{Several Enhanced Influenza Vaccine Options}} for {{Older Adults}}},
  author = {Cowling, Benjamin J and Perera, Ranawaka A P M and Valkenburg, Sophie A and Leung, Nancy H L and Iuliano, A Danielle and Tam, Yat Hung and Wong, Jennifer H F and Fang, Vicky J and Li, Athena P Y and So, Hau Chi and Ip, Dennis K M and {Azziz-Baumgartner}, Eduardo and Fry, Alicia M and Levine, Min Z and Gangappa, Shivaprakash and Sambhara, Suryaprakash and Barr, Ian G and Skowronski, Danuta M and Peiris, J S Malik and Thompson, Mark G},
  year = {2020},
  month = oct,
  journal = {Clinical Infectious Diseases},
  volume = {71},
  number = {7},
  pages = {1704--1714},
  issn = {1058-4838},
  doi = {10.1093/cid/ciz1034},
  urldate = {2023-03-14},
  abstract = {Enhanced influenza vaccines may improve protection for older adults, but comparative immunogenicity data are limited. Our objective was to examine immune responses to enhanced influenza vaccines, compared to standard-dose vaccines, in community-dwelling older adults.Community-dwelling older adults aged 65\textendash 82 years in Hong Kong were randomly allocated (October 2017\textendash January 2018) to receive 2017\textendash 2018 Northern hemisphere formulations of a standard-dose quadrivalent vaccine, MF59-adjuvanted trivalent vaccine, high-dose trivalent vaccine, or recombinant-hemagglutinin (rHA) quadrivalent vaccine. Sera collected from 200 recipients of each vaccine before and at 30-days postvaccination were assessed for antibodies to egg-propagated vaccine strains by hemagglutination inhibition (HAI) and to cell-propagated A/Hong Kong/4801/2014(H3N2) virus by microneutralization (MN). Influenza-specific CD4+ and CD8+ T cell responses were assessed in 20 participants per group.Mean fold rises (MFR) in HAI titers to egg-propagated A(H1N1) and A(H3N2) and the MFR in MN to cell-propagated A(H3N2) were statistically significantly higher in the enhanced vaccine groups, compared to the standard-dose vaccine. The MFR in MN to cell-propagated A(H3N2) was highest among rHA recipients (4.7), followed by high-dose (3.4) and MF59-adjuvanted (2.9) recipients, compared to standard-dose recipients (2.3). Similarly, the ratio of postvaccination MN titers among rHA recipients to cell-propagated A(H3N2) recipients was 2.57-fold higher than the standard-dose vaccine, which was statistically higher than the high-dose (1.33-fold) and MF59-adjuvanted (1.43-fold) recipient ratios. Enhanced vaccines also resulted in the boosting of T-cell responses.In this head-to-head comparison, older adults receiving enhanced vaccines showed improved humoral and cell-mediated immune responses, compared to standard-dose vaccine recipients.NCT03330132.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\IXL8REDS\\Cowling et al. - 2020 - Comparative Immunogenicity of Several Enhanced Inf.pdf;C\:\\Users\\Zane\\Zotero\\storage\\KL3NKH4Q\\5673516.html}
}

@article{davila2014,
  title = {Substantial {{Morbidity}} and {{Mortality Associated}} with {{Pandemic A}}/{{H1N1 Influenza}} in {{Mexico}}, {{Winter}} 2013-2014: {{Gradual Age Shift}} and {{Severity}}},
  shorttitle = {Substantial {{Morbidity}} and {{Mortality Associated}} with {{Pandemic A}}/{{H1N1 Influenza}} in {{Mexico}}, {{Winter}} 2013-2014},
  author = {D{\'a}vila, Javier and Chowell, Gerardo and {Borja-Aburto}, V{\'i}ctor H. and Viboud, C{\'e}cile and Grajales Mu{\~n}iz, Concepci{\`o}n and Miller, Mark},
  year = {2014},
  month = mar,
  journal = {PLoS Curr},
  volume = {6},
  pages = {ecurrents.outbreaks.a855a92f19db1d90ca955f5e908d6631},
  issn = {2157-3999},
  doi = {10.1371/currents.outbreaks.a855a92f19db1d90ca955f5e908d6631},
  abstract = {BACKGROUND: A recrudescent wave of pandemic influenza A/H1N1 is underway in Mexico in winter 2013-14, following a mild 2012-13 A/H3N2 influenza season. Mexico previously experienced several waves of pandemic A/H1N1 activity in spring, summer and fall 2009 and winter 2011-2012, with a gradual shift of influenza-related hospitalizations and deaths towards older ages. Here we describe changes in the epidemiology of the 2013-14 A/H1N1 influenza outbreak, relative to previous seasons dominated by the A/H1N1 pandemic virus. The analysis is intended to guide public health intervention strategies in near real time. METHODS: We analyzed demographic and geographic data on hospitalizations with severe acute respiratory infection (SARI), laboratory-confirmed A/H1N1 influenza hospitalizations, and inpatient deaths, from a large prospective surveillance system maintained by the Mexican Social Security medical system during 01-October 2013 to 31-Jan 2014. We characterized the age and regional patterns of influenza activity relative to the preceding 2011-2012 A/H1N1 influenza epidemic. We also estimated the reproduction number (R) based on the growth rate of daily case incidence by date of symptoms onset. RESULTS: A total of 7,886 SARI hospitalizations and 529 inpatient-deaths (3.2\%) were reported between 01-October 2013 and 31-January 2014 (resulting in 3.2 laboratory-confirmed A/H1N1 hospitalizations per 100,00 and 0.52 laboratory-confirmed A/H1N1-positive deaths per 100,000). The progression of daily SARI hospitalizations in 2013-14 exceeded that observed during the 2011-2012 A/H1N1 epidemic. The mean age of laboratory-confirmed A/H1N1 patients in 2013-14 was 41.1 y (SD=20.3) for hospitalizations and 49.2 y (SD=16.7) for deaths. Rates of laboratory-confirmed A/H1N1 hospitalizations and deaths were significantly higher among individuals aged 30-59 y and lower among younger age groups for the ongoing 2013-2014 epidemic, compared to the 2011-12 A/H1N1 epidemic (Chi-square test, P{$<$}0.001). The reproduction number of the winter 2013-14 wave in central Mexico was estimated at 1.3-1.4 which is slightly higher than that reported for the 2011-2012 A/H1N1 epidemic. CONCLUSIONS: We have documented a substantial and ongoing increase in the number of A/H1N1-related hospitalizations and deaths during the period October 2013-January 2014 and a proportionate shift of severe disease to middle aged adults, relative to the preceding A/H1N1 2011-2012 epidemic in Mexico. In the absence of clear antigenic drift in globally circulating A/H1N1 viruses in the post-pandemic period, the gradual change in the age distribution of A/H1N1 infections observed in Mexico suggests a slow build-up of immunity among younger populations, reminiscent of the age profile of past pandemics.},
  langid = {english},
  pmcid = {PMC3967911},
  pmid = {24744975},
  keywords = {A/H1N1,Influenza,Mexico,Pandemic},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\4MDYDKNR\\DÃ¡vila et al. - 2014 - Substantial Morbidity and Mortality Associated wit.pdf}
}

@article{dawood2021,
  title = {Comparison of the {{Immunogenicity}} of {{Cell Culture-Based}} and {{Recombinant Quadrivalent Influenza Vaccines}} to {{Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged}} 18\textendash 64 {{Years}}: {{A Randomized Open-Label Trial}}},
  shorttitle = {Comparison of the {{Immunogenicity}} of {{Cell Culture-Based}} and {{Recombinant Quadrivalent Influenza Vaccines}} to {{Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged}} 18\textendash 64 {{Years}}},
  author = {Dawood, Fatimah S and Naleway, Allison L and Flannery, Brendan and Levine, Min Z and Murthy, Kempapura and Sambhara, Suryaprakash and Gangappa, Shivaprakash and Edwards, Laura and Ball, Sarah and Grant, Lauren and Belongia, Edward and Bounds, Kelsey and Cao, Weiping and Gross, F Liaini and Groom, Holly and Fry, Alicia M and Rentz Hunt, Danielle and Jeddy, Zuha and Mishina, Margarita and Kim, Sara S and Wesley, Meredith G and Spencer, Sarah and Thompson, Mark G and Gaglani, Manjusha},
  year = {2021},
  month = dec,
  journal = {Clinical Infectious Diseases},
  volume = {73},
  number = {11},
  pages = {1973--1981},
  issn = {1058-4838, 1537-6591},
  doi = {10.1093/cid/ciab566},
  urldate = {2023-03-21},
  abstract = {Background.{$\quad$} RIV4 and cell-culture based inactivated influenza vaccine (ccIIV4) have not been compared to egg-based IIV4 in healthcare personnel, a population with frequent influenza vaccination that may blunt vaccine immune responses over time. We conducted a randomized trial among healthcare personnel (HCP) aged 18\textendash 64 years to compare humoral immune responses to ccIIV4 and RIV4 to IIV4. Methods.{$\quad$} During the 2018\textendash 2019 season, participants were randomized to receive ccIIV4, RIV4, or IIV4 and had serum samples collected prevaccination, 1 and 6 months postvaccination. Serum samples were tested by hemagglutination inhibition (HI) for influenza A/H1N1, B/Yamagata, and B/Victoria and microneutralization (MN) for A/H3N2 against cell-grown vaccine reference viruses. Primary outcomes at 1 month were seroconversion rate (SCR), geometric mean titers (GMT), GMT ratio, and mean fold rise (MFR) in the intention-to-treat population. Results.{$\quad$} In total, 727 participants were included (283 ccIIV4, 202 RIV4, and 242 IIV4). At 1 month, responses to ccIIV4 were similar to IIV4 by SCR, GMT, GMT ratio, and MFR. RIV4 induced higher SCRs, GMTs, and MFRs than IIV4 against A/H1N1, A/ H3N2, and B/Yamagata. The GMT ratio of RIV4 to egg-based vaccines was 1.5 (95\% confidence interval [CI] 1.2\textendash 1.9) for A/H1N1, 3.0 (95\% CI: 2.4\textendash 3.7) for A/H3N2, 1.1 (95\% CI: .9\textendash 1.4) for B/Yamagata, and 1.1 (95\% CI: .9\textendash 1.3) for B/Victoria. At 6 months, ccIIV4 recipients had similar GMTs to IIV4, whereas RIV4 recipients had higher GMTs against A/H3N2 and B/Yamagata. Conclusions.{$\quad$} RIV4 resulted in improved antibody responses by HI and MN compared to egg-based vaccines against 3 of 4 cellgrown vaccine strains 1 month postvaccination, suggesting a possible additional benefit from RIV4. Clinical Trials Registration:{$\quad$}NCT03722589.},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\XMN8ZR7S\\Dawood et al. - 2021 - Comparison of the Immunogenicity of Cell Culture-B.PDF}
}

@article{deem2009,
  title = {The Epitope Regions of {{H1-subtype}} Influenza {{A}}, with Application to Vaccine Efficacy},
  author = {Deem, M. W. and Pan, K.},
  year = {2009-07-03, 2009-07},
  journal = {Protein Engineering Design and Selection},
  volume = {22},
  number = {9},
  pages = {543--546},
  doi = {10.1093/protein/gzp027},
  langid = {english}
}

@article{desikan2022,
  title = {Vaccine Models Predict Rules for Updating Vaccines against Evolving Pathogens Such as {{SARS-CoV-2}} and Influenza in the Context of Pre-Existing Immunity},
  author = {Desikan, Rajat and Linderman, Susanne L. and Davis, Carl and Zarnitsyna, Veronika I. and Ahmed, Hasan and Antia, Rustom},
  year = {2022},
  journal = {Frontiers in Immunology},
  volume = {13},
  issn = {1664-3224},
  urldate = {2023-03-21},
  abstract = {Currently, vaccines for SARS-CoV-2 and influenza viruses are updated if the new vaccine induces higher antibody-titers to circulating variants than current vaccines. This approach does not account for complex dynamics of how prior immunity skews recall responses to the updated vaccine. We: (i) use computational models to mechanistically dissect how prior immunity influences recall responses; (ii) explore how this affects the rules for evaluating and deploying updated vaccines; and (iii) apply this to SARS-CoV-2. Our analysis of existing data suggests that there is a strong benefit to updating the current SARS-CoV-2 vaccines to match the currently circulating variants. We propose a general two-dose strategy for determining if vaccines need updating as well as for vaccinating high-risk individuals. Finally, we directly validate our model by reanalysis of earlier human H5N1 influenza vaccine studies.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\PGN7CTUF\\Desikan et al. - 2022 - Vaccine models predict rules for updating vaccines.pdf}
}

@article{dhakal2019,
  title = {Host {{Factors Impact Vaccine Efficacy}}: {{Implications}} for {{Seasonal}} and {{Universal Influenza Vaccine Programs}}},
  shorttitle = {Host {{Factors Impact Vaccine Efficacy}}},
  author = {Dhakal, Santosh and Klein, Sabra L.},
  year = {2019},
  month = oct,
  journal = {J Virol},
  volume = {93},
  number = {21},
  pages = {e00797-19},
  issn = {0022-538X},
  doi = {10.1128/JVI.00797-19},
  urldate = {2022-12-02},
  abstract = {Influenza is a global public health problem. Current seasonal influenza vaccines have highly variable efficacy, and thus attempts to develop broadly protective universal influenza vaccines with durable protection are under way. While much attention is given to the virus-related factors contributing to inconsistent vaccine responses, host-associated factors are often neglected., Influenza is a global public health problem. Current seasonal influenza vaccines have highly variable efficacy, and thus attempts to develop broadly protective universal influenza vaccines with durable protection are under way. While much attention is given to the virus-related factors contributing to inconsistent vaccine responses, host-associated factors are often neglected. Growing evidences suggest that host factors including age, biological sex, pregnancy, and immune history play important roles as modifiers of influenza virus vaccine efficacy. We hypothesize that host genetics, the hormonal milieu, and gut microbiota contribute to host-related differences in influenza virus vaccine efficacy. This review highlights the current insights and future perspectives into host-specific factors that impact influenza vaccine-induced immunity and protection. Consideration of the host factors that affect influenza vaccine-induced immunity might improve influenza vaccines by providing empirical evidence for optimizing or even personalizing vaccine type, dose, and use of adjuvants for current seasonal and future universal influenza vaccines.},
  pmcid = {PMC6803252},
  pmid = {31391269},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\2DMPTNFD\\Dhakal and Klein - 2019 - Host Factors Impact Vaccine Efficacy Implications.pdf}
}

@article{diazgranados2014,
  title = {Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults},
  author = {DiazGranados, Carlos A. and Dunning, Andrew J. and Kimmel, Murray and Kirby, Daniel and Treanor, John and Collins, Avi and Pollak, Richard and Christoff, Janet and Earl, John and Landolfi, Victoria and Martin, Earl and Gurunathan, Sanjay and Nathan, Richard and Greenberg, David P. and Tornieporth, Nadia G. and Decker, Michael D. and Talbot, H. Keipp},
  year = {2014},
  month = aug,
  journal = {N Engl J Med},
  volume = {371},
  number = {7},
  pages = {635--645},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1315727},
  abstract = {BACKGROUND: As compared with a standard-dose vaccine, a high-dose, trivalent, inactivated influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 years of age or older. This study evaluated whether IIV3-HD also improves protection against laboratory-confirmed influenza illness. METHODS: We conducted a phase IIIb-IV, multicenter, randomized, double-blind, active-controlled trial to compare IIV3-HD (60 {$\mu$}g of hemagglutinin per strain) with standard-dose trivalent, inactivated influenza vaccine (IIV3-SD [15 {$\mu$}g of hemagglutinin per strain]) in adults 65 years of age or older. Assessments of relative efficacy, effectiveness, safety (serious adverse events), and immunogenicity (hemagglutination-inhibition [HAI] titers) were performed during the 2011-2012 (year 1) and the 2012-2013 (year 2) northern-hemisphere influenza seasons. RESULTS: A total of 31,989 participants were enrolled from 126 research centers in the United States and Canada (15,991 were randomly assigned to receive IIV3-HD, and 15,998 to receive IIV3-SD). In the intention-to-treat analysis, 228 participants in the IIV3-HD group (1.4\%) and 301 participants in the IIV3-SD group (1.9\%) had laboratory-confirmed influenza caused by any viral type or subtype associated with a protocol-defined influenza-like illness (relative efficacy, 24.2\%; 95\% confidence interval [CI], 9.7 to 36.5). At least one serious adverse event during the safety surveillance period was reported by 1323 (8.3\%) of the participants in the IIV3-HD group, as compared with 1442 (9.0\%) of the participants in the IIV3-SD group (relative risk, 0.92; 95\% CI, 0.85 to 0.99). After vaccination, HAI titers and seroprotection rates (the percentage of participants with HAI titers {$\geq$} 1:40) were significantly higher in the IIV3-HD group. Conclusions: Among persons 65 years of age or older, IIV3-HD induced significantly higher antibody responses and provided better protection against laboratory-confirmed influenza illness than did IIV3-SD. (Funded by Sanofi Pasteur; ClinicalTrials.gov number, NCT01427309.).},
  langid = {english},
  pmid = {25119609},
  keywords = {Aged,Antibodies; Viral,Chronic Disease,Double-Blind Method,Female,Humans,Influenza Vaccines,Influenza; Human,Intention to Treat Analysis,Male,Orthomyxoviridae,Vaccines; Inactivated}
}

@article{dong2018,
  title = {Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination with Inactivated Influenza Vaccines},
  author = {Dong, Wei and Bhide, Yoshita and Sicca, Federica and Meijerhof, Tjarko and Guilfoyle, Kate and Engelhardt, Othmar G. and Boon, Louis and {de Haan}, Cornelis A. M. and Carnell, George and Temperton, Nigel and {de Vries-Idema}, Jacqueline and Kelvin, David and Huckriede, Anke},
  year = {2018-10-09, 2018-10},
  journal = {Frontiers in Immunology},
  volume = {9},
  doi = {10.3389/fimmu.2018.02312},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\PXBPDY38\\Dong et al. - 2018 - Cross-protective immune responses induced by seque.pdf}
}

@article{dugan2020,
  title = {Preexisting Immunity Shapes Distinct Antibody Landscapes after Influenza Virus Infection and Vaccination in Humans},
  author = {Dugan, Haley L. and Guthmiller, Jenna J. and Arevalo, Philip and Huang, Min and Chen, Yao-Qing and Neu, Karlynn E. and Henry, Carole and Zheng, Nai-Ying and Lan, Linda Yu-Ling and Tepora, Micah E. and Stovicek, Olivia and Bitar, Dalia and Palm, Anna-Karin E. and Stamper, Christopher T. and Changrob, Siriruk and Utset, Henry A. and Coughlan, Lynda and Krammer, Florian and Cobey, Sarah and Wilson, Patrick C.},
  year = {2020},
  month = dec,
  journal = {Sci Transl Med},
  volume = {12},
  number = {573},
  pages = {eabd3601},
  issn = {1946-6242},
  doi = {10.1126/scitranslmed.abd3601},
  abstract = {Humans are repeatedly exposed to variants of influenza virus throughout their lifetime. As a result, preexisting influenza-specific memory B cells can dominate the response after infection or vaccination. Memory B cells recalled by adulthood exposure are largely reactive to conserved viral epitopes present in childhood strains, posing unclear consequences on the ability of B cells to adapt to and neutralize newly emerged strains. We sought to investigate the impact of preexisting immunity on generation of protective antibody responses to conserved viral epitopes upon influenza virus infection and vaccination in humans. We accomplished this by characterizing monoclonal antibodies (mAbs) from plasmablasts, which are predominantly derived from preexisting memory B cells. We found that, whereas some influenza infection-induced mAbs bound conserved and neutralizing epitopes on the hemagglutinin (HA) stalk domain or neuraminidase, most of the mAbs elicited by infection targeted non-neutralizing epitopes on nucleoprotein and other unknown antigens. Furthermore, most infection-induced mAbs had equal or stronger affinity to childhood strains, indicating recall of memory B cells from childhood exposures. Vaccination-induced mAbs were similarly induced from past exposures and exhibited substantial breadth of viral binding, although, in contrast to infection-induced mAbs, they targeted neutralizing HA head epitopes. Last, cocktails of infection-induced mAbs displayed reduced protective ability in mice compared to vaccination-induced mAbs. These findings reveal that both preexisting immunity and exposure type shape protective antibody responses to conserved influenza virus epitopes in humans. Natural infection largely recalls cross-reactive memory B cells against non-neutralizing epitopes, whereas vaccination harnesses preexisting immunity to target protective HA epitopes.},
  langid = {english},
  pmcid = {PMC8115023},
  pmid = {33298562},
  keywords = {Adult,Animals,Antibodies; Neutralizing,Antibodies; Viral,Hemagglutinin Glycoproteins; Influenza Virus,Humans,Influenza Vaccines,Influenza; Human,Mice,Orthomyxoviridae,Orthomyxoviridae Infections,Vaccination},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\AQG2RNYR\\Dugan et al. - 2020 - Preexisting immunity shapes distinct antibody land.pdf}
}

@article{dugan2020a,
  title = {Aging and Influenza Vaccine-Induced Immunity},
  author = {Dugan, Haley L. and Henry, Carole and Wilson, Patrick C.},
  year = {2020},
  month = feb,
  journal = {Cell Immunol},
  volume = {348},
  pages = {103998},
  issn = {1090-2163},
  doi = {10.1016/j.cellimm.2019.103998},
  abstract = {Immunosenescence is defined as the progressive deterioration of the immune system with aging. Immunosenescence stifles the generation of protective B and T cell-mediated adaptive immunity in response to various pathogens, resulting in increased disease susceptibility and severity in the elderly population. In particular, immunosenescence has major impacts on the phenotype, function, and receptor repertoire of B and T cells in the elderly, hindering protective responses induced by seasonal influenza virus vaccination. In order to overcome the detrimental impacts of immunosenescence on protective immunity to influenza viruses, we review our current understanding of the effects of aging on adaptive immune responses to influenza and discuss current and future avenues of vaccine research for eliciting more potent anti-influenza immunity in the elderly.},
  langid = {english},
  pmid = {31733824},
  keywords = {Adaptive Immunity,Aged,Aged; 80 and over,Aging,Antibody responses,B cells,Humans,Immunosenescence,Influenza,Influenza Vaccines,Influenza; Human,T cells,Vaccination}
}

@article{durviaux2014,
  title = {Genetic and Antigenic Typing of Seasonal Influenza Virus Breakthrough Cases from a 2008-2009 Vaccine Efficacy Trial},
  author = {Durviaux, Serge and Treanor, John and Beran, Jiri and Duval, Xavier and Esen, Meral and Feldman, Gregory and Frey, Sharon E. and Launay, Odile and {Leroux-Roels}, Geert and McElhaney, Janet E. and Nowakowski, Andrzej and {Ruiz-Palacios}, Guillermo M. and {van Essen}, Gerrit A. and Oostvogels, Lidia and Devaster, Jeanne-Marie and Walravens, Karl},
  editor = {Hodinka, R. L.},
  year = {2014},
  month = mar,
  journal = {Clinical and Vaccine Immunology},
  volume = {21},
  number = {3},
  pages = {271--279},
  doi = {10.1128/cvi.00544-13},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\K8VA485P\\Durviaux et al. - 2014 - Genetic and antigenic typing of seasonal influenza.pdf}
}

@article{einav,
  title = {Mapping the {{Antibody Repertoires}} in {{Ferrets}} with {{Repeated Influenza A}}/{{H3 Infections}}: {{Is Original Antigenic Sin Really}} ``{{Sinful}}''?},
  author = {Einav, Tal and Kosikova, Martina and Radvak, Peter and Kuo, Yuan-Chia and Kwon, Hyung Joon and Xie, Hang},
  abstract = {The influenza-specific antibody repertoire is continuously reshaped by infection and vaccination. The host immune response to contemporary viruses can be redirected to preferentially boost antibodies specific for viruses encountered early in life, a phenomenon called original antigenic sin (OAS) that is suggested to be responsible for diminished vaccine effectiveness after repeated vaccination. In this study, we used a new computational tool called Neutralization Map to determine the hemagglutination inhibition profiles of individual antibodies within ferret antisera elicited by repeated influenza A/H3 infections. Our results suggest that repeated infections continuously reshape the ferret antibody repertoire, but that a broadly neutralizing antibody signature can nevertheless be induced irrespective of OAS. Overall, our study offers a new way to visualize how immune history shapes individual antibodies within a repertoire, which may help inform future vaccine design.},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\CB4T8XIG\\Einav et al. - Mapping the Antibody Repertoires in Ferrets with R.pdf}
}

@article{einav2020,
  title = {When Two Are Better than One: {{Modeling}} the Mechanisms of Antibody Mixtures},
  shorttitle = {When Two Are Better than One},
  author = {Einav, Tal and Bloom, Jesse D.},
  editor = {Antia, Rustom},
  year = {2020},
  month = may,
  journal = {PLoS Comput Biol},
  volume = {16},
  number = {5},
  pages = {e1007830},
  issn = {1553-7358},
  doi = {10.1371/journal.pcbi.1007830},
  urldate = {2023-03-21},
  abstract = {It is difficult to predict how antibodies will behave when mixed together, even after each has been independently characterized. Here, we present a statistical mechanical model for the activity of antibody mixtures that accounts for whether pairs of antibodies bind to distinct or overlapping epitopes. This model requires measuring n individual antibodies and their n\dh n\`A 1\TH{} 2 pairwise interactions to predict the 2n potential combinations. We apply this model to epidermal growth factor receptor (EGFR) antibodies and find that the activity of antibody mixtures can be predicted without positing synergy at the molecular level. In addition, we demonstrate how the model can be used in reverse, where straightforward experiments measuring the activity of antibody mixtures can be used to infer the molecular interactions between antibodies. Lastly, we generalize this model to analyze engineered multidomain antibodies, where components of different antibodies are tethered together to form novel amalgams, and characterize how well it predicts recently designed influenza antibodies.},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\GCVEZCYX\\Einav and Bloom - 2020 - When two are better than one Modeling the mechani.pdf}
}

@article{einav2022,
  title = {Extrapolating Missing Antibody-Virus Measurements across Serological Studies},
  author = {Einav, Tal and Cleary, Brian},
  year = {2022},
  month = jul,
  journal = {Cell Syst},
  volume = {13},
  number = {7},
  pages = {561-573.e5},
  issn = {2405-4720},
  doi = {10.1016/j.cels.2022.06.001},
  abstract = {The development of new vaccines, as well as our understanding of key processes that shape viral evolution and host antibody repertoires, relies on measuring multiple antibody responses against large panels of viruses. Given the enormous diversity of circulating virus strains and antibody responses, comprehensively testing all antibody-virus interactions is infeasible. Even within individual studies with limited panels, exhaustive testing is not always performed, and there is no common framework for combining information across studies with partially overlapping panels, especially when the assay type or host species differ. Prior studies have demonstrated that antibody-virus interactions can be characterized in a vastly simpler and lower dimensional space, suggesting that relatively few measurements could predict unmeasured antibody-virus interactions. Here, we apply matrix completion to several large-scale influenza and HIV-1 studies. We explore how prediction accuracy evolves as the number of measurements changes and approximates the number of additional measurements necessary in several highly incomplete datasets (suggesting {$\sim$}250,000 measurements could be saved). In addition, we show how the method can combine disparate datasets, even when the number of available measurements is below the theoretical limit that guarantees successful prediction. This approach can be readily generalized to other viruses or more broadly to other low-dimensional biological datasets.},
  langid = {english},
  pmid = {35798005},
  keywords = {Antibodies; Viral,antibody-virus interactions,hemagglutination inhibition,HIV-1,Humans,imputation,influenza,Influenza Vaccines,Influenza; Human,matrix completion,nuclear norm minimization,serology,Viruses},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\TAZ35EWS\\Einav and Cleary - 2022 - Extrapolating missing antibody-virus measurements .pdf}
}

@techreport{einav2022a,
  type = {Preprint},
  title = {Using {{Interpretable Machine Learning}} to {{Massively Increase}} the {{Number}} of {{Antibody-Virus Interactions Across Studies}}},
  author = {Einav, Tal and Ma, Rong},
  year = {2022},
  month = jun,
  institution = {{Immunology}},
  doi = {10.1101/2022.06.09.495425},
  urldate = {2023-03-21},
  abstract = {Abstract                        A central challenge in every field of biology is to use existing measurements to predict the outcomes of future experiments. In this work, we consider the wealth of antibody inhibition data against variants of the influenza virus. Due to this virus's genetic diversity and evolvability, the variants examined in one study will often have little-to-no overlap with other studies, making it difficult to discern common patterns or unify datasets for further analysis. To that end, we develop a computational framework that predicts how an antibody or serum would inhibit any variant from             any other study             . We use this framework to greatly expand seven influenza datasets utilizing hemagglutination inhibition, validating our method upon 200,000 existing measurements and predicting 2,000,000 new values {$\pm$} uncertainties. With these new values, we quantify the transferability between seven vaccination and infection studies in humans and ferrets, show that the serum potency is negatively correlated with breadth, and present a tool for pandemic preparedness. This data-driven approach does not require any information beyond each virus's name and measurements, and even datasets with as few as 5 viruses can be expanded, making this approach widely applicable. Future influenza studies using hemagglutination inhibition can directly utilize our curated datasets to predict newly measured antibody responses against {$\approx$}80 H3N2 influenza viruses from 1968-2011, whereas immunological studies utilizing other viruses or a different assay only need a single partially-overlapping dataset to extend their work. In essence, this approach enables a shift in perspective when analyzing data from ``what you see is what you get'' into ``what anyone sees is what everyone gets.''},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\6SLGCHZ8\\Einav and Ma - 2022 - Using Interpretable Machine Learning to Massively .pdf}
}

@misc{einav2022e,
  title = {Quantitatively Visualizing Bipartite Datasets},
  author = {Einav, Tal and Khoo, Yuehaw and Singer, Amit},
  year = {2022},
  month = jul,
  number = {arXiv:2207.12658},
  eprint = {arXiv:2207.12658},
  publisher = {{arXiv}},
  urldate = {2023-03-21},
  abstract = {As experiments continue to increase in size and scope, a fundamental challenge of subsequent analyses is to recast the wealth of information into an intuitive and readily-interpretable form. Often, each measurement only conveys the relationship between a pair of entries, and it is difficult to integrate these local interactions across a dataset to form a cohesive global picture. The classic localization problem tackles this question, transforming local measurements into a global map that reveals the underlying structure of a system. Here, we examine the more challenging bipartite localization problem, where pairwise distances are only available for bipartite data comprising two classes of entries (such as antibody-virus interactions, drug-cell potency, or user-rating profiles). We modify previous algorithms to solve bipartite localization and examine how each method behaves in the presence of noise, outliers, and partially-observed data. As a proof of concept, we apply these algorithms to antibody-virus neutralization measurements to create a basis set of antibody behaviors, formalize how potently inhibiting some viruses necessitates weakly inhibiting other viruses, and quantify how often combinations of antibodies exhibit degenerate behavior.},
  archiveprefix = {arxiv},
  langid = {english},
  keywords = {Physics - Biological Physics,Physics - Physics and Society,Quantitative Biology - Quantitative Methods},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\CZ4VQ5R5\\Einav et al. - 2022 - Quantitatively visualizing bipartite datasets.pdf}
}

@article{elbe2017,
  title = {Data, Disease and Diplomacy: {{GISAID}}'s Innovative Contribution to Global Health},
  author = {Elbe, Stefan and {Buckland-Merrett}, Gemma},
  year = {2017},
  month = jan,
  journal = {Global Challenges},
  volume = {1},
  number = {1},
  pages = {33--46},
  doi = {10.1002/gch2.1018},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\AL42CYE3\\Elbe and Buckland-Merrett - 2017 - Data, disease and diplomacy GISAID's innovative c.pdf}
}

@article{ellebedy2020,
  title = {Adjuvanted {{H5N1}} Influenza Vaccine Enhances Both Cross-Reactive Memory {{B}} Cell and Strain-Specific Naive {{B}} Cell Responses in Humans},
  author = {Ellebedy, Ali H. and Nachbagauer, Raffael and Jackson, Katherine J. L. and Dai, Ya-Nan and Han, Julianna and Alsoussi, Wafaa B. and Davis, Carl W. and Stadlbauer, Daniel and Rouphael, Nadine and Chromikova, Veronika and McCausland, Megan and Chang, Cathy Y. and Cortese, Mario and Bower, Mary and Chennareddy, Chakravarthy and Schmitz, Aaron J. and Zarnitsyna, Veronika I. and Lai, Lilin and Rajabhathor, Arvind and Kazemian, Cheyann and Antia, Rustom and Mulligan, Mark J. and Ward, Andrew B. and Fremont, Daved H. and Boyd, Scott D. and Pulendran, Bali and Krammer, Florian and Ahmed, Rafi},
  year = {2020},
  month = jul,
  journal = {PNAS},
  volume = {117},
  number = {30},
  pages = {17957--17964},
  publisher = {{National Academy of Sciences}},
  issn = {0027-8424, 1091-6490},
  doi = {10.1073/pnas.1906613117},
  urldate = {2021-11-29},
  abstract = {There is a need for improved influenza vaccines. In this study we compared the antibody responses in humans after vaccination with an AS03-adjuvanted versus nonadjuvanted H5N1 avian influenza virus inactivated vaccine. Healthy young adults received two doses of either formulation 3 wk apart. We found that AS03 significantly enhanced H5 hemagglutinin (HA)-specific plasmablast and antibody responses compared to the nonadjuvanted vaccine. Plasmablast response after the first immunization was exclusively directed to the conserved HA stem region and came from memory B cells. Monoclonal antibodies (mAbs) derived from these plasmablasts had high levels of somatic hypermutation (SHM) and recognized the HA stem region of multiple influenza virus subtypes. Second immunization induced a plasmablast response to the highly variable HA head region. mAbs derived from these plasmablasts exhibited minimal SHM (naive B cell origin) and largely recognized the HA head region of the immunizing H5N1 strain. Interestingly, the antibody response to H5 HA stem region was much lower after the second immunization, and this suppression was most likely due to blocking of these epitopes by stem-specific antibodies induced by the first immunization. Taken together, these findings show that an adjuvanted influenza vaccine can substantially increase antibody responses in humans by effectively recruiting preexisting memory B cells as well as naive B cells into the response. In addition, we show that high levels of preexisting antibody can have a negative effect on boosting. These findings have implications toward the development of a universal influenza vaccine.},
  chapter = {Biological Sciences},
  copyright = {\textcopyright{} 2020 . https://www.pnas.org/site/aboutpnas/licenses.xhtmlPublished under the PNAS license.},
  isbn = {9781906613112},
  langid = {english},
  pmid = {32661157},
  keywords = {adjuvant,B cells,H5N1,influenza,memory},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\4IACB2BA\\Ellebedy et al. - 2020 - Adjuvanted H5N1 influenza vaccine enhances both cr.pdf;C\:\\Users\\Zane\\Zotero\\storage\\QABQT6CK\\17957.html}
}

@article{engler2008,
  title = {Half- vs {{Full-Dose Trivalent Inactivated Influenza Vaccine}} (2004-2005): {{Age}}, {{Dose}}, and {{Sex Effects}} on {{Immune Responses}}},
  shorttitle = {Half- vs {{Full-Dose Trivalent Inactivated Influenza Vaccine}} (2004-2005)},
  author = {Engler, Renata J. M.},
  year = {2008},
  month = dec,
  journal = {Arch Intern Med},
  volume = {168},
  number = {22},
  pages = {2405},
  issn = {0003-9926},
  doi = {10.1001/archinternmed.2008.513},
  urldate = {2021-04-14},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\6Q72XC6S\\Engler - 2008 - Half- vs Full-Dose Trivalent Inactivated Influenza.pdf}
}

@article{erbelding2018,
  title = {A {{Universal Influenza Vaccine}}: {{The Strategic Plan}} for the {{National Institute}} of {{Allergy}} and {{Infectious Diseases}}},
  shorttitle = {A {{Universal Influenza Vaccine}}},
  author = {Erbelding, Emily J. and Post, Diane J. and Stemmy, Erik J. and Roberts, Paul C. and Augustine, Alison Deckhut and Ferguson, Stacy and Paules, Catharine I. and Graham, Barney S. and Fauci, Anthony S.},
  year = {2018},
  month = jul,
  journal = {J Infect Dis},
  volume = {218},
  number = {3},
  pages = {347--354},
  issn = {1537-6613},
  doi = {10.1093/infdis/jiy103},
  abstract = {A priority for the National Institute of Allergy and Infectious Diseases is development of a universal influenza vaccine providing durable protection against multiple influenza strains. NIAID will use this strategic plan as a foundation for future investments in influenza research.},
  langid = {english},
  pmcid = {PMC6279170},
  pmid = {29506129},
  keywords = {Animals,Biomedical Research,Humans,Influenza Vaccines,Influenza; Human,National Institute of Allergy and Infectious Diseases (U.S.),United States,Zoonoses},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\5G6BRTZA\\Erbelding et al. - 2018 - A Universal Influenza Vaccine The Strategic Plan .pdf}
}

@article{ferdinands2021,
  title = {Waning Vaccine Effectiveness against Influenza-Associated Hospitalizations among Adults, 2015-2016 to 2018-2019, {{US Hospitalized Adult Influenza Vaccine Effectiveness Network}}},
  author = {Ferdinands, Jill M and Gaglani, Manjusha and Martin, Emily T and Monto, Arnold S and Middleton, Donald and Silveira, Fernanda and Talbot, H Keipp and Zimmerman, Richard and Patel, Manish},
  year = {2021},
  month = jan,
  journal = {Clinical Infectious Diseases},
  number = {ciab045},
  issn = {1058-4838},
  doi = {10.1093/cid/ciab045},
  urldate = {2021-02-16},
  abstract = {We observed decreased effectiveness of influenza vaccine with increasing time since vaccination for prevention of influenza A(H3N2), influenza A(H1N1)pdm09, and influenza B(Yamagata)-associated hospitalizations among adults. Maximum VE was observed shortly after vaccination, followed by an absolute decline in VE of about 8 to 9\% per month post-vaccination.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\VCXH9EJI\\Ferdinands et al. - 2021 - Waning vaccine effectiveness against influenza-ass.pdf;C\:\\Users\\Zane\\Zotero\\storage\\UEM8GZV2\\6104243.html}
}

@article{fink2018,
  title = {Biological Sex Affects Vaccine Efficacy and Protection against Influenza in Mice},
  author = {Fink, Ashley L. and Engle, Kyrra and Ursin, Rebecca L. and Tang, Wan-Yee and Klein, Sabra L.},
  year = {2018},
  month = dec,
  journal = {Proc Natl Acad Sci U S A},
  volume = {115},
  number = {49},
  pages = {12477--12482},
  issn = {1091-6490},
  doi = {10.1073/pnas.1805268115},
  abstract = {Biological sex affects adaptive immune responses, which could impact influenza infection and vaccine efficacy. Infection of mice with 2009 H1N1 induced antibody responses, CD4+ T cell and CD8+ T cell memory responses that were greater in females than males; both sexes, however, were equally protected against secondary challenge with an H1N1 drift variant virus. To test whether greater antibody in females is sufficient for protection against influenza, males and females were immunized with an inactivated H1N1 vaccine that induced predominantly antibody-mediated immunity. Following vaccination, females had greater antibody responses and protection against challenge with an H1N1 drift variant virus than males. Antibody derived from vaccinated females was better at protecting both na\"ive males and females than antibody from males, and this protection was associated with increased antibody specificity and avidity to the H1N1 virus. The expression of Tlr7 was greater in B cells from vaccinated females than males and was associated with reduced DNA methylation in the Tlr7 promoter region, higher neutralizing antibody, class switch recombination, and antibody avidity in females. Deletion of Tlr7 reduced sex differences in vaccine-induced antibody responses and protection following challenge and had a greater impact on responses in females than males. Taken together, these data illustrate that greater TLR7 activation and antibody production in females improves the efficacy of vaccination against influenza.},
  langid = {english},
  pmcid = {PMC6298067},
  pmid = {30455317},
  keywords = {Animals,antibody secreting cells,CD8+ T cell memory,DNA methylation,Female,Immunity; Humoral,Influenza A Virus; H1N1 Subtype,Influenza Vaccines,isotope switching,Male,Mice,Orthomyxoviridae Infections,Sex Factors,toll-like receptor 7},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\T8FUBDC9\\Fink et al. - 2018 - Biological sex affects vaccine efficacy and protec.pdf}
}

@article{flaxman2018,
  title = {Methods for {{Measuring T-Cell Memory}} to {{Vaccination}}: {{From Mouse}} to {{Man}}},
  shorttitle = {Methods for {{Measuring T-Cell Memory}} to {{Vaccination}}},
  author = {Flaxman, Amy and Ewer, Katie J.},
  year = {2018},
  month = sep,
  journal = {Vaccines},
  volume = {6},
  number = {3},
  pages = {43},
  publisher = {{Multidisciplinary Digital Publishing Institute}},
  doi = {10.3390/vaccines6030043},
  urldate = {2021-06-10},
  abstract = {The development of effective vaccines continues to be a key goal for public health bodies, governments, funding bodies and pharmaceutical companies. With new vaccines such as Shingrix targeting Shingles and Bexsero for Meningitis B, licensed in recent years, today\&rsquo;s population can be protected from more infectious diseases than ever before. Despite this, we are yet to license vaccines for some of the deadliest endemic diseases affecting children, such as malaria. In addition, the threat of epidemics caused by emerging pathogens is very real as exemplified by the 2014\&ndash;2016 Ebola outbreak. Most licensed vaccines provide efficacy through humoral immunity and correlates of protection often quantify neutralising antibody titre. The role of T-cells in vaccine efficacy is less well understood and more complex to quantify. Defining T-cell responses which afford protection also remains a challenge, although more sophisticated assays for assessing cell-mediated immunity with the potential for higher throughput and scalability are now available and warrant review. Here we discuss the benefits of multiparameter cytokine analysis and omics approaches compared with flow cytometric and ELISpot assays. We also review technical challenges unique to clinical trial studies, including assay validation across laboratories and availability of sample type. Measuring T-cell immunogenicity alongside humoral responses provides information on the breadth of immune responses induced by vaccination. Accurately enumerating and phenotyping T-cell immunogenicity to vaccination is key for the determination of immune correlates of protection. However, identifying such T-cell parameters remains challenging without a clear understanding of the immunological mechanisms by which a T-cell-mediated response induces protection.},
  copyright = {http://creativecommons.org/licenses/by/3.0/},
  langid = {english},
  keywords = {clinical trial,memory,pre-clinical,T-cell,vaccine},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\JAD8FU85\\Flaxman and Ewer - 2018 - Methods for Measuring T-Cell Memory to Vaccination.pdf;C\:\\Users\\Zane\\Zotero\\storage\\ECLVXE4W\\htm.html}
}

@article{fonville2014,
  title = {Antibody Landscapes after Influenza Virus Infection or Vaccination},
  author = {{Fonville} and M., J. and Wilks, S. H. and James, S. L. and Fox, A. and Ventresca, M. and Aban, M. and Xue, L. and Jones, T. C. and H., Le N. M. and T., Pham Q. and D., Tran N. and Wong, Y. and Mosterin, A. and Katzelnick, L. C. and Labonte, D. and T., Le T. and {van der Net}, G. and Skepner, E. and Russell, C. A. and Kaplan, T. D. and Rimmelzwaan, G. F. and Masurel, N. and {de Jong}, J. C. and Palache, A. and Beyer, W. E. P. and M., Le Q. and H., Nguyen T. and Wertheim, H. F. L. and Hurt, A. C. and Osterhaus, A. D. M. E. and Barr, I. G. and Fouchier, R. A. M. and Horby, P. W. and Smith, D. J.},
  year = {2014-11-21, 2014-11},
  journal = {Science},
  volume = {346},
  number = {6212},
  pages = {996--1000},
  doi = {10.1126/science.1256427},
  langid = {english}
}

@article{fonville2014a,
  title = {Antibody Landscapes after Influenza Virus Infection or Vaccination},
  author = {Fonville, J. M. and Wilks, S. H. and James, S. L. and Fox, A. and Ventresca, M. and Aban, M. and Xue, L. and Jones, T. C. and Le, N. M. H. and Pham, Q. T. and Tran, N. D. and Wong, Y. and Mosterin, A. and Katzelnick, L. C. and Labonte, D. and Le, T. T. and {van der Net}, G. and Skepner, E. and Russell, C. A. and Kaplan, T. D. and Rimmelzwaan, G. F. and Masurel, N. and {de Jong}, J. C. and Palache, A. and Beyer, W. E. P. and Le, Q. M. and Nguyen, T. H. and Wertheim, H. F. L. and Hurt, A. C. and Osterhaus, A. D. M. E. and Barr, I. G. and Fouchier, R. a. M. and Horby, P. W. and Smith, D. J.},
  year = {2014},
  month = nov,
  journal = {Science},
  volume = {346},
  number = {6212},
  pages = {996--1000},
  issn = {1095-9203},
  doi = {10.1126/science.1256427},
  abstract = {We introduce the antibody landscape, a method for the quantitative analysis of antibody-mediated immunity to antigenically variable pathogens, achieved by accounting for antigenic variation among pathogen strains. We generated antibody landscapes to study immune profiles covering 43 years of influenza A/H3N2 virus evolution for 69 individuals monitored for infection over 6 years and for 225 individuals pre- and postvaccination. Upon infection and vaccination, titers increased broadly, including previously encountered viruses far beyond the extent of cross-reactivity observed after a primary infection. We explored implications for vaccination and found that the use of an antigenically advanced virus had the dual benefit of inducing antibodies against both advanced and previous antigenic clusters. These results indicate that preemptive vaccine updates may improve influenza vaccine efficacy in previously exposed individuals.},
  langid = {english},
  pmcid = {PMC4246172},
  pmid = {25414313},
  keywords = {Antibodies; Viral,Antigenic Variation,Evolution; Molecular,Humans,Influenza A Virus; H3N2 Subtype,Influenza Vaccines,Influenza; Human,Vaccination}
}

@article{fonville2015,
  title = {Antigenic Maps of Influenza {{A}}({{H3N2}}) Produced with Human Antisera Obtained after Primary Infection},
  author = {Fonville, Judith M. and Fraaij, Pieter L. A. and {de Mutsert}, Gerrie and Wilks, Samuel H. and {van Beek}, Ruud and Fouchier, Ron A. M. and Rimmelzwaan, Guus F.},
  year = {2015-07-03, 2015-07},
  journal = {Journal of Infectious Diseases},
  volume = {213},
  number = {1},
  pages = {31--38},
  doi = {10.1093/infdis/jiv367},
  langid = {english}
}

@article{forghani2020,
  title = {Convolutional {{Neural Network Based Approach}} to in {{Silico Non-Anticipating Prediction}} of {{Antigenic Distance}} for {{Influenza Virus}}},
  author = {Forghani, Majid and Khachay, Michael},
  year = {2020},
  month = sep,
  journal = {Viruses},
  volume = {12},
  number = {9},
  pages = {1019},
  issn = {1999-4915},
  doi = {10.3390/v12091019},
  abstract = {Evaluation of the antigenic similarity degree between the strains of the influenza virus is highly important for vaccine production. The conventional method used to measure such a degree is related to performing the immunological assays of hemagglutinin inhibition. Namely, the antigenic distance between two strains is calculated on the basis of HI assays. Usually, such distances are visualized by using some kind of antigenic cartography method. The known drawback of the HI assay is that it is rather time-consuming and expensive. In this paper, we propose a novel approach for antigenic distance approximation based on deep learning in the feature spaces induced by hemagglutinin protein sequences and Convolutional Neural Networks (CNNs). To apply a CNN to compare the protein sequences, we utilize the encoding based on the physical and chemical characteristics of amino acids. By varying (hyper)parameters of the CNN architecture design, we find the most robust network. Further, we provide insight into the relationship between approximated antigenic distance and antigenicity by evaluating the network on the HI assay database for the H1N1 subtype. The results indicate that the best-trained network gives a high-precision approximation for the ground-truth antigenic distances, and can be used as a good exploratory tool in practical tasks.},
  langid = {english},
  pmcid = {PMC7551508},
  pmid = {32932748},
  keywords = {Amino Acid Sequence,antigenic distance,Antigens; Viral,Computer Simulation,convolutional neural network,evolution,Hemagglutinin Glycoproteins; Influenza Virus,Humans,influenza,Influenza A Virus; H1N1 Subtype,Influenza; Human,Neural Networks; Computer,Orthomyxoviridae,vaccine}
}

@article{forst2022,
  title = {Vaccination {{History}}, {{Body Mass Index}}, {{Age}}, and {{Baseline Gene Expression Predict Influenza Vaccination Outcomes}}},
  author = {Forst, Christian V. and Chung, Matthew and Hockman, Megan and Lashua, Lauren and Adney, Emily and Hickey, Angela and Carlock, Michael and Ross, Ted and Ghedin, Elodie and Gresham, David},
  year = {2022},
  month = nov,
  journal = {Viruses},
  volume = {14},
  number = {11},
  pages = {2446},
  publisher = {{Multidisciplinary Digital Publishing Institute}},
  issn = {1999-4915},
  doi = {10.3390/v14112446},
  urldate = {2023-03-21},
  abstract = {Seasonal influenza is a primary public health burden in the USA and globally. Annual vaccination programs are designed on the basis of circulating influenza viral strains. However, the effectiveness of the seasonal influenza vaccine is highly variable between seasons and among individuals. A number of factors are known to influence vaccination effectiveness including age, sex, and comorbidities. Here, we sought to determine whether whole blood gene expression profiling prior to vaccination is informative about pre-existing immunological status and the immunological response to vaccine. We performed whole transcriptome analysis using RNA sequencing (RNAseq) of whole blood samples obtained prior to vaccination from 275 participants enrolled in an annual influenza vaccine trial. Serological status prior to vaccination and 28 days following vaccination was assessed using the hemagglutination inhibition assay (HAI) to define baseline immune status and the response to vaccination. We find evidence that genes with immunological functions are increased in expression in individuals with higher pre-existing immunity and in those individuals who mount a greater response to vaccination. Using a random forest model, we find that this set of genes can be used to predict vaccine response with a performance similar to a model that incorporates physiological and prior vaccination status alone. A model using both gene expression and physiological factors has the greatest predictive power demonstrating the potential utility of molecular profiling for enhancing prediction of vaccine response. Moreover, expression of genes that are associated with enhanced vaccination response may point to additional biological pathways that contribute to mounting a robust immunological response to the seasonal influenza vaccine.},
  copyright = {http://creativecommons.org/licenses/by/3.0/},
  langid = {english},
  keywords = {gene expression,influenza,random forest,vaccine response},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\Y4AV8ZS6\\Forst et al. - 2022 - Vaccination History, Body Mass Index, Age, and Bas.pdf}
}

@article{francis1960,
  title = {On the {{Doctrine}} of {{Original Antigenic Sin}}},
  author = {Francis, Thomas},
  year = {1960},
  month = dec,
  journal = {Proceedings of the American Philosophical Society},
  volume = {104},
  number = {6},
  eprint = {985534},
  eprinttype = {jstor},
  pages = {572--578},
  urldate = {2021-11-29},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\KC384GBA\\Francis - 1960 - On the Doctrine of Original Antigenic Sin.pdf;C\:\\Users\\Zane\\Zotero\\storage\\2D7SC3IR\\985534.html}
}

@article{franco2013,
  title = {Integrative Genomic Analysis of the Human Immune Response to Influenza Vaccination},
  author = {Franco, Luis M. and Bucasas, Kristine L. and Wells, Janet M. and Ni{\~n}o, Diane and Wang, Xueqing and Zapata, Gladys E. and Arden, Nancy and Renwick, Alexander and Yu, Peng and Quarles, John M. and Bray, Molly S. and Couch, Robert B. and Belmont, John W. and Shaw, Chad A.},
  year = {2013},
  month = jul,
  journal = {Elife},
  volume = {2},
  pages = {e00299},
  issn = {2050-084X},
  doi = {10.7554/eLife.00299},
  abstract = {Identification of the host genetic factors that contribute to variation in vaccine responsiveness may uncover important mechanisms affecting vaccine efficacy. We carried out an integrative, longitudinal study combining genetic, transcriptional, and immunologic data in humans given seasonal influenza vaccine. We identified 20 genes exhibiting a transcriptional response to vaccination, significant genotype effects on gene expression, and correlation between the transcriptional and antibody responses. The results show that variation at the level of genes involved in membrane trafficking and antigen processing significantly influences the human response to influenza vaccination. More broadly, we demonstrate that an integrative study design is an efficient alternative to existing methods for the identification of genes involved in complex traits. DOI:http://dx.doi.org/10.7554/eLife.00299.001.},
  langid = {english},
  pmcid = {PMC3713456},
  pmid = {23878721},
  keywords = {Adolescent,Adult,Antibodies; Viral,Biomarkers,Complex-trait genetics,eQTL,Female,Gene Expression Profiling,Gene Expression Regulation,Genetic Markers,Genomics,Genotype,Host-Pathogen Interactions,Human,Human genetics,Humans,Immunity; Humoral,Influenza A Virus; H1N1 Subtype,Influenza A Virus; H3N2 Subtype,Influenza B virus,Influenza Vaccines,Influenza; Human,Integrative biology,Longitudinal Studies,Male,Pharmacogenetics,Phenotype,Polymorphism; Single Nucleotide,Systems biology,Time Factors,Transcription; Genetic,Vaccination,Vaccines,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\2J8J8VEF\\Franco et al. - 2013 - Integrative genomic analysis of the human immune r.pdf}
}

@article{fribourg2014,
  title = {Model of Influenza {{A}} Virus Infection: Dynamics of Viral Antagonism and Innate Immune Response},
  shorttitle = {Model of Influenza {{A}} Virus Infection},
  author = {Fribourg, M. and Hartmann, B. and Schmolke, M. and Marjanovic, N. and Albrecht, R.A. and {Garc{\'i}a-Sastre}, A. and Sealfon, S. C. and Jayaprakash, C. and Hayot, F.},
  year = {2014},
  month = jun,
  journal = {J Theor Biol},
  volume = {351},
  pages = {47--57},
  issn = {0022-5193},
  doi = {10.1016/j.jtbi.2014.02.029},
  urldate = {2021-06-30},
  abstract = {Viral antagonism of host responses is an essential component of virus pathogenicity. The study of the interplay between immune response and viral antagonism is challenging due to the involvement of many processes acting at multiple time scales. Here we develop an ordinary differential equation model to investigate the early, experimentally-measured, responses of human monocyte-derived dendritic cells to infection by two H1N1 influenza A viruses of different clinical outcome: pandemic A/California/4/2009 and seasonal A/New Caledonia/20/1999. Our results reveal how the strength of virus antagonism, and the time scale over which it acts to thwart the innate immune response, differ significantly between the two viruses, as is made clear by their impact on the temporal behavior of a number of measured genes. The model thus sheds light on the mechanisms that underlie the variability of innate immune responses to different H1N1 viruses.},
  pmcid = {PMC4012420},
  pmid = {24594370},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\M8MQF399\\Fribourg et al. - 2014 - Model of influenza A virus infection dynamics of .pdf}
}

@article{furman2015,
  title = {Cytomegalovirus Infection Enhances the Immune Response to Influenza},
  author = {Furman, David and Jojic, Vladimir and Sharma, Shalini and {Shen-Orr}, Shai S. and Angel, Cesar J. L. and {Onengut-Gumuscu}, Suna and Kidd, Brian A. and Maecker, Holden T. and Concannon, Patrick and Dekker, Cornelia L. and Thomas, Paul G. and Davis, Mark M.},
  year = {2015},
  month = apr,
  journal = {Sci Transl Med},
  volume = {7},
  number = {281},
  pages = {281ra43},
  issn = {1946-6242},
  doi = {10.1126/scitranslmed.aaa2293},
  abstract = {Cytomegalovirus (CMV) is a {$\beta$}-herpesvirus present in a latent form in most people worldwide. In immunosuppressed individuals, CMV can reactivate and cause serious clinical complications, but the effect of the latent state on healthy people remains elusive. We undertook a systems approach to understand the differences between seropositive and negative subjects and measured hundreds of immune system components from blood samples including cytokines and chemokines, immune cell phenotyping, gene expression, ex vivo cell responses to cytokine stimuli, and the antibody response to seasonal influenza vaccination. As expected, we found decreased responses to vaccination and an overall down-regulation of immune components in aged individuals regardless of CMV status. In contrast, CMV-seropositive young adults exhibited enhanced antibody responses to influenza vaccination, increased CD8(+) T cell sensitivity, and elevated levels of circulating interferon-{$\gamma$} compared to seronegative individuals. Experiments with young mice infected with murine CMV also showed significant protection from an influenza virus challenge compared with uninfected animals, although this effect declined with time. These data show that CMV and its murine equivalent can have a beneficial effect on the immune response of young, healthy individuals, which may explain the ubiquity of CMV infection in humans and many other species.},
  langid = {english},
  pmcid = {PMC4505610},
  pmid = {25834109},
  keywords = {Adult,Aged,Aged; 80 and over,Aging,Animals,CD28 Antigens,CD4-Positive T-Lymphocytes,CD8-Positive T-Lymphocytes,Cross Protection,Cytomegalovirus,Cytomegalovirus Infections,Female,Humans,Immunity,Influenza; Human,Interferon-gamma,Mice; Inbred C57BL,Mice; Knockout,Middle Aged,Muromegalovirus,Polymorphism; Single Nucleotide,Time Factors,Vaccination,Viral Load,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\SVEUYI5M\\Furman et al. - 2015 - Cytomegalovirus infection enhances the immune resp.pdf}
}

@article{gabriel2014,
  title = {Sex, {{Immunity}} and {{Influenza}}},
  author = {Gabriel, G{\"u}lsah and Arck, Petra Clara},
  year = {2014},
  month = jul,
  journal = {The Journal of Infectious Diseases},
  volume = {209},
  number = {suppl\_3},
  pages = {S93-S99},
  issn = {0022-1899},
  doi = {10.1093/infdis/jiu020},
  urldate = {2021-04-14},
  abstract = {Sex-specific endocrine and immune responses are widely recognized to account for differential disease outcomes between females and males. Surprisingly, sex-specific risk assessments for influenza, a viral pathogen that affects human populations worldwide through seasonal epidemics and irregular occurring pandemics, are sparse and\textemdash if available\textemdash ambiguous. To date, this precludes proposing an unequivocal sex-dependent susceptibility to influenza. However, one undisputable observation recurrently confirmed during influenza seasons of the last decades is the significantly increased risk for pregnant women. This increased risk is likely attributable to the contradictory demands for the maternal immune system to adapt to pregnancy and to simultaneously mount an immune response to clear the influenza virus infection. Here, we review published evidence on the potential association between sex on influenza risk and propose that future epidemiologic studies should carefully dissect surveillance data for sex-specific effects. Moreover, we propose potential mechanisms involved in enhanced risk for severe influenza during pregnancy that could be studied to identify causal pathways.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\ZZVFPQ3E\\Gabriel and Arck - 2014 - Sex, Immunity and Influenza.pdf;C\:\\Users\\Zane\\Zotero\\storage\\7WTWZRV9\\2192745.html}
}

@article{gagnon2015,
  title = {Is Antigenic Sin Always "Original?" {{Re-examining}} the Evidence Regarding Circulation of a Human {{H1}} Influenza Virus Immediately Prior to the 1918 {{Spanish}} Flu},
  shorttitle = {Is Antigenic Sin Always "original?},
  author = {Gagnon, Alain and Acosta, J. Enrique and Madrenas, Joaquin and Miller, Matthew S.},
  year = {2015},
  month = mar,
  journal = {PLoS Pathog},
  volume = {11},
  number = {3},
  pages = {e1004615},
  issn = {1553-7374},
  doi = {10.1371/journal.ppat.1004615},
  langid = {english},
  pmcid = {PMC4351064},
  pmid = {25742615},
  keywords = {Adult,Female,History; 19th Century,History; 20th Century,Humans,Influenza A Virus; H1N1 Subtype,Influenza Pandemic; 1918-1919,Male,Phylogeny,Russia (Pre-1917)},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\TYT29EMH\\Gagnon et al. - 2015 - Is antigenic sin always original Re-examining t.pdf}
}

@article{gagnon2018,
  title = {Reporting and Evaluating Influenza Virus Surveillance Data: {{An}} Argument for Incidence by Single Year of Age},
  shorttitle = {Reporting and Evaluating Influenza Virus Surveillance Data},
  author = {Gagnon, Alain and Acosta, Enrique and Miller, Matthew S.},
  year = {2018},
  month = oct,
  journal = {Vaccine},
  volume = {36},
  number = {42},
  pages = {6249--6252},
  issn = {0264-410X},
  doi = {10.1016/j.vaccine.2018.08.077},
  urldate = {2021-06-22},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\5MWBNKC7\\Gagnon et al. - 2018 - Reporting and evaluating influenza virus surveilla.pdf;C\:\\Users\\Zane\\Zotero\\storage\\AV2R97W6\\S0264410X18312271.html}
}

@article{gagnon2018a,
  title = {Pandemic {{Paradox}}: {{Early Life H2N2 Pandemic Influenza Infection Enhanced Susceptibility}} to {{Death}} during the 2009 {{H1N1 Pandemic}}},
  shorttitle = {Pandemic {{Paradox}}},
  author = {Gagnon, Alain and Acosta, Enrique and Hallman, Stacey and Bourbeau, Robert and Dillon, Lisa Y. and Ouellette, Nadine and Earn, David J. D. and Herring, D. Ann and Inwood, Kris and Madrenas, Joaquin and Miller, Matthew S.},
  year = {2018},
  month = jan,
  journal = {mBio},
  volume = {9},
  number = {1},
  pages = {e02091-17},
  issn = {2150-7511},
  doi = {10.1128/mBio.02091-17},
  abstract = {Recent outbreaks of H5, H7, and H9 influenza A viruses in humans have served as a vivid reminder of the potentially devastating effects that a novel pandemic could exert on the modern world. Those who have survived infections with influenza viruses in the past have been protected from subsequent antigenically similar pandemics through adaptive immunity. For example, during the 2009 H1N1 "swine flu" pandemic, those exposed to H1N1 viruses that circulated between 1918 and the 1940s were at a decreased risk for mortality as a result of their previous immunity. It is also generally thought that past exposures to antigenically dissimilar strains of influenza virus may also be beneficial due to cross-reactive cellular immunity. However, cohorts born during prior heterosubtypic pandemics have previously experienced elevated risk of death relative to surrounding cohorts of the same population. Indeed, individuals born during the 1890 H3Nx pandemic experienced the highest levels of excess mortality during the 1918 "Spanish flu." Applying Serfling models to monthly mortality and influenza circulation data between October 1997 and July 2014 in the United States and Mexico, we show corresponding peaks in excess mortality during the 2009 H1N1 "swine flu" pandemic and during the resurgent 2013-2014 H1N1 outbreak for those born at the time of the 1957 H2N2 "Asian flu" pandemic. We suggest that the phenomenon observed in 1918 is not unique and points to exposure to pandemic influenza early in life as a risk factor for mortality during subsequent heterosubtypic pandemics.IMPORTANCE The relatively low mortality experienced by older individuals during the 2009 H1N1 influenza virus pandemic has been well documented. However, reported situations in which previous influenza virus exposures have enhanced susceptibility are rare and poorly understood. One such instance occurred in 1918-when those born during the heterosubtypic 1890 H3Nx influenza virus pandemic experienced the highest levels of excess mortality. Here, we demonstrate that this phenomenon was not unique to the 1918 H1N1 pandemic but that it also occurred during the contemporary 2009 H1N1 pandemic and 2013-2014 H1N1-dominated season for those born during the heterosubtypic 1957 H2N2 "Asian flu" pandemic. These data highlight the heretofore underappreciated phenomenon that, in certain instances, prior exposure to pandemic influenza virus strains can enhance susceptibility during subsequent pandemics. These results have important implications for pandemic risk assessment and should inform laboratory studies aimed at uncovering the mechanism responsible for this effect.},
  langid = {english},
  pmcid = {PMC5770550},
  pmid = {29339427},
  keywords = {Disease Susceptibility,Humans,Influenza A Virus; H1N1 Subtype,Influenza A Virus; H2N2 Subtype,influenza virus,Influenza; Human,Mexico,mortality,pandemics,Risk Factors,susceptibility,United States},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\KCGBAFQ8\\Gagnon et al. - 2018 - Pandemic Paradox Early Life H2N2 Pandemic Influen.pdf}
}

@article{gagnon2020,
  title = {Age-{{Specific Incidence}} of {{Influenza A Responds}} to {{Change}} in {{Virus Subtype Dominance}}},
  author = {Gagnon, Alain and Acosta, Enrique and Miller, Matthew S.},
  year = {2020},
  month = oct,
  journal = {Clin Infect Dis},
  volume = {71},
  number = {7},
  pages = {e195-e198},
  issn = {1537-6591},
  doi = {10.1093/cid/ciaa075},
  abstract = {When H3N2 replaced H1N1 as the dominant influenza A subtype during the 2018-2019 season, the pattern of age-specific incidence shifted due to the lingering effects of antigenic imprinting. The characteristic shape that imprinting leaves on influenza susceptibility could foster important advances in understanding and predicting the epidemiology of influenza.},
  langid = {english},
  pmid = {31985006},
  keywords = {Age Factors,age-specific analysis,antigenic imprinting,cohort effect,Hemagglutinin Glycoproteins; Influenza Virus,Humans,Incidence,Influenza A Virus; H1N1 Subtype,Influenza A Virus; H3N2 Subtype,influenza incidence,Influenza; Human,Seasons}
}

@article{garten2009,
  title = {Antigenic and Genetic Characteristics of Swine-Origin 2009 {{A}}({{H1N1}}) Influenza Viruses Circulating in Humans},
  author = {Garten, Rebecca J. and Davis, C. Todd and Russell, Colin A. and Shu, Bo and Lindstrom, Stephen and Balish, Amanda and Sessions, Wendy M. and Xu, Xiyan and Skepner, Eugene and Deyde, Varough and {Okomo-Adhiambo}, Margaret and Gubareva, Larisa and Barnes, John and Smith, Catherine B. and Emery, Shannon L. and Hillman, Michael J. and Rivailler, Pierre and Smagala, James and {de Graaf}, Miranda and Burke, David F. and Fouchier, Ron A. M. and Pappas, Claudia and {Alpuche-Aranda}, Celia M. and {L{\'o}pez-Gatell}, Hugo and Olivera, Hiram and L{\'o}pez, Irma and Myers, Christopher A. and Faix, Dennis and Blair, Patrick J. and Yu, Cindy and Keene, Kimberly M. and Dotson, P. David and Boxrud, David and Sambol, Anthony R. and Abid, Syed H. and St. George, Kirsten and Bannerman, Tammy and Moore, Amanda L. and Stringer, David J. and Blevins, Patricia and {Demmler-Harrison}, Gail J. and Ginsberg, Michele and Kriner, Paula and Waterman, Steve and Smole, Sandra and Guevara, Hugo F. and Belongia, Edward A. and Clark, Patricia A. and Beatrice, Sara T. and Donis, Ruben and Katz, Jacqueline and Finelli, Lyn and Bridges, Carolyn B. and Shaw, Michael and Jernigan, Daniel B. and Uyeki, Timothy M. and Smith, Derek J. and Klimov, Alexander I. and Cox, Nancy J.},
  year = {2009-07-10, 2009-07},
  journal = {Science},
  volume = {325},
  number = {5937},
  pages = {197--201},
  doi = {10.1126/science.1176225},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\HVHBJTZ2\\Garten et al. - 2009 - Antigenic and genetic characteristics of swine-ori.pdf}
}

@article{goodwin2006,
  title = {Antibody Response to Influenza Vaccination in the Elderly: A Quantitative Review},
  shorttitle = {Antibody Response to Influenza Vaccination in the Elderly},
  author = {Goodwin, Katherine and Viboud, C{\'e}cile and Simonsen, Lone},
  year = {2006},
  month = feb,
  journal = {Vaccine},
  volume = {24},
  number = {8},
  pages = {1159--1169},
  issn = {0264-410X},
  doi = {10.1016/j.vaccine.2005.08.105},
  abstract = {We performed a quantitative review of 31 vaccine antibody response studies conducted from 1986 to 2002 and compared antibody responses to influenza vaccine in groups of elderly versus younger adults. We did a weighted analysis of the probability of vaccine response (measured as seroconversion and seroprotection) for each vaccine component (H1, H3 and B antigens). Using a multiple regression model, we adjusted for factors that might affect the vaccine response. The adjusted odds-ratio (OR) of responses in elderly versus young adults ranged from 0.24 to 0.59 in terms of seroconversion and seroprotection to all three antigens. The CDC estimates of 70-90\% clinical vaccine efficacy in young adults and these estimates suggest a corresponding clinical efficacy in the elderly of 17-53\% depending on circulating viruses. We conclude that the antibody response in the elderly is considerably lower than in younger adults. This highlights the need for more immunogenic vaccine formulations for the elderly.},
  langid = {english},
  pmid = {16213065},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Aging,Antibodies; Viral,Humans,Influenza Vaccines,Middle Aged,Multivariate Analysis,Odds Ratio,Regression Analysis,Vaccination}
}

@article{gorse2015,
  title = {Safety and Immunogenicity of a Quadrivalent Intradermal Influenza Vaccine in Adults},
  author = {Gorse, Geoffrey J. and Falsey, Ann R. and {Ozol-Godfrey}, Ayca and Landolfi, Victoria and Tsang, Peter H.},
  year = {2015},
  month = feb,
  journal = {Vaccine},
  volume = {33},
  number = {9},
  pages = {1151--1159},
  issn = {0264-410X},
  doi = {10.1016/j.vaccine.2015.01.025},
  urldate = {2021-06-17},
  abstract = {Background An intradermal (ID) trivalent split-virion influenza vaccine (IIV3-ID) (Fluzone\textregistered{} Intradermal, Sanofi Pasteur, Swiftwater, PA) has been available in the US since the 2011/2012 influenza season for adults aged 18\textendash 64 years. This study examined whether adding a second B-lineage strain affects immunogenicity and safety. Methods This randomized, double-blind, multicentre trial evaluated the immunogenicity and safety of an intradermal quadrivalent split-virion influenza vaccine (IIV4-ID) in adults 18\textendash 64 years of age in the US during the 2012\textendash 2013 influenza season. Participants were randomized 2:1:1 to receive a single injection of IIV4-ID, licensed IIV3-ID, or an investigational IIV3-ID containing the alternate B-lineage strain. Haemagglutination inhibition antibody titres were assessed in two-thirds of participants before vaccination and 28 days after vaccination. Results 1672 participants were vaccinated with IIV4-ID, 837 with licensed IIV3-ID, and 846 with an investigational IIV3-ID. For all four vaccine strains, antibody responses to IIV4-ID were statistically non-inferior to the response to the IIV3-ID vaccines containing the matched strains. For both B strains, post-vaccination antibody responses to IIV4-ID were statistically superior to the responses to IIV3-ID lacking the corresponding B strain. Adverse events were similar for IIV4-ID and IIV3-ID. The most commonly reported solicited reactions were pain, pruritus, myalgia, headache, and malaise; and most were grade 1 or 2 and appeared and resolved within 3 days of vaccination. IIV4-ID was statistically non-inferior to the two pooled IIV3-ID vaccines for the proportions of participants with at least one grade 2 or 3 systemic reaction. Conclusions Antibody responses to the IIV4-ID were non-inferior to IIV3-ID for the A and matched B strains and superior for the unmatched B strains. IIV4-ID was well tolerated without any safety concerns. IIV4-ID may help address an unmet need due to mismatched B strains in previous influenza vaccines.},
  langid = {english},
  keywords = {Adults,ClinicalTrials.gov no. NCT01712984,Immunogenicity,Intradermal,Phase III,Quadrivalent influenza vaccine,Safety},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\UN2NB6SL\\Gorse et al. - 2015 - Safety and immunogenicity of a quadrivalent intrad.pdf;C\:\\Users\\Zane\\Zotero\\storage\\ZX748SI5\\S0264410X15000444.html}
}

@article{gostic2016,
  title = {Potent Protection against {{H5N1}} and {{H7N9}} Influenza via Childhood Hemagglutinin Imprinting},
  author = {Gostic, Katelyn M. and Ambrose, Monique and Worobey, Michael and {Lloyd-Smith}, James O.},
  year = {2016},
  month = nov,
  journal = {Science},
  volume = {354},
  number = {6313},
  pages = {722--726},
  publisher = {{American Association for the Advancement of Science}},
  issn = {0036-8075, 1095-9203},
  doi = {10.1126/science.aag1322},
  urldate = {2021-06-22},
  abstract = {{$<$}p{$>$}Two zoonotic influenza A viruses (IAV) of global concern, H5N1 and H7N9, exhibit unexplained differences in age distribution of human cases. Using data from all known human cases of these viruses, we show that an individual's first IAV infection confers lifelong protection against severe disease from novel hemagglutinin (HA) subtypes in the same phylogenetic group. Statistical modeling shows that protective HA imprinting is the crucial explanatory factor, and it provides 75\% protection against severe infection and 80\% protection against death for both H5N1 and H7N9. Our results enable us to predict age distributions of severe disease for future pandemics and demonstrate that a novel strain's pandemic potential increases yearly when a group-mismatched HA subtype dominates seasonal influenza circulation. These findings open new frontiers for rational pandemic risk assessment.{$<$}/p{$>$}},
  chapter = {Research Article},
  copyright = {Copyright \textcopyright{} 2016, American Association for the Advancement of Science},
  langid = {english},
  pmid = {27846599}
}

@misc{gostic2016a,
  title = {Potent {{Protection Against H5N1}} and {{H7N9 Influenza}} via {{Childhood Hemagglutinin Imprinting}}},
  author = {Gostic, Katelyn M. and Ambrose, Monique and Worobey, Michae and {Lloyd-Smith}, James O.},
  year = {2016},
  month = jul,
  primaryclass = {New Results},
  pages = {061598},
  publisher = {{bioRxiv}},
  doi = {10.1101/061598},
  urldate = {2023-03-02},
  abstract = {Two zoonotic influenza A viruses (IAV) of global concern, H5N1 and H7N9, exhibit puzzling differences in age distribution of human cases. Previous explanations cannot fully account for these patterns. We analyze data from all known human cases of H5N1 and H7N9 and show that an individual's first IAV infection confers lifelong protection against severe disease from novel hemagglutinin (HA) subtypes of the same phylogenetic group. Statistical modeling reveals protective HA imprinting to be the crucial explanatory factor, providing 75\% protection against severe infection and 80\% protection against death for both H5N1 and H7N9. Our results enable us to predict age distributions of severe disease for future pandemics and to demonstrate that a novel strain's pandemic potential increases yearly when a group-mismatched HA subtype dominates seasonal influenza circulation. These findings open new frontiers for rational pandemic risk assessment.},
  archiveprefix = {bioRxiv},
  chapter = {New Results},
  copyright = {\textcopyright{} 2016, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\NCU3TAMD\\Gostic et al. - 2016 - Potent Protection Against H5N1 and H7N9 Influenza .pdf}
}

@article{gostic2019,
  title = {Childhood Immune Imprinting to Influenza {{A}} Shapes Birth Year-Specific Risk during Seasonal {{H1N1}} and {{H3N2}} Epidemics},
  author = {Gostic, Katelyn M. and Bridge, Rebecca and Brady, Shane and Viboud, C{\'e}cile and Worobey, Michael and {Lloyd-Smith}, James O.},
  year = {2019},
  month = dec,
  journal = {PLOS Pathogens},
  volume = {15},
  number = {12},
  pages = {e1008109},
  publisher = {{Public Library of Science}},
  issn = {1553-7374},
  doi = {10.1371/journal.ppat.1008109},
  urldate = {2021-06-18},
  abstract = {Across decades of co-circulation in humans, influenza A subtypes H1N1 and H3N2 have caused seasonal epidemics characterized by different age distributions of cases and mortality. H3N2 causes the majority of severe, clinically attended cases in high-risk elderly cohorts, and the majority of overall deaths, whereas H1N1 causes fewer deaths overall, and cases shifted towards young and middle-aged adults. These contrasting age profiles may result from differences in childhood imprinting to H1N1 and H3N2 or from differences in evolutionary rate between subtypes. Here we analyze a large epidemiological surveillance dataset to test whether childhood immune imprinting shapes seasonal influenza epidemiology, and if so, whether it acts primarily via homosubtypic immune memory or via broader, heterosubtypic memory. We also test the impact of evolutionary differences between influenza subtypes on age distributions of cases. Likelihood-based model comparison shows that narrow, within-subtype imprinting shapes seasonal influenza risk alongside age-specific risk factors. The data do not support a strong effect of evolutionary rate, or of broadly protective imprinting that acts across subtypes. Our findings emphasize that childhood exposures can imprint a lifelong immunological bias toward particular influenza subtypes, and that these cohort-specific biases shape epidemic age distributions. As a consequence, newer and less ``senior'' antibody responses acquired later in life do not provide the same strength of protection as responses imprinted in childhood. Finally, we project that the relatively low mortality burden of H1N1 may increase in the coming decades, as cohorts that lack H1N1-specific imprinting eventually reach old age.},
  langid = {english},
  keywords = {*Antibody Formation,*Norovirus/immunology,*Virus Shedding,Acute Disease,Administration; Intranasal,Adolescent,Adult,Age distribution,Alkaline Phosphatase/analysis,Antibodies; Viral,Antibodies; Viral/*blood,Antibodies; Viral/blood,Antigens; Viral/*immunology,Base Sequence,Bias,Biomarkers/*blood,Biomedicine,Biopsy,breadth,Caliciviridae Infections/*prevention \& control,Caliciviridae Infections/*virology,Caliciviridae Infections/immunology/*prevention \& control,Caliciviridae Infections/transmission/*virology,Cancer Research,Categorisation,Challenge studies,Child,Clinical Protocols,Descriptive modelling,Diarrhea,Disease Outbreaks,DNA Primers/genetics,Double-Blind Method,Empirical evidence,Enzyme-Linked Immunosorbent Assay,Evolutionary rate,Feces/virology,Female,Fractional polynomials,Gastroenteritis,Gastroenteritis/*virology,Gastroenteritis/enzymology/etiology/*pathology/physiopathology,general,H1N1,hemagglutination inhibition (HAI),Hemagglutinin Glycoproteins; Influenza Virus,household,Human Experimentation,Humans,Immunity,Immunoassay/methods,immunoglobulin,Immunoglobulin A/blood,Immunoglobulin G/blood,Infectious Diseases,infectious dose,Infectivity,influenza,Influenza,Influenza A Virus; H1N1 Subtype,Influenza Vaccines,Influenza; Human,Intestine; Small/enzymology/pathology,Male,Medical risk factors,Metabolic Diseases,Methods,Methods for variable selection,Microscopy; Electron,Middle Aged,Molecular Medicine,Multilevel dose response,Natural experiments,neuraminidase,Neuraminidase,Neurosciences,neutralization,Nicaragua,norovirus,Norovirus,Norovirus/*immunology,Norwalk virus/*immunology,Norwalk virus/*pathogenicity,Norwalk virus/genetics/*isolation \& purification/pathogenicity,Pandemics,Peptide Hydrolases/*immunology,Placebos/administration \& dosage,RNA; Viral/analysis/genetics,secretor,serology,shedding,Shrinkage,Spline procedures,stalk,STRATOS initiative,Sucrase/analysis,Swine influenza,Time Factors,Trehalase/analysis,Vaccines; Virus-Like Particle/administration \& dosage/*immunology,Viral Vaccines/administration \& dosage/*immunology,Viral Vaccines/adverse effects/*immunology,Virus Diseases,Virus Shedding,Vomiting,Young Adult}
}

@misc{gostic2019a,
  title = {Childhood Immune Imprinting to Influenza {{A}} Shapes Birth Year-Specific Risk during Seasonal {{H1N1}} and {{H3N2}} Epidemics},
  author = {Gostic, Katelyn M. and Bridge, Rebecca and Brady, Shane and Viboud, C{\'e}cile and Worobey, Michael and {Lloyd-Smith}, James O.},
  year = {2019},
  month = sep,
  pages = {19001834},
  publisher = {{medRxiv}},
  doi = {10.1101/19001834},
  urldate = {2023-03-02},
  abstract = {Across decades of co-circulation in humans, influenza A subtypes H1N1 and H3N2 have caused seasonal epidemics characterized by different age distributions of cases and mortality. H3N2 causes the majority of relatively severe, clinically attended cases in high-risk elderly cohorts, and the majority of overall deaths, whereas H1N1 causes fewer deaths overall, and cases shifted towards young and middle-aged adults. These contrasting age profiles may result from differences in childhood exposure to H1N1 and H3N2 or from differences in evolutionary rate between subtypes. Here we analyze a large epidemiological surveillance dataset to test whether childhood immune imprinting shapes seasonal influenza epidemiology, and if so, whether it acts primarily via immune memory of a particular influenza subtype or via broader immune memory that protects across subtypes. We also test the impact of evolutionary differences between influenza subtypes on age distributions of cases. Likelihood-based model comparison shows that narrow, within-subtype imprinting shapes seasonal influenza risk alongside age-specific risk factors. The data do not support a strong effect of evolutionary rate, or of broadly protective imprinting that acts across subtypes. Our findings emphasize that childhood exposures can imprint a lifelong immunological bias toward particular influenza subtypes, and that these cohort-specific biases shape epidemic age distributions. As a result, newer and less ``senior'' antibody responses acquired later in life do not provide the same strength of protection as responses imprinted in childhood. Finally, we project that the relatively low mortality burden of H1N1 may increase in the coming decades, as cohorts that lack H1N1-specific imprinting eventually reach old age. Author Summary Influenza viruses of subtype H1N1 and H3N2 both cause seasonal epidemics in humans, but with different age-specific impacts. H3N2 causes a greater proportion of cases in older adults than H1N1, and more deaths overall. People tend to gain the strongest immune memory of influenza viruses encountered in childhood, and so differences in H1N1 and H3N2's age-specific impacts may reflect that individuals born in different eras of influenza circulation have been imprinted with different immunological risk profiles. Another idea is that H3N2 may be more able to infect immunologically experienced adults because it evolves slightly faster than H1N1 and can more quickly escape immune memory. We analyzed a large epidemiological data set and found the clearest signal that birth year-specific differences in childhood immune imprinting, not differences in evolutionary rate, explain differences in H1N1 and H3N2's age-specific impacts. These results can help epidemiologists understand how epidemic risk from specific influenza subtypes is distributed across the population and predict how population risk may shift as differently imprinted birth years grow older. Further, these results provide immunological clues to which facets of immune memory become biased in childhood, and then later play a strong role in protection during seasonal influenza epidemics.},
  archiveprefix = {medRxiv},
  copyright = {\textcopyright{} 2019, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\6IV2BNQF\\Gostic et al. - 2019 - Childhood immune imprinting to influenza A shapes .pdf}
}

@article{gouma2020,
  title = {Middle-Aged Individuals May Be in a Perpetual State of {{H3N2}} Influenza Virus Susceptibility},
  author = {Gouma, Sigrid and Kim, Kangchon and Weirick, Madison E. and Gumina, Megan E. and Branche, Angela and Topham, David J. and Martin, Emily T. and Monto, Arnold S. and Cobey, Sarah and Hensley, Scott E.},
  year = {2020},
  month = sep,
  journal = {Nat Commun},
  volume = {11},
  number = {1},
  pages = {4566},
  issn = {2041-1723},
  doi = {10.1038/s41467-020-18465-x},
  abstract = {Influenza virus exposures in childhood can establish long-lived memory B cell responses that can be recalled later in life. Here, we complete a large serological survey to elucidate the specificity of antibodies against contemporary H3N2 viruses in differently aged individuals who were likely primed with different H3N2 strains in childhood. We find that most humans who were first infected in childhood with H3N2 viral strains from the 1960s and 1970s possess non-neutralizing antibodies against contemporary 3c2.A H3N2 viruses. We find that 3c2.A H3N2 virus infections boost non-neutralizing H3N2 antibodies in middle-aged individuals, potentially leaving many of them in a perpetual state of 3c2.A H3N2 viral susceptibility.},
  langid = {english},
  pmcid = {PMC7486384},
  pmid = {32917903},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Antibodies; Neutralizing,Antibodies; Viral,Antigens; Viral,Child,Child; Preschool,Disease Susceptibility,Female,Hemagglutinin Glycoproteins; Influenza Virus,Humans,Infant,Influenza A Virus; H3N2 Subtype,Influenza; Human,Male,Middle Aged,Models; Biological,Philadelphia,Recombinant Proteins,Seasons,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\TNLYGP74\\Gouma et al. - 2020 - Middle-aged individuals may be in a perpetual stat.pdf}
}

@article{gouma2020a,
  title = {Comparison of {{Human H3N2 Antibody Responses Elicited}} by {{Egg-Based}}, {{Cell-Based}}, and {{Recombinant Protein-Based Influenza Vaccines During}} the 2017-2018 {{Season}}},
  author = {Gouma, Sigrid and Zost, Seth J. and Parkhouse, Kaela and Branche, Angela and Topham, David J. and Cobey, Sarah and Hensley, Scott E.},
  year = {2020},
  month = sep,
  journal = {Clin Infect Dis},
  volume = {71},
  number = {6},
  pages = {1447--1453},
  issn = {1537-6591},
  doi = {10.1093/cid/ciz996},
  abstract = {BACKGROUND: The H3N2 component of egg-based 2017-2018 influenza vaccines possessed an adaptive substitution that alters antigenicity. Several influenza vaccines include antigens that are produced through alternative systems, but a systematic comparison of different vaccines used during the 2017-2018 season has not been completed. METHODS: We compared antibody responses in humans vaccinated with Fluzone (egg-based, n = 23), Fluzone High-Dose (egg-based, n = 16), Flublok (recombinant protein-based, n = 23), or Flucelvax (cell-based, n = 23) during the 2017-2018 season. We completed neutralization assays using an egg-adapted H3N2 virus, a cell-based H3N2 virus, wild-type 3c2.A and 3c2.A2 H3N2 viruses, and the H1N1 vaccine strain. We also performed enzyme-linked immunosorbent assays using a recombinant wild-type 3c2.A hemagglutinin. Antibody responses were compared in adjusted analysis. RESULTS: Postvaccination neutralizing antibody titers to 3c2.A and 3c2.A2 were higher in Flublok recipients compared with Flucelvax or Fluzone recipients (P {$<$} .01). Postvaccination titers to 3c2.A and 3c2.A2 were similar in Flublok and Fluzone High-Dose recipients, though seroconversion rates trended higher in Flublok recipients. Postvaccination titers in Flucelvax recipients were low to all H3N2 viruses tested, including the cell-based H3N2 strain. Postvaccination neutralizing antibody titers to H1N1 were similar among the different vaccine groups. CONCLUSIONS: These data suggest that influenza vaccine antigen match and dose are both important for eliciting optimal H3N2 antibody responses in humans. Future studies should be designed to determine if our findings directly impact vaccine effectiveness. CLINICAL TRIALS REGISTRATION: NCT03068949.},
  langid = {english},
  pmcid = {PMC7486837},
  pmid = {31598646},
  keywords = {antibodies,Antibodies; Viral,Antibody Formation,Antigens; Viral,Hemagglutination Inhibition Tests,hemagglutinin,Hemagglutinin Glycoproteins; Influenza Virus,Humans,influenza,Influenza A Virus; H1N1 Subtype,Influenza A Virus; H3N2 Subtype,Influenza Vaccines,Influenza; Human,Recombinant Proteins,Seasons,vaccine},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\PM2AC58K\\Gouma et al. - 2020 - Comparison of Human H3N2 Antibody Responses Elicit.pdf}
}

@article{grebe2008,
  title = {Heterosubtypic {{Immunity To Influenza A Virus}}: {{Where Do We Stand}}?},
  shorttitle = {Heterosubtypic {{Immunity To Influenza A Virus}}},
  author = {Grebe, Kristie M. and Yewdell, Jonathan W. and Bennink, Jack R.},
  year = {2008},
  month = jul,
  journal = {Microbes Infect},
  volume = {10},
  number = {9},
  pages = {1024--1029},
  issn = {1286-4579},
  doi = {10.1016/j.micinf.2008.07.002},
  urldate = {2021-06-30},
  abstract = {Influenza A virus (IAV) strains are denoted by the subtype of their hemagglutinin (HA) and neuraminidase (NA) virion surface proteins. Major changes in HA subtype among strains circulating in humans are referred to as ``antigenic shift''. Antigenic shift can occur by two means; direct transmission of a zoonotic strain to humans or through reshuffling of the segmented genome in cells co-infected with animal and human strains. The lack of circulating anti-HA antibodies in human populations to a novel IAV results in extremely high frequency of illness and the potential for severe morbidity and mortality on a world-wide basis; the dreaded pandemic. Such pandemics could be partially controlled by developing a vaccine that generates effective heterosubtypic immunity (HSI) based on immune recognition of IAV antigens conserved across all viral strains. While it has long been known that T cells exhibit such broad cross-reactive specificity that could provide effective HSI, recent animal studies suggest a potential role for antibodies as well. Here we review current knowledge of the mechanisms contributing to HSI to influenza and speculate on the potential for this approach to contribute to public health.},
  pmcid = {PMC2584237},
  pmid = {18662798},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\2XYMJQ9Y\\Grebe et al. - 2008 - Heterosubtypic Immunity To Influenza A Virus Wher.pdf}
}

@article{gupta1999,
  title = {The Effects of Host Heterogeneity on Pathogen Population Structure},
  author = {Gupta, S. and Galvani, A.},
  year = {1999},
  month = apr,
  journal = {Philos Trans R Soc Lond B Biol Sci},
  volume = {354},
  number = {1384},
  pages = {711--719},
  issn = {0962-8436},
  doi = {10.1098/rstb.1999.0424},
  abstract = {We have shown that among pathogens, populations may self-organize into strains with non-overlapping repertoires of antigenic variants as a consequence of strong immune selection operating on polymorphic antigens. Recently, we have also demonstrated that over a wide range of intermediate levels of immune selection, pathogens may still be structured into discrete strains, but different sets of non-overlapping pathogen types will replace each other in a cyclical or chaotic manner. These models assume that the ranking of antigens in terms of the strength of the induced immune response is the same for every host. However, host immune responses may be restricted by the genotype of the individual. To explore this issue, a mathematical model was constructed under the assumption that a proportion of the host population responds principally to a variable antigen while the remainder of the population responds principally to a conserved antigen. The results of this analysis indicate that discrete strain structure (DSS) will be maintained even with a high frequency of hosts that do not respond in a variant-specific manner. Furthermore, the range of the immune selection pressure over which DSS prevails is increased (and the region of cyclical or chaotic behaviour reduced) by the inclusion of hosts that respond in a cross-reactive rather than a variant-specific manner.},
  langid = {english},
  pmcid = {PMC1692555},
  pmid = {10365397},
  keywords = {Animals,Antigens,Communicable Diseases,Epidemiologic Methods,HLA Antigens,Host-Parasite Interactions,Humans,Models; Genetic,Species Specificity},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\4EZ4E5N4\\Gupta and Galvani - 1999 - The effects of host heterogeneity on pathogen popu.pdf}
}

@article{gupta2006,
  title = {Quantifying Influenza Vaccine Efficacy and Antigenic Distance},
  author = {Gupta, Vishal and Earl, David J. and Deem, Michael W.},
  year = {2006},
  month = may,
  journal = {Vaccine},
  volume = {24},
  number = {18},
  pages = {3881--3888},
  doi = {10.1016/j.vaccine.2006.01.010},
  langid = {english}
}

@article{guthmiller2018,
  title = {Harnessing Immune History to Combat Influenza Viruses},
  author = {Guthmiller, Jenna J and Wilson, Patrick C},
  year = {2018},
  month = aug,
  journal = {Current Opinion in Immunology},
  volume = {53},
  pages = {187--195},
  issn = {0952-7915},
  doi = {10.1016/j.coi.2018.05.010},
  urldate = {2023-03-02},
  abstract = {Individuals are exposed to influenza viruses throughout their lifetime. Accumulating evidence shows the first viruses an individual is exposed to leaves an imprint on the antibody response induced by subsequent drifted and novel influenza viral exposures. Imprinted humoral immunity against influenza viruses relies on biased immune memory to influenza viruses for which memory B cell responses were initially generated against. Imprinting allows for antibodies to adapt to drifted influenza viruses while maintaining binding potential for the first influenza viruses an individual is exposed to. However, imprinting can increase susceptibility to non-imprinted influenza viruses and mismatched influenza viruses. This review highlights the role of imprinting on the regulation of antibody responses induced by influenza viruses and explores potential vaccine strategies to harness imprinted antibody responses to increase protection against influenza.},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\FG94F5LD\\Guthmiller and Wilson - 2018 - Harnessing immune history to combat influenza viru.pdf}
}

@article{hancock2009,
  title = {Cross-Reactive Antibody Responses to the 2009 Pandemic {{H1N1}} Influenza Virus},
  author = {Hancock, Kathy and Veguilla, Vic and Lu, Xiuhua and Zhong, Weimin and Butler, Ebone{\'e} N. and Sun, Hong and Liu, Feng and Dong, Libo and DeVos, Joshua R. and Gargiullo, Paul M. and Brammer, T. Lynnette and Cox, Nancy J. and Tumpey, Terrence M. and Katz, Jacqueline M.},
  year = {2009},
  month = nov,
  journal = {N Engl J Med},
  volume = {361},
  number = {20},
  pages = {1945--1952},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa0906453},
  abstract = {BACKGROUND: A new pandemic influenza A (H1N1) virus has emerged, causing illness globally, primarily in younger age groups. To assess the level of preexisting immunity in humans and to evaluate seasonal vaccine strategies, we measured the antibody response to the pandemic virus resulting from previous influenza infection or vaccination in different age groups. METHODS: Using a microneutralization assay, we measured cross-reactive antibodies to pandemic H1N1 virus (2009 H1N1) in stored serum samples from persons who either donated blood or were vaccinated with recent seasonal or 1976 swine influenza vaccines. RESULTS: A total of 4 of 107 persons (4\%) who were born after 1980 had preexisting cross-reactive antibody titers of 40 or more against 2009 H1N1, whereas 39 of 115 persons (34\%) born before 1950 had titers of 80 or more. Vaccination with seasonal trivalent inactivated influenza vaccines resulted in an increase in the level of cross-reactive antibody to 2009 H1N1 by a factor of four or more in none of 55 children between the ages of 6 months and 9 years, in 12 to 22\% of 231 adults between the ages of 18 and 64 years, and in 5\% or less of 113 adults 60 years of age or older. Seasonal vaccines that were formulated with adjuvant did not further enhance cross-reactive antibody responses. Vaccination with the A/New Jersey/1976 swine influenza vaccine substantially boosted cross-reactive antibodies to 2009 H1N1 in adults. CONCLUSIONS: Vaccination with recent seasonal nonadjuvanted or adjuvanted influenza vaccines induced little or no cross-reactive antibody response to 2009 H1N1 in any age group. Persons under the age of 30 years had little evidence of cross-reactive antibodies to the pandemic virus. However, a proportion of older adults had preexisting cross-reactive antibodies.},
  langid = {english},
  pmid = {19745214},
  keywords = {Adult,Age Distribution,Aged,Aged; 80 and over,Antibodies; Viral,Cross Reactions,Female,Humans,Influenza A Virus; H1N1 Subtype,Influenza Vaccines,Influenza; Human,Male,Middle Aged,Neutralization Tests,Young Adult}
}

@article{hansen2021,
  title = {Repeated {{Influenza Vaccination Boosts}} and {{Maintains H1N1pdm09 Neuraminidase Antibody Titers}}},
  author = {Hansen, Lena and Zhou, Fan and Amdam, H{\aa}kon and Trieu, Mai-Chi and Cox, Rebecca Jane},
  year = {2021},
  month = oct,
  journal = {Front Immunol},
  volume = {12},
  pages = {748264},
  issn = {1664-3224},
  doi = {10.3389/fimmu.2021.748264},
  urldate = {2022-01-21},
  abstract = {Antibodies to influenza surface protein neuraminidase (NA) have been found to reduce disease severity and may be an independent correlate of protection. Despite this, current influenza vaccines have no regulatory requirements for the quality or quantity of the NA antigen and are not optimized for induction of NA-specific antibodies. Here we investigate the induction and durability of NA-specific antibody titers after pandemic AS03-adjuvanted monovalent H1N1 vaccination and subsequent annual vaccination in health care workers in a five-year longitudinal study. NA-specific antibodies were measured by endpoint ELISA and functional antibodies measured by enzyme-linked lectin assay (ELLA) and plaque reduction naturalisation assay. We found robust induction of NA inhibition (NAI) titers with a 53\% seroconversion rate ({$>$}4-fold) after pandemic vaccination in 2009. Furthermore, the endpoint and NAI geometric mean titers persisted above pre-vaccination levels up to five years after vaccination in HCWs that only received the pandemic vaccine, which demonstrates considerable durability. Vaccination with non-adjuvanted trivalent influenza vaccines (TIV) in subsequent influenza seasons 2010/2011 \textendash{} 2013/2014 further boosted NA-specific antibody responses. We found that each subsequent vaccination increased durable endpoint titers and contributed to maintaining the durability of functional antibody titers. Although the trivalent influenza vaccines boosted NA-specific antibodies, the magnitude of fold-increase at day 21 declined with repeated vaccination, particularly for functional antibody titers. High levels of pre-existing antibodies were associated with lower fold-induction in repeatedly vaccinated HCWs. In summary, our results show that durable NA-specific antibody responses can be induced by an adjuvanted influenza vaccine, which can be maintained and further boosted by TIVs. Although NA-specific antibody responses are boosted by annual influenza vaccines, high pre-existing titers may negatively affect the magnitude of fold-increase in repeatedly vaccinated individuals. Our results support continued development and standardization of the NA antigen to supplement current influenza vaccines and reduce the burden of morbidity and mortality.},
  pmcid = {PMC8551669},
  pmid = {34721417},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\RGAJ457E\\Hansen et al. - 2021 - Repeated Influenza Vaccination Boosts and Maintain.pdf}
}

@article{hansen2021a,
  title = {Repeated {{Influenza Vaccination Boosts}} and {{Maintains H1N1pdm09 Neuraminidase Antibody Titers}}},
  author = {Hansen, Lena and Zhou, Fan and Amdam, H{\aa}kon and Trieu, Mai-Chi and Cox, Rebecca Jane},
  year = {2021},
  journal = {Frontiers in Immunology},
  volume = {12},
  issn = {1664-3224},
  urldate = {2023-03-22},
  abstract = {Antibodies to influenza surface protein neuraminidase (NA) have been found to reduce disease severity and may be an independent correlate of protection. Despite this, current influenza vaccines have no regulatory requirements for the quality or quantity of the NA antigen and are not optimized for induction of NA-specific antibodies. Here we investigate the induction and durability of NA-specific antibody titers after pandemic AS03-adjuvanted monovalent H1N1 vaccination and subsequent annual vaccination in health care workers in a five-year longitudinal study. NA-specific antibodies were measured by endpoint ELISA and functional antibodies measured by enzyme-linked lectin assay (ELLA) and plaque reduction naturalisation assay. We found robust induction of NA inhibition (NAI) titers with a 53\% seroconversion rate ({$>$}4-fold) after pandemic vaccination in 2009. Furthermore, the endpoint and NAI geometric mean titers persisted above pre-vaccination levels up to five years after vaccination in HCWs that only received the pandemic vaccine, which demonstrates considerable durability. Vaccination with non-adjuvanted trivalent influenza vaccines (TIV) in subsequent influenza seasons 2010/2011 \textendash{} 2013/2014 further boosted NA-specific antibody responses. We found that each subsequent vaccination increased durable endpoint titers and contributed to maintaining the durability of functional antibody titers. Although the trivalent influenza vaccines boosted NA-specific antibodies, the magnitude of fold-increase at day 21 declined with repeated vaccination, particularly for functional antibody titers. High levels of pre-existing antibodies were associated with lower fold-induction in repeatedly vaccinated HCWs. In summary, our results show that durable NA-specific antibody responses can be induced by an adjuvanted influenza vaccine, which can be maintained and further boosted by TIVs. Although NA-specific antibody responses are boosted by annual influenza vaccines, high pre-existing titers may negatively affect the magnitude of fold-increase in repeatedly vaccinated individuals. Our results support continued development and standardization of the NA antigen to supplement current influenza vaccines and reduce the burden of morbidity and mortality.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\D3NCA8L6\\Hansen et al. - 2021 - Repeated Influenza Vaccination Boosts and Maintain.pdf}
}

@article{hay2019,
  title = {Characterising Antibody Kinetics from Multiple Influenza Infection and Vaccination Events in Ferrets},
  author = {Hay, James A. and Laurie, Karen and White, Michael and Riley, Steven},
  editor = {Antia, Rustom},
  year = {2019-08-19, 2019-08},
  journal = {PLOS Computational Biology},
  volume = {15},
  number = {8},
  pages = {e1007294},
  doi = {10.1371/journal.pcbi.1007294},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\X25WWMWX\\Hay et al. - 2019 - Characterising antibody kinetics from multiple inf.pdf}
}

@article{hay2019a,
  title = {Characterising Antibody Kinetics from Multiple Influenza Infection and Vaccination Events in Ferrets},
  author = {Hay, James A. and Laurie, Karen and White, Michael and Riley, Steven},
  year = {2019},
  month = aug,
  journal = {PLoS Comput Biol},
  volume = {15},
  number = {8},
  pages = {e1007294},
  issn = {1553-734X},
  doi = {10.1371/journal.pcbi.1007294},
  urldate = {2023-03-22},
  abstract = {The strength and breadth of an individual's antibody repertoire is an important predictor of their response to influenza infection or vaccination. Although progress has been made in understanding qualitatively how repeated exposures shape the antibody mediated immune response, quantitative understanding remains limited. We developed a set of mathematical models describing short-term antibody kinetics following influenza infection or vaccination and fit them to haemagglutination inhibition (HI) titres from 5 groups of ferrets which were exposed to different combinations of trivalent inactivated influenza vaccine (TIV with or without adjuvant), A/H3N2 priming inoculation and post-vaccination A/H1N1 inoculation. We fit models with various immunological mechanisms that have been empirically observed but have not previously been included in mathematical models of antibody landscapes, including: titre ceiling effects, antigenic seniority and exposure-type specific cross reactivity. Based on the parameter estimates of the best supported models, we describe a number of key immunological features. We found quantifiable differences in the degree of homologous and cross-reactive antibody boosting elicited by different exposure types. Infection and adjuvanted vaccination generally resulted in strong, broadly reactive responses whereas unadjuvanted vaccination resulted in a weak, narrow response. We found that the order of exposure mattered: priming with A/H3N2 improved subsequent vaccine response, and the second dose of adjuvanted vaccination resulted in substantially greater antibody boosting than the first. Either antigenic seniority or a titre ceiling effect were included in the two best fitting models, suggesting a role for a mechanism describing diminishing antibody boosting with repeated exposures. Although there was considerable uncertainty in our estimates of antibody waning parameters, our results suggest that both short and long term waning were present and would be identifiable with a larger set of experiments. These results highlight the potential use of repeat exposure animal models in revealing short-term, strain-specific immune dynamics of influenza., Despite most individuals having some preexisting immunity from past influenza infections and vaccinations, a significant proportion of the human population is infected with influenza each year. Predicting how an individual's antibody profile will change following exposure is therefore useful for evaluating which populations are at greatest risk and how effective vaccination strategies might be. However, interpretation of antibody data from humans is complicated by immunological interactions between all previous, unobserved exposures in an individual's life. We developed a mathematical model to describe short-term antibody kinetics that are important in building an individual's immune profile but are difficult to observe in human populations. We validated this model using antibody data from ferrets with known, varied infection and vaccination histories. We were able to quantify the independent contributions of various exposures and immunological mechanisms in generating observed antibody titres. These results suggest that data from experimental systems may be included in models of human antibody dynamics, which may improve predictions of vaccination strategy effectiveness and how population susceptibility changes over time.},
  pmcid = {PMC6715255},
  pmid = {31425503},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\4A6929FG\\Hay et al. - 2019 - Characterising antibody kinetics from multiple inf.pdf}
}

@article{hay2020,
  title = {An Open Source Tool to Infer Epidemiological and Immunological Dynamics from Serological Data: Serosolver},
  author = {Hay, James A. and Minter, Amanda and Ainslie, Kylie E. C. and Lessler, Justin and Yang, Bingyi and Cummings, Derek A. T. and Kucharski, Adam J. and Riley, Steven},
  editor = {Regoes, Roland R},
  year = {2020-05-04, 2020-05},
  journal = {PLOS Computational Biology},
  volume = {16},
  number = {5},
  pages = {e1007840},
  doi = {10.1371/journal.pcbi.1007840},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\3MP4NVY3\\Hay et al. - 2020 - An open source tool to infer epidemiological and i.pdf}
}

@article{henn2013,
  title = {High-Resolution Temporal Response Patterns to Influenza Vaccine Reveal a Distinct Human Plasma Cell Gene Signature},
  author = {Henn, Alicia D. and Wu, Shuang and Qiu, Xing and Ruda, Melissa and Stover, Michael and Yang, Hongmei and Liu, Zhiping and Welle, Stephen L. and {Holden-Wiltse}, Jeanne and Wu, Hulin and Zand, Martin S.},
  year = {2013},
  journal = {Sci Rep},
  volume = {3},
  pages = {2327},
  issn = {2045-2322},
  doi = {10.1038/srep02327},
  abstract = {To identify sources of inter-subject variation in vaccine responses, we performed high-frequency sampling of human peripheral blood cells post-vaccination, followed by a novel systems biology analysis. Functional principal component analysis was used to examine time varying B cell vaccine responses. In subjects vaccinated within the previous three years, 90\% of transcriptome variation was explained by a single subject-specific mathematical pattern. Within individual vaccine response patterns, a common subset of 742 genes was strongly correlated with migrating plasma cells. Of these, 366 genes were associated with human plasmablasts differentiating in vitro. Additionally, subject-specific temporal transcriptome patterns in peripheral blood mononuclear cells identified migration of myeloid/dendritic cell lineage cells one day after vaccination. Upstream analyses of transcriptome changes suggested both shared and subject-specific transcription groups underlying larger patterns. With robust statistical methods, time-varying response characteristics of individual subjects were effectively captured along with a shared plasma cell gene signature.},
  langid = {english},
  pmcid = {PMC3728595},
  pmid = {23900141},
  keywords = {B-Lymphocytes,Blood Proteins,Cells; Cultured,Gene Expression Regulation,Humans,Influenza Vaccines,Transcriptome},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\BA8VSZN7\\Henn et al. - 2013 - High-resolution temporal response patterns to infl.pdf}
}

@article{henry2018,
  title = {From {{Original Antigenic Sin}} to the {{Universal Influenza Virus Vaccine}}},
  author = {Henry, Carole and Palm, Anna-Karin E. and Krammer, Florian and Wilson, Patrick C.},
  year = {2018},
  month = jan,
  journal = {Trends Immunol},
  volume = {39},
  number = {1},
  pages = {70--79},
  issn = {1471-4981},
  doi = {10.1016/j.it.2017.08.003},
  abstract = {Antibody responses are essential for protection against influenza virus infection. Humans are exposed to a multitude of influenza viruses throughout their lifetime and it is clear that immune history influences the magnitude and quality of the antibody response. The 'original antigenic sin' concept refers to the impact of the first influenza virus variant encounter on lifelong immunity. Although this model has been challenged since its discovery, past exposure, and likely one's first exposure, clearly affects the epitopes targeted in subsequent responses. Understanding how previous exposure to influenza virus shapes antibody responses to vaccination and infection is critical, especially with the prospect of future pandemics and for the effective development of a universal influenza vaccine.},
  langid = {english},
  pmcid = {PMC5748348},
  pmid = {28867526},
  keywords = {Animals,Antibodies; Viral,Antibody Diversity,Antigenic Variation,Antigens; Viral,Environmental Exposure,Humans,Immunity; Humoral,Immunodominant Epitopes,Immunologic Memory,Influenza Vaccines,Influenza; Human,Orthomyxoviridae,Orthomyxoviridae Infections,Vaccination},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\KCS2UM4B\\Henry et al. - 2018 - From Original Antigenic Sin to the Universal Influ.pdf}
}

@article{hinojosa2020,
  title = {Impact of Immune Priming, Vaccination, and Infection on Influenza {{A}}({{H3N2}}) Antibody Landscapes in Children},
  author = {Hinojosa, Michael and Shepard, Samuel S and Chung, Jessie R and King, Jennifer P and McLean, Huong Q and Flannery, Brendan and Belongia, Edward A and Levine, Min Z},
  year = {2020-10-22, 2020-10},
  journal = {The Journal of Infectious Diseases},
  doi = {10.1093/infdis/jiaa665},
  langid = {english}
}

@article{hipc2017,
  title = {Multicohort Analysis Reveals Baseline Transcriptional Predictors of Influenza Vaccination Responses},
  author = {{HIPC-CHI Signatures Project Team} and {HIPC-I Consortium}},
  year = {2017},
  month = aug,
  journal = {Sci Immunol},
  volume = {2},
  number = {14},
  pages = {eaal4656},
  issn = {2470-9468},
  doi = {10.1126/sciimmunol.aal4656},
  abstract = {Annual influenza vaccinations are currently recommended for all individuals 6 months and older. Antibodies induced by vaccination are an important mechanism of protection against infection. Despite the overall public health success of influenza vaccination, many individuals fail to induce a substantial antibody response. Systems-level immune profiling studies have discerned associations between transcriptional and cell subset signatures with the success of antibody responses. However, existing signatures have relied on small cohorts and have not been validated in large independent studies. We leveraged multiple influenza vaccination cohorts spanning distinct geographical locations and seasons from the Human Immunology Project Consortium (HIPC) and the Center for Human Immunology (CHI) to identify baseline (i.e., before vaccination) predictive transcriptional signatures of influenza vaccination responses. Our multicohort analysis of HIPC data identified nine genes (RAB24, GRB2, DPP3, ACTB, MVP, DPP7, ARPC4, PLEKHB2, and ARRB1) and three gene modules that were significantly associated with the magnitude of the antibody response, and these associations were validated in the independent CHI cohort. These signatures were specific to young individuals, suggesting that distinct mechanisms underlie the lower vaccine response in older individuals. We found an inverse correlation between the effect size of signatures in young and older individuals. Although the presence of an inflammatory gene signature, for example, was associated with better antibody responses in young individuals, it was associated with worse responses in older individuals. These results point to the prospect of predicting antibody responses before vaccination and provide insights into the biological mechanisms underlying successful vaccination responses.},
  langid = {english},
  pmcid = {PMC5800877},
  pmid = {28842433},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\XQI8KSUN\\HIPC-CHI Signatures Project Team and HIPC-I Consortium - 2017 - Multicohort analysis reveals baseline transcriptio.pdf}
}

@article{hobson1972,
  title = {The Role of Serum Haemagglutination-Inhibiting Antibody in Protection against Challenge Infection with Influenza {{A2}} and {{B}} Viruses},
  author = {Hobson, D. and Curry, R. L. and Beare, A. S. and {Ward-Gardner}, A.},
  year = {1972},
  month = dec,
  journal = {Epidemiology \& Infection},
  volume = {70},
  number = {4},
  pages = {767--777},
  publisher = {{Cambridge University Press}},
  issn = {1469-4409, 0950-2688},
  doi = {10.1017/S0022172400022610},
  urldate = {2022-05-09},
  abstract = {The intranasal inoculation of volunteers with living partially attenuated strains of influenza A and B viruses offers a new opportunity to determine the protective effect of serum haemagglutin-inhibiting antibody against a strictly homologous virus, under conditions where the time and dosage of the infective challenge can be controlled, the scoring of proven infections can be more precise and higher rates of infection can be achieved than in most natural epidemics.In 1032 adult volunteers, whose serum HI antibody titre was determined immediately before virus challenge, there was a consistent inverse quantitative relationship between the HI titre and the likelihood of infection. The PD50 (50 \% protective dose) of HI antibody was 1/18\textendash 1/36, but an unusual finding was that volunteers with no detectable pre-challenge antibody often seem to be less susceptible to infection than those with pre-challenge antibody in low titre.In one group of volunteers challenged with an influenza B strain there was no evidence that pre-challenge antibody titres against viral neuraminidase had any significant protective effect against challenge infection.},
  langid = {english},
  keywords = {Adjuvants; Immunologic,Administration; Intranasal,Adolescent,Adult,Amino Acid Substitution,Animals,Antibodies,Antibodies; Viral,antibody,Antibody response,Antigenic Variation,Antigens; Viral,Broadly Neutralizing Antibodies,Child,Child; Preschool,Computational Biology,Computer Simulation,Cross Reactions,Cross reactivity,Disease Models; Animal,Evolution; Molecular,Female,ferret,Ferrets,Genes; Viral,Genetic Drift,Genetic Variation,Hemagglutination Inhibition Tests,hemagglutinin,Hemagglutinin Glycoproteins; Influenza Virus,Hemagglutinins; Viral,High-Throughput Screening Assays,human,Humans,Immunization; Secondary,Immunoassay,Immunologic adjuvants,Infant,Infant; Newborn,influenza,Influenza,Influenza A virus,Influenza A Virus; H1N1 Subtype,Influenza A Virus; H3N2 Subtype,Influenza Vaccines,Influenza; Human,Kinetics,landscape,Male,MIADA,Mice,Mice; Inbred BALB C,Middle Aged,Models; Immunological,Models; Molecular,Molecular Sequence Data,Mutagenesis; Site-Directed,Mutation,Nanomedicine,Nanoparticles,Neuraminidase,Orthomyxoviridae,Orthomyxoviridae Infections,Seasons,Vaccination,Vaccination and immunization,Vaccines,Vaccines; Inactivated,Virology,Young Adult}
}

@article{honce2019,
  title = {Impact of {{Obesity}} on {{Influenza A Virus Pathogenesis}}, {{Immune Response}}, and {{Evolution}}},
  author = {Honce, Rebekah and {Schultz-Cherry}, Stacey},
  year = {2019},
  journal = {Front Immunol},
  volume = {10},
  pages = {1071},
  issn = {1664-3224},
  doi = {10.3389/fimmu.2019.01071},
  abstract = {With the rising prevalence of obesity has come an increasing awareness of its impact on communicable disease. As a consequence of the 2009 H1N1 influenza A virus pandemic, obesity was identified for the first time as a risk factor for increased disease severity and mortality in infected individuals. Over-nutrition that results in obesity causes a chronic state of meta-inflammation with systemic implications for immunity. Obese hosts exhibit delayed and blunted antiviral responses to influenza virus infection, and they experience poor recovery from the disease. Furthermore, the efficacy of antivirals and vaccines is reduced in this population and obesity may also play a role in altering the viral life cycle, thus complementing the already weakened immune response and leading to severe pathogenesis. Case studies and basic research in human cohorts and animal models have highlighted the prolonged viral shed in the obese host, as well as a microenvironment that permits the emergence of virulent minor variants. This review focuses on influenza A virus pathogenesis in the obese host, and on the impact of obesity on the antiviral response, viral shed, and viral evolution. We comprehensively analyze the recent literature on how and why viral pathogenesis is altered in the obese host along with the impact of the altered host and pathogenic state on viral evolutionary dynamics in multiple models. Finally, we summarized the effectiveness of current vaccines and antivirals in this populations and the questions that remain to be answered. If current trends continue, nearly 50\% of the worldwide population is projected to be obese by 2050. This population will have a growing impact on both non-communicable and communicable diseases and may affect global evolutionary trends of influenza virus.},
  langid = {english},
  pmcid = {PMC6523028},
  pmid = {31134099},
  keywords = {Animals,Antibodies; Viral,Disease Models; Animal,evolution,Humans,immunity,influenza,Influenza A Virus; H1N1 Subtype,Influenza Vaccines,Influenza; Human,Lung,Mice,Mice; Inbred C57BL,Mice; Obese,obesity,Obesity,Orthomyxoviridae Infections,pathogenesis,Risk Factors},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\5S99IT47\\Honce and Schultz-Cherry - 2019 - Impact of Obesity on Influenza A Virus Pathogenesi.pdf}
}

@article{jacobson2015,
  title = {Profiles of Influenza {{A}}/{{H1N1}} Vaccine Response Using Hemagglutination-Inhibition Titers},
  author = {Jacobson, Robert M. and Grill, Diane E. and Oberg, Ann L. and Tosh, Pritish K. and Ovsyannikova, Inna G. and Poland, Gregory A.},
  year = {2015},
  journal = {Hum Vaccin Immunother},
  volume = {11},
  number = {4},
  pages = {961--969},
  issn = {2164-554X},
  doi = {10.1080/21645515.2015.1011990},
  abstract = {To identify distinct antibody profiles among adults 50-to-74 years old using influenza A/H1N1 HI titers up to 75 days after vaccination. Healthy subjects 50 to 74 years old received the 2010-2011 trivalent inactivated influenza vaccine. We measured venous samples from Days 0, 28, and 75 for HI and VNA and B-cell ELISPOTs. Of 106 subjects, HI titers demonstrated a ceiling effect for 11 or 10\% for those with a pre-vaccination HI titer of 1:640 where no subject post-vaccination had an increase in titer. Of the remaining 95 subjects, only 37 or 35\% overall had at least a 4-fold increase by Day 28. Of these 37, 3 waned at least 4-fold, and 13 others 2-fold. Thus 15\% of the subjects showed waning antibody titers by Day 75. More than half failed to respond at all. The profiles populated by these subjects as defined by HI did not vary with age or gender. The VNA results mimicked the HI profiles, but the profiles for B-cell ELISPOT did not. HI titers at Days 0, 28, and 75 populate 4 biologically plausible profiles. Limitations include lack of consensus for operationally defining waning as well as for the apparent ceiling. Furthermore, though well accepted as a marker for vaccine response, assigning thresholds with HI has limitations. However, VNA closely matches HI in populating these profiles. Thus, we hold that these profiles, having face- and content-validity, may provide a basis for understanding variation in genomic and transcriptomic response to influenza vaccination in this age group.},
  langid = {english},
  pmcid = {PMC4514374},
  pmid = {25835513},
  keywords = {Aged,aging,antibodies,ASC; Antibody-Secreting Cells,ELISPOT; Enzyme-Linked ImmunoSpot,Et al.; Et alia (and others),Female,H1N1 subtype,hemagglutination inhibition tests,Hemagglutination Inhibition Tests,hemagglutinin glycoproteins,HI; Hemagglutination-Inhibition,Humans,IgG; Immunoglobulin G,influenza a virus,Influenza A Virus; H1N1 Subtype,influenza vaccines,Influenza Vaccines,influenza virus,Influenza; Human,IQR; Interquartile Range,Male,MDCK; Madin-Darby Canine Kidney,Middle Aged,p; p-value,PFU; Plaque-Forming Units,RBC; Red Blood Cells,TCID50; Tissue Culture Infectious Dose 50,viral,VNA; Virus Neutralization Assay,WHO; World Health Organization,Î¼l; Microliters},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\8BPTB5X3\\Jacobson et al. - 2015 - Profiles of influenza AH1N1 vaccine response usin.pdf}
}

@article{jang2021,
  title = {Hemagglutination {{Inhibition}} ({{HAI}}) Antibody Landscapes after Vaccination with {{H7Nx}} Virus like Particles},
  author = {Jang, Hyesun and Ross, Ted M.},
  year = {2021},
  journal = {PLoS One},
  volume = {16},
  number = {3},
  pages = {e0246613},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0246613},
  abstract = {BACKGROUND: A systemic evaluation of the antigenic differences of the H7 influenza hemagglutinin (HA) proteins, especially for the viruses isolated after 2016, are limited. The purpose of this study was to investigate the antigenic differences of major H7 strains with an ultimate aim to discover H7 HA proteins that can elicit protective receptor-binding antibodies against co-circulating H7 influenza strains. METHOD: A panel of eight H7 influenza strains were selected from 3,633 H7 HA amino acid sequences identified over the past two decades (2000-2018). The sequences were expressed on the surface of virus like particles (VLPs) and used to vaccinate C57BL/6 mice. Serum samples were collected and tested for hemagglutination-inhibition (HAI) activity. The vaccinated mice were challenged with lethal dose of H7N9 virus, A/Anhui/1/2013. RESULTS: VLPs expressing the H7 HA antigens elicited broadly reactive antibodies each of the selected H7 HAs, except the A/Turkey/Italy/589/2000 (Italy/00) H7 HA. A putative glycosylation due to an A169T substitution in antigenic site B was identified as a unique antigenic profile of Italy/00. Introduction of the putative glycosylation site (H7 HA-A169T) significantly altered the antigenic profile of HA of the A/Anhui/1/2013 (H7N9) strain. CONCLUSION: This study identified key amino acid mutations that result in severe vaccine mismatches for future H7 epidemics. Future universal influenza vaccine candidates will need to focus on viral variants with these key mutations.},
  langid = {english},
  pmcid = {PMC7971484},
  pmid = {33735274},
  keywords = {Animals,Antibodies; Neutralizing,Antibodies; Viral,Female,Hemagglutination Inhibition Tests,Hemagglutinin Glycoproteins; Influenza Virus,Influenza A Virus; H7N9 Subtype,Influenza Vaccines,Mice,Mice; Inbred C57BL,Mutation,Phylogeny,Vaccines; Virus-Like Particle}
}

@article{katz2009,
  title = {Serum Cross-Reactive Antibody Response to a Novel Influenza {{A}} ({{H1N1}}) Virus after Vaccination with Seasonal Influenza Vaccine.},
  author = {Katz, J. and Hancock, K. and Veguilla, V. and Zhong, W. and Lu, X. H. and Sun, H. and Butler, E. and Dong, L. and Liu, F. and Li, Z. N. and DeVos, J. and Gargiullo, P. and Cox, N.},
  year = {2009},
  journal = {Morbidity and Mortality Weekly Report},
  volume = {58},
  number = {19},
  pages = {521--524},
  publisher = {{Epidemiology Program Office, Centers for Disease Control and Prevention (CDC)}},
  issn = {0149-2195},
  urldate = {2023-03-02},
  abstract = {Using stored serum specimens collected during previous vaccine studies, CDC assessed the level of cross-reactive antibody to the novel influenza A (H1N1) virus in cohorts of children and adults before and after they had been vaccinated with the 2005-06, 2006-07, 2007-08, or 2008-09 influenza season vaccines. This report summarizes the results of that analysis which indicated that before...},
  langid = {english}
}

@article{katzelnick2021,
  title = {Antigenic Evolution of Dengue Viruses over 20 Years},
  author = {Katzelnick, Leah C. and Coello Escoto, Ana and Huang, Angkana T. and {Garcia-Carreras}, Bernardo and Chowdhury, Nayeem and Maljkovic Berry, Irina and Chavez, Chris and Buchy, Philippe and Duong, Veasna and Dussart, Philippe and Gromowski, Gregory and Macareo, Louis and Thaisomboonsuk, Butsaya and Fernandez, Stefan and Smith, Derek J. and Jarman, Richard and Whitehead, Stephen S. and Salje, Henrik and Cummings, Derek A. T.},
  year = {2021-11-19, 2021-11},
  journal = {Science},
  volume = {374},
  number = {6570},
  pages = {999--1004},
  doi = {10.1126/science.abk0058},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\8AB72S58\\Katzelnick et al. - 2021 - Antigenic evolution of dengue viruses over 20 year.pdf}
}

@article{kavian2021,
  title = {Repeated Influenza Vaccination Provides Cumulative Protection from Distinct {{H3N2}} Viruses},
  author = {Kavian, Niloufar and Hachim, Asmaa and Cowling, Benjamin J. and Valkenburg, Sophie A.},
  year = {2021},
  journal = {Clin Transl Immunology},
  volume = {10},
  number = {6},
  pages = {e1297},
  issn = {2050-0068},
  doi = {10.1002/cti2.1297},
  abstract = {OBJECTIVES: Current inactivated influenza vaccines provide suboptimal protection against antigenic drift, and repeated annual vaccinations shape antibody specificity but the effect on protection from infection is not well understood. METHODS: We studied the effects of cumulative and staggered vaccinations in mice to determine the effect of influenza vaccination on protection from infection and immune quality. RESULTS: We found that the timing of vaccination and antigenic change impacted the quality of immune responses. When mice received two different H3N2 strains (A/Hong Kong/4801/2014 and A/Singapore/INFIMH-16-0019/2016) by staggered timing of vaccination, there were higher H3HA antibody and B-cell memory responses than four cumulative vaccinations or when two vaccinations were successive. Interestingly, after challenge with a lethal-drifted H3N2 virus (A/Hong Kong/1/1968), mice with staggered vaccination were unable to produce high titres of antibodies specific to the challenge strain compared to other vaccination regimens because of high levels of vaccine-specific cross-reactive antibodies. All vaccination regimens resulted in protection, in terms of viral loads and survival, from lethal challenge, while lung IL-6 and inflammation were lowest in staggered or cumulative vaccination groups, indicating further advantage. CONCLUSION: Our findings help justify influenza vaccination policies that currently recommend repeat vaccination in infants and annual seasonal vaccination, with no evidence for impaired immunity by repeated seasonal vaccination.},
  langid = {english},
  pmcid = {PMC8200319},
  pmid = {34136219},
  keywords = {antibodies,crossâprotection,immune imprinting,influenza virus,repeated vaccination},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\W3LSGM69\\Kavian et al. - 2021 - Repeated influenza vaccination provides cumulative.pdf}
}

@article{kendra2021,
  title = {Antigenic Cartography Reveals Complexities of Genetic Determinants That Lead to Antigenic Differences among Pandemic {{GII}}.4 Noroviruses},
  author = {Kendra, Joseph A. and Tohma, Kentaro and {Ford-Siltz}, Lauren A. and Lepore, Cara J. and Parra, Gabriel I.},
  year = {2021-03-08, 2021-03},
  journal = {Proceedings of the National Academy of Sciences},
  volume = {118},
  number = {11},
  doi = {10.1073/pnas.2015874118},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\XH6VB3FQ\\Kendra et al. - 2021 - Antigenic cartography reveals complexities of gene.pdf}
}

@article{kenney2004,
  title = {Dose Sparing with Intradermal Injection of Influenza Vaccine},
  author = {Kenney, Richard T. and Frech, Sarah A. and Muenz, Larry R. and Villar, Christina P. and Glenn, Gregory M.},
  year = {2004},
  month = nov,
  journal = {N Engl J Med},
  volume = {351},
  number = {22},
  pages = {2295--2301},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa043540},
  abstract = {BACKGROUND: The loss of half the U.S. supply of influenza vaccine due to contamination has created a critical shortage. Dose-sparing strategies that use intradermal delivery of vaccines may be one approach to consider. METHODS: We conducted a randomized, open-label trial outside the influenza season in 100 healthy adults 18 to 40 years of age to compare the immunogenicity and safety of intradermal immunization with influenza vaccine with standard intramuscular immunization. Subjects were randomly assigned to receive either a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microg of hemagglutinin per strain, by means of a prefilled syringe or a single intradermal dose of 0.1 ml, containing at least 3 microg of hemagglutinin per strain, by means of a fine-gauge needle; both injections were in the deltoid region. Changes in the hemagglutination-inhibition (HAI) antibody titer were assessed by comparing geometric mean titers and fold increases relative to baseline values and by comparing changes in the seroconversion and seroprotection rates. Local and systemic adverse events were assessed after both types of vaccination. RESULTS: Subjects who received an intradermal injection with one fifth the standard dose of influenza vaccine had increases in the geometric mean HAI titer by a factor of 15.2 for the H1N1 strain in the vaccine, 19.0 for the H3N2 strain, and 12.4 for the B strain on day 21, as compared with respective increases by a factor of 14.9, 7.1, and 15.3 for the intramuscular injection of the standard dose. Seroconversion and seroprotection rates were similar in the two groups on day 21, ranging from 66 to 82 percent and 84 to 100 percent, respectively. Local reactions were significantly more frequent among recipients of intradermal injections than among recipients of intramuscular injections, but such reactions were mild and transient. CONCLUSIONS: In this study of young adults, intradermal administration of one fifth the standard intramuscular dose of an influenza vaccine elicited immunogenicity that was similar to or better than that elicited by intramuscular injection. Intradermal administration could be used to expand the supplies of influenza vaccine, but further studies are needed before this strategy can be recommended for routine use.},
  langid = {english},
  pmid = {15525714},
  keywords = {Adolescent,Adult,Antibodies; Viral,Female,Hemagglutinin Glycoproteins; Influenza Virus,Humans,Influenza A virus,Influenza B virus,Influenza Vaccines,Influenza; Human,Injections; Intradermal,Injections; Intramuscular,Male}
}

@article{keshavarz2021,
  title = {Epigenetic Reprogramming Mechanisms of Immunity during Influenza {{A}} Virus Infection},
  author = {Keshavarz, Mohsen and Sabbaghi, Ailar and Koushki, Khadijeh and Miri, Seyed Mohammad and Sarshari, Behrang and Vahdat, Katayoun and Ghaemi, Amir},
  year = {2021},
  journal = {Microbes Infect},
  volume = {23},
  number = {8},
  pages = {104831},
  issn = {1769-714X},
  doi = {10.1016/j.micinf.2021.104831},
  abstract = {This paper reviews epigenetic mechanisms by which influenza viruses affect cellular gene activity to control their life cycles, aiming to provide new insights into the complexity of functional interactions between viral and cellular factors, as well as to introduce novel targets for therapeutic intervention and vaccine development against influenza infections.},
  langid = {english},
  pmid = {33878459},
  keywords = {Antiviral strategy,Epigenesis; Genetic,Epigenetic,Gene expression,Humans,Influenza A virus,Influenza Vaccines,Influenza; Human,Orthomyxoviridae,Orthomyxoviridae Infections}
}

@article{khurana2012,
  title = {Immune {{Response Following H1N1pdm09 Vaccination}}: {{Differences}} in {{Antibody Repertoire}} and {{Avidity}} in {{Young Adults}} and {{Elderly Populations Stratified}} by {{Age}} and {{Gender}}},
  shorttitle = {Immune {{Response Following H1N1pdm09 Vaccination}}},
  author = {Khurana, Surender and Verma, Nitin and Talaat, Kawsar R. and Karron, Ruth A. and Golding, Hana},
  year = {2012},
  month = feb,
  journal = {The Journal of Infectious Diseases},
  volume = {205},
  number = {4},
  pages = {610--620},
  issn = {0022-1899},
  doi = {10.1093/infdis/jir791},
  urldate = {2021-04-14},
  abstract = {Background.{$\quad$}The H1N1 2009 influenza (H1N1pdm09) pandemic had unexpected features, including lower morbidity and mortality in elderly populations.Methods.{$\quad$}We performed in-depth elucidation of antibody responses generated post\textendash H1N1pdm09 vaccination in elderly (aged 66\textendash 83 years) and younger (aged 18\textendash 45 or 46\textendash 65 years) adults using H1N1pdm09 whole-genome-fragment phage display library and measured antibody isotype and affinity to antigenic domains within hemagglutinin (HA).Results.{$\quad$}H1N1pdm09 vaccination induced 10-fold higher antibody levels in elderly compared with younger adults. These antibodies primarily targeted the HA1 globular domain, including neutralizing epitopes in the receptor-binding domain. Antibody epitope repertoire, isotype, and affinity maturation after H1N1pdm09 vaccination evolved independently for HA2, HA1, and HA1 N-terminus antigenic regions. Postvaccination serum samples from elderly subjects demonstrated substantially higher avidity than from younger subjects (\&gt;60\% vs \&lt;30\% resistance to 7 mol/L urea) and slower antibody dissociation rates using surface plasmon resonance. We also identified a gender difference in postvaccination antibody avidity (female \&lt; male subjects) in adults \&lt;65 years old.Conclusions.{$\quad$}This is the first study in humans that provides evidence for a qualitatively superior antibody response in elderly adults after H1N1pdm09 vaccination. These findings may help explain the age-related mortality observed during the H1N1pdm09 pandemic. The difference in gender specific avidity merits further exploration.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\XZJBQE9U\\Khurana et al. - 2012 - Immune Response Following H1N1pdm09 Vaccination D.pdf;C\:\\Users\\Zane\\Zotero\\storage\\KAN6GQ88\\886153.html}
}

@article{kim2018,
  title = {Influenza {{Virus}}: {{Dealing}} with a {{Drifting}} and {{Shifting Pathogen}}},
  shorttitle = {Influenza {{Virus}}},
  author = {Kim, Hyunsuh and Webster, Robert G. and Webby, Richard J.},
  year = {2018},
  month = mar,
  journal = {Viral Immunol},
  volume = {31},
  number = {2},
  pages = {174--183},
  issn = {1557-8976},
  doi = {10.1089/vim.2017.0141},
  abstract = {Numerous modern technological and scientific advances have changed the vaccine industry. However, nearly 70 years of influenza vaccine usage have passed without substantial changes in the underlying principles of the vaccine. The challenge of vaccinating against influenza lies in the constantly changing nature of the virus itself. Influenza viruses undergo antigenic evolution through antigenic drift and shift in their surface glycoproteins. This has forced frequent updates of vaccine antigens to ensure that the somewhat narrowly focused vaccine-induced immune responses defend against circulating strains. Few vaccine production systems have been developed that can entertain such constant changes. Although influenza virus infection induces long-lived immunologic memory to the same or similar strains, most people do not encounter the same strain repeatedly in their lifespan, suggesting that enhancement of natural immunity is required to improve influenza vaccines. It is clear that transformative change of influenza vaccines requires a rethink of how we immunize. In this study, we review the problems associated with the changing nature of the virus, and highlight some of the approaches being employed to improve influenza vaccines.},
  langid = {english},
  pmid = {29373086},
  keywords = {antigenic drift,antigenic shift,Antigenic Variation,Disease Transmission; Infectious,Evolution; Molecular,Genetic Drift,Humans,Influenza Vaccines,influenza virus,Influenza; Human,Orthomyxoviridae,Technology; Pharmaceutical,vaccine}
}

@article{kissling2019,
  title = {Low 2018/19 Vaccine Effectiveness against Influenza {{A}}({{H3N2}}) among 15-64-Year-Olds in {{Europe}}: Exploration by Birth Cohort},
  shorttitle = {Low 2018/19 Vaccine Effectiveness against Influenza {{A}}({{H3N2}}) among 15-64-Year-Olds in {{Europe}}},
  author = {Kissling, Esther and Pozo, Francisco and Buda, Silke and Vilcu, Ana-Maria and Gherasim, Alin and Brytting, Mia and Domegan, Lisa and G{\'o}mez, Ver{\'o}nica and Meijer, Adam and Lazar, Mihaela and Vu{\v c}ina, Vesna Vi{\v s}ekruna and D{\"u}rrwald, Ralf and {van der Werf}, Sylvie and Larrauri, Amparo and Enkirch, Theresa and O'Donnell, Joan and Guiomar, Raquel and Hooiveld, Mari{\"e}tte and Petrovi{\'c}, Goranka and Stoian, Elena and Penttinen, Pasi and Valenciano, Marta and {I-MOVE primary care study team}},
  year = {2019},
  month = nov,
  journal = {Euro Surveill},
  volume = {24},
  number = {48},
  pages = {1900604},
  issn = {1560-7917},
  doi = {10.2807/1560-7917.ES.2019.24.48.1900604},
  abstract = {IntroductionInfluenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE).AimThe I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort.MethodsWe measured VE against influenza A(H3N2) and (sub)clades. We stratified VE by usual age groups (0-14, 15-64, {$\geq$}\,65-years). To assess the imprint-regulated effect of vaccine (I-REV) hypothesis, we further stratified the middle-aged group, notably including 32-54-year-olds (1964-86) sharing potential childhood imprinting to serine at haemagglutinin position 159.ResultsInfluenza A(H3N2) VE among all ages was -1\% (95\% confidence interval (CI): -24 to 18) and 46\% (95\% CI: 8-68), -26\% (95\% CI: -66 to 4) and 20\% (95\% CI: -20 to 46) among 0-14, 15-64 and {$\geq$}\,65-year-olds, respectively. Among 15-64-year-olds, VE against clades 3C.2a1b and 3C.3a was 15\% (95\% CI: -34 to 50) and -74\% (95\% CI: -259 to 16), respectively. VE was -18\% (95\% CI: -140 to 41), -53\% (95\% CI: -131 to -2) and -12\% (95\% CI: -74 to 28) among 15-31-year-olds (1987-2003), 32-54-year-olds (1964-86) and 55-64-year-olds (1954-63), respectively.DiscussionThe lowest 2018/19 influenza A(H3N2) VE was against clade 3C.3a and among those born 1964-86, corresponding to the I-REV hypothesis. The low influenza A(H3N2) VE in 15-64-year-olds and the public health impact of the I-REV hypothesis warrant further study.},
  langid = {english},
  pmcid = {PMC6891946},
  pmid = {31796152},
  keywords = {A(H3N2),Adolescent,Adult,Age Factors,Aged,birth cohorts,Europe,Female,Hemagglutinin Glycoproteins; Influenza Virus,Humans,Immunologic Memory,imprinting,influenza,Influenza A Virus; H3N2 Subtype,Influenza Vaccines,Influenza; Human,Male,Middle Aged,multicentre study,Population Surveillance,Respiratory Tract Infections,Seasons,Sentinel Surveillance,Treatment Outcome,Vaccination,vaccine effectiveness,Vaccine Potency},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\T4WQF75P\\Kissling et al. - 2019 - Low 201819 vaccine effectiveness against influenz.pdf}
}

@article{klein2016,
  title = {Sex Differences in Immune Responses},
  author = {Klein, Sabra L. and Flanagan, Katie L.},
  year = {2016},
  month = oct,
  journal = {Nat Rev Immunol},
  volume = {16},
  number = {10},
  pages = {626--638},
  issn = {1474-1741},
  doi = {10.1038/nri.2016.90},
  abstract = {Males and females differ in their immunological responses to foreign and self-antigens and show distinctions in innate and adaptive immune responses. Certain immunological sex differences are present throughout life, whereas others are only apparent after puberty and before reproductive senescence, suggesting that both genes and hormones are involved. Furthermore, early environmental exposures influence the microbiome and have sex-dependent effects on immune function. Importantly, these sex-based immunological differences contribute to variations in the incidence of autoimmune diseases and malignancies, susceptibility to infectious diseases and responses to vaccines in males and females. Here, we discuss these differences and emphasize that sex is a biological variable that should be considered in immunological studies.},
  langid = {english},
  pmid = {27546235},
  keywords = {Adaptive Immunity,Age Factors,Animals,Disease Susceptibility,Environment,Female,Gene-Environment Interaction,Genetic Variation,Hormones,Humans,Immunity,Immunity; Innate,Male,Reproduction,Sex Factors},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\D8JBECT7\\Klein and Flanagan - 2016 - Sex differences in immune responses.pdf}
}

@article{krammer2014,
  title = {H3 {{Stalk-Based Chimeric Hemagglutinin Influenza Virus Constructs Protect Mice}} from {{H7N9 Challenge}}},
  author = {Krammer, Florian and Margine, Irina and Hai, Rong and Flood, Alexander and Hirsh, Ariana and Tsvetnitsky, Vadim and Chen, Dexiang and Palese, Peter},
  year = {2014},
  month = feb,
  journal = {J Virol},
  volume = {88},
  number = {4},
  pages = {2340--2343},
  issn = {0022-538X},
  doi = {10.1128/JVI.03183-13},
  urldate = {2021-06-30},
  abstract = {The recent outbreak of H7N9 influenza virus infections in humans in China has raised concerns about the pandemic potential of this strain. Here, we test the efficacy of H3 stalk-based chimeric hemagglutinin universal influenza virus vaccine constructs to protect against H7N9 challenge in mice. Chimeric hemagglutinin constructs protected from viral challenge in the context of different administration routes as well as with a generic oil-in-water adjuvant similar to formulations licensed for use in humans.},
  pmcid = {PMC3911549},
  pmid = {24307585},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\9ESIS2GI\\Krammer et al. - 2014 - H3 Stalk-Based Chimeric Hemagglutinin Influenza Vi.pdf}
}

@article{krammer2018,
  title = {Influenza},
  author = {Krammer, Florian and Smith, Gavin J. D. and Fouchier, Ron A. M. and Peiris, Malik and Kedzierska, Katherine and Doherty, Peter C. and Palese, Peter and Shaw, Megan L. and Treanor, John and Webster, Robert G. and {Garc{\'i}a-Sastre}, Adolfo},
  year = {2018},
  month = jun,
  journal = {Nat Rev Dis Primers},
  volume = {4},
  number = {1},
  pages = {1--21},
  publisher = {{Nature Publishing Group}},
  issn = {2056-676X},
  doi = {10.1038/s41572-018-0002-y},
  urldate = {2021-11-29},
  abstract = {Influenza is an infectious respiratory disease that, in humans, is caused by influenza A and influenza B viruses. Typically characterized by annual seasonal epidemics, sporadic pandemic outbreaks involve influenza A virus strains of zoonotic origin. The WHO estimates that annual epidemics of influenza result in \textasciitilde 1 billion infections, 3\textendash 5 million cases of severe illness and 300,000\textendash 500,000 deaths. The severity of pandemic influenza depends on multiple factors, including the virulence of the pandemic virus strain and the level of pre-existing immunity. The most severe influenza pandemic, in 1918, resulted in\,{$>$}40 million deaths worldwide. Influenza vaccines are formulated every year to match the circulating strains, as they evolve antigenically owing to antigenic drift. Nevertheless, vaccine efficacy is not optimal and is dramatically low in the case of an antigenic mismatch between the vaccine and the circulating virus strain. Antiviral agents that target the influenza virus enzyme neuraminidase have been developed for prophylaxis and therapy. However, the use of these antivirals is still limited. Emerging approaches to combat influenza include the development of universal influenza virus vaccines that provide protection against antigenically distant influenza viruses, but these vaccines need to be tested in clinical trials to ascertain their effectiveness.},
  copyright = {2018 Macmillan Publishers Ltd., part of Springer Nature},
  langid = {english},
  keywords = {Influenza virus,Respiratory tract diseases,Vaccines,Viral pathogenesis},
  annotation = {Bandiera\_abtest: a Cg\_type: Nature Research Journals Primary\_atype: Reviews Subject\_term: Influenza virus;Respiratory tract diseases;Vaccines;Viral pathogenesis Subject\_term\_id: influenza-virus;respiratory-tract-diseases;vaccines;viral-pathogenesis},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\2259F2Y7\\Krammer et al. - 2018 - Influenza.pdf;C\:\\Users\\Zane\\Zotero\\storage\\VLSCSGG2\\s41572-018-0002-y.html}
}

@article{krammer2019,
  title = {The Human Antibody Response to Influenza {{A}} Virus Infection and Vaccination},
  author = {Krammer, Florian},
  year = {2019},
  month = jun,
  journal = {Nat Rev Immunol},
  volume = {19},
  number = {6},
  pages = {383--397},
  issn = {1474-1741},
  doi = {10.1038/s41577-019-0143-6},
  abstract = {The adaptive immune response to influenza virus infection is multifaceted and complex, involving antibody and cellular responses at both systemic and mucosal levels. Immune responses to natural infection with influenza virus in humans are relatively broad and long-lived, but influenza viruses can escape from these responses over time owing to their high mutation rates and antigenic flexibility. Vaccines are the best available countermeasure against infection, but vaccine effectiveness is low compared with other viral vaccines, and the induced immune response is narrow and short-lived. Furthermore, inactivated influenza virus vaccines focus on the~induction of systemic IgG responses but do not effectively induce mucosal IgA responses. Here, I review the differences between natural infection and vaccination in terms of the antibody responses they induce and how these responses protect against future infection. A better understanding of how natural infection induces broad and long-lived immune responses will be key to developing next-generation influenza virus vaccines.},
  langid = {english},
  pmid = {30837674},
  keywords = {Adaptive Immunity,Animals,Antibodies; Viral,Humans,Immunogenicity; Vaccine,Influenza A virus,Influenza Vaccines,Influenza; Human},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\IB6JFT58\\Krammer - 2019 - The human antibody response to influenza A virus i.pdf}
}

@article{krammer2019a,
  title = {Meeting Report and Review: {{Immunological}} Assays and Correlates of Protection for next-Generation Influenza Vaccines},
  author = {Krammer, Florian and Weir, Jerry P. and Engelhardt, Othmar and Katz, Jacqueline M. and Cox, Rebecca Jane},
  year = {2019-12-13, 2019-12},
  journal = {Influenza and Other Respiratory Viruses},
  volume = {14},
  number = {2},
  pages = {237--243},
  doi = {10.1111/irv.12706},
  langid = {english}
}

@article{krammer2021,
  title = {Antibody {{Responses}} in {{Seropositive Persons}} after a {{Single Dose}} of {{SARS-CoV-2 mRNA Vaccine}}},
  author = {Krammer, Florian and Srivastava, Komal and Alshammary, Hala and Amoako, Angela A. and Awawda, Mahmoud H. and Beach, Katherine F. and {Berm{\'u}dez-Gonz{\'a}lez}, Maria C. and Bielak, Dominika A. and Carre{\~n}o, Juan M. and Chernet, Rachel L. and Eaker, Lily Q. and Ferreri, Emily D. and Floda, Daniel L. and Gleason, Charles R. and Hamburger, Joshua Z. and Jiang, Kaijun and Kleiner, Giulio and Jurczyszak, Denise and Matthews, Julia C. and Mendez, Wanni A. and Nabeel, Ismail and Mulder, Lubbertus C. F. and Raskin, Ariel J. and Russo, Kayla T. and Salimbangon, Ashley-Beathrese T. and Saksena, Miti and Shin, Amber S. and Singh, Gagandeep and Sominsky, Levy A. and Stadlbauer, Daniel and Wajnberg, Ania and Simon, Viviana},
  year = {2021},
  month = apr,
  journal = {N Engl J Med},
  volume = {384},
  number = {14},
  pages = {1372--1374},
  issn = {1533-4406},
  doi = {10.1056/NEJMc2101667},
  langid = {english},
  pmcid = {PMC8008743},
  pmid = {33691060},
  keywords = {Adult,Aged,Antibodies; Neutralizing,Antibodies; Viral,Area Under Curve,COVID-19,COVID-19 Vaccines,Female,Humans,Immunogenetic Phenomena,Immunoglobulin G,Male,Middle Aged,SARS-CoV-2,Spike Glycoprotein; Coronavirus}
}

@article{kucharski2015,
  title = {Estimating the {{Life Course}} of {{Influenza A}}({{H3N2}}) {{Antibody Responses}} from {{Cross-Sectional Data}}},
  author = {Kucharski, Adam J. and Lessler, Justin and Read, Jonathan M. and Zhu, Huachen and Jiang, Chao Qiang and Guan, Yi and Cummings, Derek A. T. and Riley, Steven},
  year = {2015},
  month = mar,
  journal = {PLoS Biol},
  volume = {13},
  number = {3},
  pages = {e1002082},
  issn = {1544-9173},
  doi = {10.1371/journal.pbio.1002082},
  urldate = {2021-06-30},
  abstract = {The immunity of a host population against specific influenza A strains can influence a number of important biological processes, from the emergence of new virus strains to the effectiveness of vaccination programmes. However, the development of an individual's long-lived antibody response to influenza A over the course of a lifetime remains poorly understood. Accurately describing this immunological process requires a fundamental understanding of how the mechanisms of boosting and cross-reactivity respond to repeated infections. Establishing the contribution of such mechanisms to antibody titres remains challenging because the aggregate effect of immune responses over a lifetime are rarely observed directly. To uncover the aggregate effect of multiple influenza infections, we developed a mechanistic model capturing both past infections and subsequent antibody responses. We estimated parameters of the model using cross-sectional antibody titres to nine different strains spanning 40 years of circulation of influenza A(H3N2) in southern China. We found that ``antigenic seniority'' and quickly decaying cross-reactivity were important components of the immune response, suggesting that the order in which individuals were infected with influenza strains shaped observed neutralisation titres to a particular virus. We also obtained estimates of the frequency and age distribution of influenza infection, which indicate that although infections became less frequent as individuals progressed through childhood and young adulthood, they occurred at similar rates for individuals above age 30 y. By establishing what are likely to be important mechanisms driving epochal trends in population immunity, we also identified key directions for future studies. In particular, our results highlight the need for longitudinal samples that are tested against multiple historical strains. This could lead to a better understanding of how, over the course of a lifetime, fast, transient antibody dynamics combine with the longer-term immune responses considered here., A combination of cross-sectional serological data from Southern China and mathematical modeling reveals key aspects of the human immune system's response to seasonal influenza infection., Host immunity against seasonal influenza viruses influences the emergence of new virus strains, the size and severity of ``flu'' epidemics, and the effectiveness of vaccination programmes. However, the specific factors that shape the immune response of a single human to a particular strain are little understood because individual infections and the development of immunity over a lifetime in that person are rarely observed directly. To determine the aggregate effect of a lifetime of influenza infections on host immunity, we developed a mathematical model that captures the specific strains with which an individual has been infected and for the corresponding antibody response, the relative contribution of boosting, cross-reactivity, and antigenic seniority to its neutralising ability. Combining the model with data from a survey in southern China that examined antibody levels against nine different influenza strains from 1968 to 2009, we revealed key components of the immune response to influenza virus infection, and obtained estimates of the frequency of influenza infection and the ages at which infection occurred. Our results suggest that ``antigenic seniority'', whereby strains encountered earlier in life gain more ``senior'' positions in the immune response, and short-lived cross-reactivity between different strains are important components of the immune response and, therefore, could shape the evolution and emergence of influenza viruses.},
  pmcid = {PMC4348415},
  pmid = {25734701},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\BFAKSI72\\Kucharski et al. - 2015 - Estimating the Life Course of Influenza A(H3N2) An.pdf}
}

@article{kucharski2015a,
  title = {Estimating the {{Life Course}} of {{Influenza A}}({{H3N2}}) {{Antibody Responses}} from {{Cross-Sectional Data}}},
  author = {Kucharski, Adam J. and Lessler, Justin and Read, Jonathan M. and Zhu, Huachen and Jiang, Chao Qiang and Guan, Yi and Cummings, Derek A. T. and Riley, Steven},
  year = {2015},
  month = mar,
  journal = {PLOS Biology},
  volume = {13},
  number = {3},
  pages = {e1002082},
  publisher = {{Public Library of Science}},
  issn = {1545-7885},
  doi = {10.1371/journal.pbio.1002082},
  urldate = {2023-03-22},
  abstract = {The immunity of a host population against specific influenza A strains can influence a number of important biological processes, from the emergence of new virus strains to the effectiveness of vaccination programmes. However, the development of an individual's long-lived antibody response to influenza A over the course of a lifetime remains poorly understood. Accurately describing this immunological process requires a fundamental understanding of how the mechanisms of boosting and cross-reactivity respond to repeated infections. Establishing the contribution of such mechanisms to antibody titres remains challenging because the aggregate effect of immune responses over a lifetime are rarely observed directly. To uncover the aggregate effect of multiple influenza infections, we developed a mechanistic model capturing both past infections and subsequent antibody responses. We estimated parameters of the model using cross-sectional antibody titres to nine different strains spanning 40 years of circulation of influenza A(H3N2) in southern China. We found that ``antigenic seniority'' and quickly decaying cross-reactivity were important components of the immune response, suggesting that the order in which individuals were infected with influenza strains shaped observed neutralisation titres to a particular virus. We also obtained estimates of the frequency and age distribution of influenza infection, which indicate that although infections became less frequent as individuals progressed through childhood and young adulthood, they occurred at similar rates for individuals above age 30 y. By establishing what are likely to be important mechanisms driving epochal trends in population immunity, we also identified key directions for future studies. In particular, our results highlight the need for longitudinal samples that are tested against multiple historical strains. This could lead to a better understanding of how, over the course of a lifetime, fast, transient antibody dynamics combine with the longer-term immune responses considered here.},
  langid = {english},
  keywords = {Antibodies,Antibody response,Cross reactivity,Immune response,Immunity,Influenza,Influenza viruses,Serology},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\XIXZTEQA\\Kucharski et al. - 2015 - Estimating the Life Course of Influenza A(H3N2) An.pdf}
}

@article{kucharski2016,
  title = {Capturing the Dynamics of Pathogens with Many Strains},
  author = {Kucharski, Adam J. and Andreasen, Viggo and Gog, Julia R.},
  year = {2016},
  month = jan,
  journal = {J Math Biol},
  volume = {72},
  number = {1-2},
  pages = {1--24},
  issn = {1432-1416},
  doi = {10.1007/s00285-015-0873-4},
  abstract = {Pathogens that consist of multiple antigenic variants are a serious public health concern. These infections, which include dengue virus, influenza and malaria, generate substantial morbidity and mortality. However, there are considerable theoretical challenges involved in modelling such infections. As well as describing the interaction between strains that occurs as a result cross-immunity and evolution, models must balance biological realism with mathematical and computational tractability. Here we review different modelling approaches, and suggest a number of biological problems that are potential candidates for study with these methods. We provide a comprehensive outline of the benefits and disadvantages of available frameworks, and describe what biological information is preserved and lost under different modelling assumptions. We also consider the emergence of new disease strains, and discuss how models of pathogens with multiple strains could be developed further in future. This includes extending the flexibility and biological realism of current approaches, as well as interface with data.},
  langid = {english},
  pmcid = {PMC4698306},
  pmid = {25800537},
  keywords = {Antigenic Variation,Antigens; Viral,Biological Evolution,Communicable Diseases,Cross-immunity,Disease Transmission; Infectious,Epidemics,Evolution,Host-Pathogen Interactions,Humans,Influenza,Influenza; Human,Mathematical Concepts,Models; Biological,Multi-strain pathogens,Orthomyxoviridae,Stochastic Processes,Transmission model},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\7XZXVV63\\Kucharski et al. - 2016 - Capturing the dynamics of pathogens with many stra.pdf}
}

@misc{kucharski2017,
  title = {Timescales of Influenza {{A}}/{{H3N2}} Antibody Dynamics},
  author = {Kucharski, Adam J. and Lessler, Justin and Cummings, Derek A. T. and Riley, Steven},
  year = {2017},
  month = nov,
  primaryclass = {New Results},
  pages = {183111},
  publisher = {{bioRxiv}},
  doi = {10.1101/183111},
  urldate = {2023-03-02},
  abstract = {Human immunity influences the evolution and impact of novel influenza strains. Because individuals are infected with multiple influenza strains during their lifetime and each virus can generate a cross-reactive antibody response, it is challenging to quantify the processes that shape observed immune responses, or to reliably detect recent infection from serological samples. Using a Bayesian model of antibody dynamics at multiple timescales, we explain complex cross-reactive antibody landscapes by inferring participants' histories of infection with serological data from cross-sectional and longitudinal studies of influenza A/H3N2 in southern China and Vietnam. We show an individual's influenza antibody profile can be explained by a short-lived, broadly cross-reactive response that decays within a year to leave a smaller long-term response acting against a narrower range of strains. We also demonstrate that accounting for dynamic immune responses can provide a more accurate alternative to traditional definitions seroconversion for the estimation of infection attack rates. Our work provides a general model for explaining mechanisms of influenza immunity acting at multiple timescales based on contemporary serological data, and suggests a two-armed immune response to influenza infection consistent with competitive dynamics between B cell populations. This approach to analysing multiple timescales for antigenic responses could also be applied to other multi-strain pathogens such as dengue and related flaviviruses.},
  archiveprefix = {bioRxiv},
  chapter = {New Results},
  copyright = {\textcopyright{} 2017, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), CC BY-NC 4.0, as described at http://creativecommons.org/licenses/by-nc/4.0/},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\2ILT4535\\Kucharski et al. - 2017 - Timescales of influenza AH3N2 antibody dynamics.pdf}
}

@article{kucharski2018,
  title = {Timescales of Influenza {{A}}/{{H3N2}} Antibody Dynamics},
  author = {Kucharski, Adam J. and Lessler, Justin and Cummings, Derek A. T. and Riley, Steven},
  year = {2018},
  month = aug,
  journal = {PLoS Biol},
  volume = {16},
  number = {8},
  pages = {e2004974},
  issn = {1545-7885},
  doi = {10.1371/journal.pbio.2004974},
  abstract = {Human immunity influences the evolution and impact of influenza strains. Because individuals are infected with multiple influenza strains during their lifetime, and each virus can generate a cross-reactive antibody response, it is challenging to quantify the processes that shape observed immune responses or to reliably detect recent infection from serological samples. Using a Bayesian model of antibody dynamics at multiple timescales, we explain complex cross-reactive antibody landscapes by inferring participants' histories of infection with serological data from cross-sectional and longitudinal studies of influenza A/H3N2 in southern China and Vietnam. We find that individual-level influenza antibody profiles can be explained by a short-lived, broadly cross-reactive response that decays within a year to leave a smaller long-term response acting against a narrower range of strains. We also demonstrate that accounting for dynamic immune responses alongside infection history can provide a more accurate alternative to traditional definitions of seroconversion for the estimation of infection attack rates. Our work provides a general model for quantifying aspects of influenza immunity acting at multiple timescales based on contemporary serological data and suggests a two-armed immune response to influenza infection consistent with competitive dynamics between B cell populations. This approach to analysing multiple timescales for antigenic responses could also be applied to other multistrain pathogens such as dengue and related flaviviruses.},
  langid = {english},
  pmcid = {PMC6117086},
  pmid = {30125272},
  keywords = {Antibodies; Viral,B-Lymphocytes,Bayes Theorem,China,Cross Reactions,Cross-Sectional Studies,Humans,Immune Sera,Immunity; Humoral,Influenza A Virus; H3N2 Subtype,Influenza Vaccines,Influenza; Human,Longitudinal Studies,Time Factors,Vaccination,Vietnam}
}

@article{kucharski2018a,
  title = {Timescales of Influenza {{A}}/{{H3N2}} Antibody Dynamics},
  author = {Kucharski, Adam J. and Lessler, Justin and Cummings, Derek A. T. and Riley, Steven},
  year = {2018},
  month = aug,
  journal = {PLOS Biology},
  volume = {16},
  number = {8},
  pages = {e2004974},
  publisher = {{Public Library of Science}},
  issn = {1545-7885},
  doi = {10.1371/journal.pbio.2004974},
  urldate = {2023-03-22},
  abstract = {Human immunity influences the evolution and impact of influenza strains. Because individuals are infected with multiple influenza strains during their lifetime, and each virus can generate a cross-reactive antibody response, it is challenging to quantify the processes that shape observed immune responses or to reliably detect recent infection from serological samples. Using a Bayesian model of antibody dynamics at multiple timescales, we explain complex cross-reactive antibody landscapes by inferring participants' histories of infection with serological data from cross-sectional and longitudinal studies of influenza A/H3N2 in southern China and Vietnam. We find that individual-level influenza antibody profiles can be explained by a short-lived, broadly cross-reactive response that decays within a year to leave a smaller long-term response acting against a narrower range of strains. We also demonstrate that accounting for dynamic immune responses alongside infection history can provide a more accurate alternative to traditional definitions of seroconversion for the estimation of infection attack rates. Our work provides a general model for quantifying aspects of influenza immunity acting at multiple timescales based on contemporary serological data and suggests a two-armed immune response to influenza infection consistent with competitive dynamics between B cell populations. This approach to analysing multiple timescales for antigenic responses could also be applied to other multistrain pathogens such as dengue and related flaviviruses.},
  langid = {english},
  keywords = {Antibodies,Antibody response,B cells,Immune response,Immunity,Influenza,Markov models,Serology},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\QJAHF9XS\\Kucharski et al. - 2018 - Timescales of influenza AH3N2 antibody dynamics.pdf}
}

@article{lee2004,
  title = {Predicting Antigenic Variants of Influenza {{A}}/{{H3N2}} Viruses},
  author = {Lee, Min-Shi and Chen, Jack Si-En},
  year = {2004},
  month = aug,
  journal = {Emerging Infectious Diseases},
  volume = {10},
  number = {8},
  pages = {1385--1390},
  doi = {10.3201/eid1008.040107},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\PWWHYHV3\\Lee and Chen - 2004 - Predicting antigenic variants of influenza AH3N2 .pdf}
}

@article{lee2009,
  title = {Simulation and {{Prediction}} of the {{Adaptive Immune Response}} to {{Influenza A Virus Infection}}},
  author = {Lee, Ha Youn and Topham, David J. and Park, Sung Yong and Hollenbaugh, Joseph and Treanor, John and Mosmann, Tim R. and Jin, Xia and Ward, Brian M. and Miao, Hongyu and {Holden-Wiltse}, Jeanne and Perelson, Alan S. and Zand, Martin and Wu, Hulin},
  year = {2009},
  month = jul,
  journal = {J Virol},
  volume = {83},
  number = {14},
  pages = {7151--7165},
  issn = {0022-538X},
  doi = {10.1128/JVI.00098-09},
  urldate = {2021-06-30},
  abstract = {The cellular immune response to primary influenza virus infection is complex, involving multiple cell types and anatomical compartments, and is difficult to measure directly. Here we develop a two-compartment model that quantifies the interplay between viral replication and adaptive immunity. The fidelity of the model is demonstrated by accurately confirming the role of CD4 help for antibody persistence and the consequences of immune depletion experiments. The model predicts that drugs to limit viral infection and/or production must be administered within 2 days of infection, with a benefit of combination therapy when administered early, and cytotoxic CD8 T cells in the lung are as effective for viral clearance as neutralizing antibodies when present at the time of challenge. The model can be used to investigate explicit biological scenarios and generate experimentally testable hypotheses. For example, when the adaptive response depends on cellular immune cell priming, regulation of antigen presentation has greater influence on the kinetics of viral clearance than the efficiency of virus neutralization or cellular cytotoxicity. These findings suggest that the modulation of antigen presentation or the number of lung resident cytotoxic cells and the combination drug intervention are strategies to combat highly virulent influenza viruses. We further compared alternative model structures, for example, B-cell activation directly by the virus versus that through professional antigen-presenting cells or dendritic cell licensing of CD8 T cells.},
  pmcid = {PMC2704765},
  pmid = {19439465},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\7W52UMP9\\Lee et al. - 2009 - Simulation and Prediction of the Adaptive Immune R.pdf}
}

@article{lee2018,
  title = {Efficacy and Effectiveness of High-Dose versus Standard-Dose Influenza Vaccination for Older Adults: A Systematic Review and Meta-Analysis},
  shorttitle = {Efficacy and Effectiveness of High-Dose versus Standard-Dose Influenza Vaccination for Older Adults},
  author = {Lee, Jason K. H. and Lam, Gary K. L. and Shin, Thomas and Kim, Jiyeon and Krishnan, Anish and Greenberg, David P. and Chit, Ayman},
  year = {2018},
  month = may,
  journal = {Expert Rev Vaccines},
  volume = {17},
  number = {5},
  pages = {435--443},
  issn = {1744-8395},
  doi = {10.1080/14760584.2018.1471989},
  abstract = {BACKGROUND: Influenza is responsible for a significant disease burden annually, especially in older adults. This study reviews the relative vaccine efficacy or effectiveness (rVE) of high-dose inactivated trivalent influenza vaccine (HD-IIV3) compared to standard-dose influenza vaccines (SD-IIV3) in adults {$\geq$}65 against influenza-associated outcomes to inform evidence-based decision-making to shift clinical practice and standard of care in this population. METHODS: A systematic review was conducted for studies assessing the rVE of HD-IIV3 against probable/laboratory-confirmed influenza-like illness (ILI), hospital admissions, and death in adults {$\geq$}65. Results from individual seasons were meta-analyzed and a random-effects model was used to estimate pooled rVEs. RESULTS: After screening 992 studies, seven studies were meta-analyzed. HD-IIV3 demonstrated better protection against ILI compared to SD-IIV3 (rVE~=~19.5\%; 95\% CI: 8.6-29.0\%). HD-IIV3 was also more effective at preventing hospital admissions from all-causes (rVE~=~9.1\%; 95\% CI: 2.4-15.3\%), as well as from influenza (rVE~=~17.8\%; 95\% CI: 8.1-26.5\%), pneumonia (rVE~=~24.3\%, 95\% CI: 13.9-33.4\%), and cardiorespiratory events (rVE~=~18.2\%; 95\% CI: 6.8-28.1\%). rVE against post-influenza mortality was 22.2\% (95\% CI: -18.2-48.8\%) and 2.5\% (95\% CI: -5.2-9.5\%) against all-cause mortality. CONCLUSIONS: Available evidence suggests HD-IIV3 is more effective than SD-IIV3 at reducing the clinical outcomes associated with influenza infection in older adults and should be considered for routine use in the 65+ population.},
  langid = {english},
  pmid = {29715054},
  keywords = {Age Factors,Aged,death,effectiveness,efficacy,elderly,High dose influenza vaccine,hospitalization,Hospitalization,Humans,influenza,Influenza Vaccines,Influenza; Human,meta-analysis,Pneumonia,Seasons,seniors,systematic review,Vaccination}
}

@misc{lee2019,
  title = {Mapping Person-to-Person Variation in Viral Mutations That Escape Polyclonal Serum Targeting Influenza Hemagglutinin},
  author = {Lee, Juhye M. and Eguia, Rachel and Zost, Seth J. and Choudhary, Saket and Wilson, Patrick C. and Bedford, Trevor and {Stevens-Ayers}, Terry and Boeckh, Michael and Hurt, Aeron and Lakdawala, Seema S. and Hensley, Scott E. and Bloom, Jesse D.},
  year = {2019},
  month = jun,
  primaryclass = {New Results},
  pages = {670497},
  publisher = {{bioRxiv}},
  doi = {10.1101/670497},
  urldate = {2023-03-02},
  abstract = {A longstanding question is how influenza evolves to escape human immunity, which is polyclonal and can target many distinct epitopes on the virus. Here we map how all amino-acid mutations to influenza's major surface protein affect viral neutralization by polyclonal human sera. The serum of some individuals is so focused that it selects single mutations that reduce viral neutralization by over an order of magnitude. However, different viral mutations escape the sera of different individuals. This individual-to-individual variation in viral escape mutations is not present among ferrets, which are frequently used as a model in influenza studies. Our results show how different single mutations help influenza escape the immunity of different members of the human population, a phenomenon that could shape viral evolution and disease susceptibility.},
  archiveprefix = {bioRxiv},
  chapter = {New Results},
  copyright = {\textcopyright{} 2019, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\YJESABW9\\Lee et al. - 2019 - Mapping person-to-person variation in viral mutati.pdf}
}

@article{levine2022,
  title = {Influenza {{A}}({{H7N9}}) {{Pandemic Preparedness}}: {{Assessment}} of the {{Breadth}} of {{Heterologous Antibody Responses}} to {{Emerging Viruses}} from {{Multiple Pre-Pandemic Vaccines}} and {{Population Immunity}}},
  shorttitle = {Influenza {{A}}({{H7N9}}) {{Pandemic Preparedness}}},
  author = {Levine, Min Z. and Holiday, Crystal and Bai, Yaohui and Zhong, Weimin and Liu, Feng and Jefferson, Stacie and Gross, F. Liaini and Tzeng, Wen-pin and Fries, Louis and Smith, Gale and Boutet, Philippe and Friel, Damien and Innis, Bruce L. and Mallett, Corey P. and Davis, C. Todd and Wentworth, David E. and York, Ian A. and Stevens, James and Katz, Jacqueline M. and Tumpey, Terrence},
  year = {2022},
  month = nov,
  journal = {Vaccines},
  volume = {10},
  number = {11},
  pages = {1856},
  issn = {2076-393X},
  doi = {10.3390/vaccines10111856},
  urldate = {2023-03-21},
  abstract = {Influenza A(H7N9) viruses remain as a high pandemic threat. The continued evolution of the A(H7N9) viruses poses major challenges in pandemic preparedness strategies through vaccination. We assessed the breadth of the heterologous neutralizing antibody responses against the 3rd and 5th wave A(H7N9) viruses using the 1st wave vaccine sera from 4 vaccine groups: 1. inactivated vaccine with 2.8 \textmu g hemagglutinin (HA)/dose + AS03A; 2. inactivated vaccine with 5.75 \textmu g HA/dose + AS03A; 3. inactivated vaccine with 11.5 \textmu g HA/dose + MF59; and 4. recombinant virus like particle (VLP) vaccine with 15 \textmu g HA/dose + ISCOMATRIX\texttrademark. Vaccine group 1 had the highest antibody responses to the vaccine virus and the 3rd/5th wave drifted viruses. Notably, the relative levels of cross-reactivity to the drifted viruses as measured by the antibody GMT ratios to the 5th wave viruses were similar across all 4 vaccine groups. The 1st wave vaccines induced robust responses to the 3rd and Pearl River Delta lineage 5th wave viruses but lower cross-reactivity to the highly pathogenic 5th wave A(H7N9) virus. The population in the United States was largely immunologically naive to the A(H7N9) HA. Seasonal vaccination induced cross-reactive neuraminidase inhibition and binding antibodies to N9, but minimal cross-reactive antibody-dependent cell-mediated cytotoxicity (ADCC) antibodies to A(H7N9).},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\QNL8APTD\\Levine et al. - 2022 - Influenza A(H7N9) Pandemic Preparedness Assessmen.pdf}
}

@article{lewnard2018,
  title = {Immune {{History}} and {{Influenza Vaccine Effectiveness}}},
  author = {Lewnard, Joseph A. and Cobey, Sarah},
  year = {2018},
  month = jun,
  journal = {Vaccines},
  volume = {6},
  number = {2},
  pages = {28},
  publisher = {{Multidisciplinary Digital Publishing Institute}},
  doi = {10.3390/vaccines6020028},
  urldate = {2021-06-09},
  abstract = {The imperfect effectiveness of seasonal influenza vaccines is often blamed on antigenic mismatch, but even when the match appears good, effectiveness can be surprisingly low. Seasonal influenza vaccines also stand out for their variable effectiveness by age group from year to year and by recent vaccination status. These patterns suggest a role for immune history in influenza vaccine effectiveness, but inference is complicated by uncertainty about the contributions of bias to the estimates themselves. In this review, we describe unexpected patterns in the effectiveness of seasonal influenza vaccination and explain how these patterns might arise as consequences of study design, the dynamics of immune memory, or both. Resolving this uncertainty could lead to improvements in vaccination strategy, including the use of universal vaccines in experienced populations, and the evaluation of vaccine efficacy against influenza and other antigenically variable pathogens.},
  copyright = {http://creativecommons.org/licenses/by/3.0/},
  langid = {english},
  keywords = {imprinting,original antigenic sin,repeat vaccination,seasonal influenza vaccine,test-negative design,universal influenza vaccine,vaccine effectiveness},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\TGRKUR92\\Lewnard and Cobey - 2018 - Immune History and Influenza Vaccine Effectiveness.pdf;C\:\\Users\\Zane\\Zotero\\storage\\P54X3EUP\\htm.html}
}

@article{li2012,
  title = {Pandemic {{H1N1}} Influenza Vaccine Induces a Recall Response in Humans That Favors Broadly Cross-Reactive Memory {{B}} Cells},
  author = {Li, Gui-Mei and Chiu, Christopher and Wrammert, Jens and McCausland, Megan and Andrews, Sarah F. and Zheng, Nai-Ying and Lee, Jane-Hwei and Huang, Min and Qu, Xinyan and Edupuganti, Srilatha and Mulligan, Mark and Das, Suman R. and Yewdell, Jonathan W. and Mehta, Aneesh K. and Wilson, Patrick C. and Ahmed, Rafi},
  year = {2012-05-21, 2012-05},
  journal = {Proceedings of the National Academy of Sciences},
  volume = {109},
  number = {23},
  pages = {9047--9052},
  doi = {10.1073/pnas.1118979109},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\L2H2JJYR\\Li et al. - 2012 - Pandemic H1N1 influenza vaccine induces a recall r.pdf}
}

@article{li2020,
  title = {Multi-Task Learning Sparse Group Lasso: A Method for Quantifying Antigenicity of Influenza {{A}}({{H1N1}}) Virus Using Mutations and Variations in Glycosylation of {{Hemagglutinin}}},
  author = {Li, Lei and Chang, Deborah and Han, Lei and Zhang, Xiaojian and Zaia, Joseph and Wan, Xiu-Feng},
  year = {2020-05-11, 2020-05},
  journal = {BMC Bioinformatics},
  volume = {21},
  number = {1},
  doi = {10.1186/s12859-020-3527-5},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\AIRYYUWC\\Li et al. - 2020 - Multi-task learning sparse group lasso a method f.pdf}
}

@article{li2021,
  title = {Antibody Landscape Analysis Following Influenza Vaccination and Natural Infection in Humans with a High-Throughput Multiplex Influenza Antibody Detection Assay},
  author = {Li, Zhu-Nan and Liu, Feng and Gross, F. Liaini and Kim, Lindsay and Ferdinands, Jill and Carney, Paul and Chang, Jessie and Stevens, James and Tumpey, Terrence and Levine, Min Z.},
  editor = {Subbarao, Kanta},
  year = {2021-02-23, 2021-02},
  journal = {mBio},
  volume = {12},
  number = {1},
  doi = {10.1128/mbio.02808-20},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\MT5PNFMF\\Li et al. - 2021 - Antibody landscape analysis following influenza va.pdf}
}

@article{li2021a,
  title = {Immunogenicity of Standard, High-Dose, {{MF59-adjuvanted}}, and Recombinant-{{HA}} Seasonal Influenza Vaccination in Older Adults},
  author = {Li, Athena P. Y. and Cohen, Carolyn A. and Leung, Nancy H. L. and Fang, Vicky J. and Gangappa, Shivaprakash and Sambhara, Suryaprakash and Levine, Min Z. and Iuliano, A. Danielle and Perera, Ranawaka A. P. M. and Ip, Dennis K. M. and Peiris, J. S. Malik and Thompson, Mark G. and Cowling, Benjamin J. and Valkenburg, Sophie A.},
  year = {2021},
  month = feb,
  journal = {npj Vaccines},
  volume = {6},
  number = {1},
  pages = {25},
  issn = {2059-0105},
  doi = {10.1038/s41541-021-00289-5},
  urldate = {2023-03-21},
  abstract = {Abstract             The vaccine efficacy of standard-dose seasonal inactivated influenza vaccines (S-IIV) can be improved by the use of vaccines with higher antigen content or adjuvants. We conducted a randomized controlled trial in older adults to compare cellular and antibody responses of S-IIV versus enhanced vaccines (eIIV): MF59-adjuvanted (A-eIIV), high-dose (H-eIIV), and recombinant-hemagglutinin (HA) (R-eIIV). All vaccines induced comparable H3-HA-specific IgG and elevated antibody-dependent cellular cytotoxicity (ADCC) activity at day 30 post vaccination. H3-HA-specific ADCC responses were greatest following H-eIIV. Only A-eIIV increased H3-HA-IgG avidity, HA-stalk IgG and ADCC activity. eIIVs also increased polyfunctional CD4+ and CD8+ T cell responses, while cellular immune responses were skewed toward single-cytokine-producing T cells among S-IIV subjects. Our study provides further immunological evidence for the preferential use of eIIVs in older adults as each vaccine platform had an advantage over the standard-dose vaccine in terms of NK cell activation, HA-stalk antibodies, and T cell responses.},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\B73JHPGP\\Li et al. - 2021 - Immunogenicity of standard, high-dose, MF59-adjuva.pdf}
}

@article{li2023,
  title = {Influenza-{{Associated Excess Mortality}} by {{Age}}, {{Sex}}, and {{Subtype}}/{{Lineage}}: {{Population-Based Time-Series Study With}} a {{Distributed-Lag Nonlinear Model}}},
  shorttitle = {Influenza-{{Associated Excess Mortality}} by {{Age}}, {{Sex}}, and {{Subtype}}/{{Lineage}}},
  author = {Li, Li and Yan, Ze-Lin and Luo, Lei and Liu, Wenhui and Yang, Zhou and Shi, Chen and Ming, Bo-Wen and Yang, Jun and Cao, Peihua and Ou, Chun-Quan},
  year = {2023},
  month = jan,
  journal = {JMIR Public Health Surveill},
  volume = {9},
  pages = {e42530},
  issn = {2369-2960},
  doi = {10.2196/42530},
  abstract = {BACKGROUND: Accurate estimation of the influenza death burden is of great significance for influenza prevention and control. However, few studies have considered the short-term harvesting effects of influenza on mortality when estimating influenza-associated excess deaths by cause of death, age, sex, and subtype/lineage. OBJECTIVE: This study aimed to estimate the cause-, age-, and sex-specific excess mortality associated with influenza and its subtypes and lineages in Guangzhou from 2015 to 2018. METHODS: Distributed-lag nonlinear models were fitted to estimate the excess mortality related to influenza subtypes or lineages for different causes of death, age groups, and sex based on daily time-series data for mortality, influenza, and meteorological factors. RESULTS: A total of 199,777 death certificates were included in the study. The average annual influenza-associated excess mortality rate (EMR) was 25.06 (95\% empirical CI [eCI] 19.85-30.16) per 100,000 persons; 7142 of 8791 (81.2\%) deaths were due to respiratory or cardiovascular mortality (EMR 20.36, 95\% eCI 16.75-23.74). Excess respiratory and cardiovascular deaths in people aged 60 to 79 years and those aged {$\geq$}80 years accounted for 32.9\% (2346/7142) and 63.7\% (4549/7142) of deaths, respectively. The male to female ratio (MFR) of excess death from respiratory diseases was 1.34 (95\% CI 1.17-1.54), while the MFR for excess death from cardiovascular disease was 0.72 (95\% CI 0.63-0.82). The average annual excess respiratory and cardiovascular mortality rates attributed to influenza A (H3N2), B/Yamagata, B/Victoria, and A (H1N1) were 8.47 (95\% eCI 6.60-10.30), 5.81 (95\% eCI 3.35-8.25), 3.68 (95\% eCI 0.81-6.49), and 2.83 (95\% eCI -1.26 to 6.71), respectively. Among these influenza subtypes/lineages, A (H3N2) had the highest excess respiratory and cardiovascular mortality rates for people aged 60 to 79 years (20.22, 95\% eCI 14.56-25.63) and {$\geq$}80 years (180.15, 95\% eCI 130.75-227.38), while younger people were more affected by A (H1N1), with an EMR of 1.29 (95\% eCI 0.07-2.32). The mortality displacement of influenza A (H1N1), A (H3N2), and B/Yamagata was 2 to 5 days, but 5 to 13 days for B/Victoria. CONCLUSIONS: Influenza was associated with substantial mortality in Guangzhou, occurring predominantly in the elderly, even after considering mortality displacement. The mortality burden of influenza B, particularly B/Yamagata, cannot be ignored. Contrasting sex differences were found in influenza-associated excess mortality from respiratory diseases and from cardiovascular diseases; the underlying mechanisms need to be investigated in future studies. Our findings can help us better understand the magnitude and time-course of the effect of influenza on mortality and inform targeted interventions for mitigating the influenza mortality burden, such as immunizations with quadrivalent vaccines (especially for older people), behavioral campaigns, and treatment strategies.},
  langid = {english},
  pmid = {36630176},
  keywords = {Aged,Cardiovascular Diseases,disease burden,distributed-lag nonlinear model,excess mortality,Female,harvesting effects,Humans,influenza,Influenza A Virus; H1N1 Subtype,Influenza A Virus; H3N2 Subtype,Influenza; Human,Male,Nonlinear Dynamics,Seasons}
}

@article{lim2020,
  title = {Distinguishing {{Causation}} from {{Correlation}} in the {{Use}} of {{Correlates}} of {{Protection}} to {{Evaluate}} and {{Develop Influenza Vaccines}}},
  author = {Lim, Wey Wen and Leung, Nancy H L and Sullivan, Sheena G and Tchetgen Tchetgen, Eric J and Cowling, Benjamin J},
  year = {2020},
  month = mar,
  journal = {American Journal of Epidemiology},
  volume = {189},
  number = {3},
  pages = {185--192},
  issn = {0002-9262, 1476-6256},
  doi = {10.1093/aje/kwz227},
  urldate = {2023-01-17},
  abstract = {Abstract             There is increasing attention to the need to identify new immune markers for the evaluation of existing and new influenza vaccines. Immune markers that could predict individual protection against infection and disease, commonly called correlates of protection (CoPs), play an important role in vaccine development and licensing. Here, we discuss the epidemiologic considerations when evaluating immune markers as potential CoPs for influenza vaccines and emphasize the distinction between correlation and causation. While an immune marker that correlates well with protection from infection can be used as a predictor of vaccine efficacy, it should be distinguished from an immune marker that plays a mechanistic role in conferring protection against a clinical endpoint\textemdash the latter might be a more reliable predictor of vaccine efficacy and a more appropriate target for rational vaccine design. To clearly distinguish mechanistic and nonmechanistic CoPs, we suggest using the term ``correlates of protection'' for nonmechanistic CoPs, and ``mediators of protection'' for mechanistic CoPs. Furthermore, because the interactions among and relative importance of correlates or mediators of protection can vary according to age or prior vaccine experience, the effect sizes and thresholds for protective effects for CoPs could also vary in different segments of the population.},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\N8Q58SST\\Lim et al. - 2020 - Distinguishing Causation from Correlation in the U.pdf}
}

@article{lin2012,
  title = {Evolution of the Receptor Binding Properties of the Influenza {{A}}({{H3N2}}) Hemagglutinin},
  author = {Lin, Yi Pu and Xiong, Xiaoli and Wharton, Stephen A. and Martin, Stephen R. and Coombs, Peter J. and Vachieri, Sebastien G. and Christodoulou, Evangelos and Walker, Philip A. and Liu, Junfeng and Skehel, John J. and Gamblin, Steven J. and Hay, Alan J. and Daniels, Rodney S. and McCauley, John W.},
  year = {2012-12-10, 2012-12},
  journal = {Proceedings of the National Academy of Sciences},
  volume = {109},
  number = {52},
  pages = {21474--21479},
  doi = {10.1073/pnas.1218841110},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\DLN4RM77\\Lin et al. - 2012 - Evolution of the receptor binding properties of th.pdf}
}

@article{linderman2014,
  title = {Potential Antigenic Explanation for Atypical {{H1N1}} Infections among Middle-Aged Adults during the 2013-2014 Influenza Season},
  author = {Linderman, Susanne L. and Chambers, Benjamin S. and Zost, Seth J. and Parkhouse, Kaela and Li, Yang and Herrmann, Christin and Ellebedy, Ali H. and Carter, Donald M. and Andrews, Sarah F. and Zheng, Nai-Ying and Huang, Min and Huang, Yunping and Strauss, Donna and Shaz, Beth H. and Hodinka, Richard L. and {Reyes-Ter{\'a}n}, Gustavo and Ross, Ted M. and Wilson, Patrick C. and Ahmed, Rafi and Bloom, Jesse D. and Hensley, Scott E.},
  year = {2014},
  month = nov,
  journal = {Proc Natl Acad Sci U S A},
  volume = {111},
  number = {44},
  pages = {15798--15803},
  issn = {1091-6490},
  doi = {10.1073/pnas.1409171111},
  abstract = {Influenza viruses typically cause the most severe disease in children and elderly individuals. However, H1N1 viruses disproportionately affected middle-aged adults during the 2013-2014 influenza season. Although H1N1 viruses recently acquired several mutations in the hemagglutinin (HA) glycoprotein, classic serological tests used by surveillance laboratories indicate that these mutations do not change antigenic properties of the virus. Here, we show that one of these mutations is located in a region of HA targeted by antibodies elicited in many middle-aged adults. We find that over 42\% of individuals born between 1965 and 1979 possess antibodies that recognize this region of HA. Our findings offer a possible antigenic explanation of why middle-aged adults were highly susceptible to H1N1 viruses during the 2013-2014 influenza season. Our data further suggest that a drifted H1N1 strain should be included in future influenza vaccines to potentially reduce morbidity and mortality in this age group.},
  langid = {english},
  pmcid = {PMC4226110},
  pmid = {25331901},
  keywords = {Adult,Animals,antibody,antigenic drift,Antigens; Viral,Female,hemagglutinin,Hemagglutinin Glycoproteins; Influenza Virus,Humans,influenza,Influenza A Virus; H1N1 Subtype,Influenza Vaccines,Influenza; Human,Male,Mice,Mice; Inbred BALB C,Middle Aged,Mutation,vaccine},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\53ATS2NX\\Linderman et al. - 2014 - Potential antigenic explanation for atypical H1N1 .pdf}
}

@article{linderman2016,
  title = {Antibodies with '{{Original Antigenic Sin}}' {{Properties Are Valuable Components}} of {{Secondary Immune Responses}} to {{Influenza Viruses}}},
  author = {Linderman, Susanne L. and Hensley, Scott E.},
  year = {2016},
  month = aug,
  journal = {PLoS Pathog},
  volume = {12},
  number = {8},
  pages = {e1005806},
  issn = {1553-7374},
  doi = {10.1371/journal.ppat.1005806},
  abstract = {Human antibodies (Abs) elicited by influenza viruses often bind with a high affinity to past influenza virus strains, but paradoxically, do not bind to the viral strain actually eliciting the response. This phenomena is called 'original antigenic sin' (OAS) since this can occur at the expense of generating new de novo Abs. Here, we characterized the specificity and functionality of Abs elicited in mice that were sequentially exposed to two antigenically distinct H1N1 influenza virus strains. Many Abs elicited under these conditions had an OAS phenotype, in that they bound strongly to the viral strain used for the first exposure and very weakly to the viral strain used for the second exposure. We found that OAS and non-OAS Abs target the same general region of the influenza hemagglutinin protein and that B cells expressing these two types of Abs can be clonally-related. Surprisingly, although OAS Abs bound with very low affinities, some were able to effectively protect against an antigenically drifted viral strain following passive transfer in vivo. Taken together, our data indicate that OAS Abs share some level of cross-reactivity between priming and recall viral strains and that B cells producing these Abs can be protective when recalled into secondary immune responses.},
  langid = {english},
  pmcid = {PMC4990287},
  pmid = {27537358},
  keywords = {Animals,Antibodies; Viral,Antibody Affinity,Antibody Specificity,Antigens; Viral,B-Lymphocytes,Cross Reactions,Disease Models; Animal,Enzyme-Linked Immunosorbent Assay,Hemagglutinin Glycoproteins; Influenza Virus,Immunologic Memory,Influenza A Virus; H1N1 Subtype,Mice,Mice; Inbred BALB C,Orthomyxoviridae Infections},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\4BX6QFP6\\Linderman and Hensley - 2016 - Antibodies with 'Original Antigenic Sin' Propertie.pdf}
}

@article{linderman2020,
  title = {Influenza {{Immunization}} in the {{Context}} of {{Preexisting Immunity}}},
  author = {Linderman, Susanne L. and Ellebedy, Ali H. and Davis, Carl and Eberhardt, Christiane S. and Antia, Rustom and Ahmed, Rafi and Zarnitsyna, Veronika I.},
  year = {2020},
  month = sep,
  journal = {Cold Spring Harb Perspect Med},
  pages = {a040964},
  issn = {2157-1422},
  doi = {10.1101/cshperspect.a040964},
  urldate = {2021-06-09},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\UUWESED9\\Linderman et al. - 2020 - Influenza Immunization in the Context of Preexisti.pdf}
}

@article{lipsitch2019,
  title = {Challenges of {{Vaccine Effectiveness}} and {{Waning Studies}}},
  author = {Lipsitch, Marc},
  year = {2019},
  month = may,
  journal = {Clinical Infectious Diseases},
  volume = {68},
  number = {10},
  pages = {1631--1633},
  issn = {1058-4838},
  doi = {10.1093/cid/ciy773},
  urldate = {2021-02-16},
  abstract = {Better ways to evaluate flu vaccines are also urgently needed. Ethical and logistical considerations ordinarily preclude randomized, controlled trials of new seasonal influenza vaccines, because existing manufacturing processes with just a change of strain are presumed to create vaccines that will be efficacious and because delaying the release of annual vaccines until efficacy was proven would mean missing much of the season. Therefore, observational studies, measuring infection, hospitalization, and mortality outcomes in cohorts of vaccinated and unvaccinated persons, or case-control studies, comparing the vaccine status of influenza-infected persons versus controls, have been used instead to measure the direct impacts of vaccination on the vaccinated persons.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\N35MR6HE\\Lipsitch - 2019 - Challenges of Vaccine Effectiveness and Waning Stu.pdf;C\:\\Users\\Zane\\Zotero\\storage\\SKC8ARTH\\5094713.html}
}

@article{lorusso2010,
  title = {Genetic and Antigenic Characterization of {{H1}} Influenza Viruses from {{United States}} Swine from 2008},
  author = {Lorusso, A. and Vincent, A. L. and Harland, M. L. and Alt, D. and Bayles, D. O. and Swenson, S. L. and Gramer, M. R. and Russell, C. A. and Smith, D. J. and Lager, K. M. and Lewis, N. S.},
  year = {2010-12-22, 2010-12},
  journal = {Journal of General Virology},
  volume = {92},
  number = {4},
  pages = {919--930},
  doi = {10.1099/vir.0.027557-0},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\6D3HIRYY\\Lorusso et al. - 2010 - Genetic and antigenic characterization of H1 influ.pdf}
}

@article{lozano2012,
  title = {Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the {{Global Burden}} of {{Disease Study}} 2010},
  shorttitle = {Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010},
  author = {Lozano, Rafael and Naghavi, Mohsen and Foreman, Kyle and Lim, Stephen and Shibuya, Kenji and Aboyans, Victor and Abraham, Jerry and Adair, Timothy and Aggarwal, Rakesh and Ahn, Stephanie Y. and Alvarado, Miriam and Anderson, H. Ross and Anderson, Laurie M. and Andrews, Kathryn G. and Atkinson, Charles and Baddour, Larry M. and {Barker-Collo}, Suzanne and Bartels, David H. and Bell, Michelle L. and Benjamin, Emelia J. and Bennett, Derrick and Bhalla, Kavi and Bikbov, Boris and Bin Abdulhak, Aref and Birbeck, Gretchen and Blyth, Fiona and Bolliger, Ian and Boufous, Soufiane and Bucello, Chiara and Burch, Michael and Burney, Peter and Carapetis, Jonathan and Chen, Honglei and Chou, David and Chugh, Sumeet S. and Coffeng, Luc E. and Colan, Steven D. and Colquhoun, Samantha and Colson, K. Ellicott and Condon, John and Connor, Myles D. and Cooper, Leslie T. and Corriere, Matthew and Cortinovis, Monica and {de Vaccaro}, Karen Courville and Couser, William and Cowie, Benjamin C. and Criqui, Michael H. and Cross, Marita and Dabhadkar, Kaustubh C. and Dahodwala, Nabila and De Leo, Diego and Degenhardt, Louisa and Delossantos, Allyne and Denenberg, Julie and Des Jarlais, Don C. and Dharmaratne, Samath D. and Dorsey, E. Ray and Driscoll, Tim and Duber, Herbert and Ebel, Beth and Erwin, Patricia J. and Espindola, Patricia and Ezzati, Majid and Feigin, Valery and Flaxman, Abraham D. and Forouzanfar, Mohammad H. and Fowkes, Francis Gerry R. and Franklin, Richard and Fransen, Marlene and Freeman, Michael K. and Gabriel, Sherine E. and Gakidou, Emmanuela and Gaspari, Flavio and Gillum, Richard F. and {Gonzalez-Medina}, Diego and Halasa, Yara A. and Haring, Diana and Harrison, James E. and Havmoeller, Rasmus and Hay, Roderick J. and Hoen, Bruno and Hotez, Peter J. and Hoy, Damian and Jacobsen, Kathryn H. and James, Spencer L. and Jasrasaria, Rashmi and Jayaraman, Sudha and Johns, Nicole and Karthikeyan, Ganesan and Kassebaum, Nicholas and Keren, Andre and Khoo, Jon-Paul and Knowlton, Lisa Marie and Kobusingye, Olive and Koranteng, Adofo and Krishnamurthi, Rita and Lipnick, Michael and Lipshultz, Steven E. and Ohno, Summer Lockett and Mabweijano, Jacqueline and MacIntyre, Michael F. and Mallinger, Leslie and March, Lyn and Marks, Guy B. and Marks, Robin and Matsumori, Akira and Matzopoulos, Richard and Mayosi, Bongani M. and McAnulty, John H. and McDermott, Mary M. and McGrath, John and Mensah, George A. and Merriman, Tony R. and Michaud, Catherine and Miller, Matthew and Miller, Ted R. and Mock, Charles and Mocumbi, Ana Olga and Mokdad, Ali A. and Moran, Andrew and Mulholland, Kim and Nair, M. Nathan and Naldi, Luigi and Narayan, K. M. Venkat and Nasseri, Kiumarss and Norman, Paul and O'Donnell, Martin and Omer, Saad B. and Ortblad, Katrina and Osborne, Richard and Ozgediz, Doruk and Pahari, Bishnu and Pandian, Jeyaraj Durai and Rivero, Andrea Panozo and Padilla, Rogelio Perez and {Perez-Ruiz}, Fernando and Perico, Norberto and Phillips, David and Pierce, Kelsey and Pope, C. Arden and Porrini, Esteban and Pourmalek, Farshad and Raju, Murugesan and Ranganathan, Dharani and Rehm, J{\"u}rgen T. and Rein, David B. and Remuzzi, Guiseppe and Rivara, Frederick P. and Roberts, Thomas and De Le{\'o}n, Felipe Rodriguez and Rosenfeld, Lisa C. and Rushton, Lesley and Sacco, Ralph L. and Salomon, Joshua A. and Sampson, Uchechukwu and Sanman, Ella and Schwebel, David C. and {Segui-Gomez}, Maria and Shepard, Donald S. and Singh, David and Singleton, Jessica and Sliwa, Karen and Smith, Emma and Steer, Andrew and Taylor, Jennifer A. and Thomas, Bernadette and Tleyjeh, Imad M. and Towbin, Jeffrey A. and Truelsen, Thomas and Undurraga, Eduardo A. and Venketasubramanian, N. and Vijayakumar, Lakshmi and Vos, Theo and Wagner, Gregory R. and Wang, Mengru and Wang, Wenzhi and Watt, Kerrianne and Weinstock, Martin A. and Weintraub, Robert and Wilkinson, James D. and Woolf, Anthony D. and Wulf, Sarah and Yeh, Pon-Hsiu and Yip, Paul and Zabetian, Azadeh and Zheng, Zhi-Jie and Lopez, Alan D. and Murray, Christopher J. L. and AlMazroa, Mohammad A. and Memish, Ziad A.},
  year = {2012},
  month = dec,
  journal = {Lancet},
  volume = {380},
  number = {9859},
  pages = {2095--2128},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(12)61728-0},
  abstract = {BACKGROUND: Reliable and timely information on the leading causes of death in populations, and how these are changing, is a crucial input into health policy debates. In the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010), we aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex. METHODS: We attempted to identify all available data on causes of death for 187 countries from 1980 to 2010 from vital registration, verbal autopsy, mortality surveillance, censuses, surveys, hospitals, police records, and mortuaries. We assessed data quality for completeness, diagnostic accuracy, missing data, stochastic variations, and probable causes of death. We applied six different modelling strategies to estimate cause-specific mortality trends depending on the strength of the data. For 133 causes and three special aggregates we used the Cause of Death Ensemble model (CODEm) approach, which uses four families of statistical models testing a large set of different models using different permutations of covariates. Model ensembles were developed from these component models. We assessed model performance with rigorous out-of-sample testing of prediction error and the validity of 95\% UIs. For 13 causes with low observed numbers of deaths, we developed negative binomial models with plausible covariates. For 27 causes for which death is rare, we modelled the higher level cause in the cause hierarchy of the GBD 2010 and then allocated deaths across component causes proportionately, estimated from all available data in the database. For selected causes (African trypanosomiasis, congenital syphilis, whooping cough, measles, typhoid and parathyroid, leishmaniasis, acute hepatitis E, and HIV/AIDS), we used natural history models based on information on incidence, prevalence, and case-fatality. We separately estimated cause fractions by aetiology for diarrhoea, lower respiratory infections, and meningitis, as well as disaggregations by subcause for chronic kidney disease, maternal disorders, cirrhosis, and liver cancer. For deaths due to collective violence and natural disasters, we used mortality shock regressions. For every cause, we estimated 95\% UIs that captured both parameter estimation uncertainty and uncertainty due to model specification where CODEm was used. We constrained cause-specific fractions within every age-sex group to sum to total mortality based on draws from the uncertainty distributions. FINDINGS: In 2010, there were 52{$\cdot$}8 million deaths globally. At the most aggregate level, communicable, maternal, neonatal, and nutritional causes were 24{$\cdot$}9\% of deaths worldwide in 2010, down from 15{$\cdot$}9 million (34{$\cdot$}1\%) of 46{$\cdot$}5 million in 1990. This decrease was largely due to decreases in mortality from diarrhoeal disease (from 2{$\cdot$}5 to 1{$\cdot$}4 million), lower respiratory infections (from 3{$\cdot$}4 to 2{$\cdot$}8 million), neonatal disorders (from 3{$\cdot$}1 to 2{$\cdot$}2 million), measles (from 0{$\cdot$}63 to 0{$\cdot$}13 million), and tetanus (from 0{$\cdot$}27 to 0{$\cdot$}06 million). Deaths from HIV/AIDS increased from 0{$\cdot$}30 million in 1990 to 1{$\cdot$}5 million in 2010, reaching a peak of 1{$\cdot$}7 million in 2006. Malaria mortality also rose by an estimated 19{$\cdot$}9\% since 1990 to 1{$\cdot$}17 million deaths in 2010. Tuberculosis killed 1{$\cdot$}2 million people in 2010. Deaths from non-communicable diseases rose by just under 8 million between 1990 and 2010, accounting for two of every three deaths (34{$\cdot$}5 million) worldwide by 2010. 8 million people died from cancer in 2010, 38\% more than two decades ago; of these, 1{$\cdot$}5 million (19\%) were from trachea, bronchus, and lung cancer. Ischaemic heart disease and stroke collectively killed 12{$\cdot$}9 million people in 2010, or one in four deaths worldwide, compared with one in five in 1990; 1{$\cdot$}3 million deaths were due to diabetes, twice as many as in 1990. The fraction of global deaths due to injuries (5{$\cdot$}1 million deaths) was marginally higher in 2010 (9{$\cdot$}6\%) compared with two decades earlier (8{$\cdot$}8\%). This was driven by a 46\% rise in deaths worldwide due to road traffic accidents (1{$\cdot$}3 million in 2010) and a rise in deaths from falls. Ischaemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), lower respiratory infections, lung cancer, and HIV/AIDS were the leading causes of death in 2010. Ischaemic heart disease, lower respiratory infections, stroke, diarrhoeal disease, malaria, and HIV/AIDS were the leading causes of years of life lost due to premature mortality (YLLs) in 2010, similar to what was estimated for 1990, except for HIV/AIDS and preterm birth complications. YLLs from lower respiratory infections and diarrhoea decreased by 45-54\% since 1990; ischaemic heart disease and stroke YLLs increased by 17-28\%. Regional variations in leading causes of death were substantial. Communicable, maternal, neonatal, and nutritional causes still accounted for 76\% of premature mortality in sub-Saharan Africa in 2010. Age standardised death rates from some key disorders rose (HIV/AIDS, Alzheimer's disease, diabetes mellitus, and chronic kidney disease in particular), but for most diseases, death rates fell in the past two decades; including major vascular diseases, COPD, most forms of cancer, liver cirrhosis, and maternal disorders. For other conditions, notably malaria, prostate cancer, and injuries, little change was noted. INTERPRETATION: Population growth, increased average age of the world's population, and largely decreasing age-specific, sex-specific, and cause-specific death rates combine to drive a broad shift from communicable, maternal, neonatal, and nutritional causes towards non-communicable diseases. Nevertheless, communicable, maternal, neonatal, and nutritional causes remain the dominant causes of YLLs in sub-Saharan Africa. Overlaid on this general pattern of the epidemiological transition, marked regional variation exists in many causes, such as interpersonal violence, suicide, liver cancer, diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and others. Regional heterogeneity highlights the importance of sound epidemiological assessments of the causes of death on a regular basis. FUNDING: Bill \& Melinda Gates Foundation.},
  langid = {english},
  pmid = {23245604},
  keywords = {Adolescent,Adult,Age Factors,Aged,Aged; 80 and over,Cause of Death,Child,Child; Preschool,Female,Global Health,Humans,Infant,Infant; Newborn,Male,Middle Aged,Mortality,Sex Factors,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\AF7BRQUD\\Lozano et al. - 2012 - Global and regional mortality from 235 causes of d.pdf}
}

@manual{Manual,
  type = {Manual},
  title = {R: {{A}} Language and Environment for Statistical Computing},
  author = {{R Core Team}},
  year = {2021},
  address = {{Vienna, Austria}},
  organization = {{R Foundation for Statistical Computing}}
}

@article{margine2013,
  title = {Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza {{A}} Viruses},
  author = {Margine, I. and Krammer, F. and Hai, R. and Heaton, N. S. and Tan, G. S. and Andrews, S. A. and Runstadler, J. A. and Wilson, P. C. and Albrecht, R. A. and {Garc{\'i}a-Sastre}, A. and Palese, P.},
  year = {2013},
  month = oct,
  journal = {J Virol},
  volume = {87},
  number = {19},
  pages = {10435--10446},
  issn = {1098-5514},
  doi = {10.1128/JVI.01715-13},
  abstract = {Current influenza virus vaccines contain H1N1 (phylogenetic group 1 hemagglutinin), H3N2 (phylogenetic group 2 hemagglutinin), and influenza B virus components. These vaccines induce good protection against closely matched strains by predominantly eliciting antibodies against the membrane distal globular head domain of their respective viral hemagglutinins. This domain, however, undergoes rapid antigenic drift, allowing the virus to escape neutralizing antibody responses. The membrane proximal stalk domain of the hemagglutinin is much more conserved compared to the head domain. In recent years, a growing collection of antibodies that neutralize a broad range of influenza virus strains and subtypes by binding to this domain has been isolated. Here, we demonstrate that a vaccination strategy based on the stalk domain of the H3 hemagglutinin (group 2) induces in mice broadly neutralizing anti-stalk antibodies that are highly cross-reactive to heterologous H3, H10, H14, H15, and H7 (derived from the novel Chinese H7N9 virus) hemagglutinins. Furthermore, we demonstrate that these antibodies confer broad protection against influenza viruses expressing various group 2 hemagglutinins, including an H7 subtype. Through passive transfer experiments, we show that the protection is mediated mainly by neutralizing antibodies against the stalk domain. Our data suggest that, in mice, a vaccine strategy based on the hemagglutinin stalk domain can protect against viruses expressing divergent group 2 hemagglutinins.},
  langid = {english},
  pmcid = {PMC3807421},
  pmid = {23903831},
  keywords = {Animals,Antibodies; Neutralizing,Antibodies; Viral,Antibody Specificity,Cells; Cultured,Cross Reactions,Enzyme-Linked Immunosorbent Assay,Female,Fluorescent Antibody Technique,Genetic Vectors,Hemagglutinin Glycoproteins; Influenza Virus,Humans,Influenza A virus,Influenza Vaccines,Kidney,Mice,Mice; Inbred BALB C,Orthomyxoviridae Infections,Phylogeny},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\N5DWN6HE\\Margine et al. - 2013 - Hemagglutinin stalk-based universal vaccine constr.pdf}
}

@article{mclean2018,
  title = {Association of {{Prior Vaccination With Influenza Vaccine Effectiveness}} in {{Children Receiving Live Attenuated}} or {{Inactivated Vaccine}}},
  author = {McLean, Huong Q. and Caspard, Herve and Griffin, Marie R. and Gaglani, Manjusha and Peters, Timothy R. and Poehling, Katherine A. and Ambrose, Christopher S. and Belongia, Edward A.},
  year = {2018},
  month = oct,
  journal = {JAMA Network Open},
  volume = {1},
  number = {6},
  pages = {e183742-e183742},
  issn = {2574-3805},
  doi = {10.1001/jamanetworkopen.2018.3742},
  urldate = {2021-06-09},
  abstract = {Some studies have reported negative effects of prior-season influenza vaccination. Prior-season influenza vaccination effects on vaccine effectiveness (VE) in children are not well understood.To assess the association of prior-season influenza vaccination with subsequent VE in children aged 2 to 17 years.This multiseason, test-negative case-control study was conducted in outpatient clinics at 4 US sites among children aged 2 to 17 years with a medically attended febrile acute respiratory illness. Participants were recruited during the 2013-2014, 2014-2015, and 2015-2016 seasons when influenza circulated locally. Cases were children with influenza confirmed by reverse-transcription polymerase chain reaction. Test-negative control individuals were children with negative test results for influenza.Vaccination history, including influenza vaccine type received in the enrollment season (live attenuated influenza vaccine [LAIV], inactivated influenza vaccine [IIV], or no vaccine) and season before enrollment (LAIV, IIV, or no vaccine), determined from medical records and immunization registries.LAIV and IIV effectiveness by influenza type and subtype (influenza A[H1N1]pdm09, influenza A[H3N2], or influenza B), estimated as 100\,\texttimes\,(1\,-\,odds ratio) in a logistic regression model with adjustment for potential confounders. Prior season vaccination associations were assessed with an interaction term.Of 3369 children (1749 [52\%] male; median age, 6.6 years [range, 2-17 years]) included in the analysis, 772 (23\%) had a positive test result for influenza and 1674 (50\%) were vaccinated in the enrollment season. Among LAIV recipients, VE against influenza A(H3N2) was higher among children vaccinated in both the enrollment and 1 prior season (50.3\% [95\% CI, 17.0\% to 70.2\%]) than among those without 1 prior season vaccination (-82.4\% [95\% CI, -267.5\% to 9.5\%], interaction P\,\&lt;\,.001). The effectiveness of LAIV against influenza A(H1N1)pdm09 was not associated with prior season vaccination among those with prior season vaccination (47.5\% [95\% CI, 11.4\% to 68.9\%]) and among those without prior season vaccination (7.8\% [95\% CI, -101.9\% to 57.9\%]) (interaction P\,=\,.37). Prior season vaccination was not associated with effectiveness of IIV against influenza A(H3N2) (38.7\% [95\% CI, 6.8\% to 59.6\%] among those with prior-season vaccination and 23.2\% [95\% CI, -38.3\% to 57.4\%] among those without prior-season vaccination, interaction P\,=\,.16) or with effectiveness of IIV against influenza A[H1N1]pdm09 (72.4\% [95\% CI, 56.0\% to 82.7\%] among those with prior season vaccination and 67.5\% [95\% CI, 32.1\% to 84.4\%] among those without prior season vaccination, interaction P\,=\,.93). Residual protection from prior season vaccination only (no vaccination in the enrollment season) was observed for influenza B (LAIV: 60.0\% [95\% CI, 36.8\% to 74.7\%]; IIV: 60.0\% [36.9\% to 74.6\%]). Similar results were observed in analyses that included repeated vaccination in 2 and 3 prior seasons.Influenza VE varied by influenza type and subtype and vaccine type, but prior-season vaccination was not associated with reduced VE. These findings support current recommendations for annual influenza vaccination of children.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\TF9JE5YX\\McLean et al. - 2018 - Association of Prior Vaccination With Influenza Va.pdf;C\:\\Users\\Zane\\Zotero\\storage\\V89XR9NE\\2709714.html}
}

@article{mclean2021,
  title = {Serologic Response to Sequential Vaccination with Enhanced Influenza Vaccines: {{Open}} Label Randomized Trial among Adults Aged 65\textendash 74 Years},
  shorttitle = {Serologic Response to Sequential Vaccination with Enhanced Influenza Vaccines},
  author = {McLean, Huong Q. and Levine, Min Z. and King, Jennifer P. and Flannery, Brendan and Belongia, Edward A.},
  year = {2021},
  month = dec,
  journal = {Vaccine},
  volume = {39},
  number = {49},
  pages = {7146--7152},
  issn = {0264410X},
  doi = {10.1016/j.vaccine.2021.10.072},
  urldate = {2023-03-21},
  abstract = {Background: The effects of sequential vaccination with enhanced influenza vaccines are poorly understood. We conducted an exploratory open-label study to assess serologic response to sequential vaccination in older adults. Methods: 160 adults aged 65 through 74 years were randomized (1:1:1) to receive trivalent inactivated standard dose (SD), high-dose (HD), or MF59-adjuvanted (AD) vaccine in 2016/17. In 2017/18, HD and AD recipients received the same vaccine; SD recipients were re-randomized to HD or AD. Hemagglutination inhibition assays were performed using turkey erythrocytes against A/California/7/2009(H1N1)-like and B/Brisbane/60/2008(B/Victoria)-like in both seasons, and A/Michigan/45/2015(H1N1)-like in season 2. Microneutralization assays were performed against cell-propagated A/Hong Kong/4801/2014(H3N2)like using MDCK-SIAT1 cells. Postvaccination geometric mean titer (GMT), percent with titer   40, and mean fold rise (MFR, ratio of postvaccination versus prevaccination titer) in season 2 were compared across groups, and ratio of MFR in season 2 versus season 1 was assessed for each strain. Results: Analysis included 152 participants (55 HD ? HD, 58 AD ? AD, 19 SD ? HD, and 20 SD ? AD). Season 2 postvaccination GMTs and percent with titer   40 did not differ between HD ? HD and AD ? AD recipients for vaccine strains examined. However, a higher percent of HD ? HD and AD ? AD recipients had postvaccination titer   40 than SD ? AD recipients for A/H1N1 (86\%-89\% versus 60\%) and SD ? AD and SD ? HD recipients for A/H3N2 (83\%-87\% versus 40\%-53\%). GMTs were higher in AD ? AD versus SD ? AD recipients for A/H1N1 (p = .01) and A/H3N2 (p = .002). MFRs in season 2 were low in all groups for A/H3N2 (1.5\textendash 2.2) and B/Victoria (1.7\textendash 2.3). MFR was lower in season 2 versus 1 for HD ? HD and AD ? AD recipients for all vaccine strains (1.6\textendash 3.7 versus 2.6\textendash 6.2). Conclusions: Sequential vaccination with enhanced vaccines did not reduce immunogenicity in adults aged 65 through 74 years. Serologic response to cell-propagated A/H3N2 was suboptimal for all vaccines. ClinicalTrials.gov identifier. NCT02872311 \'O 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\SMHVQB85\\McLean et al. - 2021 - Serologic response to sequential vaccination with .pdf}
}

@article{miao2010,
  title = {Quantifying the {{Early Immune Response}} and {{Adaptive Immune Response Kinetics}} in {{Mice Infected}} with {{Influenza A Virus}}},
  author = {Miao, Hongyu and Hollenbaugh, Joseph A. and Zand, Martin S. and {Holden-Wiltse}, Jeanne and Mosmann, Tim R. and Perelson, Alan S. and Wu, Hulin and Topham, David J.},
  year = {2010},
  month = jul,
  journal = {J Virol},
  volume = {84},
  number = {13},
  pages = {6687--6698},
  issn = {0022-538X},
  doi = {10.1128/JVI.00266-10},
  urldate = {2021-06-30},
  abstract = {Seasonal and pandemic influenza A virus (IAV) continues to be a public health threat. However, we lack a detailed and quantitative understanding of the immune response kinetics to IAV infection and which biological parameters most strongly influence infection outcomes. To address these issues, we use modeling approaches combined with experimental data to quantitatively investigate the innate and adaptive immune responses to primary IAV infection. Mathematical models were developed to describe the dynamic interactions between target (epithelial) cells, influenza virus, cytotoxic T lymphocytes (CTLs), and virus-specific IgG and IgM. IAV and immune kinetic parameters were estimated by fitting models to a large data set obtained from primary H3N2 IAV infection of 340 mice. Prior to a detectable virus-specific immune response (before day 5), the estimated half-life of infected epithelial cells is {$\sim$}1.2 days, and the half-life of free infectious IAV is {$\sim$}4 h. During the adaptive immune response (after day 5), the average half-life of infected epithelial cells is {$\sim$}0.5 days, and the average half-life of free infectious virus is {$\sim$}1.8 min. During the adaptive phase, model fitting confirms that CD8+ CTLs are crucial for limiting infected cells, while virus-specific IgM regulates free IAV levels. This may imply that CD4 T cells and class-switched IgG antibodies are more relevant for generating IAV-specific memory and preventing future infection via a more rapid secondary immune response. Also, simulation studies were performed to understand the relative contributions of biological parameters to IAV clearance. This study provides a basis to better understand and predict influenza virus immunity.},
  pmcid = {PMC2903284},
  pmid = {20410284},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\K6AQASK8\\Miao et al. - 2010 - Quantifying the Early Immune Response and Adaptive.pdf}
}

@article{milian2015,
  title = {Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines},
  author = {Mili{\'a}n, Ernest and Kamen, Amine A.},
  year = {2015},
  journal = {Biomed Res Int},
  volume = {2015},
  pages = {504831},
  issn = {2314-6141},
  doi = {10.1155/2015/504831},
  abstract = {Annually, influenza virus infects millions of people worldwide. Vaccination programs against seasonal influenza infections require the production of hundreds of million doses within a very short period of time. The influenza vaccine is currently produced using a technology developed in the 1940s that relies on replicating the virus in embryonated hens' eggs. The monovalent viral preparation is inactivated and purified before being formulated in trivalent or tetravalent influenza vaccines. The production process has depended on a continuous supply of eggs. In the case of pandemic outbreaks, this mode of production might be problematic because of a possible drastic reduction in the egg supply and the low flexibility of the manufacturing process resulting in a lack of supply of the required vaccine doses in a timely fashion. Novel production systems using mammalian or insect cell cultures have emerged to overcome the limitations of the egg-based production system. These industrially well-established production systems have been primarily selected for a faster and more flexible response to pandemic threats. Here, we review the most important cell culture manufacturing processes that have been developed in recent years for mass production of influenza vaccines.},
  langid = {english},
  pmcid = {PMC4359798},
  pmid = {25815321},
  keywords = {Cell Culture Techniques,Humans,Influenza Vaccines,Influenza; Human,Orthomyxoviridae,Vaccination},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\C9V947P4\\MiliÃ¡n and Kamen - 2015 - Current and emerging cell culture manufacturing te.pdf}
}

@article{miller2013,
  title = {Neutralizing Antibodies against Previously Encountered Influenza Virus Strains Increase over Time: A Longitudinal Analysis},
  shorttitle = {Neutralizing Antibodies against Previously Encountered Influenza Virus Strains Increase over Time},
  author = {Miller, Matthew S. and Gardner, Thomas J. and Krammer, Florian and Aguado, Lauren C. and Tortorella, Domenico and Basler, Christopher F. and Palese, Peter},
  year = {2013},
  month = aug,
  journal = {Sci Transl Med},
  volume = {5},
  number = {198},
  pages = {198ra107},
  issn = {1946-6242},
  doi = {10.1126/scitranslmed.3006637},
  abstract = {Antigenic diversity shapes immunity in distinct and unexpected ways. This is particularly true of the humoral response generated against influenza A viruses. Although it is known that immunological memory developed against previously encountered influenza A virus strains affects the outcome of subsequent infections, exactly how sequential exposures to antigenically variant viruses shape the humoral immune response in humans remains poorly understood. To address this important question, we performed a longitudinal analysis of antibody titers against various pandemic and seasonal strains of influenza virus spanning a 20-year period (1987 to 2008) with samples from 40 individuals (birth dates, 1917 to 1952) obtained from the Framingham Heart Study. Longitudinal increases in neutralizing antibody titers were observed against previously encountered pandemic H2N2, H3N2, and H1N1 influenza A virus strains. Antibody titers against seasonal strains encountered later in life also increased longitudinally at a rate similar to that against their pandemic predecessors. Titers of cross-reactive antibodies specific to the hemagglutinin stalk domain were also investigated because they are influenced by exposure to antigenically diverse influenza A viruses. These titers rose modestly over time, even in the absence of major antigenic shifts. No sustained increase in neutralizing antibody titers against an antigenically more stable virus (human cytomegalovirus) was observed. The results herein describe a role for antigenic variation in shaping the humoral immune compartment and provide a rational basis for the hierarchical nature of antibody titers against influenza A viruses in humans.},
  langid = {english},
  pmcid = {PMC4091683},
  pmid = {23946196},
  keywords = {Adult,Aged,Aged; 80 and over,Antibodies; Neutralizing,Female,Humans,Influenza A Virus; H1N1 Subtype,Influenza A Virus; H2N2 Subtype,Influenza A Virus; H3N2 Subtype,Influenza; Human,Longitudinal Studies,Male,Middle Aged,Pandemics,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\X8YEQ2CJ\\Miller et al. - 2013 - Neutralizing antibodies against previously encount.pdf}
}

@article{mogling2017,
  title = {Neuraminidase-Mediated Haemagglutination of Recent Human Influenza {{A}}({{H3N2}}) Viruses Is Determined by Arginine 150 Flanking the Neuraminidase Catalytic Site},
  author = {M{\"o}gling, Ramona and Richard, Mathilde J. and van der Vliet, Stefan and van Beek, Ruud and Schrauwen, Eefje J. A. and Spronken, Monique I. and Rimmelzwaan, Guus F. and Fouchier, Ron A. M.},
  year = {2017},
  month = jun,
  journal = {J Gen Virol},
  volume = {98},
  number = {6},
  pages = {1274--1281},
  issn = {1465-2099},
  doi = {10.1099/jgv.0.000809},
  abstract = {Over the last decade, an increasing proportion of circulating human influenza A(H3N2) viruses exhibited haemagglutination activity that was sensitive to neuraminidase inhibitors. This change in haemagglutination as compared to older circulating A(H3N2) viruses prompted an investigation of the underlying molecular basis. Recent human influenza A(H3N2) viruses were found to agglutinate turkey erythrocytes in a manner that could be blocked with either oseltamivir or neuraminidase-specific antisera, indicating that agglutination was driven by neuraminidase, with a low or negligible contribution of haemagglutinin. Using representative virus recombinants it was shown that the haemagglutinin of a recent A(H3N2) virus indeed had decreased activity to agglutinate turkey erythrocytes, while its neuraminidase displayed increased haemagglutinating activity. Viruses with chimeric and mutant neuraminidases were used to identify the amino acid substitution histidine to arginine at position 150 flanking the neuraminidase catalytic site as the determinant of this neuraminidase-mediated haemagglutination. An analysis of publicly available neuraminidase gene sequences showed that viruses with histidine at position 150 were rapidly replaced by viruses with arginine at this position between 2005 and 2008, in agreement with the phenotypic data. As a consequence of neuraminidase-mediated haemagglutination of recent A(H3N2) viruses and poor haemagglutination via haemagglutinin, haemagglutination inhibition assays with A(H3N2) antisera are no longer useful to characterize the antigenic properties of the haemagglutinin of these viruses for vaccine strain selection purposes. Continuous monitoring of the evolution of these viruses and potential consequences for vaccine strain selection remains important.},
  langid = {english},
  pmcid = {PMC5962893},
  pmid = {28612701},
  keywords = {Animals,Arginine,Catalytic Domain,DNA Mutational Analysis,Erythrocytes,Evolution; Molecular,Hemagglutination,Hemagglutination Inhibition Tests,Humans,Influenza A Virus; H3N2 Subtype,Influenza; Human,Neuraminidase,Recombination; Genetic,Reverse Genetics,Turkeys}
}

@article{molinari2007,
  title = {The Annual Impact of Seasonal Influenza in the {{US}}: {{Measuring}} Disease Burden and Costs},
  shorttitle = {The Annual Impact of Seasonal Influenza in the {{US}}},
  author = {Molinari, Noelle-Angelique M. and {Ortega-Sanchez}, Ismael R. and Messonnier, Mark L. and Thompson, William W. and Wortley, Pascale M. and Weintraub, Eric and Bridges, Carolyn B.},
  year = {2007},
  month = jun,
  journal = {Vaccine},
  volume = {25},
  number = {27},
  pages = {5086--5096},
  issn = {0264-410X},
  doi = {10.1016/j.vaccine.2007.03.046},
  urldate = {2021-06-30},
  abstract = {Background Despite preventive efforts, influenza epidemics are responsible for substantial morbidity and mortality every year in the United States (US). Vaccination strategies to reduce disease burden have been implemented. However, no previous studies have systematically estimated the annual economic burden of influenza epidemics, an estimate necessary to guide policy makers effectively. Objective We estimate age- and risk-specific disease burden, and medical and indirect costs attributable to annual influenza epidemics in the United States. Methods Using a probabilistic model and publicly available epidemiological data we estimated the number of influenza-attributable cases leading to outpatient visits, hospitalization, and mortality, as well as time lost from work absenteeism or premature death. With data from health insurance claims and projections of either earnings or statistical life values, we then estimated healthcare resource utilization associated with influenza cases as were their medical and productivity (indirect) costs in \$2003. Results Based on 2003 US population, we estimated that annual influenza epidemics resulted in an average of 610,660 life-years lost (undiscounted), 3.1million hospitalized days, and 31.4million outpatient visits. Direct medical costs averaged \$10.4billion (95\% confidence interval [C.I.], \$4.1, \$22.2) annually. Projected lost earnings due to illness and loss of life amounted to \$16.3billion (C.I., \$8.7, \$31.0) annually. The total economic burden of annual influenza epidemics using projected statistical life values amounted to \$87.1billion (C.I., \$47.2, \$149.5). Conclusions These results highlight the enormous annual burden of influenza in the US. While hospitalization costs are important contributors, lost productivity from missed work days and lost lives comprise the bulk of the economic burden of influenza.},
  langid = {english},
  keywords = {Disease burden,Health-care cost,Influenza,Productivity losses},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\UP378QQA\\Molinari et al. - 2007 - The annual impact of seasonal influenza in the US.pdf}
}

@article{monto2008,
  title = {Epidemiology of Influenza},
  author = {Monto, Arnold S.},
  year = {2008},
  month = sep,
  journal = {Vaccine},
  volume = {26 Suppl 4},
  pages = {D45-48},
  issn = {0264-410X},
  doi = {10.1016/j.vaccine.2008.07.066},
  abstract = {The impact of influenza has been recognized for centuries. Its seasonality in temperate climates has allowed estimates of mortality and severe morbidity, such as hospitalization, to be made statistically, without identifying cases virologically. Most influenza related mortality occurs in older individuals and those with underlying conditions. In addition to those groups, influenza hospitalizations occur in younger children and pregnant women. Morbidity is more difficult to identify and laboratory confirmation is required for precise estimates to be made. Younger individuals experience the highest frequency of illnesses caused by all subtypes. This has resulted in suggested strategies for community control by vaccinating children.},
  langid = {english},
  pmid = {19230159},
  keywords = {Age Factors,Hospitalization,Humans,Influenza Vaccines,Influenza; Human,Seasons}
}

@article{monto2017,
  title = {The {{Doctrine}} of {{Original Antigenic Sin}}: {{Separating Good From Evil}}},
  shorttitle = {The {{Doctrine}} of {{Original Antigenic Sin}}},
  author = {Monto, Arnold S. and Malosh, Ryan E. and Petrie, Joshua G. and Martin, Emily T.},
  year = {2017},
  month = jun,
  journal = {J Infect Dis},
  volume = {215},
  number = {12},
  pages = {1782--1788},
  issn = {1537-6613},
  doi = {10.1093/infdis/jix173},
  abstract = {The term "original antigenic sin" was coined approximately 60 years ago to describe the imprinting by the initial first influenza A virus infection on the antibody response to subsequent vaccination. These studies did not suggest a reduction in the response to current antigens but instead suggested anamnestic recall of antibody to earlier influenza virus strains. Then, approximately 40 years ago, it was observed that sequential influenza vaccination might lead to reduced vaccine effectiveness (VE). This conclusion was largely dismissed after an experimental study involving sequential administration of then-standard influenza vaccines. Recent observations have provided convincing evidence that reduced VE after sequential influenza vaccination is a real phenomenon. We propose that such reduction in VE be termed "negative antigenic interaction," given that there is no age cohort effect. In contrast, the potentially positive protective effect of early influenza virus infection later in life continues to be observed. It is essential that we understand better the immunologic factors underlying both original antigenic sin and negative antigenic interaction, to support development of improved influenza vaccines and vaccination strategies.},
  langid = {english},
  pmcid = {PMC5853211},
  pmid = {28398521},
  keywords = {Antibody Formation,Antigens; Viral,History; 20th Century,Humans,immune response,Influenza,Influenza A virus,Influenza Vaccines,Influenza; Human,Vaccination},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\QVL6XX53\\Monto et al. - 2017 - The Doctrine of Original Antigenic Sin Separating.pdf}
}

@article{moritzky2022,
  title = {The {{Negative Effect}} of {{Preexisting Immunity}} on {{Influenza Vaccine Responses Transcends}} the {{Impact}} of {{Vaccine Formulation Type}} and {{Vaccination History}}},
  author = {Moritzky, Savannah A and Richards, Katherine A and Glover, Maryah A and Krammer, Florian and Chaves, Francisco A and Topham, David J and Branche, Angela and Nayak, Jennifer L and Sant, Andrea J},
  year = {2022},
  month = feb,
  journal = {J Infect Dis},
  volume = {227},
  number = {3},
  pages = {381--390},
  issn = {0022-1899},
  doi = {10.1093/infdis/jiac068},
  urldate = {2023-03-21},
  abstract = {The most effective measure to induce protection from influenza is vaccination. Thus, yearly vaccination is recommended, which, together with infections, establishes diverse repertoires of B cells, antibodies, and T cells. We examined the impact of this accumulated immunity on human responses in adults to split, subunit, and recombinant protein-based influenza vaccines. Enzyme-linked immunosorbent assay (ELISA) assays, to quantify serum antibodies, and peptide-stimulated CD4 T-cell cytokine ELISpots revealed that preexisting levels of hemagglutinin (HA)-specific antibodies were negatively associated with gains in antibody postvaccination, while preexisting levels of CD4 T cells were negatively correlated with vaccine-induced expansion of CD4 T cells. These patterns were seen independently of the vaccine formulation administered and the subjects' influenza vaccine history. Thus, although memory CD4 T cells and serum antibodies consist of components that can enhance vaccine responses, on balance, the accumulated immunity specific for influenza A H1 and H3 proteins is associated with diminished future responses., The impact of accumulated influenza-specific antibodies and CD4 T cells on human responses to influenza vaccines was examined. These studies revealed that, on balance, preexisting immunity specific for influenza A H1 and H3 proteins is associated with diminished future responses.},
  pmcid = {PMC9891420},
  pmid = {35199825},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\DFPH7KRF\\Moritzky et al. - 2022 - The Negative Effect of Preexisting Immunity on Inf.pdf}
}

@article{muhamed2006,
  title = {Neuraminidase Antibody Response to Inactivated Influenza Virus Vaccine Following Intranasal and Intramuscular Vaccination},
  author = {Muhamed, Gaber and Greenbaum, Evgenia and {Zakay-Rones}, Zichria},
  year = {2006},
  month = mar,
  journal = {Isr Med Assoc J},
  volume = {8},
  number = {3},
  pages = {155--158},
  issn = {1565-1088},
  abstract = {BACKGROUND: The evaluation of influenza vaccine activity and potency are based on the immune response to hemagglutinin, and protection is indicated when the titer of hemagglutination inhibition serum antibody is {$>$} or = 1:40. Neuraminidase, the second surface glycoprotein, may also have a role in protection, but little information is available on the immunologic response to this component. OBJECTIVES: To determine whether any response to neuraminidase is evoked by intranasal immunization with a novel, whole, inactivated anti-influenza vaccine. METHODS: This study was part of a more comprehensive study of mucosal and serum immune response to this vaccine. Fifty-four young adults were immunized intranasally, 9 intramuscularly and 18 received a placebo. Twenty-three elderly people were immunized intramuscularly, and 21 elderly and 17 children were immunized intranasally. Serum and nasal antibodies to antigens N1 and N2 were determined by the lectin neuraminidase test. RESULTS: Serum response following intranasal vaccination was lower than after intramuscular vaccination, and ranged from 21.4 to 35.3\% and 33.3 to 64.7\% following intranasal vaccination and from 52.2 to 77.8\% and 47.8 to 88.9\% after intramuscular vaccination, to N1 and N2 respectively. Nasal antibody response was low and was found only after intranasal vaccination, and response to N2 was better than to the N1 antigen. CONCLUSIONS: It may be beneficial if future vaccines would include competent hemagglutinin and neuraminidase, which would afford a higher level of protection.},
  langid = {english},
  pmid = {16599048},
  keywords = {Administration; Intranasal,Adult,Aged,Antibodies,Child,Enzyme-Linked Immunosorbent Assay,Humans,Influenza A virus,Influenza Vaccines,Influenza; Human,Injections; Intramuscular,Nasal Mucosa,Neuraminidase,Vaccination,Vaccines; Inactivated}
}

@article{munoz2005,
  title = {Epitope Analysis for Influenza Vaccine Design},
  author = {Mu{\~n}oz, Enrique T. and Deem, Michael W.},
  year = {2005},
  month = jan,
  journal = {Vaccine},
  volume = {23},
  number = {9},
  pages = {1144--1148},
  doi = {10.1016/j.vaccine.2004.08.028},
  langid = {english}
}

@article{nachbagauer2014,
  title = {Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an {{H5N1}} Vaccine in Humans},
  author = {Nachbagauer, Raffael and Wohlbold, Teddy John and Hirsh, Ariana and Hai, Rong and Sjursen, Haakon and Palese, Peter and Cox, Rebecca J. and Krammer, Florian},
  editor = {Lyles, D. S.},
  year = {2014-11-15, 2014-11},
  journal = {Journal of Virology},
  volume = {88},
  number = {22},
  pages = {13260--13268},
  doi = {10.1128/jvi.02133-14},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\LU4UBSWF\\Nachbagauer et al. - 2014 - Induction of broadly reactive anti-hemagglutinin s.pdf}
}

@article{nachbagauer2017,
  title = {Defining the Antibody Cross-Reactome Directed against the Influenza Virus Surface Glycoproteins},
  author = {Nachbagauer, Raffael and Choi, Angela and Hirsh, Ariana and Margine, Irina and Iida, Sayaka and Barrera, Aldo and Ferres, Marcela and Albrecht, Randy A and {Garc{\'i}a-Sastre}, Adolfo and Bouvier, Nicole M and Ito, Kimihito and Medina, Rafael A and Palese, Peter and Krammer, Florian},
  year = {2017-02-13, 2017-02},
  journal = {Nature Immunology},
  volume = {18},
  number = {4},
  pages = {464--473},
  doi = {10.1038/ni.3684},
  langid = {english}
}

@article{nachbagauer2021,
  title = {A Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccine Approach Induces Broad and Long-Lasting Immunity in a Randomized, Placebo-Controlled Phase {{I}} Trial},
  author = {Nachbagauer, Raffael and Feser, Jodi and Naficy, Abdollah and Bernstein, David I. and Guptill, Jeffrey and Walter, Emmanuel B. and {Berlanda-Scorza}, Franceso and Stadlbauer, Daniel and Wilson, Patrick C. and Aydillo, Teresa and Behzadi, Mohammad Amin and Bhavsar, Disha and Bliss, Carly and Capuano, Christina and Carre{\~n}o, Juan Manuel and Chromikova, Veronika and Claeys, Carine and Coughlan, Lynda and Freyn, Alec W. and Gast, Christopher and Javier, Andres and Jiang, Kaijun and Mariottini, Chiara and McMahon, Meagan and McNeal, Monica and Sol{\'o}rzano, Alicia and Strohmeier, Shirin and Sun, Weina and {Van der Wielen}, Marie and Innis, Bruce L. and {Garc{\'i}a-Sastre}, Adolfo and Palese, Peter and Krammer, Florian},
  year = {2021},
  month = jan,
  journal = {Nat Med},
  volume = {27},
  number = {1},
  pages = {106--114},
  publisher = {{Nature Publishing Group}},
  issn = {1546-170X},
  doi = {10.1038/s41591-020-1118-7},
  urldate = {2021-06-17},
  abstract = {Seasonal influenza viruses constantly change through antigenic drift and the emergence of pandemic influenza viruses through antigenic shift is unpredictable. Conventional influenza virus vaccines induce strain-specific neutralizing antibodies against the variable immunodominant globular head domain of the viral hemagglutinin protein. This necessitates frequent re-formulation of vaccines and handicaps pandemic preparedness. In this completed, observer-blind, randomized, placebo-controlled phase I trial (NCT03300050), safety and immunogenicity of chimeric hemagglutinin-based vaccines were tested in healthy, 18\textendash 39-year-old US adults. The study aimed to test the safety and ability of the vaccines to elicit broadly cross-reactive antibodies against the hemagglutinin stalk domain. Participants were enrolled into five groups to receive vaccinations with live-attenuated followed by\,AS03-adjuvanted inactivated vaccine (n\,=\,20), live-attenuated\,followed by\,inactivated vaccine (n\,=\,15), twice AS03-adjuvanted inactivated vaccine (n\,=\,16) or placebo (n\,=\,5, intranasal\,followed by\,intramuscular; n\,=\,10, twice intramuscular) 3\,months apart. Vaccination was found to be safe and induced a broad, strong, durable and functional immune response targeting the conserved, immunosubdominant stalk of the hemagglutinin. The results suggest that chimeric hemagglutinins have the potential to be developed as universal vaccines that protect broadly against influenza viruses.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\TR58NG9S\\Nachbagauer et al. - 2021 - A chimeric hemagglutinin-based universal influenza.pdf;C\:\\Users\\Zane\\Zotero\\storage\\R7EHS3N8\\s41591-020-1118-7.html}
}

@article{nara2010,
  title = {How {{Can Vaccines Against Influenza}} and {{Other Viral Diseases Be Made More Effective}}?},
  author = {Nara, Peter L. and Tobin, Gregory J. and Chaudhuri, A. Ray and Trujillo, Jessie D. and Lin, George and Cho, Michael W. and Levin, Simon A. and Ndifon, Wilfred and Wingreen, Ned S.},
  year = {2010},
  month = dec,
  journal = {PLoS Biol},
  volume = {8},
  number = {12},
  pages = {e1000571},
  issn = {1544-9173},
  doi = {10.1371/journal.pbio.1000571},
  urldate = {2021-06-30},
  pmcid = {PMC3006352},
  pmid = {21203586},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\28T6LLAL\\Nara et al. - 2010 - How Can Vaccines Against Influenza and Other Viral.pdf}
}

@article{ndifon2009,
  title = {Differential Neutralization Efficiency of Hemagglutinin Epitopes, Antibody Interference, and the Design of Influenza Vaccines},
  author = {Ndifon, Wilfred and Wingreen, Ned S. and Levin, Simon A.},
  year = {2009},
  month = may,
  journal = {Proc Natl Acad Sci U S A},
  volume = {106},
  number = {21},
  pages = {8701--8706},
  issn = {0027-8424},
  doi = {10.1073/pnas.0903427106},
  urldate = {2021-06-30},
  abstract = {It is generally assumed that amino acid mutations in the surface protein, hemagglutinin (HA), of influenza viruses allow these viruses to circumvent neutralization by antibodies induced during infection. However, empirical data on circulating influenza viruses show that certain amino acid changes to HA actually increase the efficiency of neutralization of the mutated virus by antibodies raised against the parent virus. Here, we suggest that this surprising increase in neutralization efficiency after HA mutation could reflect steric interference between antibodies. Specifically, if there is a steric competition for binding to HA by antibodies with different neutralization efficiencies, then a mutation that reduces the binding of antibodies with low neutralization efficiencies could increase overall viral neutralization. We use a mathematical model of virus\textendash antibody interaction to elucidate the conditions under which amino acid mutations to HA could lead to an increase in viral neutralization. Using insights gained from the model, together with genetic and structural data, we predict that amino acid mutations to epitopes C and E of the HA of influenza A/H3N2 viruses could lead on average to an increase in the neutralization of the mutated viruses. We present data supporting this prediction and discuss the implications for the design of more effective vaccines against influenza viruses and other pathogens.},
  pmcid = {PMC2688967},
  pmid = {19439657},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\25XKHGYG\\Ndifon et al. - 2009 - Differential neutralization efficiency of hemagglu.pdf}
}

@article{ndifon2009,
  title = {On the Use of Hemagglutination-Inhibition for Influenza Surveillance: {{Surveillance}} Data Are Predictive of Influenza Vaccine Effectiveness},
  author = {Ndifon, Wilfred and Dushoff, Jonathan and Levin, Simon A.},
  year = {2009},
  month = apr,
  journal = {Vaccine},
  volume = {27},
  number = {18},
  pages = {2447--2452},
  doi = {10.1016/j.vaccine.2009.02.047},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\9E5L3E49\\Ndifon et al. - 2009 - On the use of hemagglutination-inhibition for infl.pdf}
}

@article{ndifon2011,
  title = {New Methods for Analyzing Serological Data with Applications to Influenza Surveillance},
  author = {Ndifon, Wilfred},
  year = {2011-01-05, 2011-01},
  journal = {Influenza and Other Respiratory Viruses},
  volume = {5},
  number = {3},
  pages = {206--212},
  doi = {10.1111/j.1750-2659.2010.00192.x},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\PAGN5ZVL\\Ndifon - 2011 - New methods for analyzing serological data with ap.pdf}
}

@article{neerukonda2021,
  title = {{{SARS-CoV-2}} Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble {{ACE2}} Sensitivity, Enhanced Cleavage and Fusogenic Activity},
  author = {Neerukonda, Sabari Nath and Vassell, Russell and Lusvarghi, Sabrina and Wang, Richard and Echegaray, Fernando and Bentley, Lisa and Eakin, Ann E. and Erlandson, Karl J. and Katzelnick, Leah C. and Weiss, Carol D. and Wang, Wei},
  year = {2021-12-11, 2021-12},
  journal = {Viruses},
  volume = {13},
  number = {12},
  pages = {2485},
  doi = {10.3390/v13122485},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\852CKGC4\\Neerukonda et al. - 2021 - SARS-CoV-2 delta variant displays moderate resista.pdf}
}

@article{neher2016,
  title = {Prediction, Dynamics, and Visualization of Antigenic Phenotypes of Seasonal Influenza Viruses},
  author = {Neher, Richard A. and Bedford, Trevor and Daniels, Rodney S. and Russell, Colin A. and Shraiman, Boris I.},
  year = {2016-03-07, 2016-03},
  journal = {Proceedings of the National Academy of Sciences},
  volume = {113},
  number = {12},
  doi = {10.1073/pnas.1525578113},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\4MNFYTTQ\\Neher et al. - 2016 - Prediction, dynamics, and visualization of antigen.pdf}
}

@article{nelson2019,
  title = {Imprinting and {{Editing}} of the {{Human CD4 T Cell Response}} to {{Influenza Virus}}},
  author = {Nelson, Sean A. and Sant, Andrea J.},
  year = {2019},
  journal = {Front Immunol},
  volume = {10},
  pages = {932},
  issn = {1664-3224},
  doi = {10.3389/fimmu.2019.00932},
  abstract = {Immunity to influenza is unique among pathogens, in that immune memory is established both via intermittent lung localized infections with highly variable influenza virus strains and by intramuscular vaccinations with inactivated protein-based vaccines. Studies in the past decades have suggested that the B cell responses to influenza infection and vaccination are highly biased by an individual's early history of influenza infection. This reactivity likely reflects both the competitive advantage that memory B cells have in an immune response and the relatively limited diversity of epitopes in influenza hemagglutinin that are recognized by B cells. In contrast, CD4 T cells recognize a wide array of epitopes, with specificities that are heavily influenced by the diversity of influenza antigens available, and a multiplicity of functions that are determined by both priming events and subsequent confrontations with antigens. Here, we consider the events that prime and remodel the influenza-specific CD4 T cell response in humans that have highly diverse immune histories and how the CD4 repertoire may be edited in terms of functional potential and viral epitope specificity. We discuss the consequences that imprinting and remodeling may have on the potential of different human hosts to rapidly respond with protective cellular immunity to infection. Finally, these issues are discussed in the context of future avenues of investigation and vaccine strategies.},
  langid = {english},
  pmcid = {PMC6514101},
  pmid = {31134060},
  keywords = {Antibodies; Viral,B-Lymphocytes,CD4 T cells,CD4-Positive T-Lymphocytes,Epitopes,Hemagglutinin Glycoproteins; Influenza Virus,human immunology,Humans,Immunity; Cellular,imprinting,Influenza Vaccines,Influenza virus,Influenza; Human,Interferon-gamma,Orthomyxoviridae,Vaccination,vaccine},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\49ZQ9FUM\\Nelson and Sant - 2019 - Imprinting and Editing of the Human CD4 T Cell Res.pdf}
}

@article{ng2019,
  title = {Novel Correlates of Protection against Pandemic {{H1N1}} Influenza {{A}} Virus Infection},
  author = {Ng, Sophia and Nachbagauer, Raffael and Balmaseda, Angel and Stadlbauer, Daniel and Ojeda, Sergio and Patel, Mayuri and Rajabhathor, Arvind and Lopez, Roger and Guglia, Andrea F. and Sanchez, Nery and Amanat, Fatima and Gresh, Lionel and Kuan, Guillermina and Krammer, Florian and Gordon, Aubree},
  year = {2019},
  month = jun,
  journal = {Nat Med},
  volume = {25},
  number = {6},
  pages = {962--967},
  issn = {1546-170X},
  doi = {10.1038/s41591-019-0463-x},
  abstract = {Influenza viruses remain a severe threat to human health, causing up to 650,000 deaths annually1,2. Seasonal influenza virus vaccines can prevent infection, but are rendered ineffective by antigenic drift. To provide improved protection from infection, novel influenza virus vaccines that target the conserved epitopes of influenza viruses, specifically those in the hemagglutinin stalk and neuraminidase, are currently being developed3. Antibodies against the hemagglutinin stalk confer protection in animal studies4-6. However, no data exist on natural infections in humans, and these antibodies do not show activity in the hemagglutination inhibition assay, the hemagglutination inhibition titer being the current correlate of protection against influenza virus infection7-9. While previous studies have investigated the protective effect of cellular immune responses and neuraminidase-inhibiting antibodies, additional serological correlates of protection from infection could aid the development of broadly protective or universal influenza virus vaccines10-13. To address this gap, we performed a household transmission study to identify alternative correlates of protection from infection and disease in naturally exposed individuals. Using this study, we determined 50\% protective titers and levels for hemagglutination inhibition, full-length hemagglutinin, neuraminidase and hemagglutinin stalk-specific antibodies. Further, we found that hemagglutinin stalk antibodies independently correlated with protection from influenza virus infection.},
  langid = {english},
  pmcid = {PMC6608747},
  pmid = {31160818},
  keywords = {Adolescent,Adult,Aged,Antibodies; Viral,Child,Child; Preschool,Cohort Studies,Female,Hemagglutination Inhibition Tests,Hemagglutinin Glycoproteins; Influenza Virus,Humans,Infant,Infant; Newborn,Influenza A Virus; H1N1 Subtype,Influenza; Human,Male,Middle Aged,Nicaragua,Pandemics,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\BTEDIAYD\\Ng et al. - 2019 - Novel correlates of protection against pandemic H1.pdf}
}

@article{nimmerjahn2010,
  title = {Antibody-Mediated Modulation of Immune Responses},
  author = {Nimmerjahn, Falk and Ravetch, Jeffrey V.},
  year = {2010},
  journal = {Immunological Reviews},
  volume = {236},
  number = {1},
  pages = {265--275},
  issn = {1600-065X},
  doi = {10.1111/j.1600-065X.2010.00910.x},
  urldate = {2021-06-30},
  abstract = {Summary: Activation of the humoral immune system by microbial infections or self-antigens results in the initiation of strong pro-inflammatory reactions. Antibodies of the immunoglobulin G (IgG) isotype play a crucial role in this cascade of reactions, resulting in the clearance of invading microbes and the generation of long lasting immunity. In addition, IgG antibodies feedback on the generation of novel IgG antibodies by activated B cells, impact plasma cell survival, and participate actively in maintaining and returning to the steady state. This review focuses on our current models of how IgG molecules can have this diverse array of activities.},
  langid = {english},
  keywords = {Fc receptors,immunoglobulin G,inflammation,ITP,IVIg,macrophage,SignR1},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\XW2TXTUH\\Nimmerjahn and Ravetch - 2010 - Antibody-mediated modulation of immune responses.pdf;C\:\\Users\\Zane\\Zotero\\storage\\2ZH5XP9Y\\j.1600-065X.2010.00910.html}
}

@article{nunez2017,
  title = {Impact of Age and Pre-Existing Influenza Immune Responses in Humans Receiving Split Inactivated Influenza Vaccine on the Induction of the Breadth of Antibodies to Influenza {{A}} Strains},
  author = {Nu{\~n}ez, Ivette A. and Carlock, Michael A. and Allen, James D. and Owino, Simon O. and Moehling, Krissy K. and Nowalk, Patricia and Susick, Michael and Diagle, Kensington and Sweeney, Kristen and Mundle, Sophia and Vogel, Thorsten U. and Delagrave, Simon and Ramgopal, Moti and Zimmerman, Richard K. and Kleanthous, Harry and Ross, Ted M.},
  year = {2017},
  journal = {PLoS One},
  volume = {12},
  number = {11},
  pages = {e0185666},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0185666},
  abstract = {Most humans have pre-existing immunity to influenza viruses. In this study, volunteers (ages of 18-85 years) were vaccinated with split, inactivated Fluzone\texttrademark{} influenza vaccine in four consecutive influenza seasons from 2013 to 2016 seasons. The impact of repeated vaccination on breadth and durability of antibodies was assessed as a result of vaccine strain changes. Total IgG anti-hemagglutinin (HA) binding antibodies and hemagglutination-inhibition (HAI) activity increased in all age groups against both influenza A HA components in the vaccine post-vaccination (day 21). However, younger subjects maintained seroprotective titers to the vaccine strains, which resulted in higher seroconversion rates in the elderly, since the HAI titers in elderly subjects were more likely to decline prior to the next season. Young subjects had significant HAI activity against historical, as well as contemporary H1 and H3 vaccine strains from the mid-1980s to present. In contrast, elderly subjects had HAI activity to H1 strains from all years, but were more likely to have HAI activity to older strains from 1918-1950s. They also had a more restricted HAI profile against H3 viruses compared to young subjects recognizing H3N2 influenza viruses from the mid-2000s to present. Vaccine recipients were then categorized by whether subjects seroconverted from a seronegative or seropositive pre-vaccination state. Regardless of age, immunological recall or 'back-boosting' to antigenically related strains were associated with seroconversion to the vaccine strain. Overall, both younger and older people have the ability to mount a breadth of immune responses following influenza vaccination. This report describes how imprinting exposure differs across age groups, influences antibody cross-reactivity to past hemagglutinin antigenic variants, and shapes immune responses elicited by current split inactivated influenza vaccines. Understanding how current influenza vaccines are influenced by pre-existing immunity in people of different ages is critical for designing the next-generation of 'universal' or broadly-protective influenza vaccines.},
  langid = {english},
  pmcid = {PMC5665503},
  pmid = {29091724},
  keywords = {Adolescent,Adult,Aged,Aged; 80 and over,Antibodies; Viral,Enzyme-Linked Immunosorbent Assay,Female,Humans,Influenza Vaccines,Male,Middle Aged,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\8XL453M5\\NuÃ±ez et al. - 2017 - Impact of age and pre-existing influenza immune re.pdf}
}

@article{odonnell2012,
  title = {Effect of Priming with {{H1N1}} Influenza Viruses of Variable Antigenic Distances on Challenge with 2009 Pandemic {{H1N1}} Virus},
  author = {O'Donnell, Christopher D. and Wright, Amber and Vogel, Leatrice N. and Wei, Chih-Jen and Nabel, Gary J. and Subbarao, Kanta},
  year = {2012-08-15, 2012-08},
  journal = {Journal of Virology},
  volume = {86},
  number = {16},
  pages = {8625--8633},
  doi = {10.1128/jvi.00147-12},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\M3EDAZWP\\O'Donnell et al. - 2012 - Effect of priming with H1N1 influenza viruses of v.pdf}
}

@article{oidtman2021,
  title = {Influenza Immune Escape under Heterogeneous Host Immune Histories},
  author = {Oidtman, Rachel J. and Arevalo, Philip and Bi, Qifang and McGough, Lauren and Russo, Christopher Joel and Vera Cruz, Diana and Costa Vieira, Marcos and Gostic, Katelyn M.},
  year = {2021},
  month = jul,
  journal = {Trends in Microbiology},
  issn = {0966-842X},
  doi = {10.1016/j.tim.2021.05.009},
  urldate = {2021-08-12},
  abstract = {In a pattern called immune imprinting, individuals gain the strongest immune protection against the influenza strains encountered earliest in life. In many recent examples, differences in early infection history can explain birth year-associated differences in susceptibility (cohort effects). Susceptibility shapes strain fitness, but without a clear conceptual model linking host susceptibility to the identity and order of past infections general conclusions on the evolutionary and epidemic implications of cohort effects are not possible. Failure to differentiate between cohort effects caused by differences in the set, rather than the order (path), of past infections is a current source of confusion. We review and refine hypotheses for path-dependent cohort effects, which include imprinting. We highlight strategies to measure their underlying causes and emergent consequences.},
  langid = {english},
  keywords = {antigenic evolution,cohort effects,immune escape,immune imprinting,influenza,original antigenic sin},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\XTQZ696G\\Oidtman et al. - 2021 - Influenza immune escape under heterogeneous host i.pdf;C\:\\Users\\Zane\\Zotero\\storage\\MU89GG72\\S0966842X21001323.html}
}

@article{orru2013,
  title = {Genetic Variants Regulating Immune Cell Levels in Health and Disease},
  author = {Orr{\`u}, Valeria and Steri, Maristella and Sole, Gabriella and Sidore, Carlo and Virdis, Francesca and Dei, Mariano and Lai, Sandra and Zoledziewska, Magdalena and Busonero, Fabio and Mulas, Antonella and Floris, Matteo and Mentzen, Wieslawa I. and Urru, Silvana A. M. and Olla, Stefania and Marongiu, Michele and Piras, Maria G. and Lobina, Monia and Maschio, Andrea and Pitzalis, Maristella and Urru, Maria F. and Marcelli, Marco and Cusano, Roberto and Deidda, Francesca and Serra, Valentina and Oppo, Manuela and Pilu, Rosella and Reinier, Frederic and Berutti, Riccardo and Pireddu, Luca and Zara, Ilenia and Porcu, Eleonora and Kwong, Alan and Brennan, Christine and Tarrier, Brendan and Lyons, Robert and Kang, Hyun M. and Uzzau, Sergio and Atzeni, Rossano and Valentini, Maria and Firinu, Davide and Leoni, Lidia and Rotta, Gianluca and Naitza, Silvia and Angius, Andrea and Congia, Mauro and Whalen, Michael B. and Jones, Chris M. and Schlessinger, David and Abecasis, Gon{\c c}alo R. and Fiorillo, Edoardo and Sanna, Serena and Cucca, Francesco},
  year = {2013},
  month = sep,
  journal = {Cell},
  volume = {155},
  number = {1},
  pages = {242--256},
  issn = {1097-4172},
  doi = {10.1016/j.cell.2013.08.041},
  abstract = {The complex network of specialized cells and molecules in the immune system has evolved to defend against pathogens, but inadvertent immune system attacks on "self" result in autoimmune disease. Both genetic regulation of immune cell levels and their relationships with autoimmunity are largely undetermined. Here, we report genetic contributions to quantitative levels of 95 cell types encompassing 272 immune traits, in a cohort of 1,629 individuals from four clustered Sardinian villages. We first estimated trait heritability, showing that it can be substantial, accounting for up to 87\% of the variance (mean 41\%). Next, by assessing {$\sim$}8.2 million variants that we identified and confirmed in an extended set of 2,870 individuals, 23 independent variants at 13 loci associated with at least one trait. Notably, variants at three loci (HLA, IL2RA, and SH2B3/ATXN2) overlap with known autoimmune disease associations. These results connect specific cellular phenotypes to specific genetic variants, helping to explicate their involvement in disease.},
  langid = {english},
  pmcid = {PMC5541764},
  pmid = {24074872},
  keywords = {Flow Cytometry,Genetic Predisposition to Disease,Genome-Wide Association Study,Humans,Immune System Diseases,Phenotype,Polymorphism; Single Nucleotide},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\NK3Z9WHC\\OrrÃ¹ et al. - 2013 - Genetic variants regulating immune cell levels in .pdf}
}

@article{ortiz2022,
  title = {Safety and Immunogenicity of Monovalent {{H7N9}} Influenza Vaccine with {{AS03}} Adjuvant given Sequentially or Simultaneously with a Seasonal Influenza Vaccine: {{A}} Randomized Clinical Trial},
  shorttitle = {Safety and Immunogenicity of Monovalent {{H7N9}} Influenza Vaccine with {{AS03}} Adjuvant given Sequentially or Simultaneously with a Seasonal Influenza Vaccine},
  author = {Ortiz, Justin R. and Spearman, Paul W. and Goepfert, Paul A. and Cross, Kaitlyn and Buddy Creech, C. and Chen, Wilbur H. and Parker, Susan and Overton, Edgar T. and Dickey, Michelle and Logan, Heather L. and Wegel, Ashley and Neuzil, Kathleen M.},
  year = {2022},
  month = may,
  journal = {Vaccine},
  volume = {40},
  number = {23},
  pages = {3253--3262},
  issn = {1873-2518},
  doi = {10.1016/j.vaccine.2022.03.055},
  abstract = {BACKGROUND: Influenza A/H7N9 viruses have pandemic potential. METHODS: We conducted an open-label, randomized, controlled trial of AS03-adjuvanted 2017 inactivated influenza A/H7N9 vaccine (H7N9 IIV) in healthy adults. Group 1 received H7N9 IIV and seasonal quadrivalent influenza vaccine (IIV4) simultaneously, followed by H7N9 IIV three weeks later. Group 2 received IIV4 alone and then two doses of H7N9 IIV at three-week intervals. Group 3 received one dose of IIV4. We used hemagglutination inhibition (HAI) and microneutralization (MN) assays to measure geometric mean titers and seroprotection ({$\geq$}1:40 titer) to vaccine strains and monitored for safety. RESULTS: Among 149 subjects, seroprotection by HAI three weeks after H7N9 IIV dose 2 was 51\% (95~\%CI 37\%-65\%) for Group 1 and 40\% (95~\%CI 25\%-56\%) for Group 2. Seroprotection by MN at the same timepoint was 84\% (95~\%CI 72\%-93\%) for Group 1 and 74\% (95~\%CI 60\%-86\%) for Group 2. By 180~days after H7N9 IIV dose 2, seroprotection by HAI or MN was low for Groups 1 and 2. Responses measured by HAI and MN against each IIV4 strain three weeks after IIV4 vaccination were similar in all groups. Solicited local and systemic reactions were similar after a single vaccination, while those receiving simultaneous H7N9 and IIV4 had slightly more reactogenicity. There were no serious adverse events or medically-attended adverse events related to study product receipt. CONCLUSIONS: Adjuvanted H7N9 IIV was modestly immunogenic whether administered simultaneously or sequentially with IIV4, though responses declined by 180~days. IIV4 was immunogenic regardless of schedule. CLINICAL TRIALS REGISTRATION: NCT03318315.},
  langid = {english},
  pmcid = {PMC9897630},
  pmid = {35465983},
  keywords = {Adjuvants; Immunologic,Adult,alpha-Tocopherol,Animals,Antibodies; Viral,Drug Combinations,Hemagglutination Inhibition Tests,Humans,Immunogenicity; Vaccine,Influenza A Virus; H7N9 Subtype,Influenza in Birds,Influenza Vaccines,Influenza; Human,Polysorbates,Seasons,Squalene,Vaccines; Inactivated},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\N2ZTCJRY\\Ortiz et al. - 2022 - Safety and immunogenicity of monovalent H7N9 influ.pdf}
}

@article{pawelek2012,
  title = {Modeling {{Within-Host Dynamics}} of {{Influenza Virus Infection Including Immune Responses}}},
  author = {Pawelek, Kasia A. and Huynh, Giao T. and Quinlivan, Michelle and Cullinane, Ann and Rong, Libin and Perelson, Alan S.},
  year = {2012},
  month = jun,
  journal = {PLoS Comput Biol},
  volume = {8},
  number = {6},
  pages = {e1002588},
  issn = {1553-734X},
  doi = {10.1371/journal.pcbi.1002588},
  urldate = {2021-06-30},
  abstract = {Influenza virus infection remains a public health problem worldwide. The mechanisms underlying viral control during an uncomplicated influenza virus infection are not fully understood. Here, we developed a mathematical model including both innate and adaptive immune responses to study the within-host dynamics of equine influenza virus infection in horses. By comparing modeling predictions with both interferon and viral kinetic data, we examined the relative roles of target cell availability, and innate and adaptive immune responses in controlling the virus. Our results show that the rapid and substantial viral decline (about 2 to 4 logs within 1 day) after the peak can be explained by the killing of infected cells mediated by interferon activated cells, such as natural killer cells, during the innate immune response. After the viral load declines to a lower level, the loss of interferon-induced antiviral effect and an increased availability of target cells due to loss of the antiviral state can explain the observed short phase of viral plateau in which the viral level remains unchanged or even experiences a minor second peak in some animals. An adaptive immune response is needed in our model to explain the eventual viral clearance. This study provides a quantitative understanding of the biological factors that can explain the viral and interferon kinetics during a typical influenza virus infection., Influenza, commonly referred to as the flu, is a contagious respiratory illness caused by influenza virus infections. Although most infected subjects with intact immune systems are able to clear the virus without developing serious flu complications, the mechanisms underlying viral control are not fully understood. In this paper, we address this question by developing mathematical models that include both innate and adaptive immune responses, and fitting them to experimental data from horses infected with equine influenza virus. We find that the innate immune response, such as natural killer cell-mediated infected cell killing and interferon's antiviral effect, can explain the first rapid viral decline and subsequent second peak viremia, and that the adaptive immune response is needed to eventually clear the virus. This study improves our understanding of influenza virus dynamics and may provide more information for future research in influenza pathogenesis, treatment, and vaccination.},
  pmcid = {PMC3386161},
  pmid = {22761567},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\5LUYRRI5\\Pawelek et al. - 2012 - Modeling Within-Host Dynamics of Influenza Virus I.pdf}
}

@article{penkert2020,
  title = {Vitamin {{A Corrects Tissue Deficits}} in {{Diet-Induced Obese Mice}} and {{Reduces Influenza Infection After Vaccination}} and {{Challenge}}},
  author = {Penkert, Rhiannon R. and Cortez, Valerie and Karlsson, Erik A. and Livingston, Brandi and Surman, Sherri L. and Li, Yaqi and Catharine Ross, A. and {Schultz-Cherry}, Stacey and Hurwitz, Julia L.},
  year = {2020},
  month = sep,
  journal = {Obesity (Silver Spring)},
  volume = {28},
  number = {9},
  pages = {1631--1636},
  issn = {1930-739X},
  doi = {10.1002/oby.22929},
  abstract = {OBJECTIVE: Individuals with obesity suffer from an increased susceptibility to severe respiratory viral infections and respond poorly to vaccinations, making it imperative to identify interventions. Recent evidence suggesting that obesity leads to tissue-specific vitamin A deficiency led to an investigation of whether high-dose oral vitamin A, a treatment used for remediating vitamin A deficiency in developing countries, could correct obesity-associated tissue deficits. METHODS: Adult C57BL/6 diet-induced obese mice were supplemented with vitamin A for 4~weeks. A subset of mice were then vaccinated with inactivated influenza virus and challenged. Following supplementation, tissue vitamin A levels, lung immune cell composition, blood inflammatory cytokines, antibody responses, and viral clearance were evaluated. RESULTS: Supplementation significantly improved vitamin A levels in lung and adipose tissues in diet-induced obese mice. Additionally, supplementation decreased inflammatory cytokines in the blood and altered the lung immune environment. Importantly, vaccinated, vitamin A-treated diet-induced obese mice exhibited improved antibody responses and significantly reduced viral loads post challenge compared with PBS-treated mice. CONCLUSIONS: Results demonstrate a low-cost intervention that may correct vitamin A tissue deficits and help control respiratory viral infections in individuals with obesity.},
  langid = {english},
  pmcid = {PMC7483416},
  pmid = {32779401},
  keywords = {Animals,Disease Models; Animal,Humans,Influenza; Human,Male,Mice,Mice; Inbred C57BL,Mice; Obese,Obesity,Vaccination,Vitamin A},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\2MD4JBKB\\Penkert et al. - 2020 - Vitamin A Corrects Tissue Deficits in Diet-Induced.pdf}
}

@article{penkert2021,
  title = {Month of {{Influenza Virus Vaccination Influences Antibody Responses}} in {{Children}} and {{Adults}}},
  author = {Penkert, Rhiannon R. and Patel, Nehali and Webby, Richard J. and Ross, Ted M. and Hurwitz, Julia L.},
  year = {2021},
  month = feb,
  journal = {Vaccines},
  volume = {9},
  number = {2},
  pages = {68},
  publisher = {{Multidisciplinary Digital Publishing Institute}},
  doi = {10.3390/vaccines9020068},
  urldate = {2021-02-16},
  abstract = {The improvement of influenza virus vaccines and the development of a universal product have been long-standing goals in pre-clinical and clinical research. To meet these goals and to understand the strengths and weaknesses of current vaccine strategies, scientists routinely study human responses toward seasonal influenza vaccines. This research is frequently performed with clinical samples taken throughout an influenza season, often without strict attention to the month of inoculation for each study participant. Here, we ask how the timing of vaccination affects outcomes. Results demonstrate significant influences of inoculation month on the immune response. During the progression from fall to winter months, there are changes in host lifestyles and in the frequencies of clinical/sub-clinical viral infections that can significantly alter vaccine immunogenicity. We now recommend routine assessment of inoculation month during clinical studies to inform data interpretation and expedite the development of successful vaccines. This recommendation is pertinent to numerous vaccine development efforts within and outside the influenza virus field.},
  copyright = {http://creativecommons.org/licenses/by/3.0/},
  langid = {english},
  keywords = {hemagglutination inhibition,immune response,influenza virus,month,vaccination},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\EE6HM2PS\\Penkert et al. - 2021 - Month of Influenza Virus Vaccination Influences An.pdf}
}

@article{petrova2017,
  title = {The Evolution of Seasonal Influenza Viruses},
  author = {Petrova, Velislava N. and Russell, Colin A.},
  year = {2017-10-30, 2017-10},
  journal = {Nature Reviews Microbiology},
  volume = {16},
  number = {1},
  pages = {47--60},
  doi = {10.1038/nrmicro.2017.118},
  langid = {english}
}

@article{Racmacs,
  title = {Racmacs: {{R}} Antigenic Cartography Macros},
  author = {Wilks, Sam},
  year = {2021}
}

@misc{ranjeva2018,
  title = {Age-Specific Differences in the Dynamics of Protective Immunity to Influenza},
  author = {Ranjeva, Sylvia and Subramanian, Rahul and Fang, Vicky J. and Leung, Gabriel M. and Ip, Dennis K. M. and Perera, Ranawaka A. P. M. and Peiris, J. S. Malik and Cowling, Benjamin J. and Cobey, Sarah},
  year = {2018},
  month = dec,
  primaryclass = {New Results},
  pages = {330720},
  publisher = {{bioRxiv}},
  doi = {10.1101/330720},
  urldate = {2023-03-02},
  abstract = {Influenza A viruses evolve rapidly to escape host immunity, such that individuals can be infected multiple times with the same subtype. The form and duration of protective immunity after each influenza infection are poorly understood. Here, we quantify the dynamics of protective immunity against influenza A virus infections by fitting individual-level mechanistic models to longitudinal serology from children and adults in a household cohort study. We find that most protection in children is explained by antibody titers measured by the hemagglutination inhibition (HI) assay. In contrast, in adults, HI antibody titers explain a smaller fraction of protection. Protection against circulating strains wanes to approximately 50\% of peak levels 3.5-7 years after infection in both age groups, and wanes faster against influenza A(H3N2) than A(H1N1)pdm09. Protection against H3N2 lasts longer in adults than in children. Our results suggest that the focus of influenza antibody responses changes over time from the highly mutable hemagglutinin head to other epitopes, consistent with the immunological theory of original antigenic sin, and that this change of focus might affect protection. Additionally, we estimate that imprinting, or primary infection with a subtype of one phylogenetic group, has little to no effect on the risk of non-medically attended influenza infections in adults. We also find no evidence of long-term cross-protection between subtypes. This work underscores the need for longitudinal data on multiple components of the immune response to better understand the development of immunity and differences in susceptibility within populations.},
  archiveprefix = {bioRxiv},
  chapter = {New Results},
  copyright = {\textcopyright{} 2018, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\F3D66QHM\\Ranjeva et al. - 2018 - Age-specific differences in the dynamics of protec.pdf}
}

@article{ray2019,
  title = {Intraseason {{Waning}} of {{Influenza Vaccine Effectiveness}}},
  author = {Ray, G Thomas and Lewis, Ned and Klein, Nicola P and Daley, Matthew F and Wang, Shirley V and Kulldorff, Martin and Fireman, Bruce},
  year = {2019},
  month = may,
  journal = {Clinical Infectious Diseases},
  volume = {68},
  number = {10},
  pages = {1623--1630},
  issn = {1058-4838},
  doi = {10.1093/cid/ciy770},
  urldate = {2021-02-16},
  abstract = {In the United States, it is recommended that healthcare providers offer influenza vaccination by October, if possible. However, if the vaccine's effectiveness soon begins to wane, the optimal time for vaccination may be somewhat later. We examined whether the effectiveness of influenza vaccine wanes during the influenza season with increasing time since vaccination.We identified persons who were vaccinated with inactivated influenza vaccine from 1 September 2010 to 31 March 2017 and who were subsequently tested for influenza and respiratory syncytial virus (RSV) by a polymerase chain reaction test. Test-confirmed influenza was the primary outcome and days-since-vaccination was the predictor of interest in conditional logistic regression. Models were adjusted for age and conditioned on calendar day and geographic area. RSV was used as a negative-control outcome.Compared with persons vaccinated 14 to 41 days prior to being tested, persons vaccinated 42 to 69 days prior to being tested had 1.32 (95\% confidence interval [CI], 1.11 to 1.55) times the odds of testing positive for any influenza. The odds ratio (OR) increased linearly by approximately 16\% for each additional 28 days since vaccination. The OR was 2.06 (95\% CI, 1.69 to 2.51) for persons vaccinated 154 or more days prior to being tested. No evidence of waning was found for RSV.Our results suggest that effectiveness of inactivated influenza vaccine wanes during the course of a single season. These results may lead to reconsideration of the optimal timing of seasonal influenza vaccination.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\ASZEQIS9\\Ray et al. - 2019 - Intraseason Waning of Influenza Vaccine Effectiven.pdf;C\:\\Users\\Zane\\Zotero\\storage\\EUFRWNCY\\5094689.html}
}

@article{Rcpi,
  title = {Rcpi: {{R}}/{{Bioconductor}} Package to Generate Various Descriptors of Proteins, Compounds and Their Interactions},
  author = {Cao, Dong-Sheng and Xiao, Nan and Xu, Qing-Song and Chen, Alex F.},
  year = {2015},
  volume = {31},
  doi = {10.1093/bioinformatics/btu624},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\6M84B5B6\\Cao et al. - 2015 - Rcpi RBioconductor package to generate various d.pdf}
}

@article{reneer2020,
  title = {Computationally Optimized Broadly Reactive {{H2 HA}} Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges},
  author = {Reneer, Z. Beau and Jamieson, Parker J. and Skarlupka, Amanda L. and Huang, Ying and Ross, Ted M.},
  editor = {Subbarao, Kanta},
  year = {2020-12-22, 2020-12},
  journal = {Journal of Virology},
  volume = {95},
  number = {2},
  doi = {10.1128/jvi.01526-20},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\HWTBBEJ5\\Reneer et al. - 2020 - Computationally optimized broadly reactive H2 HA i.pdf}
}

@article{reneer2021,
  title = {Broadly Reactive {{H2}} Hemagglutinin Vaccines Elicit Cross-Reactive Antibodies in Ferrets Preimmune to Seasonal Influenza {{A}} Viruses},
  author = {Reneer, Z. Beau and Skarlupka, Amanda L. and Jamieson, Parker J. and Ross, Ted M.},
  editor = {Imperiale, Michael J.},
  year = {2021-04-28, 2021-04},
  journal = {mSphere},
  volume = {6},
  number = {2},
  doi = {10.1128/msphere.00052-21},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\FBC2KIAA\\Reneer et al. - 2021 - Broadly reactive H2 hemagglutinin vaccines elicit .pdf}
}

@article{richards2020,
  title = {Recombinant {{HA-based}} Vaccine Outperforms Split and Subunit Vaccines in Elicitation of Influenza-Specific {{CD4 T}} Cells and {{CD4 T}} Cell-Dependent Antibody Responses in Humans},
  author = {Richards, K. A. and Moritzky, S. and Shannon, I. and Fitzgerald, T. and Yang, H. and Branche, A. and Topham, D. J. and Treanor, J. J. and Nayak, J. and Sant, Andrea J.},
  year = {2020},
  journal = {NPJ Vaccines},
  volume = {5},
  pages = {77},
  issn = {2059-0105},
  doi = {10.1038/s41541-020-00227-x},
  abstract = {Although traditional egg-based inactivated influenza vaccines can protect against infection, there have been significant efforts to develop improved formats to overcome disadvantages of this platform. Here, we have assessed human CD4 T cell responses to a traditional egg-based influenza vaccine with recently available cell-derived vaccines and recombinant baculovirus-derived vaccines. Adults were administered either egg-derived Fluzone\textregistered, mammalian cell-derived Flucelvax\textregistered{} or recombinant HA (Flublok\textregistered ). CD4 T cell responses to each HA protein were assessed by cytokine EliSpot and intracellular staining assays. The specificity and magnitude of antibody responses were quantified by ELISA and HAI assays. By all criteria, Flublok vaccine exhibited superior performance in eliciting both CD4 T cell responses and HA-specific antibody responses, whether measured by mean response magnitude or percent of responders. Although the mechanism(s) underlying this advantage is not yet clear, it is likely that both qualitative and quantitative features of the vaccines impact the response.},
  langid = {english},
  pmcid = {PMC7450042},
  pmid = {32884842},
  keywords = {Immunology,Vaccines}
}

@article{robertson2016,
  title = {{{Fluzone}}\textregistered{} {{High-Dose Influenza Vaccine}}},
  author = {Robertson, Corwin A. and DiazGranados, Carlos A. and Decker, Michael D. and Chit, Ayman and Mercer, Monica and Greenberg, David P.},
  year = {2016},
  month = dec,
  journal = {Expert Rev Vaccines},
  volume = {15},
  number = {12},
  pages = {1495--1505},
  issn = {1744-8395},
  doi = {10.1080/14760584.2016.1254044},
  abstract = {Fluzone\textregistered{} High-Dose (IIV3-HD) is a trivalent, inactivated, split-virus influenza vaccine indicated for use in older adults ({$\geq$}65~years of age). It contains 60~\textmu g hemagglutinin of each influenza strain, which is four times the hemagglutinin content of standard-dose influenza vaccines, including Fluzone (IIV3-SD). IIV3-HD has been licensed for use in older adults in the US since December 2009 and in Canada since February 2016. Areas covered: In this review, we summarize postlicensure studies on the immunogenicity, safety, and effectiveness of IIV3-HD and estimates of its cost-effectiveness in older adults. We also discuss the potential application of IIV3-HD in adults 50-64~years of age and in individuals who may respond poorly to standard-dose influenza vaccines. Expert commentary: Multiple studies conducted since 2004 have consistently shown that, in older adults, IIV3-HD induces substantially greater antibody responses and better protection against influenza and influenza-associated hospitalization than IIV3-SD. Health economic analyses suggest that IIV3-HD can be a cost-effective alternative to standard-dose trivalent or quadrivalent inactivated influenza vaccines and can even be cost-saving compared to IIV3-SD in older adults. Further investigation of IIV3-HD vaccination as a way to improve immune responses and protection against influenza in immunocompromised individuals is warranted.},
  langid = {english},
  pmid = {27813430},
  keywords = {Aged,Aged; 80 and over,Antibodies; Viral,Canada,Cost-Benefit Analysis,high-dose,Hospitalization,Humans,immunocompromising conditions,immunosenescence,Influenza,Influenza Vaccines,Influenza; Human,Middle Aged,older adults,Product Surveillance; Postmarketing,United States,vaccine}
}

@article{ross2014,
  title = {Influence of Pre-Existing Hemagglutination Inhibition Titers against Historical Influenza Strains on Antibody Response to Inactivated Trivalent Influenza Vaccine in Adults 50\textendash 80 Years of Age},
  author = {Ross, Ted M. and Lin, Chyongchiou Jeng and Nowalk, Mary Patricia and Huang, Hsin-Hui and Spencer, Sarah M. and Shay, David K. and Sambhara, Suryaprakash and Sundaram, Maria E. and Friedrich, Thomas and Sauereisen, Sandy and Bloom, Chalise E. and Zimmerman, Richard K.},
  year = {2014},
  month = may,
  journal = {Human Vaccines \& Immunotherapeutics},
  volume = {10},
  number = {5},
  pages = {1195--1203},
  publisher = {{Taylor \& Francis}},
  issn = {2164-5515},
  doi = {10.4161/hv.28313},
  urldate = {2021-06-09},
  abstract = {Background: Concerns about influenza vaccine effectiveness in older adults and the role of influenza strains encountered earlier in life led to this study.Methods: Antibody responses against antigens in the 2011\textendash 2012 influenza vaccine at 21 days post vaccination were analyzed in 264 individuals aged 50\textendash 80 years. At Days 0 and 21, sera were tested for hemagglutination-inhibition titers against these vaccine strains and at Day 0 against a panel of 15 historical seasonal strains.Results: The proportions of participants with seroprotective titers {$\geq$}1:40 to the vaccine strains at Days 0 and 21, respectively, were 37\% and 66\% for A(H1N1) and 28\% and 63\% for A(H3N2). An increasing number of responses {$\geq$}1:40 against historical strains was associated with seroprotective responses after vaccination among participants with a titer {$<$}1:40 at Day 0 for A(H1N1) and A(H3N2) vaccine strains (P {$<$} 0.01). In multivariable regression analyses among those with Day 0 titer {$<$}1:40, after controlling for age, sex, race, site and diabetes, Day 21 titers {$\geq$} 1:40 for the vaccine A strains were significantly more likely as the number of seroprotective responses against historical strains increased (A(H1N1) odds ratio [OR] = 1.41, 95\% confidence interval [CI] = 1.09\textendash 1.82 and A(H3N2) OR = 1.32, 95\% CI = 1.07\textendash 1.62). The likelihood of seroconversion was significantly higher with an increasing number of responses to historical strains for A(H3N2) only (OR = 1.24, 95\% CI = 1.01\textendash 1.52). Seroconversion was significantly less likely as Day 0 vaccine strain titers increased.Conclusions: Seroprotective titers after influenza vaccination increased as the number of responses to historical strains increased.},
  keywords = {antibodies,Human influenza,immune response,immunogenicity},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\D4YDB57F\\Ross et al. - 2014 - Influence of pre-existing hemagglutination inhibit.pdf;C\:\\Users\\Zane\\Zotero\\storage\\QYX6KB72\\hv.html}
}

@manual{Rstudio,
  type = {Manual},
  title = {{{RStudio}}: {{Integrated}} Development Environment for {{R}}},
  author = {{RStudio Team}},
  year = {2022},
  address = {{Boston, MA}},
  organization = {{RStudio, PBC}}
}

@article{scholtissek1978,
  title = {On the Origin of the Human Influenza Virus Subtypes {{H2N2}} and {{H3N2}}},
  author = {Scholtissek, C. and Rohde, W. and Von Hoyningen, V. and Rott, R.},
  year = {1978},
  month = jun,
  journal = {Virology},
  volume = {87},
  number = {1},
  pages = {13--20},
  doi = {10.1016/0042-6822(78)90153-8},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\5SWU47AN\\Scholtissek et al. - 1978 - On the origin of the human influenza virus subtype.pdf}
}

@article{seqinr,
  title = {{{SeqinR}} 1.0-2: A Contributed Package to the {{R}} Project for Statistical Computing Devoted to Biological Sequences Retrieval and Analysis.},
  author = {Charif, D. and Lobry, J.R.},
  year = {2007},
  journal = {Structural approaches to sequence evolution: Molecules, networks, populations},
  pages = {207--232}
}

@misc{shapiro2021,
  title = {Sex-Specific Effects of Aging on the Humoral Immune Response to Repeat Vaccination with the High-Dose Seasonal Influenza Vaccine in Older Adults},
  author = {Shapiro, Janna R. and Li, Huifen and Morgan, Rosemary and Chen, Yiyin and Kuo, Helen and Ning, Xiaoxuan and Shea, Patrick and Wu, Cunjin and Merport, Katherine and Saldanha, Rayna and Liu, Suifeng and Abrams, Engle and Chen, Yan and Kelly, Denise C. and {Sheridan-Malone}, Eileen and Wang, Lan and Zeger, Scott L. and Klein, Sabra L. and Leng, Sean X.},
  year = {2021},
  month = jul,
  pages = {2021.07.21.21260712},
  publisher = {{medRxiv}},
  doi = {10.1101/2021.07.21.21260712},
  urldate = {2023-03-02},
  abstract = {Older adults ({$\geq$}65 years of age) bear a significant burden of severe disease and mortality associated with influenza, despite relatively high annual vaccination coverage and substantial pre-existing immunity to influenza. To test the hypothesis that host factors, including age and sex, play a role in determining the effect of repeat vaccination and levels of pre-existing humoral immunity to influenza, we evaluated pre- and post-vaccination strain-specific hemagglutination inhibition (HAI) titers in adults over 75 years of age who received a high-dose influenza vaccine in at least four out of six influenza seasons (NCT02200276). Neither age, sex, body mass index, frailty, nor repeat vaccination were significantly associated with post-vaccination HAI titer outcomes. Pre-vaccination titers, however, were significantly predictive of post-vaccination outcomes. Pre-vaccination titers to H1N1 remained constant with age, while those to H3N2 and influenza B decreased substantially with age in males but not in females. Our findings highlight the importance of pre-existing immunity in this highly vaccinated older adult population and suggest that older males are particularly vulnerable to reduced pre-existing humoral immunity to influenza from previous annual vaccination.},
  archiveprefix = {medRxiv},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\CUWIC9LY\\Shapiro et al. - 2021 - Sex-specific effects of aging on the humoral immun.pdf}
}

@article{skarlupka2020,
  title = {Immune Imprinting in the Influenza Ferret Model},
  author = {Skarlupka, Amanda L. and Ross, Ted M.},
  year = {2020-04-08, 2020-04},
  journal = {Vaccines},
  volume = {8},
  number = {2},
  pages = {173},
  doi = {10.3390/vaccines8020173},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\9K8XLZP6\\Skarlupka and Ross - 2020 - Immune imprinting in the influenza ferret model.pdf}
}

@article{skarlupka2020a,
  title = {An Influenza Virus Hemagglutinin Computationally Optimized Broadly Reactive Antigen Elicits Antibodies Endowed with Group 1 Heterosubtypic Breadth against Swine Influenza Viruses},
  author = {Skarlupka, Amanda L. and Reneer, Z. Beau and Abreu, Rodrigo B. and Ross, Ted M. and Sautto, Giuseppe A.},
  editor = {Heise, Mark T.},
  year = {2020-03-31, 2020-03},
  journal = {Journal of Virology},
  volume = {94},
  number = {8},
  doi = {10.1128/jvi.02061-19},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\K9KJIC6Y\\Skarlupka et al. - 2020 - An influenza virus hemagglutinin computationally o.pdf}
}

@article{skarlupka2021,
  title = {Universal {{Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses}} against {{Human Seasonal}} and {{Pre-pandemic Strains}}},
  author = {Skarlupka, Amanda L. and {Bebin-Blackwell}, Anne-Gaelle and Sumner, Spencer F. and Ross, Ted M.},
  year = {2021},
  month = aug,
  journal = {J Virol},
  volume = {95},
  number = {17},
  pages = {e0075921},
  issn = {1098-5514},
  doi = {10.1128/JVI.00759-21},
  abstract = {The hemagglutinin (HA) surface protein is the primary immune target for most influenza vaccines. The neuraminidase (NA) surface protein is often a secondary target for vaccine designs. In this study, computationally optimized broadly reactive antigen (COBRA) methodology was used to generate the N1-I NA vaccine antigen that was designed to cross-react with avian, swine, and human influenza viruses of the N1 NA subtype. The elicited antibodies bound to NA proteins derived from A/California/07/2009 (H1N1)pdm09, A/Brisbane/59/2007 (H1N1), A/Swine/North Carolina/154074/2015 (H1N1), and A/Viet Nam/1203/2004 (H5N1) influenza viruses, with NA-neutralizing activity against a broad panel of HXN1 influenza strains. Mice vaccinated with the N1-I COBRA NA vaccine were protected from mortality and viral lung titers were lower when challenged with four different viral challenges (A/California/07/2009, A/Brisbane/59/2007, A/Swine/North Carolina/154074/2015, and A/Viet Nam/1203/2004). Vaccinated mice had little to no weight loss against both homologous, but also cross-NA, genetic clade challenges. Lung viral titers were lower than the mock-vaccinated mice and, at times, equivalent to the homologous control. Thus, the N1-I COBRA NA antigen has the potential to be a complementary component in a multiantigen universal influenza virus vaccine formulation that also contains HA antigens. IMPORTANCE The development and distribution of a universal influenza vaccine would alleviate global economic and public health stress from annual influenza virus outbreaks. The influenza virus NA vaccine antigen allows for protection from multiple HA subtypes and virus host origins, but it has not been the focus of vaccine development. The N1-I NA antigen described here protected mice from direct challenge of four distinct influenza viruses and inhibited the enzymatic activity of an N1 influenza virus panel. The use of the NA antigen in combination with the HA antigen widens the breadth of protection against various virus strains. Therefore, this research opens the door to the development of a longer-lasting vaccine with increased protective breadth.},
  langid = {english},
  pmcid = {PMC8354223},
  pmid = {34160258},
  keywords = {Animals,Antibodies; Viral,Antigens; Viral,COBRA,Cross Protection,Female,Hemagglutinin Glycoproteins; Influenza Virus,Immunity,influenza,Influenza A Virus; H1N1 Subtype,Influenza A Virus; H5N1 Subtype,Influenza Vaccines,mice,Mice,Mice; Inbred BALB C,N1,Neuraminidase,neuraminidase inhibition,Orthomyxoviridae Infections,Swine,Vaccination,vaccine}
}

@article{skountzou2010,
  title = {Immunity to {{Pre-1950 H1N1 Influenza Viruses Confers Cross-Protection}} against the {{Pandemic Swine-Origin}} 2009 {{A}} ({{H1N1}}) {{Influenza Virus}}},
  author = {Skountzou, Ioanna and Koutsonanos, Dimitrios G. and Kim, Jin Hyang and Powers, Ryan and Satyabhama, Lakshmipriyadarshini and Masseoud, Feda and Weldon, William C. and Martin, Maria del Pilar and Mittler, Robert S. and Compans, Richard and Jacob, Joshy},
  year = {2010},
  month = aug,
  journal = {The Journal of Immunology},
  volume = {185},
  number = {3},
  pages = {1642--1649},
  publisher = {{American Association of Immunologists}},
  issn = {0022-1767, 1550-6606},
  doi = {10.4049/jimmunol.1000091},
  urldate = {2021-11-29},
  abstract = {The 2009 H1N1 influenza virus outbreak is the first pandemic of the twenty-first century. Epidemiological data reveal that of all the people afflicted with H1N1 virus, {$<$}5\% are over 51 y of age. Interestingly, in the uninfected population, 33\% of those {$>$}60 y old have pre-existing neutralizing Abs against the 2009 H1N1 virus. This finding suggests that influenza strains that circulated 50\textendash 60 y ago might provide cross-protection against the swine-origin 2009 H1N1 influenza virus. To test this, we determined the ability of representative H1N1 influenza viruses that circulated in the human population from 1930 to 2000, to induce cross-reactivity to and cross-protection against the pandemic swine-origin H1N1 virus, A/California/04/09. We show that exposure of mice to the 1947 virus, A/FM/1/47, or the 1934 virus, A/PR/8/34, induced robust cross-protective immune responses and these mice were protected against a lethal challenge with mouse-adapted A/California/04/09 H1N1 virus. Conversely, we observed that mice exposed to the 2009 H1N1 virus were protected against a lethal challenge with mouse-adapted 1947 or 1934 H1N1 viruses. In addition, exposure to the 2009 H1N1 virus induced broad cross-reactivity against H1N1 as well as H3N2 influenza viruses. Finally, we show that vaccination with the older H1N1 viruses, particularly A/FM/1/47, confers protective immunity against the 2009 pandemic H1N1 virus. Taken together, our data provide an explanation for the decreased susceptibility of the elderly to the 2009 H1N1 outbreak and demonstrate that vaccination with the pre-1950 influenza strains can cross-protect against the pandemic swine-origin 2009 H1N1 influenza virus.},
  chapter = {HOST DEFENSE},
  copyright = {Copyright \textcopyright{} 2010 by The American Association of Immunologists, Inc.},
  langid = {english},
  pmid = {20585035},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\9RIT5ATA\\Skountzou et al. - 2010 - Immunity to Pre-1950 H1N1 Influenza Viruses Confer.pdf;C\:\\Users\\Zane\\Zotero\\storage\\ZSSRBMYN\\1642.html}
}

@article{skowronski2019,
  title = {Paradoxical Clade- and Age-Specific Vaccine Effectiveness during the 2018/19 Influenza {{A}}({{H3N2}}) Epidemic in {{Canada}}: Potential Imprint-Regulated Effect of Vaccine ({{I-REV}})},
  shorttitle = {Paradoxical Clade- and Age-Specific Vaccine Effectiveness during the 2018/19 Influenza {{A}}({{H3N2}}) Epidemic in {{Canada}}},
  author = {Skowronski, Danuta M. and Sabaiduc, Suzana and Leir, Siobhan and Rose, Caren and Zou, Macy and Murti, Michelle and Dickinson, James A. and Olsha, Romy and Gubbay, Jonathan B. and Croxen, Matthew A. and Charest, Hugues and Bastien, Nathalie and Li, Yan and Jassem, Agatha and Krajden, Mel and Serres, Gaston De},
  year = {2019},
  month = nov,
  journal = {Eurosurveillance},
  volume = {24},
  number = {46},
  pages = {1900585},
  publisher = {{European Centre for Disease Prevention and Control}},
  issn = {1560-7917},
  doi = {10.2807/1560-7917.ES.2019.24.46.1900585},
  urldate = {2023-03-02},
  abstract = {Introduction The Canadian Sentinel Practitioner Surveillance Network reports vaccine effectiveness (VE) for the 2018/19 influenza A(H3N2) epidemic. Aim To explain a paradoxical signal of increased clade 3C.3a risk among 35\textendash 54-year-old vaccinees, we hypothesise childhood immunological imprinting and a cohort effect following the 1968 influenza A(H3N2) pandemic. Methods We assessed VE by test-negative design for influenza A(H3N2) overall and for co-circulating clades 3C.2a1b and 3C.3a. VE variation by age in 2018/19 was compared with amino acid variation in the haemagglutinin glycoprotein by year since 1968. Results Influenza A(H3N2) VE was 17\% (95\% CI: -13 to 39) overall: 27\% (95\% CI: -7 to 50) for 3C.2a1b and -32\% (95\% CI: -119 to 21) for 3C.3a. Among 20\textendash 64-year-olds, VE was -7\% (95\% CI: -56 to 26): 6\% (95\% CI: -49 to 41) for 3C.2a1b and -96\% (95\% CI: -277 to -2) for 3C.3a. Clade 3C.3a VE showed a pronounced negative dip among 35\textendash 54-year-olds in whom the odds of medically attended illness were \&gt; 4-fold increased for vaccinated vs unvaccinated participants (p \&lt; 0.005). This age group was primed in childhood to influenza A(H3N2) viruses that for two decades following the 1968 pandemic bore a serine at haemagglutinin position 159, in common with contemporary 3C.3a viruses but mismatched to 3C.2a vaccine strains instead bearing tyrosine. Discussion Imprinting by the first childhood influenza infection is known to confer long-lasting immunity focused toward priming epitopes. Our findings suggest vaccine mismatch may negatively interact with imprinted immunity. The immunological mechanisms for imprint-regulated effect of vaccine (I-REV) warrant investigation.},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\U7EHIDWU\\Skowronski et al. - 2019 - Paradoxical clade- and age-specific vaccine effect.pdf}
}

@article{smith2004a,
  title = {Mapping the Antigenic and Genetic Evolution of Influenza Virus},
  author = {Smith, Derek J. and Lapedes, Alan S. and {de Jong}, Jan C. and Bestebroer, Theo M. and Rimmelzwaan, Guus F. and Osterhaus, Albert D. M. E. and Fouchier, Ron A. M.},
  year = {2004-07-16, 2004-07},
  journal = {Science},
  volume = {305},
  number = {5682},
  pages = {371--376},
  doi = {10.1126/science.1097211},
  langid = {english}
}

@article{souquette2018,
  title = {Past {{Life}} and {{Future Effects-How Heterologous Infections Alter Immunity}} to {{Influenza Viruses}}},
  author = {Souquette, Aisha and Thomas, Paul G.},
  year = {2018},
  journal = {Front Immunol},
  volume = {9},
  pages = {1071},
  issn = {1664-3224},
  doi = {10.3389/fimmu.2018.01071},
  abstract = {Influenza virus frequently mutates due to its error-prone polymerase. This feature contributes to influenza virus's ability to evade pre-existing immunity, leading to annual epidemics and periodic pandemics. T cell memory plays a key protective role in the face of an antigenically distinct influenza virus strain because T cell targets are often derived from conserved internal proteins, whereas humoral immunity targets are often sites of increased mutation rates that are tolerated by the virus. Most studies of influenza T cell memory are conducted in naive, specific pathogen free mice and do not account for repetitive influenza infection throughout a lifetime, sequential acute heterologous infections between influenza infections, or heterologous chronic co-infections. By contrast to these mouse models, humans often experience numerous influenza infections, encounter heterologous acute infections between influenza infections, and are infected with at least one chronic virus. In this review, we discuss recent advances in understanding the effects of heterologous infections on the establishment and maintenance of CD8+ T cell immunological memory. Understanding the various factors that affect immune memory can provide insights into the development of more effective vaccines and increase reproducibility of translational studies between animal models and clinical results.},
  langid = {english},
  pmcid = {PMC5972221},
  pmid = {29872429},
  keywords = {Animals,attrition,bystander,CD8+ T cells,chronic co-infection,Coinfection,Cross Reactions,cross-reactivity,heterologous,Host-Pathogen Interactions,Humans,Immunity,Immunity; Cellular,Immunity; Humoral,Immunologic Memory,influenza,Influenza; Human,memory,Orthomyxoviridae,T-Lymphocytes},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\UP4N4LE3\\Souquette and Thomas - 2018 - Past Life and Future Effects-How Heterologous Infe.pdf}
}

@article{sullivan2019,
  title = {Reconciling Estimates of the Global Influenza Burden},
  author = {Sullivan, Sheena G. and Cowling, Benjamin J.},
  year = {2019},
  month = jan,
  journal = {Lancet Respir Med},
  volume = {7},
  number = {1},
  pages = {8--9},
  issn = {2213-2619},
  doi = {10.1016/S2213-2600(18)30511-3},
  langid = {english},
  pmid = {30553846},
  keywords = {Global Burden of Disease,Hospitalization,Humans,Influenza; Human,Morbidity,Respiratory Tract Infections},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\X22ZAZIJ\\Sullivan and Cowling - 2019 - Reconciling estimates of the global influenza burd.pdf}
}

@article{sun2013,
  title = {Using Sequence Data to Infer the Antigenicity of Influenza Virus},
  author = {Sun, Hailiang and Yang, Jialiang and Zhang, Tong and Long, Li-Ping and Jia, Kun and Yang, Guohua and Webby, Richard J. and Wan, Xiu-Feng},
  editor = {Perlman, Stanley and Biron, Christine},
  year = {2013-08-30, 2013-08},
  journal = {mBio},
  volume = {4},
  number = {4},
  doi = {10.1128/mbio.00230-13},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\UNE937HF\\Sun et al. - 2013 - Using sequence data to infer the antigenicity of i.pdf}
}

@article{tapia2020,
  title = {Antigenic Characterization of Novel {{H1}} Influenza {{A}} Viruses in Swine},
  author = {Tapia, Rodrigo and Torremorell, Montserrat and Culhane, Marie and Medina, Rafael A. and Neira, V{\'i}ctor},
  year = {2020-03-11, 2020-03},
  journal = {Scientific Reports},
  volume = {10},
  number = {1},
  doi = {10.1038/s41598-020-61315-5},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\3TGEG9HE\\Tapia et al. - 2020 - Antigenic characterization of novel H1 influenza A.pdf}
}

@article{taylor1994,
  title = {Competitive {{Binding}} of {{Neutralizing Monoclonal}} and {{Polyclonal IgG}} to the {{HA}} of {{Influenza A Virions}} in {{Solution}}: {{Only One IgG Molecule Is Bound}} per {{HA Trimer Regardless}} of the {{Specificity}} of the {{Competitor}}},
  shorttitle = {Competitive {{Binding}} of {{Neutralizing Monoclonal}} and {{Polyclonal IgG}} to the {{HA}} of {{Influenza A Virions}} in {{Solution}}},
  author = {Taylor, H. P. and Dimmock, N. J.},
  year = {1994},
  month = nov,
  journal = {Virology},
  volume = {205},
  number = {1},
  pages = {360--363},
  issn = {0042-6822},
  doi = {10.1006/viro.1994.1653},
  urldate = {2021-06-30},
  abstract = {Two-step solution competition assays were performed in solution with influenza type A virions and hemagglutinin (HA) specific neutralizing monoclonal antibodies (mabs). These demonstrated that the binding of one molecule of IgG mab per HA trimer prevented the binding of mabs directed against other antigenic sites on the HA (site A, site B, or site D), even though these are topographically separate and antigenically independent. Furthermore the same procedures showed that one molecule of mab per trimer prevented the binding of polyclonal HA-specific IgG obtained from the serum of rabbits immunized with whole virus. This restricted binding is clearly a property of the intact virion, since others using purified HA have shown that up to four IgG molecules of different specificities can bind per trimer. Since the surface area of the globular head of the trimer is equivalent to approximately 10 nonoverlapping antibody footprints, it is not understood how one prebound IgG molecule prevents the binding of other IgG molecules.},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\CXBCLYTF\\Taylor and Dimmock - 1994 - Competitive Binding of Neutralizing Monoclonal and.pdf;C\:\\Users\\Zane\\Zotero\\storage\\GEVQ4RM8\\S0042682284716539.html}
}

@article{thompson2003,
  title = {Mortality {{Associated With Influenza}} and {{Respiratory Syncytial Virus}} in the {{United States}}},
  author = {Thompson, William W. and Shay, David K. and Weintraub, Eric and Brammer, Lynnette and Cox, Nancy and Anderson, Larry J. and Fukuda, Keiji},
  year = {2003},
  month = jan,
  journal = {JAMA},
  volume = {289},
  number = {2},
  pages = {179},
  issn = {0098-7484},
  doi = {10.1001/jama.289.2.179},
  urldate = {2021-06-23},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\BUKF33LN\\Thompson et al. - 2003 - Mortality Associated With Influenza and Respirator.pdf}
}

@article{thompson2016,
  title = {Effects of {{Repeated Annual Inactivated Influenza Vaccination}} among {{Healthcare Personnel}} on {{Serum Hemagglutinin Inhibition Antibody Response}} to {{A}}/{{Perth}}/16/2009 ({{H3N2}})-like Virus during 2010-11},
  author = {Thompson, Mark G. and Naleway, Allison and Fry, Alicia M. and Ball, Sarah and Spencer, Sarah M. and Reynolds, Sue and Bozeman, Sam and Levine, Min and Katz, Jacqueline M. and Gaglani, Manjusha},
  year = {2016},
  month = feb,
  journal = {Vaccine},
  volume = {34},
  number = {7},
  pages = {981--988},
  issn = {1873-2518},
  doi = {10.1016/j.vaccine.2015.10.119},
  abstract = {BACKGROUND: Recently, lower estimates of influenza vaccine effectiveness (VE) against A(H3N2) virus illness among those vaccinated during the previous season or multiple seasons have been reported; however, it is unclear whether these effects are due to differences in immunogenicity. METHODS: We performed hemagglutination inhibition antibody (HI) assays on serum collected at preseason, {$\sim$} 30 days post-vaccination, and postseason from a prospective cohort of healthcare personnel (HCP). Eligible participants had medical and vaccination records for at least four years (since July, 2006), including 578 HCP who received 2010-11 trivalent inactivated influenza vaccine [IIV3, containing A/Perth/16/2009-like A(H3N2)] and 209 HCP who declined vaccination. Estimates of the percentage with high titers ({$\geq$} 40 and{$>$}100) and geometric mean fold change ratios (GMRs) to A/Perth/16/2009-like virus by number of prior vaccinations were adjusted for age, sex, race, education, household size, hospital care responsibilities, and study site. RESULTS: Post-vaccination GMRs were inversely associated with the number of prior vaccinations, increasing from 2.3 among those with 4 prior vaccinations to 6.2 among HCP with zero prior vaccinations (F[4,567]=9.97, p{$<$}.0005). Thirty-two percent of HCP with 1 prior vaccination achieved titers {$>$}100 compared to only 11\% of HCP with 4 prior vaccinations (adjusted odds ratio=6.8, 95\% CI=3.1 - 15.3). CONCLUSION: Our findings point to an exposure-response association between repeated IIV3 vaccination and HI for A(H3N2) and are consistent with recent VE observations. Ultimately, better vaccines and vaccine strategies may be needed in order to optimize immunogenicity and VE for HCP and other repeated vaccinees.},
  langid = {english},
  pmcid = {PMC5218812},
  pmid = {26813801},
  keywords = {Adult,Antibodies; Viral,Antibody Formation,Dose-Response Relationship; Immunologic,Female,Health Personnel,healthcare personnel,hemagglutination inhibition antibody,Hemagglutination Inhibition Tests,Humans,immunogenicity,Influenza A Virus; H3N2 Subtype,influenza vaccination,Influenza Vaccines,Influenza; Human,Male,Middle Aged,Prospective Studies,Vaccination,Vaccines; Inactivated},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\K874CVQV\\Thompson et al. - 2016 - Effects of Repeated Annual Inactivated Influenza V.pdf}
}

@article{tokars2020,
  title = {Waning of {{Measured Influenza Vaccine Effectiveness Over Time}}: {{The Potential Contribution}} of {{Leaky Vaccine Effect}}},
  shorttitle = {Waning of {{Measured Influenza Vaccine Effectiveness Over Time}}},
  author = {Tokars, Jerome I and Patel, Manish M and Foppa, Ivo M and Reed, Carrie and Fry, Alicia M and Ferdinands, Jill M},
  year = {2020},
  month = nov,
  journal = {Clinical Infectious Diseases},
  volume = {71},
  number = {10},
  pages = {e633-e641},
  issn = {1058-4838},
  doi = {10.1093/cid/ciaa340},
  urldate = {2021-02-16},
  abstract = {Several observational studies have shown decreases in measured influenza vaccine effectiveness (mVE) during influenza seasons. One study found decreases of 6\textendash 11\%/month during the 2011\textendash 2012 to 2014\textendash 2015 seasons. These findings could indicate waning immunity but could also occur if vaccine effectiveness is stable and vaccine provides partial protection in all vaccinees (``leaky'') rather than complete protection in a subset of vaccinees. Since it is unknown whether influenza vaccine is leaky, we simulated the 2011\textendash 2012 to 2014\textendash 2015 influenza seasons to estimate the potential contribution of leaky vaccine effect to the observed decline in mVE.We used available data to estimate daily numbers of vaccinations and infections with A/H1N1, A/H3N2, and B viruses. We assumed that vaccine effect was leaky, calculated mVE as 1 minus the Mantel-Haenszel relative risk of vaccine on incident cases, and determined the mean mVE change per 30 days since vaccination. Because change in mVE was highly dependent on infection rates, we performed simulations using low (15\%) and high (31\%) total (including symptomatic and asymptomatic) seasonal infection rates.For the low infection rate, decreases (absolute) in mVE per 30 days after vaccination were 2\% for A/H1N1 and 1\% for A/H3N2and B viruses. For the high infection rate, decreases were 5\% for A/H1N1, 4\% for A/H3, and 3\% for B viruses.The leaky vaccine bias could account for some, but probably not all, of the observed intraseasonal decreases in mVE. These results underscore the need for strategies to deal with intraseasonal vaccine effectiveness decline.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\9ISTBSG5\\Tokars et al. - 2020 - Waning of Measured Influenza Vaccine Effectiveness.pdf;C\:\\Users\\Zane\\Zotero\\storage\\K3U2RNZ6\\5813486.html}
}

@article{tomic2019,
  title = {The {{FluPRINT}} Dataset, a Multidimensional Analysis of the Influenza Vaccine Imprint on the Immune System},
  author = {Tomic, Adriana and Tomic, Ivan and Dekker, Cornelia L. and Maecker, Holden T. and Davis, Mark M.},
  year = {2019},
  month = oct,
  journal = {Scientific Data},
  volume = {6},
  number = {1},
  pages = {214},
  publisher = {{Nature Publishing Group}},
  issn = {2052-4463},
  doi = {10.1038/s41597-019-0213-4},
  urldate = {2021-02-17},
  abstract = {Machine learning has the potential to identify novel biological factors underlying successful antibody responses to influenza vaccines. The first attempts have revealed a high level of complexity in establishing influenza immunity, and many different cellular and molecular components are involved. Of note is that the previously identified correlates of protection fail to account for the majority of individual responses across different age groups and influenza seasons. Challenges remain from the small sample sizes in most studies and from often limited data sets, such as transcriptomic data. Here we report the creation of a unified database, FluPRINT, to enable large-scale studies exploring the cellular and molecular underpinnings of successful antibody responses to influenza vaccines. Over 3,000 parameters were considered, including serological responses to influenza strains, serum cytokines, cell phenotypes, and cytokine stimulations. FluPRINT, facilitates the application of machine learning algorithms for data mining. The data are publicly available and represent a resource to uncover new markers and mechanisms that are important for influenza vaccine immunogenicity.},
  copyright = {2019 The Author(s)},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\QNT39W8Z\\Tomic et al. - 2019 - The FluPRINT dataset, a multidimensional analysis .pdf;C\:\\Users\\Zane\\Zotero\\storage\\7BEHKJDL\\s41597-019-0213-4.html}
}

@article{trifonov2009,
  title = {Geographic {{Dependence}}, {{Surveillance}}, and {{Origins}} of the 2009 {{Influenza A}} ({{H1N1}}) {{Virus}}},
  author = {Trifonov, Vladimir and Khiabanian, Hossein and Rabadan, Raul},
  year = {2009},
  month = jul,
  journal = {New England Journal of Medicine},
  volume = {361},
  number = {2},
  pages = {115--119},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMp0904572},
  urldate = {2023-03-21},
  abstract = {In April 2009, a new strain of human H1N1 influenza A virus was identified in Mexico. According to the World Health Organization (www.who.int/csr/don/2009\_05\_25), as of May 25, 2009, the virus had spread to 43 countries, with 12,515 reported cases and 91 associated deaths, and it has been assessed as having pandemic potential.1 Genomic analysis of the 2009 influenza A (H1N1) virus in humans indicates that it is closely related to common reassortant swine influenza A viruses isolated in North America, Europe, and Asia (Figure 1).2\textendash 4 The segments coding for the polymerase complex, hemagglutinin, nuclear protein, and nonstructural proteins show . . .},
  pmid = {19474418},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\B7XGE2GF\\Trifonov et al. - 2009 - Geographic Dependence, Surveillance, and Origins o.pdf}
}

@article{tsang2014,
  title = {Global Analyses of Human Immune Variation Reveal Baseline Predictors of Postvaccination Responses},
  author = {Tsang, John S. and Schwartzberg, Pamela L. and Kotliarov, Yuri and Biancotto, Angelique and Xie, Zhi and Germain, Ronald N. and Wang, Ena and Olnes, Matthew J. and Narayanan, Manikandan and Golding, Hana and Moir, Susan and Dickler, Howard B. and Perl, Shira and Cheung, Foo and {Baylor HIPC Center} and {CHI Consortium}},
  year = {2014},
  month = apr,
  journal = {Cell},
  volume = {157},
  number = {2},
  pages = {499--513},
  issn = {1097-4172},
  doi = {10.1016/j.cell.2014.03.031},
  abstract = {A major goal of systems biology is the development of models that accurately predict responses to perturbation. Constructing such models requires the collection of dense measurements of system states, yet transformation of data into predictive constructs remains a challenge. To begin to model human immunity, we analyzed immune parameters in depth both at baseline and in response to influenza vaccination. Peripheral blood mononuclear cell transcriptomes, serum titers, cell subpopulation frequencies, and B cell responses were assessed in 63 individuals before and after vaccination and were used to develop a systematic framework to dissect inter- and intra-individual variation and build predictive models of postvaccination antibody responses. Strikingly, independent of age and pre-existing antibody titers, accurate models could be constructed using pre-perturbation cell populations alone, which were validated using independent baseline time points. Most of the parameters contributing to prediction delineated temporally stable baseline differences across individuals, raising the prospect of immune monitoring before intervention.},
  langid = {english},
  pmcid = {PMC4139290},
  pmid = {24725414},
  keywords = {Adult,Antibody Formation,B-Lymphocytes,Female,Humans,Influenza Vaccines,Leukocytes; Mononuclear,Male,Middle Aged,Transcriptome,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\PNTXXBWX\\Tsang et al. - 2014 - Global analyses of human immune variation reveal b.pdf}
}

@article{tuju2019,
  title = {Antigenic Cartography of Immune Responses to {{Plasmodium}} Falciparum Erythrocyte Membrane Protein 1 ({{PfEMP1}})},
  author = {Tuju, James and Mackinnon, Margaret J. and Abdi, Abdirahman I. and Karanja, Henry and Musyoki, Jennifer N. and Warimwe, George M. and Gitau, Evelyn N. and Marsh, Kevin and Bull, Peter C. and Urban, Britta C.},
  editor = {Hviid, Lars},
  year = {2019-07-01, 2019-07},
  journal = {PLOS Pathogens},
  volume = {15},
  number = {7},
  pages = {e1007870},
  doi = {10.1371/journal.ppat.1007870},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\KDKECQPQ\\Tuju et al. - 2019 - Antigenic cartography of immune responses to Plasm.pdf}
}

@article{uniprot2020,
  title = {{{UniProt}}: The Universal Protein Knowledgebase in 2021},
  author = {{Bateman} and {Alex} and Martin, Maria-Jesus and Orchard, Sandra and Magrane, Michele and Agivetova, Rahat and Ahmad, Shadab and Alpi, Emanuele and {Bowler-Barnett}, Emily H and Britto, Ramona and Bursteinas, Borisas and {Bye-A-Jee}, Hema and Coetzee, Ray and Cukura, Austra and Da Silva, Alan and Denny, Paul and Dogan, Tunca and Ebenezer, ThankGod and Fan, Jun and Castro, Leyla Garcia and Garmiri, Penelope and Georghiou, George and Gonzales, Leonardo and {Hatton-Ellis}, Emma and Hussein, Abdulrahman and Ignatchenko, Alexandr and Insana, Giuseppe and Ishtiaq, Rizwan and Jokinen, Petteri and Joshi, Vishal and Jyothi, Dushyanth and Lock, Antonia and Lopez, Rodrigo and Luciani, Aurelien and Luo, Jie and Lussi, Yvonne and MacDougall, Alistair and Madeira, Fabio and Mahmoudy, Mahdi and Menchi, Manuela and Mishra, Alok and Moulang, Katie and Nightingale, Andrew and Oliveira, Carla Susana and Pundir, Sangya and Qi, Guoying and Raj, Shriya and Rice, Daniel and Lopez, Milagros Rodriguez and Saidi, Rabie and Sampson, Joseph and Sawford, Tony and Speretta, Elena and Turner, Edward and Tyagi, Nidhi and Vasudev, Preethi and Volynkin, Vladimir and Warner, Kate and Watkins, Xavier and Zaru, Rossana and Zellner, Hermann and Bridge, Alan and Poux, Sylvain and Redaschi, Nicole and Aimo, Lucila and {Argoud-Puy}, Ghislaine and Auchincloss, Andrea and Axelsen, Kristian and Bansal, Parit and Baratin, Delphine and Blatter, Marie-Claude and Bolleman, Jerven and Boutet, Emmanuel and Breuza, Lionel and {Casals-Casas}, Cristina and {de Castro}, Edouard and Echioukh, Kamal Chikh and Coudert, Elisabeth and Cuche, Beatrice and Doche, Mikael and Dornevil, Dolnide and Estreicher, Anne and Famiglietti, Maria Livia and Feuermann, Marc and Gasteiger, Elisabeth and Gehant, Sebastien and Gerritsen, Vivienne and Gos, Arnaud and {Gruaz-Gumowski}, Nadine and Hinz, Ursula and Hulo, Chantal and {Hyka-Nouspikel}, Nevila and Jungo, Florence and Keller, Guillaume and Kerhornou, Arnaud and Lara, Vicente and Le Mercier, Philippe and Lieberherr, Damien and Lombardot, Thierry and Martin, Xavier and Masson, Patrick and Morgat, Anne and Neto, Teresa Batista and Paesano, Salvo and Pedruzzi, Ivo and Pilbout, Sandrine and Pourcel, Lucille and Pozzato, Monica and Pruess, Manuela and Rivoire, Catherine and Sigrist, Christian and Sonesson, Karin and Stutz, Andre and Sundaram, Shyamala and Tognolli, Michael and Verbregue, Laure and Wu, Cathy H and Arighi, Cecilia N and Arminski, Leslie and Chen, Chuming and Chen, Yongxing and Garavelli, John S and Huang, Hongzhan and Laiho, Kati and McGarvey, Peter and Natale, Darren A and Ross, Karen and Vinayaka, C R and Wang, Qinghua and Wang, Yuqi and Yeh, Lai-Su and Zhang, Jian and Ruch, Patrick and Teodoro, Douglas},
  year = {2020-11-25, 2020-11},
  journal = {Nucleic Acids Research},
  volume = {49},
  number = {D1},
  pages = {D480--D489},
  doi = {10.1093/nar/gkaa1100},
  langid = {english}
}

@article{valkenburg2022,
  title = {Exploring the Landscape of Immune Responses to Influenza Infection and Vaccination},
  author = {Valkenburg, Sophie A. and Poon, Leo L. M.},
  year = {2022},
  month = feb,
  journal = {Nature Medicine},
  volume = {28},
  number = {2},
  pages = {239--240},
  doi = {10.1038/s41591-021-01656-4},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\J7JUU5D6\\Valkenburg and Poon - 2022 - Exploring the landscape of immune responses to inf.pdf}
}

@article{viboud2016,
  title = {First Flu Is Forever},
  author = {Viboud, C{\'e}cile and Epstein, Suzanne L.},
  year = {2016},
  month = nov,
  journal = {Science},
  volume = {354},
  number = {6313},
  pages = {706--707},
  issn = {1095-9203},
  doi = {10.1126/science.aak9816},
  langid = {english},
  pmid = {27846592},
  keywords = {Humans,Influenza; Human}
}

@misc{vieira2021,
  title = {Lineage-Specific Protection and Immune Imprinting Shape the Age Distributions of Influenza {{B}} Cases},
  author = {Vieira, Marcos C. and Donato, Celeste M. and Arevalo, Philip and Rimmelzwaan, Guus F. and Wood, Timothy and Lopez, Liza and Huang, Q. Sue and Dhanasekaran, Vijaykrishna and Koelle, Katia and Cobey, Sarah},
  year = {2021},
  month = jun,
  pages = {2020.09.30.20204909},
  publisher = {{medRxiv}},
  doi = {10.1101/2020.09.30.20204909},
  urldate = {2023-03-02},
  abstract = {How a history of influenza virus infections contributes to protection is not fully understood, but such protection might explain the contrasting age distributions of cases of the two lineages of influenza B, B/Victoria and B/Yamagata. Fitting a statistical model to those distributions using surveillance data from New Zealand, we found they could be explained by historical changes in lineage frequencies combined with cross-protection between strains of the same lineage. We found additional protection against B/Yamagata in people for whom it was their first influenza B infection, similar to the immune imprinting observed in influenza A. While the data were not informative about B/Victoria imprinting, B/Yamagata imprinting could explain the fewer B/Yamagata than B/Victoria cases in cohorts born in the 1990s and the bimodal age distribution of B/Yamagata cases. Longitudinal studies can test if these forms of protection inferred from historical data extend to more recent strains and other populations.},
  archiveprefix = {medRxiv},
  copyright = {\textcopyright{} 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\IFSJLJDF\\Vieira et al. - 2021 - Lineage-specific protection and immune imprinting .pdf}
}

@article{vieira2021a,
  title = {Lineage-Specific Protection and Immune Imprinting Shape the Age Distributions of Influenza {{B}} Cases},
  author = {Vieira, Marcos C. and Donato, Celeste M. and Arevalo, Philip and Rimmelzwaan, Guus F. and Wood, Timothy and Lopez, Liza and Huang, Q. Sue and Dhanasekaran, Vijaykrishna and Koelle, Katia and Cobey, Sarah},
  year = {2021},
  month = jul,
  journal = {Nat Commun},
  volume = {12},
  number = {1},
  pages = {4313},
  issn = {2041-1723},
  doi = {10.1038/s41467-021-24566-y},
  abstract = {How a history of influenza virus infections contributes to protection is not fully understood, but such protection might explain the contrasting age distributions of cases of the two lineages of influenza B, B/Victoria and B/Yamagata. Fitting a statistical model to those distributions using surveillance data from New Zealand, we found they could be explained by historical changes in lineage frequencies combined with cross-protection between strains of the same lineage. We found additional protection against B/Yamagata in people for whom it was their first influenza B infection, similar to the immune imprinting observed in influenza A. While the data were not informative about B/Victoria imprinting, B/Yamagata imprinting could explain the fewer B/Yamagata than B/Victoria cases in cohorts born in the 1990s and the bimodal age distribution of B/Yamagata cases. Longitudinal studies can test if these forms of protection inferred from historical data extend to more recent strains and other populations.},
  langid = {english},
  pmcid = {PMC8280188},
  pmid = {34262041},
  keywords = {Age Distribution,Cross Protection,Humans,Immunologic Memory,Influenza B virus,Influenza; Human,Models; Statistical,New Zealand,Probability},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\A4ED2R8Z\\Vieira et al. - 2021 - Lineage-specific protection and immune imprinting .pdf}
}

@article{vogel2020,
  title = {Broadly {{Protective Strategies Against Influenza Viruses}}: {{Universal Vaccines}} and {{Therapeutics}}},
  shorttitle = {Broadly {{Protective Strategies Against Influenza Viruses}}},
  author = {Vogel, Olivia A. and Manicassamy, Balaji},
  year = {2020},
  journal = {Front Microbiol},
  volume = {11},
  pages = {135},
  issn = {1664-302X},
  doi = {10.3389/fmicb.2020.00135},
  abstract = {Influenza virus is a respiratory pathogen that can cause disease in humans, with symptoms ranging from mild to life-threatening. The vast majority of influenza virus infections in humans are observed during seasonal epidemics and occasional pandemics. Given the substantial public health burden associated with influenza virus infection, yearly vaccination is recommended for protection against seasonal influenza viruses. Despite vigilant surveillance for new variants and careful selection of seasonal vaccine strains, the efficacy of seasonal vaccines can vary widely from year to year. This often results in lowered protection within the population, regardless of vaccination status. In order to broaden the protection afforded by seasonal influenza vaccines, the National Institute of Allergy and Infectious Diseases (NIAID) has deemed the development of a universal influenza virus vaccine to be a priority in influenza virus vaccine research. This universal vaccine would provide protection against all influenza virus strains, eliminating the need for the yearly reformulations of seasonal influenza vaccines. In addition to universal influenza vaccine efforts, substantial progress has been made in developing novel influenza virus therapeutics that utilize broadly neutralizing antibodies to provide protection against influenza virus infection and to mitigate disease outcomes during infection. In this review, we discuss various approaches toward the goal of improving influenza virus vaccine efficacy through a universal influenza virus vaccine. We also address the novel methods of discovery and utilization of broadly neutralizing antibodies to improve influenza disease outcomes.},
  langid = {english},
  pmcid = {PMC7020694},
  pmid = {32117155},
  keywords = {immunization,influenza,influenza therapeutics,universal influenza vaccine,vaccine}
}

@article{voigt2019,
  title = {Sex {{Differences}} in {{Older Adults}}' {{Immune Responses}} to {{Seasonal Influenza Vaccination}}},
  author = {Voigt, Emily A. and Ovsyannikova, Inna G. and Kennedy, Richard B. and Grill, Diane E. and Goergen, Krista M. and Schaid, Daniel J. and Poland, Gregory A.},
  year = {2019},
  journal = {Front Immunol},
  volume = {10},
  pages = {180},
  issn = {1664-3224},
  doi = {10.3389/fimmu.2019.00180},
  abstract = {Background: Sex differences in immune responses to influenza vaccine may impact efficacy across populations. Methods: In a cohort of 138 older adults (50-74 years old), we measured influenza A/H1N1 antibody titers, B-cell ELISPOT response, PBMC transcriptomics, and PBMC cell compositions at 0, 3, and 28 days post-immunization with the 2010/11 seasonal inactivated influenza vaccine. Results: We identified higher B-cell ELISPOT responses in females than males. Potential mechanisms for sex effects were identified in four gene clusters related to T, NK, and B cells. Mediation analysis indicated that sex-dependent expression in T and NK cell genes can be partially attributed to higher CD4+ T cell and lower NK cell fractions in females. We identified strong sex effects in 135 B cell genes whose expression correlates with ELISPOT measures, and found that cell subset differences did not explain the effect of sex on these genes' expression. Post-vaccination expression of these genes, however, mediated 41\% of the sex effect on ELISPOT responses. Conclusions: These results improve our understanding of sexual dimorphism in immunity and influenza vaccine response.},
  langid = {english},
  pmcid = {PMC6400991},
  pmid = {30873150},
  keywords = {Age Factors,Aged,Antibodies; Viral,B-Lymphocytes,Biomarkers,elderly,Enzyme-Linked Immunospot Assay,Female,Geriatric Assessment,Humans,immunity,Immunity,Immunity; Cellular,Immunity; Humoral,influenza,Influenza A virus,influenza vaccine,Influenza Vaccines,Influenza; Human,Leukocytes; Mononuclear,Male,Middle Aged,sex differences,Sex Factors,sexual dimorphism,systems biology,T-Lymphocytes,Vaccination,vaccinomics},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\FF7NFL8F\\Voigt et al. - 2019 - Sex Differences in Older Adults' Immune Responses .pdf}
}

@article{waldock2021,
  title = {Assay Harmonization and Use of Biological Standards to Improve the Reproducibility of the Hemagglutination Inhibition Assay: A {{FLUCOP}} Collaborative Study},
  author = {Waldock, Joanna and Zheng, Lingyi and Remarque, Edmond J. and Civet, Alexandre and Hu, Branda and Jalloh, Sarah Lartey and Cox, Rebecca Jane and Ho, Sammy and Hoschler, Katja and Ollinger, Thierry and Trombetta, Claudia Maria and Engelhardt, Othmar G. and Caillet, Catherine},
  editor = {Pasetti, Marcela F.},
  year = {2021-08-25, 2021-08},
  journal = {mSphere},
  volume = {6},
  number = {4},
  doi = {10.1128/msphere.00567-21},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\95WCBG8Q\\Waldock et al. - 2021 - Assay harmonization and use of biological standard.pdf}
}

@article{wang2021,
  title = {Broadly {{Reactive IgG Responses}} to {{Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped}} by {{Antigenic Relatedness}} to {{Priming Strains}}},
  author = {Wang, Jiong and Li, Dongmei and Perry, Sheldon and Hilchey, Shannon P. and Wiltse, Alexander and Treanor, John J. and Sangster, Mark Y. and Zand, Martin S.},
  year = {2021},
  month = aug,
  journal = {mBio},
  volume = {12},
  number = {4},
  pages = {e0044921},
  issn = {2150-7511},
  doi = {10.1128/mBio.00449-21},
  abstract = {Prime-boost vaccinations of humans with different H5 strains have generated broadly protective antibody levels. However, the effect of an individual's H5 exposure history on antibody responses to subsequent H5 vaccination is poorly understood. To investigate this, we analyzed the IgG responses to H5 influenza A/Indonesia/5/2005 (Ind05) virus vaccination in three cohorts: (i) a doubly primed group that had received two H5 virus vaccinations, namely, against influenza A/Vietnam/203/2004 (Vie04) virus 5\,years prior and A/Hong Kong/156/1997 (HK97) 11\,years prior to the Ind05 vaccination; (ii) a singly primed group that had received a vaccination against Vie04 virus 5\,years prior to the Ind05 vaccination; and (iii) an H5-naive group that received two doses of the Ind05 vaccine 28\,days apart. Hemagglutinin (HA)-reactive IgG levels were estimated by a multiplex assay against an HA panel that included 21 H5 strains and 9 other strains representing the H1, H3, H7, and H9 subtypes. Relative HA antibody landscapes were generated to quantitatively analyze the magnitude and breadth of antibody binding after vaccination. We found that short-interval priming and boosting with the Ind05 vaccine in the naive group generated a low anti-H5 response. Both primed groups generated robust antibody responses reactive to a broad range of H5 strains after receiving a booster injection of Ind05 vaccine; IgG antibody levels persisted longer in subjects who had been doubly primed years ago. Notably, the IgG responses were strongest against the first priming H5 strain, which reflects influenza virus immune imprinting. Finally, the broad anti-H5 IgG response was stronger against strains having a small antigenic distance from the initial priming strain. IMPORTANCE The antigenic shift and draft of hemagglutinin (HA) in influenza viruses is accepted as one of the major reasons for immune evasion. The analysis of B cell immune responses to influenza infection and vaccination is complicated by the impact of exposure history and antibody cross-reactions between antigenically similar influenza strains. To assist in such analyses, the influenza "antibody landscape" method has been used to analyze and visualize the relationship of antibody-mediated immunity to antigenic distances between influenza strains. In this study, we describe a "relative antibody landscape" method that calculates the antigenic distance between the vaccine influenza strain and other H5 strains and uses this relative antigenic distance to plot the anti-H5 IgG levels postvaccination. This new method quantitatively estimates and visualizes the correlation between the humoral response to a particular influenza strain and the antigenic distance from other strains. Our findings demonstrate the effect of a subject's H5 exposure history on H5 vaccine responses quantified by the relative antibody landscape method.},
  langid = {english},
  pmcid = {PMC8406322},
  pmid = {34225490},
  keywords = {Adult,Antibodies; Viral,Antigenic Drift and Shift,Cohort Studies,H5 monovalent influenza vaccine (MIV),HA imprinting,hemagglutinin (HA) antigenic distance,Hemagglutinin Glycoproteins; Influenza Virus,Humans,Immunoglobulin G,Influenza A Virus; H5N1 Subtype,Influenza Vaccines,influenza virus antibody landscape,Influenza; Human,Middle Aged,original antigenic sin (OAS),Vaccination}
}

@article{wang2021a,
  title = {Antigenic Characterization of Influenza and {{SARS-CoV-2}} Viruses},
  author = {Wang, Yang and Tang, Cynthia Y. and Wan, Xiu-Feng},
  year = {2021-12-14, 2021-12},
  journal = {Analytical and Bioanalytical Chemistry},
  volume = {414},
  number = {9},
  pages = {2841--2881},
  doi = {10.1007/s00216-021-03806-6},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\ZHT82EFW\\Wang et al. - 2021 - Antigenic characterization of influenza and SARS-C.pdf}
}

@article{webster1992,
  title = {Evolution and Ecology of Influenza {{A}} Viruses.},
  author = {Webster, R G and Bean, W J and Gorman, O T and Chambers, T M and Kawaoka, Y},
  year = {1992},
  month = mar,
  journal = {Microbiol Rev},
  volume = {56},
  number = {1},
  pages = {152--179},
  issn = {0146-0749},
  urldate = {2021-06-30},
  abstract = {In this review we examine the hypothesis that aquatic birds are the primordial source of all influenza viruses in other species and study the ecological features that permit the perpetuation of influenza viruses in aquatic avian species. Phylogenetic analysis of the nucleotide sequence of influenza A virus RNA segments coding for the spike proteins (HA, NA, and M2) and the internal proteins (PB2, PB1, PA, NP, M, and NS) from a wide range of hosts, geographical regions, and influenza A virus subtypes support the following conclusions. (i) Two partly overlapping reservoirs of influenza A viruses exist in migrating waterfowl and shorebirds throughout the world. These species harbor influenza viruses of all the known HA and NA subtypes. (ii) Influenza viruses have evolved into a number of host-specific lineages that are exemplified by the NP gene and include equine Prague/56, recent equine strains, classical swine and human strains, H13 gull strains, and all other avian strains. Other genes show similar patterns, but with extensive evidence of genetic reassortment. Geographical as well as host-specific lineages are evident. (iii) All of the influenza A viruses of mammalian sources originated from the avian gene pool, and it is possible that influenza B viruses also arose from the same source. (iv) The different virus lineages are predominantly host specific, but there are periodic exchanges of influenza virus genes or whole viruses between species, giving rise to pandemics of disease in humans, lower animals, and birds. (v) The influenza viruses currently circulating in humans and pigs in North America originated by transmission of all genes from the avian reservoir prior to the 1918 Spanish influenza pandemic; some of the genes have subsequently been replaced by others from the influenza gene pool in birds. (vi) The influenza virus gene pool in aquatic birds of the world is probably perpetuated by low-level transmission within that species throughout the year. (vii) There is evidence that most new human pandemic strains and variants have originated in southern China. (viii) There is speculation that pigs may serve as the intermediate host in genetic exchange between influenza viruses in avian and humans, but experimental evidence is lacking. (ix) Once the ecological properties of influenza viruses are understood, it may be possible to interdict the introduction of new influenza viruses into humans.},
  pmcid = {PMC372859},
  pmid = {1579108},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\DGTCRPM4\\Webster et al. - 1992 - Evolution and ecology of influenza A viruses..pdf}
}

@article{wei2020,
  title = {Next-Generation Influenza Vaccines: Opportunities and Challenges},
  author = {Wei, Chih-Jen and Crank, Michelle C. and Shiver, John and Graham, Barney S. and Mascola, John R. and Nabel, Gary J.},
  year = {2020-02-14, 2020-02},
  journal = {Nature Reviews Drug Discovery},
  volume = {19},
  number = {4},
  pages = {239--252},
  doi = {10.1038/s41573-019-0056-x},
  langid = {english}
}

@article{wilkinson2017,
  title = {Efficacy and Safety of High-Dose Influenza Vaccine in Elderly Adults: {{A}} Systematic Review and Meta-Analysis},
  shorttitle = {Efficacy and Safety of High-Dose Influenza Vaccine in Elderly Adults},
  author = {Wilkinson, Krista and Wei, Yichun and Szwajcer, Andrea and Rabbani, Rasheda and Zarychanski, Ryan and {Abou-Setta}, Ahmed M. and Mahmud, Salaheddin M.},
  year = {2017},
  month = may,
  journal = {Vaccine},
  volume = {35},
  number = {21},
  pages = {2775--2780},
  issn = {1873-2518},
  doi = {10.1016/j.vaccine.2017.03.092},
  abstract = {INTRODUCTION: Older adults are prioritized for influenza vaccination but also have lowered antibody responses to the vaccine. Higher-doses of influenza antigen may increase immune response and thus be more effective. Our objectives were to compare the efficacy and safety of the high-dose influenza vaccine to the standard-dose influenza vaccine in the elderly (age{$>$}65). METHODS: Data sources: Randomized trials (RCTs) from Medline (Ovid), EMBASE (Ovid), Cochrane Library (Wiley), ClinicalTrials.gov, reference lists of relevant articles, and gray literature. STUDY SELECTION: Two reviewers independently identified RCTs comparing high-dose influenza vaccine (60{$\mu$}g of hemagglutinin per strain) to standard-dose influenza vaccine (15{$\mu$}g of hemagglutinin per strain) in adults over the age of 65years. DATA EXTRACTION: Two reviewers independently extracted trial-level data including population characteristics, interventions, outcomes, and funding sources. Risk of bias was assessed using the Cochrane Risk of Bias tool. RESULTS: We included seven eligible trials; all were categorized as having a low (n=3) or unclear (n=4) risk of bias. Patients receiving the high-dose vaccine had significantly less risk of developing laboratory-confirmed influenza infections (Relative Risk 0.76, 95\%CI 0.65 to 0.90; I2 0\%, 2 trials, 41,141 patients). Post-vaccination geometric mean titres and seroprotection rates were also higher in high-dose vaccine recipients. There were no protocol-defined serious adverse events in the included trials in either group. CONCLUSIONS: In elderly adults, the high-dose influenza vaccine was well-tolerated, more immunogenic, and more efficacious in preventing influenza infections than the standard-dose vaccine. Further pragmatic trials are needed to determine if the higher efficacy translates into higher vaccine effectiveness in adults over the age of 65.},
  langid = {english},
  pmid = {28431815},
  keywords = {Aged,Drug-Related Side Effects and Adverse Reactions,High-dose,Humans,Influenza,Influenza vaccines,Influenza Vaccines,Influenza; Human,Meta-analysis,Randomized control trial,Systematic review,Treatment Outcome}
}

@article{wimmers2021,
  title = {The Single-Cell Epigenomic and Transcriptional Landscape of Immunity to Influenza Vaccination},
  author = {Wimmers, Florian and Donato, Michele and Kuo, Alex and Ashuach, Tal and Gupta, Shakti and Li, Chunfeng and Dvorak, Mai and Foecke, Mariko Hinton and Chang, Sarah E. and Hagan, Thomas and De Jong, Sanne E. and Maecker, Holden T. and {van der Most}, Robbert and Cheung, Peggie and Cortese, Mario and Bosinger, Steven E. and Davis, Mark and Rouphael, Nadine and Subramaniam, Shankar and Yosef, Nir and Utz, Paul J. and Khatri, Purvesh and Pulendran, Bali},
  year = {2021},
  month = jul,
  journal = {Cell},
  volume = {184},
  number = {15},
  pages = {3915-3935.e21},
  issn = {1097-4172},
  doi = {10.1016/j.cell.2021.05.039},
  abstract = {Emerging evidence indicates a fundamental role for the epigenome in immunity. Here, we mapped the epigenomic and transcriptional landscape of immunity to influenza vaccination in humans at the single-cell level. Vaccination against seasonal influenza induced persistently diminished H3K27ac in monocytes and myeloid dendritic cells (mDCs), which was associated with impaired cytokine responses to Toll-like receptor stimulation. Single-cell ATAC-seq analysis revealed an epigenomically distinct subcluster of monocytes with reduced chromatin accessibility at AP-1-targeted loci after vaccination. Similar effects were observed in response to vaccination with the AS03-adjuvanted H5N1 pandemic influenza vaccine. However, this vaccine also stimulated persistently increased chromatin accessibility at interferon response factor (IRF) loci in monocytes and mDCs. This was associated with elevated expression of antiviral genes and heightened resistance to the unrelated Zika and Dengue viruses. These results demonstrate that vaccination stimulates persistent epigenomic remodeling of the innate immune system and reveal AS03's potential as an epigenetic adjuvant.},
  langid = {english},
  pmcid = {PMC8316438},
  pmid = {34174187},
  keywords = {adjuvant,Adolescent,Adult,alpha-Tocopherol,Anti-Bacterial Agents,Antigens; CD34,Antiviral Agents,antiviral immunity,Cellular Reprogramming,Chromatin,Cytokines,Drug Combinations,epigenome,Epigenomics,Female,Gene Expression Regulation,Histones,Humans,Immunity,Immunity; Innate,influenza,Influenza A Virus; H5N1 Subtype,Influenza Vaccines,innate memory,Interferon Type I,Male,monocyte,Myeloid Cells,Polysorbates,single cell,Single-Cell Analysis,Squalene,systems biology,Toll-Like Receptors,trained immunity,Transcription Factor AP-1,Transcription; Genetic,Transcriptome,Vaccination,vaccines,Young Adult},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\55B9X346\\Wimmers et al. - 2021 - The single-cell epigenomic and transcriptional lan.pdf}
}

@article{wu2022,
  title = {Evaluation of Determinants of the Serological Response to the Quadrivalent Split-Inactivated Influenza Vaccine},
  author = {Wu, Shaohuan and Ross, Ted M. and Carlock, Michael A. and Ghedin, Elodie and Choi, Hyungwon and Vogel, Christine},
  year = {2022},
  month = may,
  journal = {Mol Syst Biol},
  volume = {18},
  number = {5},
  pages = {e10724},
  issn = {1744-4292},
  doi = {10.15252/msb.202110724},
  abstract = {The seasonal influenza vaccine is only effective in half of the vaccinated population. To identify determinants of vaccine efficacy, we used data from {$>$}\,1,300 vaccination events to predict the response to vaccination measured as seroconversion as well as hemagglutination inhibition (HAI) titer levels one year after. We evaluated the predictive capabilities of age, body mass index (BMI), sex, race, comorbidities, vaccination history, and baseline HAI titers, as well as vaccination month and vaccine dose in multiple linear regression models. The models predicted the categorical response for {$>$}\,75\% of the cases in all subsets with one exception. Prior vaccination, baseline titer level, and age were the major determinants of seroconversion, all of which had negative effects. Further, we identified a gender effect in older participants and an effect of vaccination month. BMI had a surprisingly small effect, likely due to its correlation with age. Comorbidities, vaccine dose, and race had negligible effects. Our models can generate a new seroconversion score that is corrected for the impact of these factors which can facilitate future biomarker identification.},
  langid = {english},
  pmcid = {PMC9073386},
  pmid = {35514207},
  keywords = {Aged,Antibodies; Viral,Hemagglutination Inhibition Tests,human cohort,Humans,immune response,influenza,Influenza Vaccines,Influenza; Human,split-inactivated influenza vaccine,statistical modeling,Vaccination},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\9ZPKNMN2\\Wu et al. - 2022 - Evaluation of determinants of the serological resp.pdf}
}

@article{wu2022a,
  title = {Evaluation of Determinants of the Serological Response to the Quadrivalent Split-Inactivated Influenza Vaccine},
  author = {Wu, Shaohuan and Ross, Ted M and Carlock, Michael A and Ghedin, Elodie and Choi, Hyungwon and Vogel, Christine},
  year = {2022},
  month = may,
  journal = {Molecular Systems Biology},
  volume = {18},
  number = {5},
  pages = {e10724},
  publisher = {{John Wiley \& Sons, Ltd}},
  issn = {1744-4292},
  doi = {10.15252/msb.202110724},
  urldate = {2023-03-22},
  abstract = {Abstract The seasonal influenza vaccine is only effective in half of the vaccinated population. To identify determinants of vaccine efficacy, we used data from {$>$}?1,300 vaccination events to predict the response to vaccination measured as seroconversion as well as hemagglutination inhibition (HAI) titer levels one year after. We evaluated the predictive capabilities of age, body mass index (BMI), sex, race, comorbidities, vaccination history, and baseline HAI titers, as well as vaccination month and vaccine dose in multiple linear regression models. The models predicted the categorical response for {$>$}?75\% of the cases in all subsets with one exception. Prior vaccination, baseline titer level, and age were the major determinants of seroconversion, all of which had negative effects. Further, we identified a gender effect in older participants and an effect of vaccination month. BMI had a surprisingly small effect, likely due to its correlation with age. Comorbidities, vaccine dose, and race had negligible effects. Our models can generate a new seroconversion score that is corrected for the impact of these factors which can facilitate future biomarker identification.},
  keywords = {human cohort,immune response,influenza,split-inactivated influenza vaccine,statistical modeling},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\GXPBTNS3\\Wu et al. - 2022 - Evaluation of determinants of the serological resp.pdf}
}

@article{yang2014,
  title = {Sequence-Based Antigenic Change Prediction by a Sparse Learning Method Incorporating Co-Evolutionary Information},
  author = {Yang, Jialiang and Zhang, Tong and Wan, Xiu-Feng},
  editor = {Raghava, Gajendra P. S.},
  year = {2014-09-04, 2014-09},
  journal = {PLoS ONE},
  volume = {9},
  number = {9},
  pages = {e106660},
  doi = {10.1371/journal.pone.0106660},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\BVR56CHZ\\Yang et al. - 2014 - Sequence-based antigenic change prediction by a sp.pdf}
}

@article{yang2020,
  title = {Life Course Exposures Continually Shape Antibody Profiles and Risk of Seroconversion to Influenza},
  author = {Yang, Bingyi and Lessler, Justin and Zhu, Huachen and Jiang, Chao Qiang and Read, Jonathan M. and Hay, James A. and Kwok, Kin On and Shen, Ruiyin and Guan, Yi and Riley, Steven and Cummings, Derek A. T.},
  year = {2020},
  month = jul,
  journal = {PLOS Pathogens},
  volume = {16},
  number = {7},
  pages = {e1008635},
  publisher = {{Public Library of Science}},
  issn = {1553-7374},
  doi = {10.1371/journal.ppat.1008635},
  urldate = {2023-02-20},
  abstract = {Complex exposure histories and immune mediated interactions between influenza strains contribute to the life course of human immunity to influenza. Antibody profiles can be generated by characterizing immune responses to multiple antigenically variant strains, but how these profiles vary across individuals and determine future responses is unclear. We used hemagglutination inhibition titers from 21 H3N2 strains to construct 777 paired antibody profiles from people aged 2 to 86, and developed novel metrics to capture features of these profiles. Total antibody titer per potential influenza exposure increases in early life, then decreases in middle age. Increased titers to one or more strains were seen in 97.8\% of participants during a roughly four-year interval, suggesting widespread influenza exposure. While titer changes were seen to all strains, recently circulating strains exhibited the greatest titer rise. Higher pre-existing, homologous titers at baseline reduced the risk of seroconversion to recent strains. After adjusting for homologous titer, we also found an increased frequency of seroconversion against recent strains among those with higher immunity to older previously exposed strains. Including immunity to previously exposures also improved the deviance explained by the models. Our results suggest that a comprehensive quantitative description of immunity encompassing past exposures could lead to improved correlates of risk of influenza infection.},
  langid = {english},
  keywords = {Age groups,Antibodies,Antibody response,Immune response,Immunity,Influenza,Medical risk factors,Vaccination and immunization}
}

@article{yewdell2002,
  title = {Influenza Virus Still Surprises},
  author = {Yewdell, Jonathan and {Garc{\'{\i}}a-Sastre}, Adolfo},
  year = {2002},
  month = aug,
  journal = {Current Opinion in Microbiology},
  volume = {5},
  number = {4},
  pages = {414--418},
  issn = {1369-5274},
  doi = {10.1016/S1369-5274(02)00346-6},
  urldate = {2021-06-30},
  abstract = {Influenza virus remains a major public heath concern, both in its annual toll in death and debilitation and its potential to cause devastating pandemics. A number of recent surprising discoveries emphasize how little we know about influenza virus and its interaction with its hosts. These include the description of a novel viral protein encoded by an overlapping reading frame, the demonstration that the most abundant viral non-structural protein interferes with the induction of interferons by infected cells, and the finding that natural killer cells express activating receptors that detect viral cell-surface proteins. The introduction of improved methods for genetically manipulating influenza virus promises to revolutionize our understanding of viral replication and its interaction with the host innate and acquired immune systems, and will also enable the improvement of vaccines. Using knowledge of viral sequences recovered from archived or interred tissues from victims of the 1918 influenza pandemic, it is now possible to investigate why this virus was so pathogenic \textemdash{} it killed more than 20\hphantom{,}000\hphantom{,}000 people, most of whom were young adults in the prime of their lives.},
  langid = {english},
  keywords = {immunity,Influenza virus,interferon,pathogenesis,virus},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\GDURXHUV\\Yewdell and GarcÄ±Ìa-Sastre - 2002 - Influenza virus still surprises.pdf;C\:\\Users\\Zane\\Zotero\\storage\\SQQ4R3HU\\S1369527402003466.html}
}

@article{zacour2016,
  title = {Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories},
  author = {Zacour, Mary and Ward, Brian J. and Brewer, Angela and Tang, Patrick and Boivin, Guy and Li, Yan and Warhuus, Michelle and McNeil, Shelly A. and LeBlanc, Jason J. and Hatchette, Todd F.},
  editor = {Hodinka, R. L.},
  year = {2016},
  month = mar,
  journal = {Clinical and Vaccine Immunology},
  volume = {23},
  number = {3},
  pages = {236--242},
  doi = {10.1128/cvi.00613-15},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\3VRKWYHU\\Zacour et al. - 2016 - Standardization of hemagglutination inhibition ass.pdf}
}

@article{zarnitsyna2015,
  title = {Masking of Antigenic Epitopes by Antibodies Shapes the Humoral Immune Response to Influenza},
  author = {Zarnitsyna, Veronika I. and Ellebedy, Ali H. and Davis, Carl and Jacob, Joshy and Ahmed, Rafi and Antia, Rustom},
  year = {2015},
  month = sep,
  journal = {Philosophical Transactions of the Royal Society B: Biological Sciences},
  volume = {370},
  number = {1676},
  pages = {20140248},
  publisher = {{Royal Society}},
  doi = {10.1098/rstb.2014.0248},
  urldate = {2021-04-14},
  abstract = {The immune responses to influenza, a virus that exhibits strain variation, show complex dynamics where prior immunity shapes the response to the subsequent infecting strains. Original antigenic sin (OAS) describes the observation that antibodies to the first encountered influenza strain, specifically antibodies to the epitopes on the head of influenza's main surface glycoprotein, haemagglutinin (HA), dominate following infection with new drifted strains. OAS suggests that responses to the original strain are preferentially boosted. Recent studies also show limited boosting of the antibodies to conserved epitopes on the stem of HA, which are attractive targets for a `universal vaccine'. We develop multi-epitope models to explore how pre-existing immunity modulates the immune response to new strains following immunization. Our models suggest that the masking of antigenic epitopes by antibodies may play an important role in describing the complex dynamics of OAS and limited boosting of antibodies to the stem of HA. Analysis of recently published data confirms model predictions for how pre-existing antibodies to an epitope on HA decrease the magnitude of boosting of the antibody response to this epitope following immunization. We explore strategies for boosting of antibodies to conserved epitopes and generating broadly protective immunity to multiple strains.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\35I9X5TL\\Zarnitsyna et al. - 2015 - Masking of antigenic epitopes by antibodies shapes.pdf;C\:\\Users\\Zane\\Zotero\\storage\\BQG6AZKU\\rstb.2014.html}
}

@article{zarnitsyna2016,
  title = {Multi-Epitope {{Models Explain How Pre-existing Antibodies Affect}} the {{Generation}} of {{Broadly Protective Responses}} to {{Influenza}}},
  author = {Zarnitsyna, Veronika I. and Lavine, Jennie and Ellebedy, Ali and Ahmed, Rafi and Antia, Rustom},
  year = {2016},
  month = jun,
  journal = {PLoS Pathog},
  volume = {12},
  number = {6},
  issn = {1553-7366},
  doi = {10.1371/journal.ppat.1005692},
  urldate = {2021-04-14},
  abstract = {The development of next-generation influenza vaccines that elicit strain-transcendent immunity against both seasonal and pandemic viruses is a key public health goal. Targeting the evolutionarily conserved epitopes on the stem of influenza's major surface molecule, hemagglutinin, is an appealing prospect, and novel vaccine formulations show promising results in animal model systems. However, studies in humans indicate that natural infection and vaccination result in limited boosting of antibodies to the stem of HA, and the level of stem-specific antibody elicited is insufficient to provide broad strain-transcendent immunity. Here, we use mathematical models of the humoral immune response to explore how pre-existing immunity affects the ability of vaccines to boost antibodies to the head and stem of HA in humans, and, in particular, how it leads to the apparent lack of boosting of broadly cross-reactive antibodies to the stem epitopes. We consider hypotheses where binding of antibody to an epitope: (i) results in more rapid clearance of the antigen; (ii) leads to the formation of antigen-antibody complexes which inhibit B cell activation through Fc{$\gamma$} receptor-mediated mechanism; and (iii) masks the epitope and prevents the stimulation and proliferation of specific B cells. We find that only epitope masking but not the former two mechanisms to be key in recapitulating patterns in data. We discuss the ramifications of our findings for the development of vaccines against both seasonal and pandemic influenza., The current influenza vaccine requires frequent updating in order to protect against small changes in the virus from one year to the next as well as larger changes associated with the emergence of new influenza strains from zoonotic reservoirs that cause pandemics. There is a considerable interest in developing ``universal'' vaccines that will boost immune responses to the conserved regions of the virus, in particular, to the stem region of the major virus surface molecule hemagglutinin (HA). However, recent data reveals that vaccination results in very limited boosting of antibodies to the stem of HA. We use mathematical models to explore different hypotheses that may explain why vaccination does not boost antibodies to the conserved parts of the virus. By confronting our models with the data from the human vaccination trials we found that the key mechanism preventing effective boosting of the responses to the stem of HA is masking of the stem by pre-existing antibodies developed during previous infections and vaccinations. We discuss how this masking effect could be overcome in a ``universal'' influenza vaccine.},
  pmcid = {PMC4918916},
  pmid = {27336297},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\8KX6F9AT\\Zarnitsyna et al. - 2016 - Multi-epitope Models Explain How Pre-existing Anti.pdf}
}

@article{zelner2019,
  title = {Effects of {{Sequential Influenza A}}({{H1N1}})Pdm09 {{Vaccination}} on {{Antibody Waning}}},
  author = {Zelner, Jon and Petrie, Joshua G and Trangucci, Rob and Martin, Emily T and Monto, Arnold S},
  year = {2019},
  month = jun,
  journal = {The Journal of Infectious Diseases},
  volume = {220},
  number = {1},
  pages = {12--19},
  issn = {0022-1899},
  doi = {10.1093/infdis/jiz055},
  urldate = {2021-06-09},
  abstract = {Antibody waning following influenza vaccination has been repeatedly evaluated, but waning has rarely been studied in the context of longitudinal vaccination history.We developed a Bayesian hierarchical model to assess the effects of sequential influenza A(H1N1)pdm09 vaccination on hemagglutination inhibition antibody boosting and waning in a longitudinal cohort of older children and adults from 2011 to 2016, a period during which the A(H1N1)pdm09 vaccine strain did not change.Antibody measurements from 2057 serum specimens longitudinally collected from 388 individuals were included. Average postvaccination antibody titers were similar across successive vaccinations, but the rate of antibody waning increased with each vaccination. The antibody half-life was estimated to decrease from 32 months (95\% credible interval [CrI], 22\textendash 61 months) following first vaccination to 9 months (95\% CrI, 7\textendash 15 months) following a seventh vaccination.Although the rate of antibody waning increased with successive vaccination, the estimated antibody half-life was longer than a typical influenza season even among the most highly vaccinated. This supports current recommendations for vaccination at the earliest opportunity. Patterns of boosting and waning might be different with the influenza A(H3N2) subtype, which evolves more rapidly and has been most associated with reduced effectiveness following repeat vaccination.},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\TMKTSGB6\\Zelner et al. - 2019 - Effects of Sequential Influenza A(H1N1)pdm09 Vacci.pdf;C\:\\Users\\Zane\\Zotero\\storage\\LIH45LTA\\5306487.html}
}

@article{zhang2019,
  title = {Original {{Antigenic Sin}}: {{How First Exposure Shapes Lifelong Anti-Influenza Virus Immune Responses}}},
  shorttitle = {Original {{Antigenic Sin}}},
  author = {Zhang, Ali and Stacey, Hannah D. and Mullarkey, Caitlin E. and Miller, Matthew S.},
  year = {2019},
  month = jan,
  journal = {J Immunol},
  volume = {202},
  number = {2},
  pages = {335--340},
  issn = {1550-6606},
  doi = {10.4049/jimmunol.1801149},
  abstract = {The term "original antigenic sin" (OAS) was first used in the 1960s to describe how one's first exposure to influenza virus shapes the outcome of subsequent exposures to antigenically related strains. In the decades that have passed, OAS-like responses have been shown to play an integral role in both protection from and susceptibility to infections. OAS may also have an important deterministic role in the differential efficacy of influenza vaccine responses observed for various age cohorts across seasons. In this article, we review how the understanding of OAS has progressed from its initial description and highlight important outstanding questions in need of further study.},
  langid = {english},
  pmid = {30617114},
  keywords = {Age Factors,Antigenic Variation,Antigens; Viral,Humans,Immunity,Immunologic Memory,Influenza Vaccines,Influenza; Human,Orthomyxoviridae,Treatment Outcome}
}

@article{zimmermann2016,
  title = {System-{{Wide Associations}} between {{DNA-Methylation}}, {{Gene Expression}}, and {{Humoral Immune Response}} to {{Influenza Vaccination}}},
  author = {Zimmermann, Michael T. and Oberg, Ann L. and Grill, Diane E. and Ovsyannikova, Inna G. and Haralambieva, Iana H. and Kennedy, Richard B. and Poland, Gregory A.},
  year = {2016},
  journal = {PLoS One},
  volume = {11},
  number = {3},
  pages = {e0152034},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0152034},
  abstract = {Failure to achieve a protected state after influenza vaccination is poorly understood but occurs commonly among aged populations experiencing greater immunosenescence. In order to better understand immune response in the elderly, we studied epigenetic and transcriptomic profiles and humoral immune response outcomes in 50-74 year old healthy participants. Associations between DNA methylation and gene expression reveal a system-wide regulation of immune-relevant functions, likely playing a role in regulating a participant's propensity to respond to vaccination. Our findings show that sites of methylation regulation associated with humoral response to vaccination impact known cellular differentiation signaling and antigen presentation pathways. We performed our analysis using per-site and regionally average methylation levels, in addition to continuous or dichotomized outcome measures. The genes and molecular functions implicated by each analysis were compared, highlighting different aspects of the biologic mechanisms of immune response affected by differential methylation. Both cis-acting (within the gene or promoter) and trans-acting (enhancers and transcription factor binding sites) sites show significant associations with measures of humoral immunity. Specifically, we identified a group of CpGs that, when coordinately hypo-methylated, are associated with lower humoral immune response, and methylated with higher response. Additionally, CpGs that individually predict humoral immune responses are enriched for polycomb-group and FOXP2 transcription factor binding sites. The most robust associations implicate differential methylation affecting gene expression levels of genes with known roles in immunity (e.g. HLA-B and HLA-DQB2) and immunosenescence. We believe our data and analysis strategy highlight new and interesting epigenetic trends affecting humoral response to vaccination against influenza; one of the most common and impactful viral pathogens.},
  langid = {english},
  pmcid = {PMC4816338},
  pmid = {27031986},
  keywords = {Aged,DNA Methylation,Epigenesis; Genetic,Female,Humans,Immunity; Humoral,Influenza Vaccines,Influenza; Human,Male,Middle Aged,Vaccination},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\ERS8FMG2\\Zimmermann et al. - 2016 - System-Wide Associations between DNA-Methylation, .pdf}
}

@article{zost2017,
  title = {Contemporary {{H3N2}} Influenza Viruses Have a Glycosylation Site That Alters Binding of Antibodies Elicited by Egg-Adapted Vaccine Strains},
  author = {Zost, Seth J. and Parkhouse, Kaela and Gumina, Megan E. and Kim, Kangchon and Diaz Perez, Sebastian and Wilson, Patrick C. and Treanor, John J. and Sant, Andrea J. and Cobey, Sarah and Hensley, Scott E.},
  year = {2017},
  month = nov,
  journal = {Proc Natl Acad Sci U S A},
  volume = {114},
  number = {47},
  pages = {12578--12583},
  issn = {1091-6490},
  doi = {10.1073/pnas.1712377114},
  abstract = {H3N2 viruses continuously acquire mutations in the hemagglutinin (HA) glycoprotein that abrogate binding of human antibodies. During the 2014-2015 influenza season, clade 3C.2a H3N2 viruses possessing a new predicted glycosylation site in antigenic site B of HA emerged, and these viruses remain prevalent today. The 2016-2017 seasonal influenza vaccine was updated to include a clade 3C.2a H3N2 strain; however, the egg-adapted version of this viral strain lacks the new putative glycosylation site. Here, we biochemically demonstrate that the HA antigenic site B of circulating clade 3C.2a viruses is glycosylated. We show that antibodies elicited in ferrets and humans exposed to the egg-adapted 2016-2017 H3N2 vaccine strain poorly neutralize a glycosylated clade 3C.2a H3N2 virus. Importantly, antibodies elicited in ferrets infected with the current circulating H3N2 viral strain (that possesses the glycosylation site) and humans vaccinated with baculovirus-expressed H3 antigens (that possess the glycosylation site motif) were able to efficiently recognize a glycosylated clade 3C.2a H3N2 virus. We propose that differences in glycosylation between H3N2 egg-adapted vaccines and circulating strains likely contributed to reduced vaccine effectiveness during the 2016-2017 influenza season. Furthermore, our data suggest that influenza virus antigens prepared via systems not reliant on egg adaptations are more likely to elicit protective antibody responses that are not affected by glycosylation of antigenic site B of H3N2 HA.},
  langid = {english},
  pmcid = {PMC5703309},
  pmid = {29109276},
  keywords = {Animals,Antibodies; Viral,antibody,Antigens; Viral,Chickens,Ferrets,Glycosylation,hemagglutinin,Hemagglutinin Glycoproteins; Influenza Virus,Humans,Immunogenicity; Vaccine,influenza,Influenza A Virus; H3N2 Subtype,Influenza Vaccines,Influenza; Human,Mutation,Neutralization Tests,Ovum,vaccine},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\TBV8LWDE\\Zost et al. - 2017 - Contemporary H3N2 influenza viruses have a glycosy.pdf}
}

@misc{zost2019,
  title = {Identification of Antibodies Targeting the {{H3N2}} Hemagglutinin Receptor Binding Site Following Vaccination of Humans},
  author = {Zost, Seth J. and Lee, Juhye and Gumina, Megan E. and Parkhouse, Kaela and Henry, Carole and Wilson, Patrick C. and Bloom, Jesse D. and Hensley, Scott E.},
  year = {2019},
  month = jun,
  primaryclass = {New Results},
  pages = {675272},
  publisher = {{bioRxiv}},
  doi = {10.1101/675272},
  urldate = {2023-03-02},
  abstract = {Antibodies targeting the receptor binding site (RBS) of the influenza virus hemagglutinin (HA) protein are usually not broadly-reactive because their footprints are typically large and extend to nearby variable HA residues. Here, we identified several human H3N2 HA RBS-targeting monoclonal antibodies (mAbs) that were sensitive to substitutions in conventional antigenic sites and were not broadly-reactive. However, we also identified one H3N2 HA RBS-targeting mAb that was exceptionally broadly reactive despite being sensitive to substitutions in residues outside of the RBS. We determined that similar antibodies are present at measurable levels in the sera of some individuals but that they are inefficiently elicited by conventional vaccines. Our data indicate that some HA RBS-targeting antibodies can be surprisingly effective against variable viral strains even if they are somewhat sensitive to substitutions in HA residues adjacent to the RBS.},
  archiveprefix = {bioRxiv},
  chapter = {New Results},
  copyright = {\textcopyright{} 2019, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {C\:\\Users\\Zane\\Zotero\\storage\\366F3HXN\\Zost et al. - 2019 - Identification of antibodies targeting the H3N2 he.pdf}
}
